

COVID-19 Immunogenicity Analysis Report
mock Study

USG COVID-19 Response Biostatistics Team

April 19, 2021

Contents

1	Tabular Description of Immunogenicity Data	15
2	Graphical Description of Immunogenicity Data	411
2.1	Pairs plots of antibody markers for overall per-protocol cohort	411
2.2	RCDF plots of antibody markers for overall per-protocol cohort	428
2.3	Scatter plots of antibody markers versus age for overall per-protocol cohort	444
2.4	Box plots of antibody markers for overall per-protocol cohort	448
2.5	Spaghetti plots of antibody markers over time for the overall per-protocol cohort	464
2.6	RCDF plots of antibody markers by demographics for per-protocol cohort	466
2.7	Boxplots of antibody markers by demographics for per-protocol cohort	538

List of Tables

1.1	Table 1. Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Negative Per-Protocol Cohort	15
1.2	Table 2. Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Positive Per-Protocol Cohort	17
1.3	Table 3a. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by All participants	18
1.4	Table 3b. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Age	20
1.5	Table 3c. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Risk for Severe Covid-19	24
1.6	Table 3d. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Age, Risk for Severe Covid-19	28
1.7	Table 3e. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Sex	37
1.8	Table 3f. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Age, sex	41
1.9	Table 3g. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Hispanic or Latino ethnicity	49
1.10	Table 3h. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Race	56
1.11	Table 3i. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Underrepresented minority status	74
1.12	Table 3j. Percentage of responders, and participants with concentrations $\geq 2\times$ LLOD or $\geq 4\times$ LLOD for binding antibody markers by Age, Underrepresented minority status	79
1.13	Table 4a. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by All participants	90
1.14	Table 4b. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age . . .	91
1.15	Table 4c. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Risk for Severe Covid-19	93
1.16	Table 4d. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, Risk for Severe Covid-19	95

1.17 Table 4e. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Sex	98
1.18 Table 4f. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, sex	100
1.19 Table 4g. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Hispanic or Latino ethnicity	103
1.20 Table 4h. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Race	106
1.21 Table 4i. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Underrepresented minority status	112
1.22 Table 4j. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, Underrepresented minority status	114
1.23 Table 5a. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by All participants	118
1.24 Table 5b. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age	122
1.25 Table 5c. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Risk for Severe Covid-19	130
1.26 Table 5d. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, Risk for Severe Covid-19	138
1.27 Table 5e. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Sex	154
1.28 Table 5f. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, sex	162
1.29 Table 5g. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Hispanic or Latino ethnicity	178
1.30 Table 5h. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Race	190
1.31 Table 5i. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Underrepresented minority status	222
1.32 Table 5j. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, Underrepresented minority status	230
1.33 Table 6a. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by All participants	246
1.34 Table 6b. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age	249
1.35 Table 6c. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Risk for Severe Covid-19	255
1.36 Table 6d. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, Risk for Severe Covid-19	261
1.37 Table 6e. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Sex	272
1.38 Table 6f. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, sex	278

1.39 Table 6g. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Hispanic or Latino ethnicity	289
1.40 Table 6h. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Race	298
1.41 Table 6i. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Underrepresented minority status . .	322
1.42 Table 6j. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, Underrepresented minority status	328
1.43 Table 7a. The ratios of GMTs/GMCs between groups by Age	342
1.44 Table 7b. The ratios of GMTs/GMCs between groups by Risk for Severe Covid-19	346
1.45 Table 7c. The ratios of GMTs/GMCs between groups by Age < 65, Risk for Severe Covid-19	350
1.46 Table 7d. The ratios of GMTs/GMCs between groups by Age >= 65, Risk for Severe Covid-19	356
1.47 Table 7e. The ratios of GMTs/GMCs between groups by Sex	362
1.48 Table 7f. The ratios of GMTs/GMCs between groups by Hispanic or Latino ethnicity	366
1.49 Table 7g. The ratios of GMTs/GMCs between groups by Underrepresented minority status .	372
1.50 Table 8a. Differences in the responder rates, 2FRs, 4FRs between the groups by Arm	378
1.51 Table 8b. Differences in the responder rates, 2FRs, 4FRs between the groups by Baseline SARS-CoV-2	380
1.52 Table 8c. Differences in the responder rates, 2FRs, 4FRs between the groups by Age	382
1.53 Table 8d. Differences in the responder rates, 2FRs, 4FRs between the groups by Risk for Severe Covid-19	385
1.54 Table 8e. Differences in the responder rates, 2FRs, 4FRs between the groups by Age < 65, Risk for Severe Covid-19	388
1.55 Table 8f. Differences in the responder rates, 2FRs, 4FRs between the groups by Age >= 65, Risk for Severe Covid-19	392
1.56 Table 8g. Differences in the responder rates, 2FRs, 4FRs between the groups by Sex	396
1.57 Table 8h. Differences in the responder rates, 2FRs, 4FRs between the groups by Hispanic or Latino ethnicity	399
1.58 Table 8i. Differences in the responder rates, 2FRs, 4FRs between the groups by Underrepresented minority status	403
1.59 Table 9. Antibody levels in the baseline SARS-CoV-2 negative per-protocol cohort (vaccine vs. placebo)	407
1.60 Table 10. Antibody levels in the baseline SARS-CoV-2 positive per-protocol cohort (vaccine vs. placebo)	408
1.61 Table 11. Antibody levels in the per-protocol cohort (vaccine recipients)	409
1.62 Table 12. Antibody levels in the per-protocol cohort (placebo recipients)	410

List of Figures

2.1	Pair plots of D29 Ab markers: baseline negative vaccine arm	412
2.2	Pair plots of D57 Ab markers: baseline negative vaccine arm	413
2.3	Pair plots of D29 fold-rise over D1 Ab markers: baseline negative vaccine arm	414
2.4	Pair plots of D57 fold-rise over D1 Ab markers: baseline negative vaccine arm	415
2.5	Pair plots of D1, D29 and D57 Binding Antibody to Spike: baseline negative vaccine arm . .	416
2.6	Pair plots of D1, D29 and D57 Binding Antibody to RBD: baseline negative vaccine arm . .	417
2.7	Pair plots of D1, D29 and D57 PsV Neutralization 50% Titer: baseline negative vaccine arm	418
2.8	Pair plots of D1, D29 and D57 PsV Neutralization 80% Titer: Baseline negative vaccine arm	419
2.9	Pair plots of D29 Ab markers: baseline positive vaccine arm	420
2.10	Pair plots of D57 Ab markers: baseline positive vaccine arm	421
2.11	Pair plots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm	422
2.12	Pair plots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm	423
2.13	Pair plots of D1, D29 and D57 Binding Antibody to Spike: baseline positive vaccine arm . .	424
2.14	Pair plots of D1, D29 and D57 Binding Antibody to RBD: baseline positive vaccine arm . .	425
2.15	Pair plots of D1, D29 and D57 PsV Neutralization 50% Titer: baseline positive vaccine arm	426
2.16	Pair plots of D1, D29 and D57 PsV Neutralization 80% Titer: Baseline positive vaccine arm	427
2.17	RCDF plots for D29 Ab markers: by baseline status x randomization arm	428
2.18	RCDF plots for D57 Ab markers: by baseline status x randomization arm	429
2.19	RCDF plots for D29 fold-rise over D1 Ab markers: by baseline status x randomization arm .	430
2.20	RCDF plots for D57 fold-rise over D1 Ab markers: by baseline status x randomization arm .	431
2.21	RCDF plots for D29 Ab markers: by baseline status for the vaccine arm	432
2.22	RCDF plots for D57 Ab markers: by baseline status for the vaccine arm	433
2.23	RCDF plots for D29 over D1 fold-rise Ab markers: by baseline status for the vaccine arm .	434
2.24	RCDF plots for D57 fold-rise over D1 Ab markers: by baseline status for the vaccine arm .	435
2.25	RCDF plots for D29 Ab markers: baseline negative vaccine arm	436
2.26	RCDF plots for D57 Ab markers: baseline negative vaccine arm	437
2.27	RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm	438
2.28	RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm	439

2.29 RCDF plots for D29 Ab markers: baseline positive vaccine arm	440
2.30 RCDF plots for D57 Ab markers: baseline positive vaccine arm	441
2.31 RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm	442
2.32 RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm	443
2.33 Scatter plots for D29 Ab markers vs. age: baseline negative vaccine arm	444
2.34 Scatter plots for D57 Ab markers vs. age: baseline negative vaccine arm	445
2.35 Scatter plots for D29 Ab markers vs. age: baseline positive vaccine arm	446
2.36 Scatter plots for D57 Ab markers vs. age: baseline positive vaccine arm	447
2.37 Boxplots of D29 Ab markers: baseline negative vaccine + placebo arms	448
2.38 Boxplots of D57 Ab markers: baseline negative vaccine + placebo arms	449
2.39 Boxplots of D29 fold-rise over D1 Ab markers: baseline negative vaccine + placebo arms	450
2.40 Boxplots of D57 fold-rise over D1 Ab markers: baseline negative vaccine + placebo arms	451
2.41 Boxplots of D29 Ab markers: baseline positive vaccine + placebo arms	452
2.42 Boxplots of D57 Ab markers: baseline positive vaccine + placebo arms	453
2.43 Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine + placebo arms	454
2.44 Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine + placebo arms	455
2.45 Boxplots of D29 Ab markers: baseline positive + negative vaccine arm	456
2.46 Boxplots of D57 Ab markers: baseline positive + negative vaccine arm	457
2.47 Boxplots of D29 fold-rise over D1 Ab markers: baseline positive + negative vaccine arm	458
2.48 Boxplots of D57 fold-rise over D1 Ab markers: baseline positive + negative vaccine arm	459
2.49 Boxplots of D29 Ab markers: baseline positive + negative placebo arm	460
2.50 Boxplots of D57 Ab markers: baseline positive + negative placebo arm	461
2.51 Boxplots of D29 fold-rise over D1 Ab markers: baseline positive + negative placebo arm	462
2.52 Boxplots of D57 fold-rise over D1 Ab markers: baseline positive + negative placebo arm	463
2.53 Spaghetti plots of Ab markers over time: baseline negative vaccine + placebo arm	464
2.54 Spaghetti plots of Ab markers over time: baseline positive vaccine + placebo arm	465
2.55 RCDF plots for D29 Ab markers: baseline negative vaccine arm by age groups.	466
2.56 RCDF plots for D57 Ab markers: baseline negative vaccine arm by age groups.	467
2.57 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age groups.	468
2.58 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age groups.	469
2.59 RCDF plots for D29 Ab markers: baseline negative vaccine arm by high-risk condition.	470
2.60 RCDF plots for D57 Ab markers: baseline negative vaccine arm by high-risk condition.	471
2.61 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by high-risk condition.	472
2.62 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by high-risk condition.	473
2.63 RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and high-risk condition.	474

2.64 RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and high-risk condition.	475
2.65 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and high-risk condition.	476
2.66 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and high-risk condition.	477
2.67 RCDF plots for D29 Ab markers: baseline negative vaccine arm by sex assigned at birth.	478
2.68 RCDF plots for D57 Ab markers: baseline negative vaccine arm by sex assigned at birth.	479
2.69 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by sex assigned at birth.	480
2.70 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by sex assigned at birth.	481
2.71 RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and sex assigned at birth.	482
2.72 RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and sex assigned at birth.	483
2.73 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and sex assigned at birth.	484
2.74 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and sex at birth.	485
2.75 RCDF plots for D29 Ab markers: baseline negative vaccine arm by ethnicity.	486
2.76 RCDF plots for D57 Ab markers: baseline negative vaccine arm by ethnicity.	487
2.77 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by ethnicity. .	488
2.78 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by ethnicity. .	489
2.79 RCDF plots for D29 Ab markers: baseline negative vaccine arm by race.	490
2.80 RCDF plots for D57 Ab markers: baseline negative vaccine arm by race.	491
2.81 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by race. .	492
2.82 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by race. .	493
2.83 RCDF plots for D29 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.	494
2.84 RCDF plots for D57 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.	495
2.85 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.	496
2.86 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.	497
2.87 RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.	498
2.88 RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.	499
2.89 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.	500

2.90 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.	501
2.91 RCDF plots for D29 Ab markers: baseline positive vaccine arm by age groups.	502
2.92 RCDF plots for D57 Ab markers: baseline positive vaccine arm by age groups.	503
2.93 RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age groups.	504
2.94 RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age groups.	505
2.95 RCDF plots for D29 Ab markers: baseline positive vaccine arm by high-risk condition.	506
2.96 RCDF plots for D57 Ab markers: baseline positive vaccine arm by high-risk condition.	507
2.97 RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.	508
2.98 RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.	509
2.99 RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and high-risk condition.	510
2.100RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and high-risk condition.	511
2.101RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.	512
2.102RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.	513
2.103RCDF plots for D29 Ab markers: baseline positive vaccine arm by sex assigned at birth.	514
2.104RCDF plots for D57 Ab markers: baseline positive vaccine arm by sex assigned at birth.	515
2.105RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.	516
2.106RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.	517
2.107RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.	518
2.108RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.	519
2.109RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.	520
2.110RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.	521
2.111RCDF plots for D29 Ab markers: baseline positive vaccine arm by ethnicity.	522
2.112RCDF plots for D57 Ab markers: baseline positive vaccine arm by ethnicity.	523
2.113RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity.	524
2.114RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity.	525
2.115RCDF plots for D29 Ab markers: baseline positive vaccine arm by race.	526
2.116RCDF plots for D57 Ab markers: baseline positive vaccine arm by race.	527
2.117RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by race.	528
2.118RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by race.	529

2.119RCDF plots for D29 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.	530
2.120RCDF plots for D57 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.	531
2.121RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.	532
2.122RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.	533
2.123RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.	534
2.124RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.	535
2.125RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.	536
2.126RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.	537
2.127Boxplots of D29 Ab markers: Baseline negative vaccine arm by age group.	538
2.128Boxplots of D57 Ab markers: Baseline negative vaccine arm by age group.	539
2.129Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and sex assigned at birth.	540
2.130Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and sex assigned at birth.	541
2.131Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by ethnicity. . .	542
2.132Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by ethnicity. .	543
2.133Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by race. . . .	544
2.134Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by race. . . .	545
2.135Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by dichotomous classification of race and ethnic group.	546
2.136Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by dichotomous classification of race and ethnic group.	547
2.137Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.	548
2.138Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.	549
2.139Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age group. .	551
2.140Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age group. .	552
2.141Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.	553
2.142Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.	554
2.143Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.	555

2.144Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.	556
2.145Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.	557
2.146Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.	558
2.147Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.	559
2.148Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.	560
2.149Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity. .	561
2.150Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity. .	562
2.151Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by race.	563
2.152Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by race.	564
2.153Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.	565
2.154Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.	566
2.155Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.	567
2.156Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.	568

Chapter 1

Tabular Description of Immunogenicity Data

Table 1. Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Negative Per-Protocol Cohort

Characteristics	Vaccine (N = 904)	Placebo (N = 155)	Total (N = 1059)
Age			
Age < 65	436 (48.2%)	76 (49.0%)	512 (48.3%)
Age ≥ 65	468 (51.8%)	79 (51.0%)	547 (51.7%)
Mean (Range)	59.0 (18.0, 85.0)	58.5 (18.0, 85.0)	58.9 (18.0, 85.0)
BMI			
Mean ± SD	29.8 ± 6.9	30.2 ± 6.5	29.9 ± 6.9
Risk for Severe Covid-19			
At-risk	459 (50.8%)	76 (49.0%)	535 (50.5%)
Not at-risk	445 (49.2%)	79 (51.0%)	524 (49.5%)
Age, Risk for Severe Covid-19			
Age < 65 At-risk	216 (23.9%)	36 (23.2%)	252 (23.8%)
Age < 65 Not at-risk	220 (24.3%)	40 (25.8%)	260 (24.6%)
Age ≥ 65	468 (51.8%)	79 (51.0%)	547 (51.7%)
Sex			
Female	540 (59.7%)	81 (52.3%)	621 (58.6%)
Male	364 (40.3%)	74 (47.7%)	438 (41.4%)
Hispanic or Latino ethnicity			
Hispanic or Latino	127 (14.0%)	15 (9.7%)	142 (13.4%)
Not Hispanic or Latino	679 (75.1%)	122 (78.7%)	801 (75.6%)
Not reported and unknown	98 (10.8%)	18 (11.6%)	116 (11.0%)
Race			
White Non-Hispanic	355 (39.3%)	64 (41.3%)	419 (39.6%)
Black or African American	205 (22.7%)	25 (16.1%)	230 (21.7%)
Asian	57 (6.3%)	12 (7.7%)	69 (6.5%)
American Indian or Alaska Native	22 (2.4%)	7 (4.5%)	29 (2.7%)
Native Hawaiian or Other Pacific Islander	17 (1.9%)	1 (0.6%)	18 (1.7%)
Multiracial	54 (6.0%)	11 (7.1%)	65 (6.1%)
Other	21 (2.3%)	4 (2.6%)	25 (2.4%)

(continued)

Characteristics	Vaccine (N = 904)	Placebo (N = 155)	Total (N = 1059)
Not reported and unknown	85 (9.4%)	18 (11.6%)	103 (9.7%)
Communities of Color	424 (46.9%)	63 (40.6%)	487 (46.0%)

This table summarizes the random subcohort, which was randomly sampled from the per-protocol cohort, and excludes individuals with a COVID failure event < 7 days post Day 57. The sampling was stratified by 24 strata defined by enrollment characteristics: Assigned treatment arm × Baseline SARS-CoV-2 naïve vs. non-naïve status (defined by serostatus and NAAT testing) × Randomization strata (Age < 65 and at-risk, Age < 65 and not at-risk, Age ≥ 65) × Communities of color (Yes/No) defined by White Non-Hispanic vs. all others (following the primary COVE trial paper).

MOCH

Table 2. Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Positive Per-Protocol Cohort

Characteristics	Vaccine (N = 277)	Placebo (N = 274)	Total (N = 551)
Age			
Age < 65	145 (52.3%)	143 (52.2%)	288 (52.3%)
Age ≥ 65	132 (47.7%)	131 (47.8%)	263 (47.7%)
Mean (Range)	56.2 (18.0, 85.0)	57.9 (18.0, 85.0)	57.0 (18.0, 85.0)
BMI			
Mean ± SD	30.2 ± 7.6	30.3 ± 6.5	30.2 ± 7.0
Risk for Severe Covid-19			
At-risk	126 (45.5%)	124 (45.3%)	250 (45.4%)
Not at-risk	151 (54.5%)	150 (54.7%)	301 (54.6%)
Age, Risk for Severe Covid-19			
Age < 65 At-risk	72 (26.0%)	70 (25.5%)	142 (25.8%)
Age < 65 Not at-risk	73 (26.4%)	73 (26.6%)	146 (26.5%)
Age ≥ 65	132 (47.7%)	131 (47.8%)	263 (47.7%)
Sex			
Female	162 (58.5%)	149 (54.4%)	311 (56.4%)
Male	115 (41.5%)	125 (45.6%)	240 (43.6%)
Hispanic or Latino ethnicity			
Hispanic or Latino	29 (10.5%)	46 (16.8%)	75 (13.6%)
Not Hispanic or Latino	209 (75.5%)	203 (74.1%)	412 (74.8%)
Not reported and unknown	39 (14.1%)	25 (9.1%)	64 (11.6%)
Race			
White Non-Hispanic	121 (43.7%)	116 (42.3%)	237 (43.0%)
Black or African American	61 (22.0%)	48 (17.5%)	109 (19.8%)
Asian	18 (6.5%)	16 (5.8%)	34 (6.2%)
American Indian or Alaska Native	8 (2.9%)	8 (2.9%)	16 (2.9%)
Native Hawaiian or Other Pacific Islander	3 (1.1%)	7 (2.6%)	10 (1.8%)
Multiracial	15 (5.4%)	22 (8.0%)	37 (6.7%)
Other	1 (0.4%)	9 (3.3%)	10 (1.8%)
Not reported and unknown	22 (7.9%)	23 (8.4%)	45 (8.2%)
Communities of Color	120 (43.3%)	124 (45.3%)	244 (44.3%)

This table summarizes the random subcohort, which was randomly sampled from the per-protocol cohort, and excludes individuals with a COVID failure event < 7 days post Day 57. The sampling was stratified by 24 strata defined by enrollment characteristics: Assigned treatment arm × Baseline SARS-CoV-2 naïve vs. non-naïve status (defined by serostatus and NAAT testing) × Randomization strata (Age < 65 and at-risk, Age < 65 and not at-risk, Age ≥ 65) × Communities of color (Yes/No) defined by White Non-Hispanic vs. all others (following the primary COVE trial paper).

Table 3a. Percentage of responders, and participants with concentrations $\geq 2 \times$ LLOD or $\geq 4 \times$ LLOD for binding antibody markers by All participants

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
All participants								
	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	904	13264/13264 = 100.0% (100.0%, 100.0%)	13264/13264 = 100.0% (100.0%, 100.0%)	13264/13264 = 100.0% (100.0%, 100.0%)
	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	904	13264/13264 = 100.0% (100.0%, 100.0%)	13264/13264 = 100.0% (100.0%, 100.0%)	13264/13264 = 100.0% (100.0%, 100.0%)
	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	904	13264/13264 = 100.0% (100.0%, 100.0%)	13264/13264 = 100.0% (100.0%, 100.0%)	13264/13264 = 100.0% (100.0%, 100.0%)
	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	277	1432/1432 = 100.0% (100.0%, 100.0%)	1432/1432 = 100.0% (100.0%, 100.0%)	1432/1432 = 100.0% (100.0%, 100.0%)
	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	277	1432/1432 = 100.0% (100.0%, 100.0%)	1432/1432 = 100.0% (100.0%, 100.0%)	1432/1432 = 100.0% (100.0%, 100.0%)
	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	277	1432/1432 = 100.0% (100.0%, 100.0%)	1432/1432 = 100.0% (100.0%, 100.0%)	1432/1432 = 100.0% (100.0%, 100.0%)
	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	155	0/13308 = 0.0% (0.0%, 0.0%)	0/13308 = 0.0% (0.0%, 0.0%)	0/13308 = 0.0% (0.0%, 0.0%)
	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	155	0/13308 = 0.0% (0.0%, 0.0%)	0/13308 = 0.0% (0.0%, 0.0%)	0/13308 = 0.0% (0.0%, 0.0%)
	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	155	88.8/13308 = 0.7% (0.2%, 2.9%)	0/13308 = 0.0% (0.0%, 0.0%)	0/13308 = 0.0% (0.0%, 0.0%)
	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	274	1337/1337 = 100.0% (100.0%, 100.0%)	1337/1337 = 100.0% (100.0%, 100.0%)	1337/1337 = 100.0% (100.0%, 100.0%)
	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	274	1337/1337 = 100.0% (100.0%, 100.0%)	1337/1337 = 100.0% (100.0%, 100.0%)	1337/1337 = 100.0% (100.0%, 100.0%)
	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	274	1337/1337 = 100.0% (100.0%, 100.0%)	1337/1337 = 100.0% (100.0%, 100.0%)	1337/1337 = 100.0% (100.0%, 100.0%)
	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	904	13264/13264 = 100.0% (100.0%, 100.0%)	13264/13264 = 100.0% (100.0%, 100.0%)	13264/13264 = 100.0% (100.0%, 100.0%)
	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	904	13264/13264 = 100.0% (100.0%, 100.0%)	13264/13264 = 100.0% (100.0%, 100.0%)	13264/13264 = 100.0% (100.0%, 100.0%)
	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	904	13264/13264 = 100.0% (100.0%, 100.0%)	13264/13264 = 100.0% (100.0%, 100.0%)	13264/13264 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	277	1432/1432 = 100.0% (100.0%, 100.0%)	1432/1432 = 100.0% (100.0%, 100.0%)	1432/1432 = 100.0% (100.0%, 100.0%)
	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	277	1432/1432 = 100.0% (100.0%, 100.0%)	1432/1432 = 100.0% (100.0%, 100.0%)	1432/1432 = 100.0% (100.0%, 100.0%)
	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	277	1432/1432 = 100.0% (100.0%, 100.0%)	1432/1432 = 100.0% (100.0%, 100.0%)	1432/1432 = 100.0% (100.0%, 100.0%)
	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	155	0/13308 = 0.0% (0.0%, 0.0%)	0/13308 = 0.0% (0.0%, 0.0%)	0/13308 = 0.0% (0.0%, 0.0%)
	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	155	140.5/13308 = 1.1% (0.3%, 3.2%)	140.5/13308 = 1.1% (0.3%, 3.2%)	46.8/13308 = 0.4% (0.0%, 2.5%)
	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	155	0/13308 = 0.0% (0.0%, 0.0%)	0/13308 = 0.0% (0.0%, 0.0%)	0/13308 = 0.0% (0.0%, 0.0%)
	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	274	1337/1337 = 100.0% (100.0%, 100.0%)	1337/1337 = 100.0% (100.0%, 100.0%)	1337/1337 = 100.0% (100.0%, 100.0%)
	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	274	1337/1337 = 100.0% (100.0%, 100.0%)	1337/1337 = 100.0% (100.0%, 100.0%)	1337/1337 = 100.0% (100.0%, 100.0%)
	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	274	1337/1337 = 100.0% (100.0%, 100.0%)	1337/1337 = 100.0% (100.0%, 100.0%)	1337/1337 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.




Table 3b. Percentage of responders, and participants with concentrations $\geq 2 \times$ LLOD or $\geq 4 \times$ LLOD for binding antibody markers by Age

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
Age								
Age < 65	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	436	10438/10438 = 100.0% (100.0%, 100.0%)	10438/10438 = 100.0% (100.0%, 100.0%)	10438/10438 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	436	10438/10438 = 100.0% (100.0%, 100.0%)	10438/10438 = 100.0% (100.0%, 100.0%)	10438/10438 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	436	10438/10438 = 100.0% (100.0%, 100.0%)	10438/10438 = 100.0% (100.0%, 100.0%)	10438/10438 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	145	1151/1151 = 100.0% (100.0%, 100.0%)	1151/1151 = 100.0% (100.0%, 100.0%)	1151/1151 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	145	1151/1151 = 100.0% (100.0%, 100.0%)	1151/1151 = 100.0% (100.0%, 100.0%)	1151/1151 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	145	1151/1151 = 100.0% (100.0%, 100.0%)	1151/1151 = 100.0% (100.0%, 100.0%)	1151/1151 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	76	0/10180 = 0.0% (0.0%, 0.0%)	0/10180 = 0.0% (0.0%, 0.0%)	0/10180 = 0.0% (0.0%, 0.0%)
Age < 65	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	76	0/10180 = 0.0% (0.0%, 0.0%)	0/10180 = 0.0% (0.0%, 0.0%)	0/10180 = 0.0% (0.0%, 0.0%)
Age < 65	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	76	58.8/10180 = 0.6% (0.1%, 4.1%)	0/10180 = 0.0% (0.0%, 0.0%)	0/10180 = 0.0% (0.0%, 0.0%)
Age < 65	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	143	1048/1048 = 100.0% (100.0%, 100.0%)	1048/1048 = 100.0% (100.0%, 100.0%)	1048/1048 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	143	1048/1048 = 100.0% (100.0%, 100.0%)	1048/1048 = 100.0% (100.0%, 100.0%)	1048/1048 = 100.0% (100.0%, 100.0%)
Age < 65	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	143	1048/1048 = 100.0% (100.0%, 100.0%)	1048/1048 = 100.0% (100.0%, 100.0%)	1048/1048 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	436	10438/10438 = 100.0% (100.0%, 100.0%)	10438/10438 = 100.0% (100.0%, 100.0%)	10438/10438 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	436	10438/10438 = 100.0% (100.0%, 100.0%)	10438/10438 = 100.0% (100.0%, 100.0%)	10438/10438 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	436	10438/10438 = 100.0% (100.0%, 100.0%)	10438/10438 = 100.0% (100.0%, 100.0%)	10438/10438 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	145	1151/1151 = 100.0% (100.0%, 100.0%)	1151/1151 = 100.0% (100.0%, 100.0%)	1151/1151 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	145	1151/1151 = 100.0% (100.0%, 100.0%)	1151/1151 = 100.0% (100.0%, 100.0%)	1151/1151 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	145	1151/1151 = 100.0% (100.0%, 100.0%)	1151/1151 = 100.0% (100.0%, 100.0%)	1151/1151 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	76	0/10180 = 0.0% (0.0%, 0.0%)	0/10180 = 0.0% (0.0%, 0.0%)	0/10180 = 0.0% (0.0%, 0.0%)
Age < 65	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	76	0/10180 = 0.0% (0.0%, 0.0%)	0/10180 = 0.0% (0.0%, 0.0%)	0/10180 = 0.0% (0.0%, 0.0%)
Age < 65	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	76	0/10180 = 0.0% (0.0%, 0.0%)	0/10180 = 0.0% (0.0%, 0.0%)	0/10180 = 0.0% (0.0%, 0.0%)
Age < 65	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	143	1048/1048 = 100.0% (100.0%, 100.0%)	1048/1048 = 100.0% (100.0%, 100.0%)	1048/1048 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	143	1048/1048 = 100.0% (100.0%, 100.0%)	1048/1048 = 100.0% (100.0%, 100.0%)	1048/1048 = 100.0% (100.0%, 100.0%)
Age < 65	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	143	1048/1048 = 100.0% (100.0%, 100.0%)	1048/1048 = 100.0% (100.0%, 100.0%)	1048/1048 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	468	2826/2826 = 100.0% (100.0%, 100.0%)	2826/2826 = 100.0% (100.0%, 100.0%)	2826/2826 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	468	2826/2826 = 100.0% (100.0%, 100.0%)	2826/2826 = 100.0% (100.0%, 100.0%)	2826/2826 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	468	2826/2826 = 100.0% (100.0%, 100.0%)	2826/2826 = 100.0% (100.0%, 100.0%)	2826/2826 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	132	281/281 = 100.0% (100.0%, 100.0%)	281/281 = 100.0% (100.0%, 100.0%)	281/281 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	132	281/281 = 100.0% (100.0%, 100.0%)	281/281 = 100.0% (100.0%, 100.0%)	281/281 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	132	281/281 = 100.0% (100.0%, 100.0%)	281/281 = 100.0% (100.0%, 100.0%)	281/281 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	79	0/3128 = 0.0% (0.0%, 0.0%)	0/3128 = 0.0% (0.0%, 0.0%)	0/3128 = 0.0% (0.0%, 0.0%)
Age ≥ 65	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	79	0/3128 = 0.0% (0.0%, 0.0%)	0/3128 = 0.0% (0.0%, 0.0%)	0/3128 = 0.0% (0.0%, 0.0%)
Age ≥ 65	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	79	30/3128 = 1.0% (0.1%, 6.7%)	0/3128 = 0.0% (0.0%, 0.0%)	0/3128 = 0.0% (0.0%, 0.0%)
Age ≥ 65	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	131	289/289 = 100.0% (100.0%, 100.0%)	289/289 = 100.0% (100.0%, 100.0%)	289/289 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	131	289/289 = 100.0% (100.0%, 100.0%)	289/289 = 100.0% (100.0%, 100.0%)	289/289 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	131	289/289 = 100.0% (100.0%, 100.0%)	289/289 = 100.0% (100.0%, 100.0%)	289/289 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	468	2826/2826 = 100.0% (100.0%, 100.0%)	2826/2826 = 100.0% (100.0%, 100.0%)	2826/2826 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	468	2826/2826 = 100.0% (100.0%, 100.0%)	2826/2826 = 100.0% (100.0%, 100.0%)	2826/2826 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	468	2826/2826 = 100.0% (100.0%, 100.0%)	2826/2826 = 100.0% (100.0%, 100.0%)	2826/2826 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	132	281/281 = 100.0% (100.0%, 100.0%)	281/281 = 100.0% (100.0%, 100.0%)	281/281 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	132	281/281 = 100.0% (100.0%, 100.0%)	281/281 = 100.0% (100.0%, 100.0%)	281/281 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	132	281/281 = 100.0% (100.0%, 100.0%)	281/281 = 100.0% (100.0%, 100.0%)	281/281 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	79	0/3128 = 0.0% (0.0%, 0.0%)	0/3128 = 0.0% (0.0%, 0.0%)	0/3128 = 0.0% (0.0%, 0.0%)
Age ≥ 65	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	79	140.5/3128 = 4.5% (1.4%, 13.2%)	140.5/3128 = 4.5% (1.4%, 13.2%)	46.8/3128 = 1.5% (0.2%, 10.3%)
Age ≥ 65	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	79	0/3128 = 0.0% (0.0%, 0.0%)	0/3128 = 0.0% (0.0%, 0.0%)	0/3128 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age \geq 65	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	131	289/289 = 100.0% (100.0%, 100.0%)	289/289 = 100.0% (100.0%, 100.0%)	289/289 = 100.0% (100.0%, 100.0%)
Age \geq 65	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	131	289/289 = 100.0% (100.0%, 100.0%)	289/289 = 100.0% (100.0%, 100.0%)	289/289 = 100.0% (100.0%, 100.0%)
Age \geq 65	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	131	289/289 = 100.0% (100.0%, 100.0%)	289/289 = 100.0% (100.0%, 100.0%)	289/289 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3c. Percentage of responders, and participants with concentrations $\geq 2 \times$ LLOD or $\geq 4 \times$ LLOD for binding antibody markers by Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
Risk for Severe Covid-19								
At-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	459	3549.5/3549.5 = 100.0% (100.0%, 100.0%)	3549.5/3549.5 = 100.0% (100.0%, 100.0%)	3549.5/3549.5 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	459	3549.5/3549.5 = 100.0% (100.0%, 100.0%)	3549.5/3549.5 = 100.0% (100.0%, 100.0%)	3549.5/3549.5 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	459	3549.5/3549.5 = 100.0% (100.0%, 100.0%)	3549.5/3549.5 = 100.0% (100.0%, 100.0%)	3549.5/3549.5 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	126	350.8/350.8 = 100.0% (100.0%, 100.0%)	350.8/350.8 = 100.0% (100.0%, 100.0%)	350.8/350.8 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	126	350.8/350.8 = 100.0% (100.0%, 100.0%)	350.8/350.8 = 100.0% (100.0%, 100.0%)	350.8/350.8 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	126	350.8/350.8 = 100.0% (100.0%, 100.0%)	350.8/350.8 = 100.0% (100.0%, 100.0%)	350.8/350.8 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	76	0/3955.4 = 0.0% (0.0%, 0.0%)	0/3955.4 = 0.0% (0.0%, 0.0%)	0/3955.4 = 0.0% (0.0%, 0.0%)
At-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	76	0/3955.4 = 0.0% (0.0%, 0.0%)	0/3955.4 = 0.0% (0.0%, 0.0%)	0/3955.4 = 0.0% (0.0%, 0.0%)
At-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	76	58.8/3955.4 = 1.5% (0.2%, 10.3%)	0/3955.4 = 0.0% (0.0%, 0.0%)	0/3955.4 = 0.0% (0.0%, 0.0%)
At-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	124	314.6/314.6 = 100.0% (100.0%, 100.0%)	314.6/314.6 = 100.0% (100.0%, 100.0%)	314.6/314.6 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	124	314.6/314.6 = 100.0% (100.0%, 100.0%)	314.6/314.6 = 100.0% (100.0%, 100.0%)	314.6/314.6 = 100.0% (100.0%, 100.0%)
At-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	124	314.6/314.6 = 100.0% (100.0%, 100.0%)	314.6/314.6 = 100.0% (100.0%, 100.0%)	314.6/314.6 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	459	3549.5/3549.5 = 100.0% (100.0%, 100.0%)	3549.5/3549.5 = 100.0% (100.0%, 100.0%)	3549.5/3549.5 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	459	3549.5/3549.5 = 100.0% (100.0%, 100.0%)	3549.5/3549.5 = 100.0% (100.0%, 100.0%)	3549.5/3549.5 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	459	3549.5/3549.5 = 100.0% (100.0%, 100.0%)	3549.5/3549.5 = 100.0% (100.0%, 100.0%)	3549.5/3549.5 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
At-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	126	350.8/350.8 = 100.0% (100.0%, 100.0%)	350.8/350.8 = 100.0% (100.0%, 100.0%)	350.8/350.8 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	126	350.8/350.8 = 100.0% (100.0%, 100.0%)	350.8/350.8 = 100.0% (100.0%, 100.0%)	350.8/350.8 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	126	350.8/350.8 = 100.0% (100.0%, 100.0%)	350.8/350.8 = 100.0% (100.0%, 100.0%)	350.8/350.8 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	76	0/3955.4 = 0.0% (0.0%, 0.0%)	0/3955.4 = 0.0% (0.0%, 0.0%)	0/3955.4 = 0.0% (0.0%, 0.0%)
At-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	76	140.5/3955.4 = 3.6% (1.2%, 10.4%)	140.5/3955.4 = 3.6% (1.2%, 10.4%)	46.8/3955.4 = 1.2% (0.2%, 8.2%)
At-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	76	0/3955.4 = 0.0% (0.0%, 0.0%)	0/3955.4 = 0.0% (0.0%, 0.0%)	0/3955.4 = 0.0% (0.0%, 0.0%)
At-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	124	314.6/314.6 = 100.0% (100.0%, 100.0%)	314.6/314.6 = 100.0% (100.0%, 100.0%)	314.6/314.6 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	124	314.6/314.6 = 100.0% (100.0%, 100.0%)	314.6/314.6 = 100.0% (100.0%, 100.0%)	314.6/314.6 = 100.0% (100.0%, 100.0%)
At-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	124	314.6/314.6 = 100.0% (100.0%, 100.0%)	314.6/314.6 = 100.0% (100.0%, 100.0%)	314.6/314.6 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	445	9714.5/9714.5 = 100.0% (100.0%, 100.0%)	9714.5/9714.5 = 100.0% (100.0%, 100.0%)	9714.5/9714.5 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	445	9714.5/9714.5 = 100.0% (100.0%, 100.0%)	9714.5/9714.5 = 100.0% (100.0%, 100.0%)	9714.5/9714.5 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	445	9714.5/9714.5 = 100.0% (100.0%, 100.0%)	9714.5/9714.5 = 100.0% (100.0%, 100.0%)	9714.5/9714.5 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	151	1081.2/1081.2 = 100.0% (100.0%, 100.0%)	1081.2/1081.2 = 100.0% (100.0%, 100.0%)	1081.2/1081.2 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	151	1081.2/1081.2 = 100.0% (100.0%, 100.0%)	1081.2/1081.2 = 100.0% (100.0%, 100.0%)	1081.2/1081.2 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	151	1081.2/1081.2 = 100.0% (100.0%, 100.0%)	1081.2/1081.2 = 100.0% (100.0%, 100.0%)	1081.2/1081.2 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	79	0/9352.6 = 0.0% (0.0%, 0.0%)	0/9352.6 = 0.0% (0.0%, 0.0%)	0/9352.6 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	79	0/9352.6 = 0.0% (0.0%, 0.0%)	0/9352.6 = 0.0% (0.0%, 0.0%)	0/9352.6 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	79	30/9352.6 = 0.3% (0.0%, 2.3%)	0/9352.6 = 0.0% (0.0%, 0.0%)	0/9352.6 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	150	1022.4/1022.4 = 100.0% (100.0%, 100.0%)	1022.4/1022.4 = 100.0% (100.0%, 100.0%)	1022.4/1022.4 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	150	1022.4/1022.4 = 100.0% (100.0%, 100.0%)	1022.4/1022.4 = 100.0% (100.0%, 100.0%)	1022.4/1022.4 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	150	1022.4/1022.4 = 100.0% (100.0%, 100.0%)	1022.4/1022.4 = 100.0% (100.0%, 100.0%)	1022.4/1022.4 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	445	9714.5/9714.5 = 100.0% (100.0%, 100.0%)	9714.5/9714.5 = 100.0% (100.0%, 100.0%)	9714.5/9714.5 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	445	9714.5/9714.5 = 100.0% (100.0%, 100.0%)	9714.5/9714.5 = 100.0% (100.0%, 100.0%)	9714.5/9714.5 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	445	9714.5/9714.5 = 100.0% (100.0%, 100.0%)	9714.5/9714.5 = 100.0% (100.0%, 100.0%)	9714.5/9714.5 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	151	1081.2/1081.2 = 100.0% (100.0%, 100.0%)	1081.2/1081.2 = 100.0% (100.0%, 100.0%)	1081.2/1081.2 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	151	1081.2/1081.2 = 100.0% (100.0%, 100.0%)	1081.2/1081.2 = 100.0% (100.0%, 100.0%)	1081.2/1081.2 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	151	1081.2/1081.2 = 100.0% (100.0%, 100.0%)	1081.2/1081.2 = 100.0% (100.0%, 100.0%)	1081.2/1081.2 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	79	0/9352.6 = 0.0% (0.0%, 0.0%)	0/9352.6 = 0.0% (0.0%, 0.0%)	0/9352.6 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	79	0/9352.6 = 0.0% (0.0%, 0.0%)	0/9352.6 = 0.0% (0.0%, 0.0%)	0/9352.6 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	79	0/9352.6 = 0.0% (0.0%, 0.0%)	0/9352.6 = 0.0% (0.0%, 0.0%)	0/9352.6 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	150	1022.4/1022.4 = 100.0% (100.0%, 100.0%)	1022.4/1022.4 = 100.0% (100.0%, 100.0%)	1022.4/1022.4 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	150	1022.4/1022.4 = 100.0% (100.0%, 100.0%)	1022.4/1022.4 = 100.0% (100.0%, 100.0%)	1022.4/1022.4 = 100.0% (100.0%, 100.0%)
Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	150	1022.4/1022.4 = 100.0% (100.0%, 100.0%)	1022.4/1022.4 = 100.0% (100.0%, 100.0%)	1022.4/1022.4 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3d. Percentage of responders, and participants with concentrations $\geq 2 \times$ LLOD or $\geq 4 \times$ LLOD for binding antibody markers by Age, Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
Age, Risk for Severe Covid-19								
Age < 65 At-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	216	2104/2104 = 100.0% (100.0%, 100.0%)	2104/2104 = 100.0% (100.0%, 100.0%)	2104/2104 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	216	2104/2104 = 100.0% (100.0%, 100.0%)	2104/2104 = 100.0% (100.0%, 100.0%)	2104/2104 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	216	2104/2104 = 100.0% (100.0%, 100.0%)	2104/2104 = 100.0% (100.0%, 100.0%)	2104/2104 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	72	234/234 = 100.0% (100.0%, 100.0%)	234/234 = 100.0% (100.0%, 100.0%)	234/234 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	72	234/234 = 100.0% (100.0%, 100.0%)	234/234 = 100.0% (100.0%, 100.0%)	234/234 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	72	234/234 = 100.0% (100.0%, 100.0%)	234/234 = 100.0% (100.0%, 100.0%)	234/234 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	36	0/2368 = 0.0% (0.0%, 0.0%)	0/2368 = 0.0% (0.0%, 0.0%)	0/2368 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	36	0/2368 = 0.0% (0.0%, 0.0%)	0/2368 = 0.0% (0.0%, 0.0%)	0/2368 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	36	58.8/2368 = 2.5% (0.3%, 17.0%)	0/2368 = 0.0% (0.0%, 0.0%)	0/2368 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	70	197/197 = 100.0% (100.0%, 100.0%)	197/197 = 100.0% (100.0%, 100.0%)	197/197 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	70	197/197 = 100.0% (100.0%, 100.0%)	197/197 = 100.0% (100.0%, 100.0%)	197/197 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 At-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	70	197/197 = 100.0% (100.0%, 100.0%)	197/197 = 100.0% (100.0%, 100.0%)	197/197 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	216	2104/2104 = 100.0% (100.0%, 100.0%)	2104/2104 = 100.0% (100.0%, 100.0%)	2104/2104 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	216	2104/2104 = 100.0% (100.0%, 100.0%)	2104/2104 = 100.0% (100.0%, 100.0%)	2104/2104 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	216	2104/2104 = 100.0% (100.0%, 100.0%)	2104/2104 = 100.0% (100.0%, 100.0%)	2104/2104 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	72	234/234 = 100.0% (100.0%, 100.0%)	234/234 = 100.0% (100.0%, 100.0%)	234/234 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	72	234/234 = 100.0% (100.0%, 100.0%)	234/234 = 100.0% (100.0%, 100.0%)	234/234 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	72	234/234 = 100.0% (100.0%, 100.0%)	234/234 = 100.0% (100.0%, 100.0%)	234/234 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	36	0/2368 = 0.0% (0.0%, 0.0%)	0/2368 = 0.0% (0.0%, 0.0%)	0/2368 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	36	0/2368 = 0.0% (0.0%, 0.0%)	0/2368 = 0.0% (0.0%, 0.0%)	0/2368 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	36	0/2368 = 0.0% (0.0%, 0.0%)	0/2368 = 0.0% (0.0%, 0.0%)	0/2368 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	70	197/197 = 100.0% (100.0%, 100.0%)	197/197 = 100.0% (100.0%, 100.0%)	197/197 = 100.0% (100.0%, 100.0%)
Age < 65 At-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	70	197/197 = 100.0% (100.0%, 100.0%)	197/197 = 100.0% (100.0%, 100.0%)	197/197 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 At-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	70	197/197 = 100.0% (100.0%, 100.0%)	197/197 = 100.0% (100.0%, 100.0%)	197/197 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	220	8334/8334 = 100.0% (100.0%, 100.0%)	8334/8334 = 100.0% (100.0%, 100.0%)	8334/8334 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	220	8334/8334 = 100.0% (100.0%, 100.0%)	8334/8334 = 100.0% (100.0%, 100.0%)	8334/8334 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	220	8334/8334 = 100.0% (100.0%, 100.0%)	8334/8334 = 100.0% (100.0%, 100.0%)	8334/8334 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	73	917/917 = 100.0% (100.0%, 100.0%)	917/917 = 100.0% (100.0%, 100.0%)	917/917 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	73	917/917 = 100.0% (100.0%, 100.0%)	917/917 = 100.0% (100.0%, 100.0%)	917/917 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	73	917/917 = 100.0% (100.0%, 100.0%)	917/917 = 100.0% (100.0%, 100.0%)	917/917 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	40	0/7812 = 0.0% (0.0%, 0.0%)	0/7812 = 0.0% (0.0%, 0.0%)	0/7812 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	40	0/7812 = 0.0% (0.0%, 0.0%)	0/7812 = 0.0% (0.0%, 0.0%)	0/7812 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	40	0/7812 = 0.0% (0.0%, 0.0%)	0/7812 = 0.0% (0.0%, 0.0%)	0/7812 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	73	851/851 = 100.0% (100.0%, 100.0%)	851/851 = 100.0% (100.0%, 100.0%)	851/851 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	73	851/851 = 100.0% (100.0%, 100.0%)	851/851 = 100.0% (100.0%, 100.0%)	851/851 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	73	851/851 = 100.0% (100.0%, 100.0%)	851/851 = 100.0% (100.0%, 100.0%)	851/851 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	220	8334/8334 = 100.0% (100.0%, 100.0%)	8334/8334 = 100.0% (100.0%, 100.0%)	8334/8334 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	220	8334/8334 = 100.0% (100.0%, 100.0%)	8334/8334 = 100.0% (100.0%, 100.0%)	8334/8334 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	220	8334/8334 = 100.0% (100.0%, 100.0%)	8334/8334 = 100.0% (100.0%, 100.0%)	8334/8334 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	73	917/917 = 100.0% (100.0%, 100.0%)	917/917 = 100.0% (100.0%, 100.0%)	917/917 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	73	917/917 = 100.0% (100.0%, 100.0%)	917/917 = 100.0% (100.0%, 100.0%)	917/917 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	73	917/917 = 100.0% (100.0%, 100.0%)	917/917 = 100.0% (100.0%, 100.0%)	917/917 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	40	0/7812 = 0.0% (0.0%, 0.0%)	0/7812 = 0.0% (0.0%, 0.0%)	0/7812 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	40	0/7812 = 0.0% (0.0%, 0.0%)	0/7812 = 0.0% (0.0%, 0.0%)	0/7812 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	40	0/7812 = 0.0% (0.0%, 0.0%)	0/7812 = 0.0% (0.0%, 0.0%)	0/7812 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	73	851/851 = 100.0% (100.0%, 100.0%)	851/851 = 100.0% (100.0%, 100.0%)	851/851 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	73	851/851 = 100.0% (100.0%, 100.0%)	851/851 = 100.0% (100.0%, 100.0%)	851/851 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	73	851/851 = 100.0% (100.0%, 100.0%)	851/851 = 100.0% (100.0%, 100.0%)	851/851 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	243	1445.5/1445.5 = 100.0% (100.0%, 100.0%)	1445.5/1445.5 = 100.0% (100.0%, 100.0%)	1445.5/1445.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	243	1445.5/1445.5 = 100.0% (100.0%, 100.0%)	1445.5/1445.5 = 100.0% (100.0%, 100.0%)	1445.5/1445.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	243	1445.5/1445.5 = 100.0% (100.0%, 100.0%)	1445.5/1445.5 = 100.0% (100.0%, 100.0%)	1445.5/1445.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	54	116.8/116.8 = 100.0% (100.0%, 100.0%)	116.8/116.8 = 100.0% (100.0%, 100.0%)	116.8/116.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	54	116.8/116.8 = 100.0% (100.0%, 100.0%)	116.8/116.8 = 100.0% (100.0%, 100.0%)	116.8/116.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	54	116.8/116.8 = 100.0% (100.0%, 100.0%)	116.8/116.8 = 100.0% (100.0%, 100.0%)	116.8/116.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	40	0/1587.4 = 0.0% (0.0%, 0.0%)	0/1587.4 = 0.0% (0.0%, 0.0%)	0/1587.4 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	40	0/1587.4 = 0.0% (0.0%, 0.0%)	0/1587.4 = 0.0% (0.0%, 0.0%)	0/1587.4 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	40	0/1587.4 = 0.0% (0.0%, 0.0%)	0/1587.4 = 0.0% (0.0%, 0.0%)	0/1587.4 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	54	117.6/117.6 = 100.0% (100.0%, 100.0%)	117.6/117.6 = 100.0% (100.0%, 100.0%)	117.6/117.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	54	117.6/117.6 = 100.0% (100.0%, 100.0%)	117.6/117.6 = 100.0% (100.0%, 100.0%)	117.6/117.6 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 At-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	54	117.6/117.6 = 100.0% (100.0%, 100.0%)	117.6/117.6 = 100.0% (100.0%, 100.0%)	117.6/117.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	243	1445.5/1445.5 = 100.0% (100.0%, 100.0%)	1445.5/1445.5 = 100.0% (100.0%, 100.0%)	1445.5/1445.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	243	1445.5/1445.5 = 100.0% (100.0%, 100.0%)	1445.5/1445.5 = 100.0% (100.0%, 100.0%)	1445.5/1445.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	243	1445.5/1445.5 = 100.0% (100.0%, 100.0%)	1445.5/1445.5 = 100.0% (100.0%, 100.0%)	1445.5/1445.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	54	116.8/116.8 = 100.0% (100.0%, 100.0%)	116.8/116.8 = 100.0% (100.0%, 100.0%)	116.8/116.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	54	116.8/116.8 = 100.0% (100.0%, 100.0%)	116.8/116.8 = 100.0% (100.0%, 100.0%)	116.8/116.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	54	116.8/116.8 = 100.0% (100.0%, 100.0%)	116.8/116.8 = 100.0% (100.0%, 100.0%)	116.8/116.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	40	0/1587.4 = 0.0% (0.0%, 0.0%)	0/1587.4 = 0.0% (0.0%, 0.0%)	0/1587.4 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	40	140.5/1587.4 = 8.8% (2.8%, 24.7%)	140.5/1587.4 = 8.8% (2.8%, 24.7%)	46.8/1587.4 = 2.9% (0.4%, 19.4%)
Age ≥ 65 At-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	40	0/1587.4 = 0.0% (0.0%, 0.0%)	0/1587.4 = 0.0% (0.0%, 0.0%)	0/1587.4 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	54	117.6/117.6 = 100.0% (100.0%, 100.0%)	117.6/117.6 = 100.0% (100.0%, 100.0%)	117.6/117.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	54	117.6/117.6 = 100.0% (100.0%, 100.0%)	117.6/117.6 = 100.0% (100.0%, 100.0%)	117.6/117.6 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 At-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	54	117.6/117.6 = 100.0% (100.0%, 100.0%)	117.6/117.6 = 100.0% (100.0%, 100.0%)	117.6/117.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	225	1380.5/1380.5 = 100.0% (100.0%, 100.0%)	1380.5/1380.5 = 100.0% (100.0%, 100.0%)	1380.5/1380.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	225	1380.5/1380.5 = 100.0% (100.0%, 100.0%)	1380.5/1380.5 = 100.0% (100.0%, 100.0%)	1380.5/1380.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	225	1380.5/1380.5 = 100.0% (100.0%, 100.0%)	1380.5/1380.5 = 100.0% (100.0%, 100.0%)	1380.5/1380.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	78	164.2/164.2 = 100.0% (100.0%, 100.0%)	164.2/164.2 = 100.0% (100.0%, 100.0%)	164.2/164.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	78	164.2/164.2 = 100.0% (100.0%, 100.0%)	164.2/164.2 = 100.0% (100.0%, 100.0%)	164.2/164.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	78	164.2/164.2 = 100.0% (100.0%, 100.0%)	164.2/164.2 = 100.0% (100.0%, 100.0%)	164.2/164.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	39	0/1540.6 = 0.0% (0.0%, 0.0%)	0/1540.6 = 0.0% (0.0%, 0.0%)	0/1540.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	39	0/1540.6 = 0.0% (0.0%, 0.0%)	0/1540.6 = 0.0% (0.0%, 0.0%)	0/1540.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	39	30/1540.6 = 1.9% (0.3%, 13.5%)	0/1540.6 = 0.0% (0.0%, 0.0%)	0/1540.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	77	171.4/171.4 = 100.0% (100.0%, 100.0%)	171.4/171.4 = 100.0% (100.0%, 100.0%)	171.4/171.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	77	171.4/171.4 = 100.0% (100.0%, 100.0%)	171.4/171.4 = 100.0% (100.0%, 100.0%)	171.4/171.4 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	77	171.4/171.4 = 100.0% (100.0%, 100.0%)	171.4/171.4 = 100.0% (100.0%, 100.0%)	171.4/171.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	225	1380.5/1380.5 = 100.0% (100.0%, 100.0%)	1380.5/1380.5 = 100.0% (100.0%, 100.0%)	1380.5/1380.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	225	1380.5/1380.5 = 100.0% (100.0%, 100.0%)	1380.5/1380.5 = 100.0% (100.0%, 100.0%)	1380.5/1380.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	225	1380.5/1380.5 = 100.0% (100.0%, 100.0%)	1380.5/1380.5 = 100.0% (100.0%, 100.0%)	1380.5/1380.5 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	78	164.2/164.2 = 100.0% (100.0%, 100.0%)	164.2/164.2 = 100.0% (100.0%, 100.0%)	164.2/164.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	78	164.2/164.2 = 100.0% (100.0%, 100.0%)	164.2/164.2 = 100.0% (100.0%, 100.0%)	164.2/164.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	78	164.2/164.2 = 100.0% (100.0%, 100.0%)	164.2/164.2 = 100.0% (100.0%, 100.0%)	164.2/164.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	39	0/1540.6 = 0.0% (0.0%, 0.0%)	0/1540.6 = 0.0% (0.0%, 0.0%)	0/1540.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	39	0/1540.6 = 0.0% (0.0%, 0.0%)	0/1540.6 = 0.0% (0.0%, 0.0%)	0/1540.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	39	0/1540.6 = 0.0% (0.0%, 0.0%)	0/1540.6 = 0.0% (0.0%, 0.0%)	0/1540.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	77	171.4/171.4 = 100.0% (100.0%, 100.0%)	171.4/171.4 = 100.0% (100.0%, 100.0%)	171.4/171.4 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	77	171.4/171.4 = 100.0% (100.0%, 100.0%)	171.4/171.4 = 100.0% (100.0%, 100.0%)	171.4/171.4 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	77	171.4/171.4 = 100.0% (100.0%, 100.0%)	171.4/171.4 = 100.0% (100.0%, 100.0%)	171.4/171.4 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3e. Percentage of responders, and participants with concentrations $\geq 2 \times$ LLOD or $\geq 4 \times$ LLOD for binding antibody markers by Sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
Sex								
Male	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	364	5129.6/5129.6 = 100.0% (100.0%, 100.0%)	5129.6/5129.6 = 100.0% (100.0%, 100.0%)	5129.6/5129.6 = 100.0% (100.0%, 100.0%)
Male	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	364	5129.6/5129.6 = 100.0% (100.0%, 100.0%)	5129.6/5129.6 = 100.0% (100.0%, 100.0%)	5129.6/5129.6 = 100.0% (100.0%, 100.0%)
Male	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	364	5129.6/5129.6 = 100.0% (100.0%, 100.0%)	5129.6/5129.6 = 100.0% (100.0%, 100.0%)	5129.6/5129.6 = 100.0% (100.0%, 100.0%)
Male	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	115	574.9/574.9 = 100.0% (100.0%, 100.0%)	574.9/574.9 = 100.0% (100.0%, 100.0%)	574.9/574.9 = 100.0% (100.0%, 100.0%)
Male	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	115	574.9/574.9 = 100.0% (100.0%, 100.0%)	574.9/574.9 = 100.0% (100.0%, 100.0%)	574.9/574.9 = 100.0% (100.0%, 100.0%)
Male	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	115	574.9/574.9 = 100.0% (100.0%, 100.0%)	574.9/574.9 = 100.0% (100.0%, 100.0%)	574.9/574.9 = 100.0% (100.0%, 100.0%)
Male	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	74	0/6201.9 = 0.0% (0.0%, 0.0%)	0/6201.9 = 0.0% (0.0%, 0.0%)	0/6201.9 = 0.0% (0.0%, 0.0%)
Male	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	74	0/6201.9 = 0.0% (0.0%, 0.0%)	0/6201.9 = 0.0% (0.0%, 0.0%)	0/6201.9 = 0.0% (0.0%, 0.0%)
Male	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	74	58.8/6201.9 = 0.9% (0.1%, 6.7%)	0/6201.9 = 0.0% (0.0%, 0.0%)	0/6201.9 = 0.0% (0.0%, 0.0%)
Male	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	125	679.4/679.4 = 100.0% (100.0%, 100.0%)	679.4/679.4 = 100.0% (100.0%, 100.0%)	679.4/679.4 = 100.0% (100.0%, 100.0%)
Male	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	125	679.4/679.4 = 100.0% (100.0%, 100.0%)	679.4/679.4 = 100.0% (100.0%, 100.0%)	679.4/679.4 = 100.0% (100.0%, 100.0%)
Male	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	125	679.4/679.4 = 100.0% (100.0%, 100.0%)	679.4/679.4 = 100.0% (100.0%, 100.0%)	679.4/679.4 = 100.0% (100.0%, 100.0%)
Male	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	364	5129.6/5129.6 = 100.0% (100.0%, 100.0%)	5129.6/5129.6 = 100.0% (100.0%, 100.0%)	5129.6/5129.6 = 100.0% (100.0%, 100.0%)
Male	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	364	5129.6/5129.6 = 100.0% (100.0%, 100.0%)	5129.6/5129.6 = 100.0% (100.0%, 100.0%)	5129.6/5129.6 = 100.0% (100.0%, 100.0%)
Male	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	364	5129.6/5129.6 = 100.0% (100.0%, 100.0%)	5129.6/5129.6 = 100.0% (100.0%, 100.0%)	5129.6/5129.6 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Male	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	115	574.9/574.9 = 100.0% (100.0%, 100.0%)	574.9/574.9 = 100.0% (100.0%, 100.0%)	574.9/574.9 = 100.0% (100.0%, 100.0%)
Male	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	115	574.9/574.9 = 100.0% (100.0%, 100.0%)	574.9/574.9 = 100.0% (100.0%, 100.0%)	574.9/574.9 = 100.0% (100.0%, 100.0%)
Male	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	115	574.9/574.9 = 100.0% (100.0%, 100.0%)	574.9/574.9 = 100.0% (100.0%, 100.0%)	574.9/574.9 = 100.0% (100.0%, 100.0%)
Male	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	74	0/6201.9 = 0.0% (0.0%, 0.0%)	0/6201.9 = 0.0% (0.0%, 0.0%)	0/6201.9 = 0.0% (0.0%, 0.0%)
Male	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	74	0/6201.9 = 0.0% (0.0%, 0.0%)	0/6201.9 = 0.0% (0.0%, 0.0%)	0/6201.9 = 0.0% (0.0%, 0.0%)
Male	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	74	0/6201.9 = 0.0% (0.0%, 0.0%)	0/6201.9 = 0.0% (0.0%, 0.0%)	0/6201.9 = 0.0% (0.0%, 0.0%)
Male	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	125	679.4/679.4 = 100.0% (100.0%, 100.0%)	679.4/679.4 = 100.0% (100.0%, 100.0%)	679.4/679.4 = 100.0% (100.0%, 100.0%)
Male	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	125	679.4/679.4 = 100.0% (100.0%, 100.0%)	679.4/679.4 = 100.0% (100.0%, 100.0%)	679.4/679.4 = 100.0% (100.0%, 100.0%)
Male	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	125	679.4/679.4 = 100.0% (100.0%, 100.0%)	679.4/679.4 = 100.0% (100.0%, 100.0%)	679.4/679.4 = 100.0% (100.0%, 100.0%)
Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	540	8134.4/8134.4 = 100.0% (100.0%, 100.0%)	8134.4/8134.4 = 100.0% (100.0%, 100.0%)	8134.4/8134.4 = 100.0% (100.0%, 100.0%)
Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	540	8134.4/8134.4 = 100.0% (100.0%, 100.0%)	8134.4/8134.4 = 100.0% (100.0%, 100.0%)	8134.4/8134.4 = 100.0% (100.0%, 100.0%)
Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	540	8134.4/8134.4 = 100.0% (100.0%, 100.0%)	8134.4/8134.4 = 100.0% (100.0%, 100.0%)	8134.4/8134.4 = 100.0% (100.0%, 100.0%)
Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	162	857.1/857.1 = 100.0% (100.0%, 100.0%)	857.1/857.1 = 100.0% (100.0%, 100.0%)	857.1/857.1 = 100.0% (100.0%, 100.0%)
Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	162	857.1/857.1 = 100.0% (100.0%, 100.0%)	857.1/857.1 = 100.0% (100.0%, 100.0%)	857.1/857.1 = 100.0% (100.0%, 100.0%)
Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	162	857.1/857.1 = 100.0% (100.0%, 100.0%)	857.1/857.1 = 100.0% (100.0%, 100.0%)	857.1/857.1 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	81	0/7106.1 = 0.0% (0.0%, 0.0%)	0/7106.1 = 0.0% (0.0%, 0.0%)	0/7106.1 = 0.0% (0.0%, 0.0%)
Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	81	0/7106.1 = 0.0% (0.0%, 0.0%)	0/7106.1 = 0.0% (0.0%, 0.0%)	0/7106.1 = 0.0% (0.0%, 0.0%)
Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	81	30/7106.1 = 0.4% (0.1%, 3.1%)	0/7106.1 = 0.0% (0.0%, 0.0%)	0/7106.1 = 0.0% (0.0%, 0.0%)
Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	149	657.6/657.6 = 100.0% (100.0%, 100.0%)	657.6/657.6 = 100.0% (100.0%, 100.0%)	657.6/657.6 = 100.0% (100.0%, 100.0%)
Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	149	657.6/657.6 = 100.0% (100.0%, 100.0%)	657.6/657.6 = 100.0% (100.0%, 100.0%)	657.6/657.6 = 100.0% (100.0%, 100.0%)
Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	149	657.6/657.6 = 100.0% (100.0%, 100.0%)	657.6/657.6 = 100.0% (100.0%, 100.0%)	657.6/657.6 = 100.0% (100.0%, 100.0%)
Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	540	8134.4/8134.4 = 100.0% (100.0%, 100.0%)	8134.4/8134.4 = 100.0% (100.0%, 100.0%)	8134.4/8134.4 = 100.0% (100.0%, 100.0%)
Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	540	8134.4/8134.4 = 100.0% (100.0%, 100.0%)	8134.4/8134.4 = 100.0% (100.0%, 100.0%)	8134.4/8134.4 = 100.0% (100.0%, 100.0%)
Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	540	8134.4/8134.4 = 100.0% (100.0%, 100.0%)	8134.4/8134.4 = 100.0% (100.0%, 100.0%)	8134.4/8134.4 = 100.0% (100.0%, 100.0%)
Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	162	857.1/857.1 = 100.0% (100.0%, 100.0%)	857.1/857.1 = 100.0% (100.0%, 100.0%)	857.1/857.1 = 100.0% (100.0%, 100.0%)
Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	162	857.1/857.1 = 100.0% (100.0%, 100.0%)	857.1/857.1 = 100.0% (100.0%, 100.0%)	857.1/857.1 = 100.0% (100.0%, 100.0%)
Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	162	857.1/857.1 = 100.0% (100.0%, 100.0%)	857.1/857.1 = 100.0% (100.0%, 100.0%)	857.1/857.1 = 100.0% (100.0%, 100.0%)
Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	81	0/7106.1 = 0.0% (0.0%, 0.0%)	0/7106.1 = 0.0% (0.0%, 0.0%)	0/7106.1 = 0.0% (0.0%, 0.0%)
Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	81	140.5/7106.1 = 2.0% (0.6%, 6.0%)	140.5/7106.1 = 2.0% (0.6%, 6.0%)	46.8/7106.1 = 0.7% (0.1%, 4.7%)
Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	81	0/7106.1 = 0.0% (0.0%, 0.0%)	0/7106.1 = 0.0% (0.0%, 0.0%)	0/7106.1 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	149	657.6/657.6 = 100.0% (100.0%, 100.0%)	657.6/657.6 = 100.0% (100.0%, 100.0%)	657.6/657.6 = 100.0% (100.0%, 100.0%)
Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	149	657.6/657.6 = 100.0% (100.0%, 100.0%)	657.6/657.6 = 100.0% (100.0%, 100.0%)	657.6/657.6 = 100.0% (100.0%, 100.0%)
Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	149	657.6/657.6 = 100.0% (100.0%, 100.0%)	657.6/657.6 = 100.0% (100.0%, 100.0%)	657.6/657.6 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3f. Percentage of responders, and participants with concentrations $\geq 2 \times$ LLOD or $\geq 4 \times$ LLOD for binding antibody markers by Age, sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
Age, sex								
Age < 65 Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	262	6444.2/6444.2 = 100.0% (100.0%, 100.0%)	6444.2/6444.2 = 100.0% (100.0%, 100.0%)	6444.2/6444.2 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	262	6444.2/6444.2 = 100.0% (100.0%, 100.0%)	6444.2/6444.2 = 100.0% (100.0%, 100.0%)	6444.2/6444.2 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	262	6444.2/6444.2 = 100.0% (100.0%, 100.0%)	6444.2/6444.2 = 100.0% (100.0%, 100.0%)	6444.2/6444.2 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	90	701.8/701.8 = 100.0% (100.0%, 100.0%)	701.8/701.8 = 100.0% (100.0%, 100.0%)	701.8/701.8 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	90	701.8/701.8 = 100.0% (100.0%, 100.0%)	701.8/701.8 = 100.0% (100.0%, 100.0%)	701.8/701.8 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	90	701.8/701.8 = 100.0% (100.0%, 100.0%)	701.8/701.8 = 100.0% (100.0%, 100.0%)	701.8/701.8 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	39	0/5425 = 0.0% (0.0%, 0.0%)	0/5425 = 0.0% (0.0%, 0.0%)	0/5425 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	39	0/5425 = 0.0% (0.0%, 0.0%)	0/5425 = 0.0% (0.0%, 0.0%)	0/5425 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	39	0/5425 = 0.0% (0.0%, 0.0%)	0/5425 = 0.0% (0.0%, 0.0%)	0/5425 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	75	493.8/493.8 = 100.0% (100.0%, 100.0%)	493.8/493.8 = 100.0% (100.0%, 100.0%)	493.8/493.8 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	75	493.8/493.8 = 100.0% (100.0%, 100.0%)	493.8/493.8 = 100.0% (100.0%, 100.0%)	493.8/493.8 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	75	493.8/493.8 = 100.0% (100.0%, 100.0%)	493.8/493.8 = 100.0% (100.0%, 100.0%)	493.8/493.8 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	262	6444.2/6444.2 = 100.0% (100.0%, 100.0%)	6444.2/6444.2 = 100.0% (100.0%, 100.0%)	6444.2/6444.2 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	262	6444.2/6444.2 = 100.0% (100.0%, 100.0%)	6444.2/6444.2 = 100.0% (100.0%, 100.0%)	6444.2/6444.2 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	262	6444.2/6444.2 = 100.0% (100.0%, 100.0%)	6444.2/6444.2 = 100.0% (100.0%, 100.0%)	6444.2/6444.2 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	90	701.8/701.8 = 100.0% (100.0%, 100.0%)	701.8/701.8 = 100.0% (100.0%, 100.0%)	701.8/701.8 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	90	701.8/701.8 = 100.0% (100.0%, 100.0%)	701.8/701.8 = 100.0% (100.0%, 100.0%)	701.8/701.8 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	90	701.8/701.8 = 100.0% (100.0%, 100.0%)	701.8/701.8 = 100.0% (100.0%, 100.0%)	701.8/701.8 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	39	0/5425 = 0.0% (0.0%, 0.0%)	0/5425 = 0.0% (0.0%, 0.0%)	0/5425 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	39	0/5425 = 0.0% (0.0%, 0.0%)	0/5425 = 0.0% (0.0%, 0.0%)	0/5425 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	39	0/5425 = 0.0% (0.0%, 0.0%)	0/5425 = 0.0% (0.0%, 0.0%)	0/5425 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	75	493.8/493.8 = 100.0% (100.0%, 100.0%)	493.8/493.8 = 100.0% (100.0%, 100.0%)	493.8/493.8 = 100.0% (100.0%, 100.0%)
Age < 65 Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	75	493.8/493.8 = 100.0% (100.0%, 100.0%)	493.8/493.8 = 100.0% (100.0%, 100.0%)	493.8/493.8 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	75	493.8/493.8 = 100.0% (100.0%, 100.0%)	493.8/493.8 = 100.0% (100.0%, 100.0%)	493.8/493.8 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	174	3993.8/3993.8 = 100.0% (100.0%, 100.0%)	3993.8/3993.8 = 100.0% (100.0%, 100.0%)	3993.8/3993.8 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	174	3993.8/3993.8 = 100.0% (100.0%, 100.0%)	3993.8/3993.8 = 100.0% (100.0%, 100.0%)	3993.8/3993.8 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	174	3993.8/3993.8 = 100.0% (100.0%, 100.0%)	3993.8/3993.8 = 100.0% (100.0%, 100.0%)	3993.8/3993.8 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	55	449.2/449.2 = 100.0% (100.0%, 100.0%)	449.2/449.2 = 100.0% (100.0%, 100.0%)	449.2/449.2 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	55	449.2/449.2 = 100.0% (100.0%, 100.0%)	449.2/449.2 = 100.0% (100.0%, 100.0%)	449.2/449.2 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	55	449.2/449.2 = 100.0% (100.0%, 100.0%)	449.2/449.2 = 100.0% (100.0%, 100.0%)	449.2/449.2 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	37	0/4755 = 0.0% (0.0%, 0.0%)	0/4755 = 0.0% (0.0%, 0.0%)	0/4755 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	37	0/4755 = 0.0% (0.0%, 0.0%)	0/4755 = 0.0% (0.0%, 0.0%)	0/4755 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	37	58.8/4755 = 1.2% (0.2%, 9.0%)	0/4755 = 0.0% (0.0%, 0.0%)	0/4755 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	68	554.2/554.2 = 100.0% (100.0%, 100.0%)	554.2/554.2 = 100.0% (100.0%, 100.0%)	554.2/554.2 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	68	554.2/554.2 = 100.0% (100.0%, 100.0%)	554.2/554.2 = 100.0% (100.0%, 100.0%)	554.2/554.2 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	68	554.2/554.2 = 100.0% (100.0%, 100.0%)	554.2/554.2 = 100.0% (100.0%, 100.0%)	554.2/554.2 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	174	3993.8/3993.8 = 100.0% (100.0%, 100.0%)	3993.8/3993.8 = 100.0% (100.0%, 100.0%)	3993.8/3993.8 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	174	3993.8/3993.8 = 100.0% (100.0%, 100.0%)	3993.8/3993.8 = 100.0% (100.0%, 100.0%)	3993.8/3993.8 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Male	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	174	3993.8/3993.8 = 100.0% (100.0%, 100.0%)	3993.8/3993.8 = 100.0% (100.0%, 100.0%)	3993.8/3993.8 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	55	449.2/449.2 = 100.0% (100.0%, 100.0%)	449.2/449.2 = 100.0% (100.0%, 100.0%)	449.2/449.2 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	55	449.2/449.2 = 100.0% (100.0%, 100.0%)	449.2/449.2 = 100.0% (100.0%, 100.0%)	449.2/449.2 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	55	449.2/449.2 = 100.0% (100.0%, 100.0%)	449.2/449.2 = 100.0% (100.0%, 100.0%)	449.2/449.2 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	37	0/4755 = 0% (0.0%, 0.0%)	0/4755 = 0% (0.0%, 0.0%)	0/4755 = 0% (0.0%, 0.0%)
Age < 65 Male	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	37	0/4755 = 0% (0.0%, 0.0%)	0/4755 = 0% (0.0%, 0.0%)	0/4755 = 0% (0.0%, 0.0%)
Age < 65 Male	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	37	0/4755 = 0% (0.0%, 0.0%)	0/4755 = 0% (0.0%, 0.0%)	0/4755 = 0% (0.0%, 0.0%)
Age < 65 Male	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	68	554.2/554.2 = 100.0% (100.0%, 100.0%)	554.2/554.2 = 100.0% (100.0%, 100.0%)	554.2/554.2 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	68	554.2/554.2 = 100.0% (100.0%, 100.0%)	554.2/554.2 = 100.0% (100.0%, 100.0%)	554.2/554.2 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	68	554.2/554.2 = 100.0% (100.0%, 100.0%)	554.2/554.2 = 100.0% (100.0%, 100.0%)	554.2/554.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	190	1135.8/1135.8 = 100.0% (100.0%, 100.0%)	1135.8/1135.8 = 100.0% (100.0%, 100.0%)	1135.8/1135.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	190	1135.8/1135.8 = 100.0% (100.0%, 100.0%)	1135.8/1135.8 = 100.0% (100.0%, 100.0%)	1135.8/1135.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	190	1135.8/1135.8 = 100.0% (100.0%, 100.0%)	1135.8/1135.8 = 100.0% (100.0%, 100.0%)	1135.8/1135.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	60	125.7/125.7 = 100.0% (100.0%, 100.0%)	125.7/125.7 = 100.0% (100.0%, 100.0%)	125.7/125.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	60	125.7/125.7 = 100.0% (100.0%, 100.0%)	125.7/125.7 = 100.0% (100.0%, 100.0%)	125.7/125.7 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Male	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	60	125.7/125.7 = 100.0% (100.0%, 100.0%)	125.7/125.7 = 100.0% (100.0%, 100.0%)	125.7/125.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	37	0/1446.9 = 0.0% (0.0%, 0.0%)	0/1446.9 = 0.0% (0.0%, 0.0%)	0/1446.9 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	37	0/1446.9 = 0.0% (0.0%, 0.0%)	0/1446.9 = 0.0% (0.0%, 0.0%)	0/1446.9 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	37	0/1446.9 = 0.0% (0.0%, 0.0%)	0/1446.9 = 0.0% (0.0%, 0.0%)	0/1446.9 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	57	125.2/125.2 = 100.0% (100.0%, 100.0%)	125.2/125.2 = 100.0% (100.0%, 100.0%)	125.2/125.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	57	125.2/125.2 = 100.0% (100.0%, 100.0%)	125.2/125.2 = 100.0% (100.0%, 100.0%)	125.2/125.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	57	125.2/125.2 = 100.0% (100.0%, 100.0%)	125.2/125.2 = 100.0% (100.0%, 100.0%)	125.2/125.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	190	1135.8/1135.8 = 100.0% (100.0%, 100.0%)	1135.8/1135.8 = 100.0% (100.0%, 100.0%)	1135.8/1135.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	190	1135.8/1135.8 = 100.0% (100.0%, 100.0%)	1135.8/1135.8 = 100.0% (100.0%, 100.0%)	1135.8/1135.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	190	1135.8/1135.8 = 100.0% (100.0%, 100.0%)	1135.8/1135.8 = 100.0% (100.0%, 100.0%)	1135.8/1135.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	60	125.7/125.7 = 100.0% (100.0%, 100.0%)	125.7/125.7 = 100.0% (100.0%, 100.0%)	125.7/125.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	60	125.7/125.7 = 100.0% (100.0%, 100.0%)	125.7/125.7 = 100.0% (100.0%, 100.0%)	125.7/125.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	60	125.7/125.7 = 100.0% (100.0%, 100.0%)	125.7/125.7 = 100.0% (100.0%, 100.0%)	125.7/125.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	37	0/1446.9 = 0.0% (0.0%, 0.0%)	0/1446.9 = 0.0% (0.0%, 0.0%)	0/1446.9 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	37	0/1446.9 = 0.0% (0.0%, 0.0%)	0/1446.9 = 0.0% (0.0%, 0.0%)	0/1446.9 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Male	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	37	0/1446.9 = 0.0% (0.0%, 0.0%)	0/1446.9 = 0.0% (0.0%, 0.0%)	0/1446.9 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	57	125.2/125.2 = 100.0% (100.0%, 100.0%)	125.2/125.2 = 100.0% (100.0%, 100.0%)	125.2/125.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	57	125.2/125.2 = 100.0% (100.0%, 100.0%)	125.2/125.2 = 100.0% (100.0%, 100.0%)	125.2/125.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	57	125.2/125.2 = 100.0% (100.0%, 100.0%)	125.2/125.2 = 100.0% (100.0%, 100.0%)	125.2/125.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	278	1690.2/1690.2 = 100.0% (100.0%, 100.0%)	1690.2/1690.2 = 100.0% (100.0%, 100.0%)	1690.2/1690.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	278	1690.2/1690.2 = 100.0% (100.0%, 100.0%)	1690.2/1690.2 = 100.0% (100.0%, 100.0%)	1690.2/1690.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	278	1690.2/1690.2 = 100.0% (100.0%, 100.0%)	1690.2/1690.2 = 100.0% (100.0%, 100.0%)	1690.2/1690.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	72	155.3/155.3 = 100.0% (100.0%, 100.0%)	155.3/155.3 = 100.0% (100.0%, 100.0%)	155.3/155.3 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	72	155.3/155.3 = 100.0% (100.0%, 100.0%)	155.3/155.3 = 100.0% (100.0%, 100.0%)	155.3/155.3 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	72	155.3/155.3 = 100.0% (100.0%, 100.0%)	155.3/155.3 = 100.0% (100.0%, 100.0%)	155.3/155.3 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	42	0/1681.1 = 0.0% (0.0%, 0.0%)	0/1681.1 = 0.0% (0.0%, 0.0%)	0/1681.1 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	42	0/1681.1 = 0.0% (0.0%, 0.0%)	0/1681.1 = 0.0% (0.0%, 0.0%)	0/1681.1 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	42	30/1681.1 = 1.8% (0.2%, 12.4%)	0/1681.1 = 0.0% (0.0%, 0.0%)	0/1681.1 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	74	163.8/163.8 = 100.0% (100.0%, 100.0%)	163.8/163.8 = 100.0% (100.0%, 100.0%)	163.8/163.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	74	163.8/163.8 = 100.0% (100.0%, 100.0%)	163.8/163.8 = 100.0% (100.0%, 100.0%)	163.8/163.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	74	163.8/163.8 = 100.0% (100.0%, 100.0%)	163.8/163.8 = 100.0% (100.0%, 100.0%)	163.8/163.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	278	1690.2/1690.2 = 100.0% (100.0%, 100.0%)	1690.2/1690.2 = 100.0% (100.0%, 100.0%)	1690.2/1690.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	278	1690.2/1690.2 = 100.0% (100.0%, 100.0%)	1690.2/1690.2 = 100.0% (100.0%, 100.0%)	1690.2/1690.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	278	1690.2/1690.2 = 100.0% (100.0%, 100.0%)	1690.2/1690.2 = 100.0% (100.0%, 100.0%)	1690.2/1690.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	72	155.3/155.3 = 100.0% (100.0%, 100.0%)	155.3/155.3 = 100.0% (100.0%, 100.0%)	155.3/155.3 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	72	155.3/155.3 = 100.0% (100.0%, 100.0%)	155.3/155.3 = 100.0% (100.0%, 100.0%)	155.3/155.3 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	72	155.3/155.3 = 100.0% (100.0%, 100.0%)	155.3/155.3 = 100.0% (100.0%, 100.0%)	155.3/155.3 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	42	0/1681.1 = 0.0% (0.0%, 0.0%)	0/1681.1 = 0.0% (0.0%, 0.0%)	0/1681.1 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	42	140.5/1681.1 = 8.4% (2.6%, 23.5%)	140.5/1681.1 = 8.4% (2.6%, 23.5%)	46.8/1681.1 = 2.8% (0.4%, 18.4%)
Age ≥ 65 Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	42	0/1681.1 = 0.0% (0.0%, 0.0%)	0/1681.1 = 0.0% (0.0%, 0.0%)	0/1681.1 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	74	163.8/163.8 = 100.0% (100.0%, 100.0%)	163.8/163.8 = 100.0% (100.0%, 100.0%)	163.8/163.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	74	163.8/163.8 = 100.0% (100.0%, 100.0%)	163.8/163.8 = 100.0% (100.0%, 100.0%)	163.8/163.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	74	163.8/163.8 = 100.0% (100.0%, 100.0%)	163.8/163.8 = 100.0% (100.0%, 100.0%)	163.8/163.8 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3g. Percentage of responders, and participants with concentrations $\geq 2 \times$ LLOD or $\geq 4 \times$ LLOD for binding antibody markers by Hispanic or Latino ethnicity

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
Hispanic or Latino ethnicity								
Hispanic or Latino	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	127	1246.3/1246.3 = 100.0% (100.0%, 100.0%)	1246.3/1246.3 = 100.0% (100.0%, 100.0%)	1246.3/1246.3 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	127	1246.3/1246.3 = 100.0% (100.0%, 100.0%)	1246.3/1246.3 = 100.0% (100.0%, 100.0%)	1246.3/1246.3 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	127	1246.3/1246.3 = 100.0% (100.0%, 100.0%)	1246.3/1246.3 = 100.0% (100.0%, 100.0%)	1246.3/1246.3 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	29	135.4/135.4 = 100.0% (100.0%, 100.0%)	135.4/135.4 = 100.0% (100.0%, 100.0%)	135.4/135.4 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	29	135.4/135.4 = 100.0% (100.0%, 100.0%)	135.4/135.4 = 100.0% (100.0%, 100.0%)	135.4/135.4 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	29	135.4/135.4 = 100.0% (100.0%, 100.0%)	135.4/135.4 = 100.0% (100.0%, 100.0%)	135.4/135.4 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	15	0/1152.8 = 0.0% (0.0%, 0.0%)	0/1152.8 = 0.0% (0.0%, 0.0%)	0/1152.8 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	15	0/1152.8 = 0.0% (0.0%, 0.0%)	0/1152.8 = 0.0% (0.0%, 0.0%)	0/1152.8 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	15	30/1152.8 = 2.6% (0.3%, 20.7%)	0/1152.8 = 0.0% (0.0%, 0.0%)	0/1152.8 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	46	143/143 = 100.0% (100.0%, 100.0%)	143/143 = 100.0% (100.0%, 100.0%)	143/143 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	46	143/143 = 100.0% (100.0%, 100.0%)	143/143 = 100.0% (100.0%, 100.0%)	143/143 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Hispanic or Latino	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	46	143/143 = 100.0% (100.0%, 100.0%)	143/143 = 100.0% (100.0%, 100.0%)	143/143 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	127	1246.3/1246.3 = 100.0% (100.0%, 100.0%)	1246.3/1246.3 = 100.0% (100.0%, 100.0%)	1246.3/1246.3 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	127	1246.3/1246.3 = 100.0% (100.0%, 100.0%)	1246.3/1246.3 = 100.0% (100.0%, 100.0%)	1246.3/1246.3 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	127	1246.3/1246.3 = 100.0% (100.0%, 100.0%)	1246.3/1246.3 = 100.0% (100.0%, 100.0%)	1246.3/1246.3 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	29	135.4/135.4 = 100.0% (100.0%, 100.0%)	135.4/135.4 = 100.0% (100.0%, 100.0%)	135.4/135.4 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	29	135.4/135.4 = 100.0% (100.0%, 100.0%)	135.4/135.4 = 100.0% (100.0%, 100.0%)	135.4/135.4 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	29	135.4/135.4 = 100.0% (100.0%, 100.0%)	135.4/135.4 = 100.0% (100.0%, 100.0%)	135.4/135.4 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	15	0/1152.8 = 0.0% (0.0%, 0.0%)	0/1152.8 = 0.0% (0.0%, 0.0%)	0/1152.8 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	15	0/1152.8 = 0.0% (0.0%, 0.0%)	0/1152.8 = 0.0% (0.0%, 0.0%)	0/1152.8 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	15	0/1152.8 = 0.0% (0.0%, 0.0%)	0/1152.8 = 0.0% (0.0%, 0.0%)	0/1152.8 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	46	143/143 = 100.0% (100.0%, 100.0%)	143/143 = 100.0% (100.0%, 100.0%)	143/143 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	46	143/143 = 100.0% (100.0%, 100.0%)	143/143 = 100.0% (100.0%, 100.0%)	143/143 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Hispanic or Latino	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	46	143/143 = 100.0% (100.0%, 100.0%)	143/143 = 100.0% (100.0%, 100.0%)	143/143 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	679	10531/10531 = 100.0% (100.0%, 100.0%)	10531/10531 = 100.0% (100.0%, 100.0%)	10531/10531 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	679	10531/10531 = 100.0% (100.0%, 100.0%)	10531/10531 = 100.0% (100.0%, 100.0%)	10531/10531 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	679	10531/10531 = 100.0% (100.0%, 100.0%)	10531/10531 = 100.0% (100.0%, 100.0%)	10531/10531 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	209	1098.5/1098.5 = 100.0% (100.0%, 100.0%)	1098.5/1098.5 = 100.0% (100.0%, 100.0%)	1098.5/1098.5 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	209	1098.5/1098.5 = 100.0% (100.0%, 100.0%)	1098.5/1098.5 = 100.0% (100.0%, 100.0%)	1098.5/1098.5 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	209	1098.5/1098.5 = 100.0% (100.0%, 100.0%)	1098.5/1098.5 = 100.0% (100.0%, 100.0%)	1098.5/1098.5 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	122	0/10217.3 = 0.0% (0.0%, 0.0%)	0/10217.3 = 0.0% (0.0%, 0.0%)	0/10217.3 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	122	0/10217.3 = 0.0% (0.0%, 0.0%)	0/10217.3 = 0.0% (0.0%, 0.0%)	0/10217.3 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	122	58.8/10217.3 = 0.6% (0.1%, 4.1%)	0/10217.3 = 0.0% (0.0%, 0.0%)	0/10217.3 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	203	1074.2/1074.2 = 100.0% (100.0%, 100.0%)	1074.2/1074.2 = 100.0% (100.0%, 100.0%)	1074.2/1074.2 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	203	1074.2/1074.2 = 100.0% (100.0%, 100.0%)	1074.2/1074.2 = 100.0% (100.0%, 100.0%)	1074.2/1074.2 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not Hispanic or Latino	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	203	1074.2/1074.2 = 100.0% (100.0%, 100.0%)	1074.2/1074.2 = 100.0% (100.0%, 100.0%)	1074.2/1074.2 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	679	10531/10531 = 100.0% (100.0%, 100.0%)	10531/10531 = 100.0% (100.0%, 100.0%)	10531/10531 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	679	10531/10531 = 100.0% (100.0%, 100.0%)	10531/10531 = 100.0% (100.0%, 100.0%)	10531/10531 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	679	10531/10531 = 100.0% (100.0%, 100.0%)	10531/10531 = 100.0% (100.0%, 100.0%)	10531/10531 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	209	1098.5/1098.5 = 100.0% (100.0%, 100.0%)	1098.5/1098.5 = 100.0% (100.0%, 100.0%)	1098.5/1098.5 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	209	1098.5/1098.5 = 100.0% (100.0%, 100.0%)	1098.5/1098.5 = 100.0% (100.0%, 100.0%)	1098.5/1098.5 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	209	1098.5/1098.5 = 100.0% (100.0%, 100.0%)	1098.5/1098.5 = 100.0% (100.0%, 100.0%)	1098.5/1098.5 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	122	0/10217.3 = 0.0% (0.0%, 0.0%)	0/10217.3 = 0.0% (0.0%, 0.0%)	0/10217.3 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	122	140.5/10217.3 = 1.4% (0.4%, 4.2%)	140.5/10217.3 = 1.4% (0.4%, 4.2%)	46.8/10217.3 = 0.5% (0.1%, 3.3%)
Not Hispanic or Latino	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	122	0/10217.3 = 0.0% (0.0%, 0.0%)	0/10217.3 = 0.0% (0.0%, 0.0%)	0/10217.3 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	203	1074.2/1074.2 = 100.0% (100.0%, 100.0%)	1074.2/1074.2 = 100.0% (100.0%, 100.0%)	1074.2/1074.2 = 100.0% (100.0%, 100.0%)
Not Hispanic or Latino	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	203	1074.2/1074.2 = 100.0% (100.0%, 100.0%)	1074.2/1074.2 = 100.0% (100.0%, 100.0%)	1074.2/1074.2 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not Hispanic or Latino	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	203	1074.2/1074.2 = 100.0% (100.0%, 100.0%)	1074.2/1074.2 = 100.0% (100.0%, 100.0%)	1074.2/1074.2 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	98	1486.6/1486.6 = 100.0% (100.0%, 100.0%)	1486.6/1486.6 = 100.0% (100.0%, 100.0%)	1486.6/1486.6 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	98	1486.6/1486.6 = 100.0% (100.0%, 100.0%)	1486.6/1486.6 = 100.0% (100.0%, 100.0%)	1486.6/1486.6 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	98	1486.6/1486.6 = 100.0% (100.0%, 100.0%)	1486.6/1486.6 = 100.0% (100.0%, 100.0%)	1486.6/1486.6 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	39	198.1/198.1 = 100.0% (100.0%, 100.0%)	198.1/198.1 = 100.0% (100.0%, 100.0%)	198.1/198.1 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	39	198.1/198.1 = 100.0% (100.0%, 100.0%)	198.1/198.1 = 100.0% (100.0%, 100.0%)	198.1/198.1 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	39	198.1/198.1 = 100.0% (100.0%, 100.0%)	198.1/198.1 = 100.0% (100.0%, 100.0%)	198.1/198.1 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	18	0/1937.9 = 0.0% (0.0%, 0.0%)	0/1937.9 = 0.0% (0.0%, 0.0%)	0/1937.9 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	18	0/1937.9 = 0.0% (0.0%, 0.0%)	0/1937.9 = 0.0% (0.0%, 0.0%)	0/1937.9 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	18	0/1937.9 = 0.0% (0.0%, 0.0%)	0/1937.9 = 0.0% (0.0%, 0.0%)	0/1937.9 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	25	119.8/119.8 = 100.0% (100.0%, 100.0%)	119.8/119.8 = 100.0% (100.0%, 100.0%)	119.8/119.8 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	25	119.8/119.8 = 100.0% (100.0%, 100.0%)	119.8/119.8 = 100.0% (100.0%, 100.0%)	119.8/119.8 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not reported and unknown	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	25	119.8/119.8 = 100.0% (100.0%, 100.0%)	119.8/119.8 = 100.0% (100.0%, 100.0%)	119.8/119.8 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	98	1486.6/1486.6 = 100.0% (100.0%, 100.0%)	1486.6/1486.6 = 100.0% (100.0%, 100.0%)	1486.6/1486.6 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	98	1486.6/1486.6 = 100.0% (100.0%, 100.0%)	1486.6/1486.6 = 100.0% (100.0%, 100.0%)	1486.6/1486.6 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	98	1486.6/1486.6 = 100.0% (100.0%, 100.0%)	1486.6/1486.6 = 100.0% (100.0%, 100.0%)	1486.6/1486.6 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	39	198.1/198.1 = 100.0% (100.0%, 100.0%)	198.1/198.1 = 100.0% (100.0%, 100.0%)	198.1/198.1 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	39	198.1/198.1 = 100.0% (100.0%, 100.0%)	198.1/198.1 = 100.0% (100.0%, 100.0%)	198.1/198.1 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	39	198.1/198.1 = 100.0% (100.0%, 100.0%)	198.1/198.1 = 100.0% (100.0%, 100.0%)	198.1/198.1 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	18	0/1937.9 = 0.0% (0.0%, 0.0%)	0/1937.9 = 0.0% (0.0%, 0.0%)	0/1937.9 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	18	0/1937.9 = 0.0% (0.0%, 0.0%)	0/1937.9 = 0.0% (0.0%, 0.0%)	0/1937.9 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	18	0/1937.9 = 0.0% (0.0%, 0.0%)	0/1937.9 = 0.0% (0.0%, 0.0%)	0/1937.9 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	25	119.8/119.8 = 100.0% (100.0%, 100.0%)	119.8/119.8 = 100.0% (100.0%, 100.0%)	119.8/119.8 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	25	119.8/119.8 = 100.0% (100.0%, 100.0%)	119.8/119.8 = 100.0% (100.0%, 100.0%)	119.8/119.8 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not reported and unknown	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	25	119.8/119.8 = 100.0% (100.0%, 100.0%)	119.8/119.8 = 100.0% (100.0%, 100.0%)	119.8/119.8 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.




Table 3h. Percentage of responders, and participants with concentrations $\geq 2 \times$ LLOD or $\geq 4 \times$ LLOD for binding antibody markers by Race

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
Race								
White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	355	6572.1/6572.1 = 100.0% (100.0%, 100.0%)	6572.1/6572.1 = 100.0% (100.0%, 100.0%)	6572.1/6572.1 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	355	6572.1/6572.1 = 100.0% (100.0%, 100.0%)	6572.1/6572.1 = 100.0% (100.0%, 100.0%)	6572.1/6572.1 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	355	6572.1/6572.1 = 100.0% (100.0%, 100.0%)	6572.1/6572.1 = 100.0% (100.0%, 100.0%)	6572.1/6572.1 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	121	681.2/681.2 = 100.0% (100.0%, 100.0%)	681.2/681.2 = 100.0% (100.0%, 100.0%)	681.2/681.2 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	121	681.2/681.2 = 100.0% (100.0%, 100.0%)	681.2/681.2 = 100.0% (100.0%, 100.0%)	681.2/681.2 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	121	681.2/681.2 = 100.0% (100.0%, 100.0%)	681.2/681.2 = 100.0% (100.0%, 100.0%)	681.2/681.2 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	64	0/5953.5 = 0.0% (0.0%, 0.0%)	0/5953.5 = 0.0% (0.0%, 0.0%)	0/5953.5 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	64	0/5953.5 = 0.0% (0.0%, 0.0%)	0/5953.5 = 0.0% (0.0%, 0.0%)	0/5953.5 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	64	0/5953.5 = 0.0% (0.0%, 0.0%)	0/5953.5 = 0.0% (0.0%, 0.0%)	0/5953.5 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	116	726.6/726.6 = 100.0% (100.0%, 100.0%)	726.6/726.6 = 100.0% (100.0%, 100.0%)	726.6/726.6 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	116	726.6/726.6 = 100.0% (100.0%, 100.0%)	726.6/726.6 = 100.0% (100.0%, 100.0%)	726.6/726.6 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	116	726.6/726.6 = 100.0% (100.0%, 100.0%)	726.6/726.6 = 100.0% (100.0%, 100.0%)	726.6/726.6 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	355	6572.1/6572.1 = 100.0% (100.0%, 100.0%)	6572.1/6572.1 = 100.0% (100.0%, 100.0%)	6572.1/6572.1 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	355	6572.1/6572.1 = 100.0% (100.0%, 100.0%)	6572.1/6572.1 = 100.0% (100.0%, 100.0%)	6572.1/6572.1 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	355	6572.1/6572.1 = 100.0% (100.0%, 100.0%)	6572.1/6572.1 = 100.0% (100.0%, 100.0%)	6572.1/6572.1 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	121	681.2/681.2 = 100.0% (100.0%, 100.0%)	681.2/681.2 = 100.0% (100.0%, 100.0%)	681.2/681.2 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	121	681.2/681.2 = 100.0% (100.0%, 100.0%)	681.2/681.2 = 100.0% (100.0%, 100.0%)	681.2/681.2 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	121	681.2/681.2 = 100.0% (100.0%, 100.0%)	681.2/681.2 = 100.0% (100.0%, 100.0%)	681.2/681.2 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	64	0/5953.5 = 0.0% (0.0%, 0.0%)	0/5953.5 = 0.0% (0.0%, 0.0%)	0/5953.5 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	64	93.6/5953.5 = 1.6% (0.4%, 6.2%)	93.6/5953.5 = 1.6% (0.4%, 6.2%)	46.8/5953.5 = 0.8% (0.1%, 5.6%)
White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	64	0/5953.5 = 0.0% (0.0%, 0.0%)	0/5953.5 = 0.0% (0.0%, 0.0%)	0/5953.5 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	116	726.6/726.6 = 100.0% (100.0%, 100.0%)	726.6/726.6 = 100.0% (100.0%, 100.0%)	726.6/726.6 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	116	726.6/726.6 = 100.0% (100.0%, 100.0%)	726.6/726.6 = 100.0% (100.0%, 100.0%)	726.6/726.6 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	116	726.6/726.6 = 100.0% (100.0%, 100.0%)	726.6/726.6 = 100.0% (100.0%, 100.0%)	726.6/726.6 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	205	2138.3/2138.3 = 100.0% (100.0%, 100.0%)	2138.3/2138.3 = 100.0% (100.0%, 100.0%)	2138.3/2138.3 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	205	2138.3/2138.3 = 100.0% (100.0%, 100.0%)	2138.3/2138.3 = 100.0% (100.0%, 100.0%)	2138.3/2138.3 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	205	2138.3/2138.3 = 100.0% (100.0%, 100.0%)	2138.3/2138.3 = 100.0% (100.0%, 100.0%)	2138.3/2138.3 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	61	279.9/279.9 = 100.0% (100.0%, 100.0%)	279.9/279.9 = 100.0% (100.0%, 100.0%)	279.9/279.9 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	61	279.9/279.9 = 100.0% (100.0%, 100.0%)	279.9/279.9 = 100.0% (100.0%, 100.0%)	279.9/279.9 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	61	279.9/279.9 = 100.0% (100.0%, 100.0%)	279.9/279.9 = 100.0% (100.0%, 100.0%)	279.9/279.9 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	25	0/1926.2 = 0.0% (0.0%, 0.0%)	0/1926.2 = 0.0% (0.0%, 0.0%)	0/1926.2 = 0.0% (0.0%, 0.0%)
Black or African American	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	25	0/1926.2 = 0.0% (0.0%, 0.0%)	0/1926.2 = 0.0% (0.0%, 0.0%)	0/1926.2 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Black or African American	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	25	88.8/1926.2 = 4.6% (1.0%, 19.6%)	0/1926.2 = 0.0% (0.0%, 0.0%)	0/1926.2 = 0.0% (0.0%, 0.0%)
Black or African American	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	48	170.3/170.3 = 100.0% (100.0%, 100.0%)	170.3/170.3 = 100.0% (100.0%, 100.0%)	170.3/170.3 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	48	170.3/170.3 = 100.0% (100.0%, 100.0%)	170.3/170.3 = 100.0% (100.0%, 100.0%)	170.3/170.3 = 100.0% (100.0%, 100.0%)
Black or African American	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	48	170.3/170.3 = 100.0% (100.0%, 100.0%)	170.3/170.3 = 100.0% (100.0%, 100.0%)	170.3/170.3 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	205	2138.3/2138.3 = 100.0% (100.0%, 100.0%)	2138.3/2138.3 = 100.0% (100.0%, 100.0%)	2138.3/2138.3 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	205	2138.3/2138.3 = 100.0% (100.0%, 100.0%)	2138.3/2138.3 = 100.0% (100.0%, 100.0%)	2138.3/2138.3 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	205	2138.3/2138.3 = 100.0% (100.0%, 100.0%)	2138.3/2138.3 = 100.0% (100.0%, 100.0%)	2138.3/2138.3 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	61	279.9/279.9 = 100.0% (100.0%, 100.0%)	279.9/279.9 = 100.0% (100.0%, 100.0%)	279.9/279.9 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	61	279.9/279.9 = 100.0% (100.0%, 100.0%)	279.9/279.9 = 100.0% (100.0%, 100.0%)	279.9/279.9 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Black or African American	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	61	279.9/279.9 = 100.0% (100.0%, 100.0%)	279.9/279.9 = 100.0% (100.0%, 100.0%)	279.9/279.9 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	25	0/1926.2 = 0.0% (0.0%, 0.0%)	0/1926.2 = 0.0% (0.0%, 0.0%)	0/1926.2 = 0.0% (0.0%, 0.0%)
Black or African American	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	25	0/1926.2 = 0.0% (0.0%, 0.0%)	0/1926.2 = 0.0% (0.0%, 0.0%)	0/1926.2 = 0.0% (0.0%, 0.0%)
Black or African American	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	25	0/1926.2 = 0.0% (0.0%, 0.0%)	0/1926.2 = 0.0% (0.0%, 0.0%)	0/1926.2 = 0.0% (0.0%, 0.0%)
Black or African American	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	48	170.3/170.3 = 100.0% (100.0%, 100.0%)	170.3/170.3 = 100.0% (100.0%, 100.0%)	170.3/170.3 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	48	170.3/170.3 = 100.0% (100.0%, 100.0%)	170.3/170.3 = 100.0% (100.0%, 100.0%)	170.3/170.3 = 100.0% (100.0%, 100.0%)
Black or African American	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	48	170.3/170.3 = 100.0% (100.0%, 100.0%)	170.3/170.3 = 100.0% (100.0%, 100.0%)	170.3/170.3 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	57	653.6/653.6 = 100.0% (100.0%, 100.0%)	653.6/653.6 = 100.0% (100.0%, 100.0%)	653.6/653.6 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	57	653.6/653.6 = 100.0% (100.0%, 100.0%)	653.6/653.6 = 100.0% (100.0%, 100.0%)	653.6/653.6 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	57	653.6/653.6 = 100.0% (100.0%, 100.0%)	653.6/653.6 = 100.0% (100.0%, 100.0%)	653.6/653.6 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Asian	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	18	60.4/60.4 = 100.0% (100.0%, 100.0%)	60.4/60.4 = 100.0% (100.0%, 100.0%)	60.4/60.4 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	18	60.4/60.4 = 100.0% (100.0%, 100.0%)	60.4/60.4 = 100.0% (100.0%, 100.0%)	60.4/60.4 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	18	60.4/60.4 = 100.0% (100.0%, 100.0%)	60.4/60.4 = 100.0% (100.0%, 100.0%)	60.4/60.4 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	12	0/804.7 = 0.0% (0.0%, 0.0%)	0/804.7 = 0.0% (0.0%, 0.0%)	0/804.7 = 0.0% (0.0%, 0.0%)
Asian	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	12	0/804.7 = 0.0% (0.0%, 0.0%)	0/804.7 = 0.0% (0.0%, 0.0%)	0/804.7 = 0.0% (0.0%, 0.0%)
Asian	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	12	0/804.7 = 0.0% (0.0%, 0.0%)	0/804.7 = 0.0% (0.0%, 0.0%)	0/804.7 = 0.0% (0.0%, 0.0%)
Asian	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	16	58.7/58.7 = 100.0% (100.0%, 100.0%)	58.7/58.7 = 100.0% (100.0%, 100.0%)	58.7/58.7 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	16	58.7/58.7 = 100.0% (100.0%, 100.0%)	58.7/58.7 = 100.0% (100.0%, 100.0%)	58.7/58.7 = 100.0% (100.0%, 100.0%)
Asian	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	16	58.7/58.7 = 100.0% (100.0%, 100.0%)	58.7/58.7 = 100.0% (100.0%, 100.0%)	58.7/58.7 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	57	653.6/653.6 = 100.0% (100.0%, 100.0%)	653.6/653.6 = 100.0% (100.0%, 100.0%)	653.6/653.6 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	57	653.6/653.6 = 100.0% (100.0%, 100.0%)	653.6/653.6 = 100.0% (100.0%, 100.0%)	653.6/653.6 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	57	653.6/653.6 = 100.0% (100.0%, 100.0%)	653.6/653.6 = 100.0% (100.0%, 100.0%)	653.6/653.6 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	18	60.4/60.4 = 100.0% (100.0%, 100.0%)	60.4/60.4 = 100.0% (100.0%, 100.0%)	60.4/60.4 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	18	60.4/60.4 = 100.0% (100.0%, 100.0%)	60.4/60.4 = 100.0% (100.0%, 100.0%)	60.4/60.4 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	18	60.4/60.4 = 100.0% (100.0%, 100.0%)	60.4/60.4 = 100.0% (100.0%, 100.0%)	60.4/60.4 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Asian	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	12	0/804.7 = 0.0% (0.0%, 0.0%)	0/804.7 = 0.0% (0.0%, 0.0%)	0/804.7 = 0.0% (0.0%, 0.0%)
Asian	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	12	0/804.7 = 0.0% (0.0%, 0.0%)	0/804.7 = 0.0% (0.0%, 0.0%)	0/804.7 = 0.0% (0.0%, 0.0%)
Asian	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	12	0/804.7 = 0.0% (0.0%, 0.0%)	0/804.7 = 0.0% (0.0%, 0.0%)	0/804.7 = 0.0% (0.0%, 0.0%)
Asian	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	16	58.7/58.7 = 100.0% (100.0%, 100.0%)	58.7/58.7 = 100.0% (100.0%, 100.0%)	58.7/58.7 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	16	58.7/58.7 = 100.0% (100.0%, 100.0%)	58.7/58.7 = 100.0% (100.0%, 100.0%)	58.7/58.7 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	16	58.7/58.7 = 100.0% (100.0%, 100.0%)	58.7/58.7 = 100.0% (100.0%, 100.0%)	58.7/58.7 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	22	173.5/173.5 = 100.0% (100.0%, 100.0%)	173.5/173.5 = 100.0% (100.0%, 100.0%)	173.5/173.5 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	22	173.5/173.5 = 100.0% (100.0%, 100.0%)	173.5/173.5 = 100.0% (100.0%, 100.0%)	173.5/173.5 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	22	173.5/173.5 = 100.0% (100.0%, 100.0%)	173.5/173.5 = 100.0% (100.0%, 100.0%)	173.5/173.5 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	8	17.3/17.3 = 100.0% (100.0%, 100.0%)	17.3/17.3 = 100.0% (100.0%, 100.0%)	17.3/17.3 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	8	17.3/17.3 = 100.0% (100.0%, 100.0%)	17.3/17.3 = 100.0% (100.0%, 100.0%)	17.3/17.3 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
American Indian or Alaska Native	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	8	17.3/17.3 = 100.0% (100.0%, 100.0%)	17.3/17.3 = 100.0% (100.0%, 100.0%)	17.3/17.3 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	7	0/267.7 = 0.0% (0.0%, 0.0%)	0/267.7 = 0.0% (0.0%, 0.0%)	0/267.7 = 0.0% (0.0%, 0.0%)
American Indian or Alaska Native	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	7	0/267.7 = 0.0% (0.0%, 0.0%)	0/267.7 = 0.0% (0.0%, 0.0%)	0/267.7 = 0.0% (0.0%, 0.0%)
American Indian or Alaska Native	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	7	0/267.7 = 0.0% (0.0%, 0.0%)	0/267.7 = 0.0% (0.0%, 0.0%)	0/267.7 = 0.0% (0.0%, 0.0%)
American Indian or Alaska Native	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	8	20.6/20.6 = 100.0% (100.0%, 100.0%)	20.6/20.6 = 100.0% (100.0%, 100.0%)	20.6/20.6 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	8	20.6/20.6 = 100.0% (100.0%, 100.0%)	20.6/20.6 = 100.0% (100.0%, 100.0%)	20.6/20.6 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	8	20.6/20.6 = 100.0% (100.0%, 100.0%)	20.6/20.6 = 100.0% (100.0%, 100.0%)	20.6/20.6 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	22	173.5/173.5 = 100.0% (100.0%, 100.0%)	173.5/173.5 = 100.0% (100.0%, 100.0%)	173.5/173.5 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	22	173.5/173.5 = 100.0% (100.0%, 100.0%)	173.5/173.5 = 100.0% (100.0%, 100.0%)	173.5/173.5 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
American Indian or Alaska Native	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	22	173.5/173.5 = 100.0% (100.0%, 100.0%)	173.5/173.5 = 100.0% (100.0%, 100.0%)	173.5/173.5 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	8	17.3/17.3 = 100.0% (100.0%, 100.0%)	17.3/17.3 = 100.0% (100.0%, 100.0%)	17.3/17.3 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	8	17.3/17.3 = 100.0% (100.0%, 100.0%)	17.3/17.3 = 100.0% (100.0%, 100.0%)	17.3/17.3 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	8	17.3/17.3 = 100.0% (100.0%, 100.0%)	17.3/17.3 = 100.0% (100.0%, 100.0%)	17.3/17.3 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	7	0/267.7 = 0.0% (0.0%, 0.0%)	0/267.7 = 0.0% (0.0%, 0.0%)	0/267.7 = 0.0% (0.0%, 0.0%)
American Indian or Alaska Native	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	7	0/267.7 = 0.0% (0.0%, 0.0%)	0/267.7 = 0.0% (0.0%, 0.0%)	0/267.7 = 0.0% (0.0%, 0.0%)
American Indian or Alaska Native	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	7	0/267.7 = 0.0% (0.0%, 0.0%)	0/267.7 = 0.0% (0.0%, 0.0%)	0/267.7 = 0.0% (0.0%, 0.0%)
American Indian or Alaska Native	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	8	20.6/20.6 = 100.0% (100.0%, 100.0%)	20.6/20.6 = 100.0% (100.0%, 100.0%)	20.6/20.6 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	8	20.6/20.6 = 100.0% (100.0%, 100.0%)	20.6/20.6 = 100.0% (100.0%, 100.0%)	20.6/20.6 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
American Indian or Alaska Native	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	8	20.6/20.6 = 100.0% (100.0%, 100.0%)	20.6/20.6 = 100.0% (100.0%, 100.0%)	20.6/20.6 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	17	150/150 = 100.0% (100.0%, 100.0%)	150/150 = 100.0% (100.0%, 100.0%)	150/150 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	17	150/150 = 100.0% (100.0%, 100.0%)	150/150 = 100.0% (100.0%, 100.0%)	150/150 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	17	150/150 = 100.0% (100.0%, 100.0%)	150/150 = 100.0% (100.0%, 100.0%)	150/150 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	3	6.1/6.1 = 100.0%	6.1/6.1 = 100.0%	6.1/6.1 = 100.0%
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	3	6.1/6.1 = 100.0%	6.1/6.1 = 100.0%	6.1/6.1 = 100.0%
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	3	6.1/6.1 = 100.0%	6.1/6.1 = 100.0%	6.1/6.1 = 100.0%

The diagram illustrates the data from the table using arrows and circles. Arrows point from the 'N' values in the table to the corresponding 'Responder' percentages. Circles highlight specific data points: one circle surrounds the 'Anti Spike IgG (IU/ml)' row for Day 29, Vaccine, Negative; another circle surrounds the 'Anti N IgG (IU/ml)' row for Day 29, Vaccine, Positive; and a third circle surrounds the 'Anti RBD IgG (IU/ml)' row for Day 29, Vaccine, Negative. Arrows also point from these circled rows to their respective 'Responder' percentages.

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	1	0/30 = 0.0%	0/30 = 0.0%	0/30 = 0.0%
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	1	0/30 = 0.0%	0/30 = 0.0%	0/30 = 0.0%
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	1	0/30 = 0.0%	0/30 = 0.0%	0/30 = 0.0%
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	7	42/42 = 100.0% (100.0%, 100.0%)	42/42 = 100.0% (100.0%, 100.0%)	42/42 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	7	42/42 = 100.0% (100.0%, 100.0%)	42/42 = 100.0% (100.0%, 100.0%)	42/42 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	7	42/42 = 100.0% (100.0%, 100.0%)	42/42 = 100.0% (100.0%, 100.0%)	42/42 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	17	150/150 = 100.0% (100.0%, 100.0%)	150/150 = 100.0% (100.0%, 100.0%)	150/150 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	17	150/150 = 100.0% (100.0%, 100.0%)	150/150 = 100.0% (100.0%, 100.0%)	150/150 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	17	150/150 = 100.0% (100.0%, 100.0%)	150/150 = 100.0% (100.0%, 100.0%)	150/150 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	3	6.1/6.1 = 100.0%	6.1/6.1 = 100.0%	6.1/6.1 = 100.0%
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	3	6.1/6.1 = 100.0%	6.1/6.1 = 100.0%	6.1/6.1 = 100.0%
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	3	6.1/6.1 = 100.0%	6.1/6.1 = 100.0%	6.1/6.1 = 100.0%
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	1	0/30 = 0.0%	0/30 = 0.0%	0/30 = 0.0%
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	1	0/30 = 0.0%	0/30 = 0.0%	0/30 = 0.0%

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	1	0/30 = 0.0%	0/30 = 0.0%	0/30 = 0.0%
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	7	42/42 = 100.0% (100.0%, 100.0%)	42/42 = 100.0% (100.0%, 100.0%)	42/42 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	7	42/42 = 100.0% (100.0%, 100.0%)	42/42 = 100.0% (100.0%, 100.0%)	42/42 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	7	42/42 = 100.0% (100.0%, 100.0%)	42/42 = 100.0% (100.0%, 100.0%)	42/42 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	54	490.2/490.2 = 100.0% (100.0%, 100.0%)	490.2/490.2 = 100.0% (100.0%, 100.0%)	490.2/490.2 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	54	490.2/490.2 = 100.0% (100.0%, 100.0%)	490.2/490.2 = 100.0% (100.0%, 100.0%)	490.2/490.2 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	54	490.2/490.2 = 100.0% (100.0%, 100.0%)	490.2/490.2 = 100.0% (100.0%, 100.0%)	490.2/490.2 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	15	82.9/82.9 = 100.0% (100.0%, 100.0%)	82.9/82.9 = 100.0% (100.0%, 100.0%)	82.9/82.9 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	15	82.9/82.9 = 100.0% (100.0%, 100.0%)	82.9/82.9 = 100.0% (100.0%, 100.0%)	82.9/82.9 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	15	82.9/82.9 = 100.0% (100.0%, 100.0%)	82.9/82.9 = 100.0% (100.0%, 100.0%)	82.9/82.9 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	11	0/932.4 = 0.0% (0.0%, 0.0%)	0/932.4 = 0.0% (0.0%, 0.0%)	0/932.4 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Multiracial	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	11	0/932.4 = 0.0% (0.0%, 0.0%)	0/932.4 = 0.0% (0.0%, 0.0%)	0/932.4 = 0.0% (0.0%, 0.0%)
Multiracial	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	11	0/932.4 = 0.0% (0.0%, 0.0%)	0/932.4 = 0.0% (0.0%, 0.0%)	0/932.4 = 0.0% (0.0%, 0.0%)
Multiracial	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	22	69.8/69.8 = 100.0% (100.0%, 100.0%)	69.8/69.8 = 100.0% (100.0%, 100.0%)	69.8/69.8 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	22	69.8/69.8 = 100.0% (100.0%, 100.0%)	69.8/69.8 = 100.0% (100.0%, 100.0%)	69.8/69.8 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	22	69.8/69.8 = 100.0% (100.0%, 100.0%)	69.8/69.8 = 100.0% (100.0%, 100.0%)	69.8/69.8 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	54	490.2/490.2 = 100.0% (100.0%, 100.0%)	490.2/490.2 = 100.0% (100.0%, 100.0%)	490.2/490.2 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	54	490.2/490.2 = 100.0% (100.0%, 100.0%)	490.2/490.2 = 100.0% (100.0%, 100.0%)	490.2/490.2 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	54	490.2/490.2 = 100.0% (100.0%, 100.0%)	490.2/490.2 = 100.0% (100.0%, 100.0%)	490.2/490.2 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	15	82.9/82.9 = 100.0% (100.0%, 100.0%)	82.9/82.9 = 100.0% (100.0%, 100.0%)	82.9/82.9 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	15	82.9/82.9 = 100.0% (100.0%, 100.0%)	82.9/82.9 = 100.0% (100.0%, 100.0%)	82.9/82.9 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	15	82.9/82.9 = 100.0% (100.0%, 100.0%)	82.9/82.9 = 100.0% (100.0%, 100.0%)	82.9/82.9 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	11	0/932.4 = 0.0% (0.0%, 0.0%)	0/932.4 = 0.0% (0.0%, 0.0%)	0/932.4 = 0.0% (0.0%, 0.0%)
Multiracial	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	11	0/932.4 = 0.0% (0.0%, 0.0%)	0/932.4 = 0.0% (0.0%, 0.0%)	0/932.4 = 0.0% (0.0%, 0.0%)
Multiracial	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	11	0/932.4 = 0.0% (0.0%, 0.0%)	0/932.4 = 0.0% (0.0%, 0.0%)	0/932.4 = 0.0% (0.0%, 0.0%)
Multiracial	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	22	69.8/69.8 = 100.0% (100.0%, 100.0%)	69.8/69.8 = 100.0% (100.0%, 100.0%)	69.8/69.8 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Multiracial	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	22	69.8/69.8 = 100.0% (100.0%, 100.0%)	69.8/69.8 = 100.0% (100.0%, 100.0%)	69.8/69.8 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	22	69.8/69.8 = 100.0% (100.0%, 100.0%)	69.8/69.8 = 100.0% (100.0%, 100.0%)	69.8/69.8 = 100.0% (100.0%, 100.0%)
Other	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	21	212.6/212.6 = 100.0% (100.0%, 100.0%)	212.6/212.6 = 100.0% (100.0%, 100.0%)	212.6/212.6 = 100.0% (100.0%, 100.0%)
Other	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	21	212.6/212.6 = 100.0% (100.0%, 100.0%)	212.6/212.6 = 100.0% (100.0%, 100.0%)	212.6/212.6 = 100.0% (100.0%, 100.0%)
Other	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	21	212.6/212.6 = 100.0% (100.0%, 100.0%)	212.6/212.6 = 100.0% (100.0%, 100.0%)	212.6/212.6 = 100.0% (100.0%, 100.0%)
Other	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	1	2.5/2.5 = 100.0%	2.5/2.5 = 100.0%	2.5/2.5 = 100.0%
Other	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	1	2.5/2.5 = 100.0%	2.5/2.5 = 100.0%	2.5/2.5 = 100.0%
Other	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	1	2.5/2.5 = 100.0%	2.5/2.5 = 100.0%	2.5/2.5 = 100.0%
Other	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	4	0/277.8 = 0.0%	0/277.8 = 0.0%	0/277.8 = 0.0%
Other	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0/277.8 = 0.0%	0/277.8 = 0.0%	0/277.8 = 0.0%
Other	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0/277.8 = 0.0%	0/277.8 = 0.0%	0/277.8 = 0.0%
Other	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	9	22.8/22.8 = 100.0% (100.0%, 100.0%)	22.8/22.8 = 100.0% (100.0%, 100.0%)	22.8/22.8 = 100.0% (100.0%, 100.0%)
Other	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	9	22.8/22.8 = 100.0% (100.0%, 100.0%)	22.8/22.8 = 100.0% (100.0%, 100.0%)	22.8/22.8 = 100.0% (100.0%, 100.0%)
Other	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	9	22.8/22.8 = 100.0% (100.0%, 100.0%)	22.8/22.8 = 100.0% (100.0%, 100.0%)	22.8/22.8 = 100.0% (100.0%, 100.0%)
Other	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	21	212.6/212.6 = 100.0% (100.0%, 100.0%)	212.6/212.6 = 100.0% (100.0%, 100.0%)	212.6/212.6 = 100.0% (100.0%, 100.0%)
Other	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	21	212.6/212.6 = 100.0% (100.0%, 100.0%)	212.6/212.6 = 100.0% (100.0%, 100.0%)	212.6/212.6 = 100.0% (100.0%, 100.0%)
Other	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	21	212.6/212.6 = 100.0% (100.0%, 100.0%)	212.6/212.6 = 100.0% (100.0%, 100.0%)	212.6/212.6 = 100.0% (100.0%, 100.0%)
Other	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	1	2.5/2.5 = 100.0%	2.5/2.5 = 100.0%	2.5/2.5 = 100.0%
Other	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	1	2.5/2.5 = 100.0%	2.5/2.5 = 100.0%	2.5/2.5 = 100.0%
Other	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	1	2.5/2.5 = 100.0%	2.5/2.5 = 100.0%	2.5/2.5 = 100.0%

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Other	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	4	0/277.8 = 0.0%	0/277.8 = 0.0%	0/277.8 = 0.0%
Other	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0/277.8 = 0.0%	0/277.8 = 0.0%	0/277.8 = 0.0%
Other	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0/277.8 = 0.0%	0/277.8 = 0.0%	0/277.8 = 0.0%
Other	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	9	22.8/22.8 = 100.0% (100.0%, 100.0%)	22.8/22.8 = 100.0% (100.0%, 100.0%)	22.8/22.8 = 100.0% (100.0%, 100.0%)
Other	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	9	22.8/22.8 = 100.0% (100.0%, 100.0%)	22.8/22.8 = 100.0% (100.0%, 100.0%)	22.8/22.8 = 100.0% (100.0%, 100.0%)
Other	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	9	22.8/22.8 = 100.0% (100.0%, 100.0%)	22.8/22.8 = 100.0% (100.0%, 100.0%)	22.8/22.8 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	85	1467.7/1467.7 = 100.0% (100.0%, 100.0%)	1467.7/1467.7 = 100.0% (100.0%, 100.0%)	1467.7/1467.7 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	85	1467.7/1467.7 = 100.0% (100.0%, 100.0%)	1467.7/1467.7 = 100.0% (100.0%, 100.0%)	1467.7/1467.7 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	85	1467.7/1467.7 = 100.0% (100.0%, 100.0%)	1467.7/1467.7 = 100.0% (100.0%, 100.0%)	1467.7/1467.7 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	22	149.8/149.8 = 100.0% (100.0%, 100.0%)	149.8/149.8 = 100.0% (100.0%, 100.0%)	149.8/149.8 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	22	149.8/149.8 = 100.0% (100.0%, 100.0%)	149.8/149.8 = 100.0% (100.0%, 100.0%)	149.8/149.8 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	22	149.8/149.8 = 100.0% (100.0%, 100.0%)	149.8/149.8 = 100.0% (100.0%, 100.0%)	149.8/149.8 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	18	0/1631.3 = 0.0% (0.0%, 0.0%)	0/1631.3 = 0.0% (0.0%, 0.0%)	0/1631.3 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	18	0/1631.3 = 0.0% (0.0%, 0.0%)	0/1631.3 = 0.0% (0.0%, 0.0%)	0/1631.3 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	18	0/1631.3 = 0.0% (0.0%, 0.0%)	0/1631.3 = 0.0% (0.0%, 0.0%)	0/1631.3 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not reported and unknown	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	23	129/129 = 100.0% (100.0%, 100.0%)	129/129 = 100.0% (100.0%, 100.0%)	129/129 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	23	129/129 = 100.0% (100.0%, 100.0%)	129/129 = 100.0% (100.0%, 100.0%)	129/129 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	23	129/129 = 100.0% (100.0%, 100.0%)	129/129 = 100.0% (100.0%, 100.0%)	129/129 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	85	1467.7/1467.7 = 100.0% (100.0%, 100.0%)	1467.7/1467.7 = 100.0% (100.0%, 100.0%)	1467.7/1467.7 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	85	1467.7/1467.7 = 100.0% (100.0%, 100.0%)	1467.7/1467.7 = 100.0% (100.0%, 100.0%)	1467.7/1467.7 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	85	1467.7/1467.7 = 100.0% (100.0%, 100.0%)	1467.7/1467.7 = 100.0% (100.0%, 100.0%)	1467.7/1467.7 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	22	149.8/149.8 = 100.0% (100.0%, 100.0%)	149.8/149.8 = 100.0% (100.0%, 100.0%)	149.8/149.8 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	22	149.8/149.8 = 100.0% (100.0%, 100.0%)	149.8/149.8 = 100.0% (100.0%, 100.0%)	149.8/149.8 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	22	149.8/149.8 = 100.0% (100.0%, 100.0%)	149.8/149.8 = 100.0% (100.0%, 100.0%)	149.8/149.8 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	18	0/1631.3 = 0.0% (0.0%, 0.0%)	0/1631.3 = 0.0% (0.0%, 0.0%)	0/1631.3 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	18	46.8/1631.3 = 2.9% (0.3%, 21.7%)	46.8/1631.3 = 2.9% (0.3%, 21.7%)	0/1631.3 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	18	0/1631.3 = 0.0% (0.0%, 0.0%)	0/1631.3 = 0.0% (0.0%, 0.0%)	0/1631.3 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Not reported and unknown	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	23	129/129 = 100.0% (100.0%, 100.0%)	129/129 = 100.0% (100.0%, 100.0%)	129/129 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	23	129/129 = 100.0% (100.0%, 100.0%)	129/129 = 100.0% (100.0%, 100.0%)	129/129 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	23	129/129 = 100.0% (100.0%, 100.0%)	129/129 = 100.0% (100.0%, 100.0%)	129/129 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3i. Percentage of responders, and participants with concentrations $\geq 2 \times$ LLOD or $\geq 4 \times$ LLOD for binding antibody markers by Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
Underrepresented minority status								
Communities of Color	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	424	4327/4327 = 100.0% (100.0%, 100.0%)	4327/4327 = 100.0% (100.0%, 100.0%)	4327/4327 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	424	4327/4327 = 100.0% (100.0%, 100.0%)	4327/4327 = 100.0% (100.0%, 100.0%)	4327/4327 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	424	4327/4327 = 100.0% (100.0%, 100.0%)	4327/4327 = 100.0% (100.0%, 100.0%)	4327/4327 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	120	500/500 = 100.0% (100.0%, 100.0%)	500/500 = 100.0% (100.0%, 100.0%)	500/500 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	120	500/500 = 100.0% (100.0%, 100.0%)	500/500 = 100.0% (100.0%, 100.0%)	500/500 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	120	500/500 = 100.0% (100.0%, 100.0%)	500/500 = 100.0% (100.0%, 100.0%)	500/500 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	63	0/4329 = 0.0% (0.0%, 0.0%)	0/4329 = 0.0% (0.0%, 0.0%)	0/4329 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	63	0/4329 = 0.0% (0.0%, 0.0%)	0/4329 = 0.0% (0.0%, 0.0%)	0/4329 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	63	88.8/4329 = 2.1% (0.5%, 8.7%)	0/4329 = 0.0% (0.0%, 0.0%)	0/4329 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	124	427/427 = 100.0% (100.0%, 100.0%)	427/427 = 100.0% (100.0%, 100.0%)	427/427 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	124	427/427 = 100.0% (100.0%, 100.0%)	427/427 = 100.0% (100.0%, 100.0%)	427/427 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Communities of Color	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	124	427/427 = 100.0% (100.0%, 100.0%)	427/427 = 100.0% (100.0%, 100.0%)	427/427 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	424	4327/4327 = 100.0% (100.0%, 100.0%)	4327/4327 = 100.0% (100.0%, 100.0%)	4327/4327 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	424	4327/4327 = 100.0% (100.0%, 100.0%)	4327/4327 = 100.0% (100.0%, 100.0%)	4327/4327 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	424	4327/4327 = 100.0% (100.0%, 100.0%)	4327/4327 = 100.0% (100.0%, 100.0%)	4327/4327 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	120	500/500 = 100.0% (100.0%, 100.0%)	500/500 = 100.0% (100.0%, 100.0%)	500/500 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	120	500/500 = 100.0% (100.0%, 100.0%)	500/500 = 100.0% (100.0%, 100.0%)	500/500 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	120	500/500 = 100.0% (100.0%, 100.0%)	500/500 = 100.0% (100.0%, 100.0%)	500/500 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	63	0/4329 = 0.0% (0.0%, 0.0%)	0/4329 = 0.0% (0.0%, 0.0%)	0/4329 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	63	0/4329 = 0.0% (0.0%, 0.0%)	0/4329 = 0.0% (0.0%, 0.0%)	0/4329 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	63	0/4329 = 0.0% (0.0%, 0.0%)	0/4329 = 0.0% (0.0%, 0.0%)	0/4329 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	124	427/427 = 100.0% (100.0%, 100.0%)	427/427 = 100.0% (100.0%, 100.0%)	427/427 = 100.0% (100.0%, 100.0%)
Communities of Color	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	124	427/427 = 100.0% (100.0%, 100.0%)	427/427 = 100.0% (100.0%, 100.0%)	427/427 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Communities of Color	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	124	427/427 = 100.0% (100.0%, 100.0%)	427/427 = 100.0% (100.0%, 100.0%)	427/427 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	355	6572.1/6572.1 = 100.0% (100.0%, 100.0%)	6572.1/6572.1 = 100.0% (100.0%, 100.0%)	6572.1/6572.1 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	355	6572.1/6572.1 = 100.0% (100.0%, 100.0%)	6572.1/6572.1 = 100.0% (100.0%, 100.0%)	6572.1/6572.1 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	355	6572.1/6572.1 = 100.0% (100.0%, 100.0%)	6572.1/6572.1 = 100.0% (100.0%, 100.0%)	6572.1/6572.1 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	121	681.2/681.2 = 100.0% (100.0%, 100.0%)	681.2/681.2 = 100.0% (100.0%, 100.0%)	681.2/681.2 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	121	681.2/681.2 = 100.0% (100.0%, 100.0%)	681.2/681.2 = 100.0% (100.0%, 100.0%)	681.2/681.2 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	121	681.2/681.2 = 100.0% (100.0%, 100.0%)	681.2/681.2 = 100.0% (100.0%, 100.0%)	681.2/681.2 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	64	0/5953.5 = 0.0% (0.0%, 0.0%)	0/5953.5 = 0.0% (0.0%, 0.0%)	0/5953.5 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	64	0/5953.5 = 0.0% (0.0%, 0.0%)	0/5953.5 = 0.0% (0.0%, 0.0%)	0/5953.5 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	64	0/5953.5 = 0.0% (0.0%, 0.0%)	0/5953.5 = 0.0% (0.0%, 0.0%)	0/5953.5 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	116	726.6/726.6 = 100.0% (100.0%, 100.0%)	726.6/726.6 = 100.0% (100.0%, 100.0%)	726.6/726.6 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	116	726.6/726.6 = 100.0% (100.0%, 100.0%)	726.6/726.6 = 100.0% (100.0%, 100.0%)	726.6/726.6 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	116	726.6/726.6 = 100.0% (100.0%, 100.0%)	726.6/726.6 = 100.0% (100.0%, 100.0%)	726.6/726.6 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	355	6572.1/6572.1 = 100.0% (100.0%, 100.0%)	6572.1/6572.1 = 100.0% (100.0%, 100.0%)	6572.1/6572.1 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	355	6572.1/6572.1 = 100.0% (100.0%, 100.0%)	6572.1/6572.1 = 100.0% (100.0%, 100.0%)	6572.1/6572.1 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	355	6572.1/6572.1 = 100.0% (100.0%, 100.0%)	6572.1/6572.1 = 100.0% (100.0%, 100.0%)	6572.1/6572.1 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	121	681.2/681.2 = 100.0% (100.0%, 100.0%)	681.2/681.2 = 100.0% (100.0%, 100.0%)	681.2/681.2 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	121	681.2/681.2 = 100.0% (100.0%, 100.0%)	681.2/681.2 = 100.0% (100.0%, 100.0%)	681.2/681.2 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	121	681.2/681.2 = 100.0% (100.0%, 100.0%)	681.2/681.2 = 100.0% (100.0%, 100.0%)	681.2/681.2 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	64	0/5953.5 = 0.0% (0.0%, 0.0%)	0/5953.5 = 0.0% (0.0%, 0.0%)	0/5953.5 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	64	93.6/5953.5 = 1.6% (0.4%, 6.2%)	93.6/5953.5 = 1.6% (0.4%, 6.2%)	46.8/5953.5 = 0.8% (0.1%, 5.6%)
White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	64	0/5953.5 = 0.0% (0.0%, 0.0%)	0/5953.5 = 0.0% (0.0%, 0.0%)	0/5953.5 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	116	726.6/726.6 = 100.0% (100.0%, 100.0%)	726.6/726.6 = 100.0% (100.0%, 100.0%)	726.6/726.6 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	116	726.6/726.6 = 100.0% (100.0%, 100.0%)	726.6/726.6 = 100.0% (100.0%, 100.0%)	726.6/726.6 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	116	726.6/726.6 = 100.0% (100.0%, 100.0%)	726.6/726.6 = 100.0% (100.0%, 100.0%)	726.6/726.6 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3j. Percentage of responders, and participants with concentrations $\geq 2 \times$ LLOD or $\geq 4 \times$ LLOD for binding antibody markers by Age, Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than $2 \times$ LLOD	% Greater than $4 \times$ LLOD
Age, Underrepresented minority status								
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	203	3401/3401 = 100.0% (100.0%, 100.0%)	3401/3401 = 100.0% (100.0%, 100.0%)	3401/3401 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	203	3401/3401 = 100.0% (100.0%, 100.0%)	3401/3401 = 100.0% (100.0%, 100.0%)	3401/3401 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	203	3401/3401 = 100.0% (100.0%, 100.0%)	3401/3401 = 100.0% (100.0%, 100.0%)	3401/3401 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	66	404/404 = 100.0% (100.0%, 100.0%)	404/404 = 100.0% (100.0%, 100.0%)	404/404 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	66	404/404 = 100.0% (100.0%, 100.0%)	404/404 = 100.0% (100.0%, 100.0%)	404/404 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	66	404/404 = 100.0% (100.0%, 100.0%)	404/404 = 100.0% (100.0%, 100.0%)	404/404 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	29	0/3308 = 0.0% (0.0%, 0.0%)	0/3308 = 0.0% (0.0%, 0.0%)	0/3308 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	29	0/3308 = 0.0% (0.0%, 0.0%)	0/3308 = 0.0% (0.0%, 0.0%)	0/3308 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Communities of Color	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	29	58.8/3308 = 1.8% (0.2%, 12.7%)	0/3308 = 0.0% (0.0%, 0.0%)	0/3308 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	66	322/322 = 100.0% (100.0%, 100.0%)	322/322 = 100.0% (100.0%, 100.0%)	322/322 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	66	322/322 = 100.0% (100.0%, 100.0%)	322/322 = 100.0% (100.0%, 100.0%)	322/322 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	66	322/322 = 100.0% (100.0%, 100.0%)	322/322 = 100.0% (100.0%, 100.0%)	322/322 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	203	3401/3401 = 100.0% (100.0%, 100.0%)	3401/3401 = 100.0% (100.0%, 100.0%)	3401/3401 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	203	3401/3401 = 100.0% (100.0%, 100.0%)	3401/3401 = 100.0% (100.0%, 100.0%)	3401/3401 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	203	3401/3401 = 100.0% (100.0%, 100.0%)	3401/3401 = 100.0% (100.0%, 100.0%)	3401/3401 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	66	404/404 = 100.0% (100.0%, 100.0%)	404/404 = 100.0% (100.0%, 100.0%)	404/404 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	66	404/404 = 100.0% (100.0%, 100.0%)	404/404 = 100.0% (100.0%, 100.0%)	404/404 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	66	404/404 = 100.0% (100.0%, 100.0%)	404/404 = 100.0% (100.0%, 100.0%)	404/404 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	29	0/3308 = 0.0% (0.0%, 0.0%)	0/3308 = 0.0% (0.0%, 0.0%)	0/3308 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	29	0/3308 = 0.0% (0.0%, 0.0%)	0/3308 = 0.0% (0.0%, 0.0%)	0/3308 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	29	0/3308 = 0.0% (0.0%, 0.0%)	0/3308 = 0.0% (0.0%, 0.0%)	0/3308 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	66	322/322 = 100.0% (100.0%, 100.0%)	322/322 = 100.0% (100.0%, 100.0%)	322/322 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	66	322/322 = 100.0% (100.0%, 100.0%)	322/322 = 100.0% (100.0%, 100.0%)	322/322 = 100.0% (100.0%, 100.0%)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	66	322/322 = 100.0% (100.0%, 100.0%)	322/322 = 100.0% (100.0%, 100.0%)	322/322 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	177	5202.9/5202.9 = 100.0% (100.0%, 100.0%)	5202.9/5202.9 = 100.0% (100.0%, 100.0%)	5202.9/5202.9 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	177	5202.9/5202.9 = 100.0% (100.0%, 100.0%)	5202.9/5202.9 = 100.0% (100.0%, 100.0%)	5202.9/5202.9 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	177	5202.9/5202.9 = 100.0% (100.0%, 100.0%)	5202.9/5202.9 = 100.0% (100.0%, 100.0%)	5202.9/5202.9 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	57	529.4/529.4 = 100.0% (100.0%, 100.0%)	529.4/529.4 = 100.0% (100.0%, 100.0%)	529.4/529.4 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	57	529.4/529.4 = 100.0% (100.0%, 100.0%)	529.4/529.4 = 100.0% (100.0%, 100.0%)	529.4/529.4 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	57	529.4/529.4 = 100.0% (100.0%, 100.0%)	529.4/529.4 = 100.0% (100.0%, 100.0%)	529.4/529.4 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	31	0/4408.3 = 0.0% (0.0%, 0.0%)	0/4408.3 = 0.0% (0.0%, 0.0%)	0/4408.3 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	31	0/4408.3 = 0.0% (0.0%, 0.0%)	0/4408.3 = 0.0% (0.0%, 0.0%)	0/4408.3 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	31	0/4408.3 = 0.0% (0.0%, 0.0%)	0/4408.3 = 0.0% (0.0%, 0.0%)	0/4408.3 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	61	587.9/587.9 = 100.0% (100.0%, 100.0%)	587.9/587.9 = 100.0% (100.0%, 100.0%)	587.9/587.9 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	61	587.9/587.9 = 100.0% (100.0%, 100.0%)	587.9/587.9 = 100.0% (100.0%, 100.0%)	587.9/587.9 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	61	587.9/587.9 = 100.0% (100.0%, 100.0%)	587.9/587.9 = 100.0% (100.0%, 100.0%)	587.9/587.9 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	177	5202.9/5202.9 = 100.0% (100.0%, 100.0%)	5202.9/5202.9 = 100.0% (100.0%, 100.0%)	5202.9/5202.9 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	177	5202.9/5202.9 = 100.0% (100.0%, 100.0%)	5202.9/5202.9 = 100.0% (100.0%, 100.0%)	5202.9/5202.9 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	177	5202.9/5202.9 = 100.0% (100.0%, 100.0%)	5202.9/5202.9 = 100.0% (100.0%, 100.0%)	5202.9/5202.9 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	57	529.4/529.4 = 100.0% (100.0%, 100.0%)	529.4/529.4 = 100.0% (100.0%, 100.0%)	529.4/529.4 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	57	529.4/529.4 = 100.0% (100.0%, 100.0%)	529.4/529.4 = 100.0% (100.0%, 100.0%)	529.4/529.4 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	57	529.4/529.4 = 100.0% (100.0%, 100.0%)	529.4/529.4 = 100.0% (100.0%, 100.0%)	529.4/529.4 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	31	0/4408.3 = 0.0% (0.0%, 0.0%)	0/4408.3 = 0.0% (0.0%, 0.0%)	0/4408.3 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	31	0/4408.3 = 0.0% (0.0%, 0.0%)	0/4408.3 = 0.0% (0.0%, 0.0%)	0/4408.3 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	31	0/4408.3 = 0.0% (0.0%, 0.0%)	0/4408.3 = 0.0% (0.0%, 0.0%)	0/4408.3 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	61	587.9/587.9 = 100.0% (100.0%, 100.0%)	587.9/587.9 = 100.0% (100.0%, 100.0%)	587.9/587.9 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	61	587.9/587.9 = 100.0% (100.0%, 100.0%)	587.9/587.9 = 100.0% (100.0%, 100.0%)	587.9/587.9 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	61	587.9/587.9 = 100.0% (100.0%, 100.0%)	587.9/587.9 = 100.0% (100.0%, 100.0%)	587.9/587.9 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	221	926/926 = 100.0% (100.0%, 100.0%)	926/926 = 100.0% (100.0%, 100.0%)	926/926 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	221	926/926 = 100.0% (100.0%, 100.0%)	926/926 = 100.0% (100.0%, 100.0%)	926/926 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	221	926/926 = 100.0% (100.0%, 100.0%)	926/926 = 100.0% (100.0%, 100.0%)	926/926 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	54	96/96 = 100.0% (100.0%, 100.0%)	96/96 = 100.0% (100.0%, 100.0%)	96/96 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	54	96/96 = 100.0% (100.0%, 100.0%)	96/96 = 100.0% (100.0%, 100.0%)	96/96 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Communities of Color	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	54	96/96 = 100.0% (100.0%, 100.0%)	96/96 = 100.0% (100.0%, 100.0%)	96/96 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	34	0/1021 = 0.0% (0.0%, 0.0%)	0/1021 = 0.0% (0.0%, 0.0%)	0/1021 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	34	0/1021 = 0.0% (0.0%, 0.0%)	0/1021 = 0.0% (0.0%, 0.0%)	0/1021 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	34	30/1021 = 2.9% (0.4%, 19.8%)	0/1021 = 0.0% (0.0%, 0.0%)	0/1021 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	58	105/105 = 100.0% (100.0%, 100.0%)	105/105 = 100.0% (100.0%, 100.0%)	105/105 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	58	105/105 = 100.0% (100.0%, 100.0%)	105/105 = 100.0% (100.0%, 100.0%)	105/105 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	58	105/105 = 100.0% (100.0%, 100.0%)	105/105 = 100.0% (100.0%, 100.0%)	105/105 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	221	926/926 = 100.0% (100.0%, 100.0%)	926/926 = 100.0% (100.0%, 100.0%)	926/926 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	221	926/926 = 100.0% (100.0%, 100.0%)	926/926 = 100.0% (100.0%, 100.0%)	926/926 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Communities of Color	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	221	926/926 = 100.0% (100.0%, 100.0%)	926/926 = 100.0% (100.0%, 100.0%)	926/926 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	54	96/96 = 100.0% (100.0%, 100.0%)	96/96 = 100.0% (100.0%, 100.0%)	96/96 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	54	96/96 = 100.0% (100.0%, 100.0%)	96/96 = 100.0% (100.0%, 100.0%)	96/96 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	54	96/96 = 100.0% (100.0%, 100.0%)	96/96 = 100.0% (100.0%, 100.0%)	96/96 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	34	0/1021 = 0.0% (0.0%, 0.0%)	0/1021 = 0.0% (0.0%, 0.0%)	0/1021 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	34	0/1021 = 0.0% (0.0%, 0.0%)	0/1021 = 0.0% (0.0%, 0.0%)	0/1021 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	34	0/1021 = 0.0% (0.0%, 0.0%)	0/1021 = 0.0% (0.0%, 0.0%)	0/1021 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	58	105/105 = 100.0% (100.0%, 100.0%)	105/105 = 100.0% (100.0%, 100.0%)	105/105 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	58	105/105 = 100.0% (100.0%, 100.0%)	105/105 = 100.0% (100.0%, 100.0%)	105/105 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 Communities of Color	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	58	105/105 = 100.0% (100.0%, 100.0%)	105/105 = 100.0% (100.0%, 100.0%)	105/105 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	178	1369.2/1369.2 = 100.0% (100.0%, 100.0%)	1369.2/1369.2 = 100.0% (100.0%, 100.0%)	1369.2/1369.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	178	1369.2/1369.2 = 100.0% (100.0%, 100.0%)	1369.2/1369.2 = 100.0% (100.0%, 100.0%)	1369.2/1369.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	178	1369.2/1369.2 = 100.0% (100.0%, 100.0%)	1369.2/1369.2 = 100.0% (100.0%, 100.0%)	1369.2/1369.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	64	151.8/151.8 = 100.0% (100.0%, 100.0%)	151.8/151.8 = 100.0% (100.0%, 100.0%)	151.8/151.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	64	151.8/151.8 = 100.0% (100.0%, 100.0%)	151.8/151.8 = 100.0% (100.0%, 100.0%)	151.8/151.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	64	151.8/151.8 = 100.0% (100.0%, 100.0%)	151.8/151.8 = 100.0% (100.0%, 100.0%)	151.8/151.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	33	0/1545.1 = 0.0% (0.0%, 0.0%)	0/1545.1 = 0.0% (0.0%, 0.0%)	0/1545.1 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	33	0/1545.1 = 0.0% (0.0%, 0.0%)	0/1545.1 = 0.0% (0.0%, 0.0%)	0/1545.1 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	33	0/1545.1 = 0.0% (0.0%, 0.0%)	0/1545.1 = 0.0% (0.0%, 0.0%)	0/1545.1 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	55	138.6/138.6 = 100.0% (100.0%, 100.0%)	138.6/138.6 = 100.0% (100.0%, 100.0%)	138.6/138.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	55	138.6/138.6 = 100.0% (100.0%, 100.0%)	138.6/138.6 = 100.0% (100.0%, 100.0%)	138.6/138.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	55	138.6/138.6 = 100.0% (100.0%, 100.0%)	138.6/138.6 = 100.0% (100.0%, 100.0%)	138.6/138.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	178	1369.2/1369.2 = 100.0% (100.0%, 100.0%)	1369.2/1369.2 = 100.0% (100.0%, 100.0%)	1369.2/1369.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	178	1369.2/1369.2 = 100.0% (100.0%, 100.0%)	1369.2/1369.2 = 100.0% (100.0%, 100.0%)	1369.2/1369.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	178	1369.2/1369.2 = 100.0% (100.0%, 100.0%)	1369.2/1369.2 = 100.0% (100.0%, 100.0%)	1369.2/1369.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	64	151.8/151.8 = 100.0% (100.0%, 100.0%)	151.8/151.8 = 100.0% (100.0%, 100.0%)	151.8/151.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	64	151.8/151.8 = 100.0% (100.0%, 100.0%)	151.8/151.8 = 100.0% (100.0%, 100.0%)	151.8/151.8 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% Greater than 2 × LLOD	% Greater than 4 × LLOD
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	64	151.8/151.8 = 100.0% (100.0%, 100.0%)	151.8/151.8 = 100.0% (100.0%, 100.0%)	151.8/151.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	33	0/1545.1 = 0.0% (0.0%, 0.0%)	0/1545.1 = 0.0% (0.0%, 0.0%)	0/1545.1 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	33	93.6/1545.1 = 6.1% (1.4%, 22.5%)	93.6/1545.1 = 6.1% (1.4%, 22.5%)	46.8/1545.1 = 3.0% (0.4%, 20.2%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	33	0/1545.1 = 0.0% (0.0%, 0.0%)	0/1545.1 = 0.0% (0.0%, 0.0%)	0/1545.1 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	55	138.6/138.6 = 100.0% (100.0%, 100.0%)	138.6/138.6 = 100.0% (100.0%, 100.0%)	138.6/138.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	55	138.6/138.6 = 100.0% (100.0%, 100.0%)	138.6/138.6 = 100.0% (100.0%, 100.0%)	138.6/138.6 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	55	138.6/138.6 = 100.0% (100.0%, 100.0%)	138.6/138.6 = 100.0% (100.0%, 100.0%)	138.6/138.6 = 100.0% (100.0%, 100.0%)

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4a. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by All participants

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
All participants								
	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	904	11850.9/13264 = 89.3% (86.0%, 92.0%)	11850.9/13264 = 89.3% (86.0%, 92.0%)	10789.6/13264 = 81.3% (77.5%, 84.7%)
	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	277	1311.5/1432 = 91.6% (85.1%, 95.4%)	1314.1/1432 = 91.8% (85.2%, 95.6%)	1241.5/1432 = 86.7% (79.7%, 91.5%)
	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	155	266.3/13308 = 2.0% (0.4%, 10.0%)	266.3/13308 = 2.0% (0.4%, 10.0%)	0/13308 = 0.0% (0.0%, 0.0%)
	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	274	1063.5/1337 = 79.5% (71.7%, 85.6%)	1063.5/1337 = 79.5% (71.7%, 85.6%)	851.2/1337 = 63.7% (55.3%, 71.3%)
	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	904	13027.1/13264 = 98.2% (96.4%, 99.1%)	13027.1/13264 = 98.2% (96.4%, 99.1%)	12884.2/13264 = 97.1% (95.3%, 98.3%)
	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	277	1429.5/1432 = 99.8% (98.7%, 100.0%)	1429.5/1432 = 99.8% (98.7%, 100.0%)	1429.5/1432 = 99.8% (98.7%, 100.0%)
	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	155	140.5/13308 = 1.1% (0.3%, 3.2%)	140.5/13308 = 1.1% (0.3%, 3.2%)	0/13308 = 0.0% (0.0%, 0.0%)
	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	274	1267.2/1337 = 94.8% (89.3%, 97.5%)	1267.2/1337 = 94.8% (89.3%, 97.5%)	1224.4/1337 = 91.6% (85.6%, 95.2%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4b. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age								
Age < 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	436	9130.5/10438 = 87.5% (83.3%, 90.7%)	9130.5/10438 = 87.5% (83.3%, 90.7%)	8160.7/10438 = 78.2% (73.3%, 82.4%)
Age < 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	145	1037/1151 = 90.1% (82.0%, 94.8%)	1039.6/1151 = 90.3% (82.2%, 95.0%)	970.6/1151 = 84.3% (75.7%, 90.3%)
Age < 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	76	219.5/10180 = 2.2% (0.3%, 14.5%)	219.5/10180 = 2.2% (0.3%, 14.5%)	0/10180 = 0.0% (0.0%, 0.0%)
Age < 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	143	797.9/1048 = 76.1% (66.3%, 83.8%)	797.9/1048 = 76.1% (66.3%, 83.8%)	599.7/1048 = 57.2% (46.9%, 66.9%)
Age < 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	436	10205.3/10438 = 97.8% (95.5%, 98.9%)	10205.3/10438 = 97.8% (95.5%, 98.9%)	10098.1/10438 = 96.7% (94.3%, 98.1%)
Age < 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	145	1148.5/1151 = 99.8% (98.4%, 100.0%)	1148.5/1151 = 99.8% (98.4%, 100.0%)	1148.5/1151 = 99.8% (98.4%, 100.0%)
Age < 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	76	0/10180 = 0.0% (0.0%, 0.0%)	0/10180 = 0.0% (0.0%, 0.0%)	0/10180 = 0.0% (0.0%, 0.0%)
Age < 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	143	980/1048 = 93.5% (86.5%, 97.0%)	980/1048 = 93.5% (86.5%, 97.0%)	937.2/1048 = 89.4% (81.9%, 94.1%)
Age ≥ 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	468	2720.4/2826 = 96.3% (93.9%, 97.7%)	2720.4/2826 = 96.3% (93.9%, 97.7%)	2628.9/2826 = 93.0% (90.2%, 95.1%)
Age ≥ 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	132	274.5/281 = 97.7% (92.9%, 99.3%)	274.5/281 = 97.7% (92.9%, 99.3%)	270.9/281 = 96.4% (91.5%, 98.5%)
Age ≥ 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	79	46.8/3128 = 1.5% (0.2%, 10.3%)	46.8/3128 = 1.5% (0.2%, 10.3%)	0/3128 = 0.0% (0.0%, 0.0%)
Age ≥ 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	131	265.5/289 = 91.9% (85.7%, 95.5%)	265.5/289 = 91.9% (85.7%, 95.5%)	251.4/289 = 87.0% (80.1%, 91.8%)
Age ≥ 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	468	2821.8/2826 = 99.9% (98.9%, 100.0%)	2821.8/2826 = 99.9% (98.9%, 100.0%)	2786.2/2826 = 98.6% (97.0%, 99.4%)
Age ≥ 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	132	281/281 = 100.0% (100.0%, 100.0%)	281/281 = 100.0% (100.0%, 100.0%)	281/281 = 100.0% (100.0%, 100.0%)
Age ≥ 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	79	140.5/3128 = 4.5% (1.4%, 13.2%)	140.5/3128 = 4.5% (1.4%, 13.2%)	0/3128 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age \geq 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	131	287.2/289 = 99.4% (95.6%, 99.9%)	287.2/289 = 99.4% (95.6%, 99.9%)	287.2/289 = 99.4% (95.6%, 99.9%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4c. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Risk for Severe Covid-19								
At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	459	3238.2/3549.5 = 91.2% (87.9%, 93.7%)	3238.2/3549.5 = 91.2% (87.9%, 93.7%)	2931.9/3549.5 = 82.6% (78.4%, 86.1%)
At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	126	340.6/350.8 = 97.1% (91.1%, 99.1%)	343.1/350.8 = 97.8% (91.6%, 99.5%)	326/350.8 = 92.9% (86.1%, 96.5%)
At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	76	46.8/3955.4 = 1.2% (0.2%, 8.2%)	46.8/3955.4 = 1.2% (0.2%, 8.2%)	0/3955.4 = 0.0% (0.0%, 0.0%)
At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	124	254.1/314.6 = 80.7% (72.2%, 87.2%)	254.1/314.6 = 80.7% (72.2%, 87.2%)	223.2/314.6 = 70.9% (61.9%, 78.6%)
At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	459	3487.6/3549.5 = 98.3% (96.2%, 99.2%)	3487.6/3549.5 = 98.3% (96.2%, 99.2%)	3442.1/3549.5 = 97.0% (94.7%, 98.3%)
At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	126	348.2/350.8 = 99.3% (94.9%, 99.9%)	348.2/350.8 = 99.3% (94.9%, 99.9%)	348.2/350.8 = 99.3% (94.9%, 99.9%)
At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	76	93.6/3955.4 = 2.4% (0.6%, 9.1%)	93.6/3955.4 = 2.4% (0.6%, 9.1%)	0/3955.4 = 0.0% (0.0%, 0.0%)
At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	124	305.7/314.6 = 97.2% (91.1%, 99.1%)	305.7/314.6 = 97.2% (91.1%, 99.1%)	285.7/314.6 = 90.8% (83.4%, 95.1%)
Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	445	8612.7/9714.5 = 88.7% (84.1%, 92.0%)	8612.7/9714.5 = 88.7% (84.1%, 92.0%)	7857.6/9714.5 = 80.9% (75.7%, 85.2%)
Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	151	971/1081.2 = 89.8% (81.2%, 94.7%)	971/1081.2 = 89.8% (81.2%, 94.7%)	915.5/1081.2 = 84.7% (75.5%, 90.8%)
Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	79	219.5/9352.6 = 2.3% (0.3%, 15.6%)	219.5/9352.6 = 2.3% (0.3%, 15.6%)	0/9352.6 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	150	809.4/1022.4 = 79.2% (69.0%, 86.7%)	809.4/1022.4 = 79.2% (69.0%, 86.7%)	628/1022.4 = 61.4% (50.8%, 71.0%)
Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	445	9539.5/9714.5 = 98.2% (95.6%, 99.3%)	9539.5/9714.5 = 98.2% (95.6%, 99.3%)	9442.1/9714.5 = 97.2% (94.6%, 98.6%)
Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	151	1081.2/1081.2 = 100.0% (100.0%, 100.0%)	1081.2/1081.2 = 100.0% (100.0%, 100.0%)	1081.2/1081.2 = 100.0% (100.0%, 100.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	79	46.8/9352.6 = 0.5% (0.1%, 3.6%)	46.8/9352.6 = 0.5% (0.1%, 3.6%)	0/9352.6 = 0.0% (0.0%, 0.0%)
Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	150	961.5/1022.4 = 94.0% (86.7%, 97.5%)	961.5/1022.4 = 94.0% (86.7%, 97.5%)	938.7/1022.4 = 91.8% (83.8%, 96.1%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4d. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age, Risk for Severe Covid-19								
Age < 65 At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	216	1859.2/2104 = 88.4% (83.2%, 92.1%)	1859.2/2104 = 88.4% (83.2%, 92.1%)	1596.9/2104 = 75.9% (69.5%, 81.3%)
Age < 65 At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	72	223.8/234 = 95.6% (86.7%, 98.6%)	226.3/234 = 96.7% (87.5%, 99.2%)	211/234 = 90.2% (80.2%, 95.4%)
Age < 65 At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	36	0/2368 = 0.0% (0.0%, 0.0%)	0/2368 = 0.0% (0.0%, 0.0%)	0/2368 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	70	144.4/197 = 73.3% (60.8%, 82.9%)	144.4/197 = 73.3% (60.8%, 82.9%)	120.8/197 = 61.3% (48.6%, 72.6%)
Age < 65 At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	216	2046.4/2104 = 97.3% (93.8%, 98.8%)	2046.4/2104 = 97.3% (93.8%, 98.8%)	2020.5/2104 = 96.0% (92.3%, 98.0%)
Age < 65 At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	72	231.5/234 = 98.9% (92.4%, 99.9%)	231.5/234 = 98.9% (92.4%, 99.9%)	231.5/234 = 98.9% (92.4%, 99.9%)
Age < 65 At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	36	0/2368 = 0.0% (0.0%, 0.0%)	0/2368 = 0.0% (0.0%, 0.0%)	0/2368 = 0.0% (0.0%, 0.0%)
Age < 65 At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	70	189.9/197 = 96.4% (86.3%, 99.1%)	189.9/197 = 96.4% (86.3%, 99.1%)	169.9/197 = 86.2% (74.9%, 92.9%)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	220	7271.3/8334 = 87.2% (82.0%, 91.1%)	7271.3/8334 = 87.2% (82.0%, 91.1%)	6563.8/8334 = 78.8% (72.8%, 83.7%)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	73	813.3/917 = 88.7% (78.4%, 94.4%)	813.3/917 = 88.7% (78.4%, 94.4%)	759.6/917 = 82.8% (72.0%, 90.1%)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	40	219.5/7812 = 2.8% (0.4%, 18.8%)	219.5/7812 = 2.8% (0.4%, 18.8%)	0/7812 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age < 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	73	653.6/851 = 76.8% (64.6%, 85.7%)	653.6/851 = 76.8% (64.6%, 85.7%)	479/851 = 56.3% (43.9%, 67.9%)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	220	8159/8334 = 97.9% (94.9%, 99.2%)	8159/8334 = 97.9% (94.9%, 99.2%)	8077.6/8334 = 96.9% (93.8%, 98.5%)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	73	917/917 = 100.0% (100.0%, 100.0%)	917/917 = 100.0% (100.0%, 100.0%)	917/917 = 100.0% (100.0%, 100.0%)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	40	0/7812 = 0.0% (0.0%, 0.0%)	0/7812 = 0.0% (0.0%, 0.0%)	0/7812 = 0.0% (0.0%, 0.0%)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	73	790.1/851 = 92.8% (84.0%, 97.0%)	790.1/851 = 92.8% (84.0%, 97.0%)	767.3/851 = 90.2% (80.5%, 95.3%)
Age ≥ 65 At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	243	1379/1445.5 = 95.4% (91.5%, 97.6%)	1379/1445.5 = 95.4% (91.5%, 97.6%)	1335/1445.5 = 92.4% (88.0%, 95.2%)
Age ≥ 65 At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	54	116.8/116.8 = 100.0% (100.0%, 100.0%)	116.8/116.8 = 100.0% (100.0%, 100.0%)	115/116.8 = 98.5% (89.5%, 99.8%)
Age ≥ 65 At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	40	46.8/1587.4 = 2.9% (0.4%, 19.4%)	46.8/1587.4 = 2.9% (0.4%, 19.4%)	0/1587.4 = 0.0% (0.0%, 0.0%)
Age ≥ 65 At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	54	109.7/117.6 = 93.2% (82.7%, 97.5%)	109.7/117.6 = 93.2% (82.7%, 97.5%)	102.5/117.6 = 87.1% (75.8%, 93.6%)
Age ≥ 65 At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	243	1441.3/1445.5 = 99.7% (97.9%, 100.0%)	1441.3/1445.5 = 99.7% (97.9%, 100.0%)	1421.7/1445.5 = 98.4% (95.5%, 99.4%)
Age ≥ 65 At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	54	116.8/116.8 = 100.0% (100.0%, 100.0%)	116.8/116.8 = 100.0% (100.0%, 100.0%)	116.8/116.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	40	93.6/1587.4 = 5.9% (1.4%, 21.6%)	93.6/1587.4 = 5.9% (1.4%, 21.6%)	0/1587.4 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age ≥ 65 At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	54	115.8/117.6 = 98.5% (89.4%, 99.8%)	115.8/117.6 = 98.5% (89.4%, 99.8%)	115.8/117.6 = 98.5% (89.4%, 99.8%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	225	1341.4/1380.5 = 97.2% (93.7%, 98.8%)	1341.4/1380.5 = 97.2% (93.7%, 98.8%)	1293.9/1380.5 = 93.7% (89.4%, 96.3%)
Age ≥ 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	78	157.7/164.2 = 96.0% (88.1%, 98.8%)	157.7/164.2 = 96.0% (88.1%, 98.8%)	155.9/164.2 = 94.9% (86.9%, 98.1%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	39	0/1540.6 = 0.0% (0.0%, 0.0%)	0/1540.6 = 0.0% (0.0%, 0.0%)	0/1540.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	77	155.8/171.4 = 90.9% (81.8%, 95.7%)	155.8/171.4 = 90.9% (81.8%, 95.7%)	149/171.4 = 86.9% (77.0%, 93.0%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	225	1380.5/1380.5 = 100.0% (100.0%, 100.0%)	1380.5/1380.5 = 100.0% (100.0%, 100.0%)	1364.5/1380.5 = 98.8% (96.2%, 99.6%)
Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	78	164.2/164.2 = 100.0% (100.0%, 100.0%)	164.2/164.2 = 100.0% (100.0%, 100.0%)	164.2/164.2 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	39	46.8/1540.6 = 3.0% (0.4%, 19.9%)	46.8/1540.6 = 3.0% (0.4%, 19.9%)	0/1540.6 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	77	171.4/171.4 = 100.0% (100.0%, 100.0%)	171.4/171.4 = 100.0% (100.0%, 100.0%)	171.4/171.4 = 100.0% (100.0%, 100.0%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4e. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Sex								
Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	364	4567.6/5129.6 = 89.0% (83.3%, 93.0%)	4567.6/5129.6 = 89.0% (83.3%, 93.0%)	3996.6/5129.6 = 77.9% (71.1%, 83.5%)
Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	115	532.4/574.9 = 92.6% (81.9%, 97.2%)	534.9/574.9 = 93.1% (82.1%, 97.5%)	532.4/574.9 = 92.6% (81.9%, 97.2%)
Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	74	219.5/6201.9 = 3.5% (0.5%, 21.9%)	219.5/6201.9 = 3.5% (0.5%, 21.9%)	0/6201.9 = 0.0% (0.0%, 0.0%)
Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	125	544.8/679.4 = 80.2% (68.1%, 88.5%)	544.8/679.4 = 80.2% (68.1%, 88.5%)	428.1/679.4 = 63.0% (50.2%, 74.2%)
Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	364	5029.8/5129.6 = 98.1% (94.2%, 99.4%)	5029.8/5129.6 = 98.1% (94.2%, 99.4%)	4972.6/5129.6 = 96.9% (93.3%, 98.6%)
Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	115	574.9/574.9 = 100.0% (100.0%, 100.0%)	574.9/574.9 = 100.0% (100.0%, 100.0%)	574.9/574.9 = 100.0% (100.0%, 100.0%)
Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	74	46.8/6201.9 = 0.8% (0.1%, 5.4%)	46.8/6201.9 = 0.8% (0.1%, 5.4%)	0/6201.9 = 0.0% (0.0%, 0.0%)
Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	125	636.1/679.4 = 93.6% (83.1%, 97.8%)	636.1/679.4 = 93.6% (83.1%, 97.8%)	632.6/679.4 = 93.1% (82.8%, 97.4%)
Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	540	7283.3/8134.4 = 89.5% (85.1%, 92.8%)	7283.3/8134.4 = 89.5% (85.1%, 92.8%)	6792.9/8134.4 = 83.5% (78.7%, 87.4%)
Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	162	779.1/857.1 = 90.9% (81.2%, 95.8%)	779.1/857.1 = 90.9% (81.2%, 95.8%)	709.1/857.1 = 82.7% (72.6%, 89.6%)
Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	81	46.8/7106.1 = 0.7% (0.1%, 4.7%)	46.8/7106.1 = 0.7% (0.1%, 4.7%)	0/7106.1 = 0.0% (0.0%, 0.0%)
Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	149	518.7/657.6 = 78.9% (67.8%, 86.9%)	518.7/657.6 = 78.9% (67.8%, 86.9%)	423.1/657.6 = 64.3% (52.9%, 74.4%)
Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	540	7997.4/8134.4 = 98.3% (95.9%, 99.3%)	7997.4/8134.4 = 98.3% (95.9%, 99.3%)	7911.7/8134.4 = 97.3% (94.8%, 98.6%)
Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	162	854.6/857.1 = 99.7% (97.9%, 100.0%)	854.6/857.1 = 99.7% (97.9%, 100.0%)	854.6/857.1 = 99.7% (97.9%, 100.0%)
Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	81	93.6/7106.1 = 1.3% (0.3%, 5.2%)	93.6/7106.1 = 1.3% (0.3%, 5.2%)	0/7106.1 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	149	631.1/657.6 = 96.0% (89.4%, 98.5%)	631.1/657.6 = 96.0% (89.4%, 98.5%)	591.8/657.6 = 90.0% (81.3%, 94.9%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4f. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age, sex								
Age < 65 Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	262	5651.9/6444.2 = 87.7% (82.1%, 91.7%)	5651.9/6444.2 = 87.7% (82.1%, 91.7%)	5229.3/6444.2 = 81.1% (75.1%, 86.0%)
Age < 65 Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	90	628.6/701.8 = 89.6% (77.7%, 95.5%)	628.6/701.8 = 89.6% (77.7%, 95.5%)	562.1/701.8 = 80.1% (67.8%, 88.5%)
Age < 65 Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	39	0/5425 = 0.0% (0.0%, 0.0%)	0/5425 = 0.0% (0.0%, 0.0%)	0/5425 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	75	364.3/493.8 = 73.8% (59.5%, 84.3%)	364.3/493.8 = 73.8% (59.5%, 84.3%)	279.2/493.8 = 56.5% (42.3%, 69.7%)
Age < 65 Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	262	6311.4/6444.2 = 97.9% (94.8%, 99.2%)	6311.4/6444.2 = 97.9% (94.8%, 99.2%)	6257.2/6444.2 = 97.1% (93.8%, 98.7%)
Age < 65 Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	90	699.3/701.8 = 99.6% (97.4%, 100.0%)	699.3/701.8 = 99.6% (97.4%, 100.0%)	699.3/701.8 = 99.6% (97.4%, 100.0%)
Age < 65 Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	39	0/5425 = 0.0% (0.0%, 0.0%)	0/5425 = 0.0% (0.0%, 0.0%)	0/5425 = 0.0% (0.0%, 0.0%)
Age < 65 Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	75	467.3/493.8 = 94.6% (85.9%, 98.1%)	467.3/493.8 = 94.6% (85.9%, 98.1%)	428/493.8 = 86.7% (75.2%, 93.3%)
Age < 65 Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	174	3478.6/3993.8 = 87.1% (79.8%, 92.0%)	3478.6/3993.8 = 87.1% (79.8%, 92.0%)	2931.4/3993.8 = 73.4% (64.8%, 80.6%)
Age < 65 Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	55	408.5/449.2 = 90.9% (77.1%, 96.8%)	411/449.2 = 91.5% (77.4%, 97.1%)	408.5/449.2 = 90.9% (77.1%, 96.8%)
Age < 65 Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	37	219.5/4755 = 4.6% (0.6%, 28.1%)	219.5/4755 = 4.6% (0.6%, 28.1%)	0/4755 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	68	433.7/554.2 = 78.3% (63.4%, 88.2%)	433.7/554.2 = 78.3% (63.4%, 88.2%)	320.6/554.2 = 57.8% (42.7%, 71.6%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age < 65 Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	174	3893.9/3993.8 = 97.5% (92.6%, 99.2%)	3893.9/3993.8 = 97.5% (92.6%, 99.2%)	3840.9/3993.8 = 96.2% (91.4%, 98.3%)
Age < 65 Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	55	449.2/449.2 = 100.0% (100.0%, 100.0%)	449.2/449.2 = 100.0% (100.0%, 100.0%)	449.2/449.2 = 100.0% (100.0%, 100.0%)
Age < 65 Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	37	0/4755 = 0.0% (0.0%, 0.0%)	0/4755 = 0.0% (0.0%, 0.0%)	0/4755 = 0.0% (0.0%, 0.0%)
Age < 65 Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	68	512.7/554.2 = 92.5% (79.4%, 97.5%)	512.7/554.2 = 92.5% (79.4%, 97.5%)	509.2/554.2 = 91.9% (79.1%, 97.1%)
Age ≥ 65 Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	190	1089/1135.8 = 95.9% (91.4%, 98.1%)	1089/1135.8 = 95.9% (91.4%, 98.1%)	1065.2/1135.8 = 93.8% (88.9%, 96.6%)
Age ≥ 65 Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	60	123.9/125.7 = 98.6% (90.2%, 99.8%)	123.9/125.7 = 98.6% (90.2%, 99.8%)	123.9/125.7 = 98.6% (90.2%, 99.8%)
Age ≥ 65 Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	37	0/1446.9 = 0.0% (0.0%, 0.0%)	0/1446.9 = 0.0% (0.0%, 0.0%)	0/1446.9 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	57	111.1/125.2 = 88.7% (77.7%, 94.7%)	111.1/125.2 = 88.7% (77.7%, 94.7%)	107.5/125.2 = 85.9% (74.5%, 92.7%)
Age ≥ 65 Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	190	1135.8/1135.8 = 100.0% (100.0%, 100.0%)	1135.8/1135.8 = 100.0% (100.0%, 100.0%)	1131.6/1135.8 = 99.6% (97.4%, 99.9%)
Age ≥ 65 Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	60	125.7/125.7 = 100.0% (100.0%, 100.0%)	125.7/125.7 = 100.0% (100.0%, 100.0%)	125.7/125.7 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	37	46.8/1446.9 = 3.2% (0.4%, 21.0%)	46.8/1446.9 = 3.2% (0.4%, 21.0%)	0/1446.9 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	57	123.4/125.2 = 98.6% (90.0%, 99.8%)	123.4/125.2 = 98.6% (90.0%, 99.8%)	123.4/125.2 = 98.6% (90.0%, 99.8%)
Age ≥ 65 Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	278	1631.4/1690.2 = 96.5% (93.3%, 98.2%)	1631.4/1690.2 = 96.5% (93.3%, 98.2%)	1563.7/1690.2 = 92.5% (88.6%, 95.2%)
Age ≥ 65 Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	72	150.6/155.3 = 96.9% (88.3%, 99.3%)	150.6/155.3 = 96.9% (88.3%, 99.3%)	147/155.3 = 94.7% (86.2%, 98.0%)
Age ≥ 65 Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	42	46.8/1681.1 = 2.8% (0.4%, 18.4%)	46.8/1681.1 = 2.8% (0.4%, 18.4%)	0/1681.1 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age ≥ 65 Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	74	154.4/163.8 = 94.3% (85.4%, 97.9%)	154.4/163.8 = 94.3% (85.4%, 97.9%)	143.9/163.8 = 87.9% (77.9%, 93.7%)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	278	1686/1690.2 = 99.8% (98.2%, 100.0%)	1686/1690.2 = 99.8% (98.2%, 100.0%)	1654.5/1690.2 = 97.9% (95.2%, 99.1%)
Age ≥ 65 Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	72	155.3/155.3 = 100.0% (100.0%, 100.0%)	155.3/155.3 = 100.0% (100.0%, 100.0%)	155.3/155.3 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	42	93.6/1681.1 = 5.6% (1.3%, 20.5%)	93.6/1681.1 = 5.6% (1.3%, 20.5%)	0/1681.1 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	74	163.8/163.8 = 100.0% (100.0%, 100.0%)	163.8/163.8 = 100.0% (100.0%, 100.0%)	163.8/163.8 = 100.0% (100.0%, 100.0%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4g. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Hispanic or Latino ethnicity

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Hispanic or Latino ethnicity								
Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	127	1100.2/1246.3 = 88.3% (77.1%, 94.4%)	1100.2/1246.3 = 88.3% (77.1%, 94.4%)	1020.3/1246.3 = 81.9% (70.6%, 89.4%)
Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	29	123.1/135.4 = 91.0% (62.9%, 98.4%)	125.7/135.4 = 92.8% (60.4%, 99.1%)	103.7/135.4 = 76.6% (48.7%, 91.9%)
Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	15	0/1152.8 = 0.0% (0.0%, 0.0%)	0/1152.8 = 0.0% (0.0%, 0.0%)	0/1152.8 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	46	108.9/143 = 76.1% (55.5%, 89.0%)	108.9/143 = 76.1% (55.5%, 89.0%)	93.7/143 = 65.5% (45.7%, 81.1%)
Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	127	1208.3/1246.3 = 97.0% (87.7%, 99.3%)	1208.3/1246.3 = 97.0% (87.7%, 99.3%)	1170.3/1246.3 = 93.9% (84.0%, 97.8%)
Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	29	135.4/135.4 = 100.0% (100.0%, 100.0%)	135.4/135.4 = 100.0% (100.0%, 100.0%)	135.4/135.4 = 100.0% (100.0%, 100.0%)
Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	15	0/1152.8 = 0.0% (0.0%, 0.0%)	0/1152.8 = 0.0% (0.0%, 0.0%)	0/1152.8 = 0.0% (0.0%, 0.0%)
Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	46	141.2/143 = 98.7% (91.0%, 99.8%)	141.2/143 = 98.7% (91.0%, 99.8%)	137.4/143 = 96.0% (87.8%, 98.8%)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	679	9367.1/10531 = 88.9% (85.0%, 92.0%)	9367.1/10531 = 88.9% (85.0%, 92.0%)	8450.5/10531 = 80.2% (75.6%, 84.2%)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	209	1005.2/1098.5 = 91.5% (83.7%, 95.8%)	1005.2/1098.5 = 91.5% (83.7%, 95.8%)	954.6/1098.5 = 86.9% (78.7%, 92.2%)
Not Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	122	266.3/10217.3 = 2.6% (0.5%, 12.9%)	266.3/10217.3 = 2.6% (0.5%, 12.9%)	0/10217.3 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Not Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	203	859.6/1074.2 = 80.0% (70.9%, 86.8%)	859.6/1074.2 = 80.0% (70.9%, 86.8%)	677.2/1074.2 = 63.0% (53.3%, 71.8%)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	679	10359.3/10531 = 98.4% (96.2%, 99.3%)	10359.3/10531 = 98.4% (96.2%, 99.3%)	10254.4/10531 = 97.4% (95.2%, 98.6%)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	209	1096/1098.5 = 99.8% (98.4%, 100.0%)	1096/1098.5 = 99.8% (98.4%, 100.0%)	1096/1098.5 = 99.8% (98.4%, 100.0%)
Not Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	122	93.6/10217.3 = 0.9% (0.2%, 3.6%)	93.6/10217.3 = 0.9% (0.2%, 3.6%)	0/10217.3 = 0.0% (0.0%, 0.0%)
Not Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	203	1009.7/1074.2 = 94.0% (87.1%, 97.3%)	1009.7/1074.2 = 94.0% (87.1%, 97.3%)	978.4/1074.2 = 91.1% (83.8%, 95.3%)
Not reported and unknown	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	98	1383.6/1486.6 = 93.1% (84.6%, 97.0%)	1383.6/1486.6 = 93.1% (84.6%, 97.0%)	1318.7/1486.6 = 88.7% (79.5%, 94.1%)
Not reported and unknown	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	39	183.2/198.1 = 92.5% (60.1%, 99.0%)	183.2/198.1 = 92.5% (60.1%, 99.0%)	183.2/198.1 = 92.5% (60.1%, 99.0%)
Not reported and unknown	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	18	0/1937.9 = 0.0% (0.0%, 0.0%)	0/1937.9 = 0.0% (0.0%, 0.0%)	0/1937.9 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	25	95/119.8 = 79.3% (46.0%, 94.5%)	95/119.8 = 79.3% (46.0%, 94.5%)	80.2/119.8 = 67.0% (37.9%, 87.1%)
Not reported and unknown	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	98	1459.5/1486.6 = 98.2% (87.9%, 99.8%)	1459.5/1486.6 = 98.2% (87.9%, 99.8%)	1459.5/1486.6 = 98.2% (87.9%, 99.8%)
Not reported and unknown	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	39	198.1/198.1 = 100.0% (100.0%, 100.0%)	198.1/198.1 = 100.0% (100.0%, 100.0%)	198.1/198.1 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	18	46.8/1937.9 = 2.4% (0.3%, 19.2%)	46.8/1937.9 = 2.4% (0.3%, 19.2%)	0/1937.9 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Not reported and unknown	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	25	116.2/119.8 = 97.0% (78.9%, 99.7%)	116.2/119.8 = 97.0% (78.9%, 99.7%)	108.6/119.8 = 90.6% (64.2%, 98.1%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

MOCY

Table 4h. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Race

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Race								
White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	355	5910.4/6572.1 = 89.9% (84.4%, 93.6%)	5910.4/6572.1 = 89.9% (84.4%, 93.6%)	5492.3/6572.1 = 83.6% (77.5%, 88.3%)
White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	121	609.1/681.2 = 89.4% (77.8%, 95.3%)	609.1/681.2 = 89.4% (77.8%, 95.3%)	590.3/681.2 = 86.7% (74.6%, 93.5%)
White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	64	266.3/5953.5 = 4.5% (0.8%, 21.1%)	266.3/5953.5 = 4.5% (0.8%, 21.1%)	0/5953.5 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	116	582/726.6 = 80.1% (68.0%, 88.4%)	582/726.6 = 80.1% (68.0%, 88.4%)	429.9/726.6 = 59.2% (46.5%, 70.7%)
White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	355	6487.7/6572.1 = 98.7% (95.8%, 99.6%)	6487.7/6572.1 = 98.7% (95.8%, 99.6%)	6467.5/6572.1 = 98.4% (95.7%, 99.4%)
White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	121	681.2/681.2 = 100.0% (100.0%, 100.0%)	681.2/681.2 = 100.0% (100.0%, 100.0%)	681.2/681.2 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	64	46.8/5953.5 = 0.8% (0.1%, 5.6%)	46.8/5953.5 = 0.8% (0.1%, 5.6%)	0/5953.5 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	116	692.7/726.6 = 95.3% (84.7%, 98.7%)	692.7/726.6 = 95.3% (84.7%, 98.7%)	663.4/726.6 = 91.3% (80.9%, 96.3%)
Black or African American	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	205	1796.8/2138.3 = 84.0% (75.2%, 90.1%)	1796.8/2138.3 = 84.0% (75.2%, 90.1%)	1567.7/2138.3 = 73.3% (63.7%, 81.1%)
Black or African American	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	61	260.5/279.9 = 93.1% (75.6%, 98.3%)	260.5/279.9 = 93.1% (75.6%, 98.3%)	222.7/279.9 = 79.6% (62.2%, 90.2%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Black or African American	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	25	0/1926.2 = 0.0% (0.0%, 0.0%)	0/1926.2 = 0.0% (0.0%, 0.0%)	0/1926.2 = 0.0% (0.0%, 0.0%)
Black or African American	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	48	143.7/170.3 = 84.4% (66.9%, 93.6%)	143.7/170.3 = 84.4% (66.9%, 93.6%)	132.5/170.3 = 77.8% (59.4%, 89.4%)
Black or African American	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	205	2070.7/2138.3 = 96.8% (90.5%, 99.0%)	2070.7/2138.3 = 96.8% (90.5%, 99.0%)	2028.5/2138.3 = 94.9% (88.3%, 97.8%)
Black or African American	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	61	277.3/279.9 = 99.1% (93.5%, 99.9%)	277.3/279.9 = 99.1% (93.5%, 99.9%)	277.3/279.9 = 99.1% (93.5%, 99.9%)
Black or African American	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	25	0/1926.2 = 0.0% (0.0%, 0.0%)	0/1926.2 = 0.0% (0.0%, 0.0%)	0/1926.2 = 0.0% (0.0%, 0.0%)
Black or African American	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	48	147.3/170.3 = 86.5% (65.3%, 95.6%)	147.3/170.3 = 86.5% (65.3%, 95.6%)	145.4/170.3 = 85.4% (64.8%, 94.9%)
Asian	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	57	579.2/653.6 = 88.6% (71.2%, 96.1%)	579.2/653.6 = 88.6% (71.2%, 96.1%)	484.5/653.6 = 74.1% (55.1%, 87.0%)
Asian	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	18	48.9/60.4 = 81.0% (37.1%, 96.8%)	48.9/60.4 = 81.0% (37.1%, 96.8%)	48.9/60.4 = 81.0% (37.1%, 96.8%)
Asian	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	12	0/804.7 = 0.0% (0.0%, 0.0%)	0/804.7 = 0.0% (0.0%, 0.0%)	0/804.7 = 0.0% (0.0%, 0.0%)
Asian	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	16	51/58.7 = 87.0% (40.2%, 98.5%)	51/58.7 = 87.0% (40.2%, 98.5%)	39.6/58.7 = 67.5% (31.6%, 90.3%)
Asian	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	57	653.6/653.6 = 100.0% (100.0%, 100.0%)	653.6/653.6 = 100.0% (100.0%, 100.0%)	615.6/653.6 = 94.2% (77.6%, 98.7%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Asian	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	18	60.4/60.4 = 100.0% (100.0%, 100.0%)	60.4/60.4 = 100.0% (100.0%, 100.0%)	60.4/60.4 = 100.0% (100.0%, 100.0%)
Asian	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	12	0/804.7 = 0.0% (0.0%, 0.0%)	0/804.7 = 0.0% (0.0%, 0.0%)	0/804.7 = 0.0% (0.0%, 0.0%)
Asian	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	16	51/58.7 = 87.0% (40.2%, 98.5%)	51/58.7 = 87.0% (40.2%, 98.5%)	51/58.7 = 87.0% (40.2%, 98.5%)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	22	173.5/173.5 = 100.0% (100.0%, 100.0%)	173.5/173.5 = 100.0% (100.0%, 100.0%)	131.3/173.5 = 75.7% (39.0%, 93.8%)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	8	17.3/17.3 = 100.0% (100.0%, 100.0%)	17.3/17.3 = 100.0% (100.0%, 100.0%)	17.3/17.3 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	7	0/267.7 = 0.0% (0.0%, 0.0%)	0/267.7 = 0.0% (0.0%, 0.0%)	0/267.7 = 0.0% (0.0%, 0.0%)
American Indian or Alaska Native	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	8	20.6/20.6 = 100.0% (100.0%, 100.0%)	20.6/20.6 = 100.0% (100.0%, 100.0%)	20.6/20.6 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	22	173.5/173.5 = 100.0% (100.0%, 100.0%)	173.5/173.5 = 100.0% (100.0%, 100.0%)	173.5/173.5 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	8	17.3/17.3 = 100.0% (100.0%, 100.0%)	17.3/17.3 = 100.0% (100.0%, 100.0%)	17.3/17.3 = 100.0% (100.0%, 100.0%)
American Indian or Alaska Native	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	7	0/267.7 = 0.0% (0.0%, 0.0%)	0/267.7 = 0.0% (0.0%, 0.0%)	0/267.7 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
American Indian or Alaska Native	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	8	20.6/20.6 = 100.0% (100.0%, 100.0%)	20.6/20.6 = 100.0% (100.0%, 100.0%)	20.6/20.6 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	17	150/150 = 100.0% (100.0%, 100.0%)	150/150 = 100.0% (100.0%, 100.0%)	145.8/150 = 97.2% (78.3%, 99.7%)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	3	6.1/6.1 = 100.0%	6.1/6.1 = 100.0%	6.1/6.1 = 100.0%
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	1	0/30 = 0.0%	0/30 = 0.0%	0/30 = 0.0%
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	7	42/42 = 100.0% (100.0%, 100.0%)	42/42 = 100.0% (100.0%, 100.0%)	32.5/42 = 77.5% (18.9%, 98.1%)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	17	150/150 = 100.0% (100.0%, 100.0%)	150/150 = 100.0% (100.0%, 100.0%)	150/150 = 100.0% (100.0%, 100.0%)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	3	6.1/6.1 = 100.0%	6.1/6.1 = 100.0%	6.1/6.1 = 100.0%

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	1	0/30 = 0.0%	0/30 = 0.0%	0/30 = 0.0%
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	7	42/42 = 100.0% (100.0%, 100.0%)	42/42 = 100.0% (100.0%, 100.0%)	42/42 = 100.0% (100.0%, 100.0%)
Multiracial	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	54	382.1/490.2 = 77.9% (56.7%, 90.5%)	382.1/490.2 = 77.9% (56.7%, 90.5%)	269.8/490.2 = 55.0% (36.5%, 72.3%)
Multiracial	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	15	80.3/82.9 = 96.9% (76.5%, 99.7%)	82.9/82.9 = 100.0% (100.0%, 100.0%)	70.6/82.9 = 85.2% (44.8%, 97.6%)
Multiracial	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	11	0/932.4 = 0.0% (0.0%, 0.0%)	0/932.4 = 0.0% (0.0%, 0.0%)	0/932.4 = 0.0% (0.0%, 0.0%)
Multiracial	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	22	41.1/69.8 = 59.0% (30.3%, 82.6%)	41.1/69.8 = 59.0% (30.3%, 82.6%)	31.6/69.8 = 45.2% (21.8%, 71.0%)
Multiracial	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	54	456.4/490.2 = 93.1% (71.0%, 98.7%)	456.4/490.2 = 93.1% (71.0%, 98.7%)	429.3/490.2 = 87.6% (64.9%, 96.4%)
Multiracial	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	15	82.9/82.9 = 100.0% (100.0%, 100.0%)	82.9/82.9 = 100.0% (100.0%, 100.0%)	82.9/82.9 = 100.0% (100.0%, 100.0%)
Multiracial	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	11	0/932.4 = 0.0% (0.0%, 0.0%)	0/932.4 = 0.0% (0.0%, 0.0%)	0/932.4 = 0.0% (0.0%, 0.0%)
Multiracial	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	22	69.8/69.8 = 100.0% (100.0%, 100.0%)	69.8/69.8 = 100.0% (100.0%, 100.0%)	60.2/69.8 = 86.3% (49.9%, 97.5%)
Other	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	21	212.6/212.6 = 100.0% (100.0%, 100.0%)	212.6/212.6 = 100.0% (100.0%, 100.0%)	212.6/212.6 = 100.0% (100.0%, 100.0%)
Other	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	1	2.5/2.5 = 100.0%	2.5/2.5 = 100.0%	2.5/2.5 = 100.0%
Other	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	4	0/277.8 = 0.0%	0/277.8 = 0.0%	0/277.8 = 0.0%
Other	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	9	19/22.8 = 83.5% (38.6%, 97.6%)	19/22.8 = 83.5% (38.6%, 97.6%)	17.1/22.8 = 75.0% (31.2%, 95.2%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Other	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	21	212.6/212.6 = 100.0% (100.0%, 100.0%)	212.6/212.6 = 100.0% (100.0%, 100.0%)	212.6/212.6 = 100.0% (100.0%, 100.0%)
Other	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	1	2.5/2.5 = 100.0%	2.5/2.5 = 100.0%	2.5/2.5 = 100.0%
Other	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	4	0/277.8 = 0.0%	0/277.8 = 0.0%	0/277.8 = 0.0%
Other	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	9	21/22.8 = 92.0% (44.5%, 99.4%)	21/22.8 = 92.0% (44.5%, 99.4%)	19/22.8 = 83.5% (38.6%, 97.6%)
Not reported and unknown	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	85	1287.4/1467.7 = 87.7% (72.9%, 95.0%)	1287.4/1467.7 = 87.7% (72.9%, 95.0%)	1168.6/1467.7 = 79.6% (64.0%, 89.6%)
Not reported and unknown	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	22	149.8/149.8 = 100.0% (100.0%, 100.0%)	149.8/149.8 = 100.0% (100.0%, 100.0%)	145.9/149.8 = 97.4% (81.1%, 99.7%)
Not reported and unknown	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	18	0/1631.3 = 0.0% (0.0%, 0.0%)	0/1631.3 = 0.0% (0.0%, 0.0%)	0/1631.3 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	23	74.6/129 = 57.8% (28.2%, 82.8%)	74.6/129 = 57.8% (28.2%, 82.8%)	74.6/129 = 57.8% (28.2%, 82.8%)
Not reported and unknown	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	85	1416.7/1467.7 = 96.5% (81.1%, 99.4%)	1416.7/1467.7 = 96.5% (81.1%, 99.4%)	1401.3/1467.7 = 95.5% (82.7%, 98.9%)
Not reported and unknown	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	22	149.8/149.8 = 100.0% (100.0%, 100.0%)	149.8/149.8 = 100.0% (100.0%, 100.0%)	149.8/149.8 = 100.0% (100.0%, 100.0%)
Not reported and unknown	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	18	46.8/1631.3 = 2.9% (0.3%, 21.7%)	46.8/1631.3 = 2.9% (0.3%, 21.7%)	0/1631.3 = 0.0% (0.0%, 0.0%)
Not reported and unknown	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	23	125.4/129 = 97.2% (79.9%, 99.7%)	125.4/129 = 97.2% (79.9%, 99.7%)	125.4/129 = 97.2% (79.9%, 99.7%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4i. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Underrepresented minority status								
Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	424	3792.2/4327 = 87.6% (82.3%, 91.5%)	3792.2/4327 = 87.6% (82.3%, 91.5%)	3287.9/4327 = 76.0% (69.7%, 81.3%)
Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	120	466.6/500 = 93.3% (83.0%, 97.6%)	469.1/500 = 93.8% (83.2%, 97.9%)	419.2/500 = 83.8% (72.2%, 91.2%)
Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	63	0/4329 = 0.0% (0.0%, 0.0%)	0/4329 = 0.0% (0.0%, 0.0%)	0/4329 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	124	356.7/427 = 83.5% (73.2%, 90.4%)	356.7/427 = 83.5% (73.2%, 90.4%)	303.6/427 = 71.1% (59.7%, 80.3%)
Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	424	4221.4/4327 = 97.6% (94.1%, 99.0%)	4221.4/4327 = 97.6% (94.1%, 99.0%)	4114.1/4327 = 95.1% (91.0%, 97.4%)
Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	120	497.5/500 = 99.5% (96.4%, 99.9%)	497.5/500 = 99.5% (96.4%, 99.9%)	497.5/500 = 99.5% (96.4%, 99.9%)
Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	63	0/4329 = 0.0% (0.0%, 0.0%)	0/4329 = 0.0% (0.0%, 0.0%)	0/4329 = 0.0% (0.0%, 0.0%)
Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	124	394.6/427 = 92.4% (82.2%, 97.0%)	394.6/427 = 92.4% (82.2%, 97.0%)	381.1/427 = 89.3% (78.9%, 94.9%)
White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	355	5910.4/6572.1 = 89.9% (84.4%, 93.6%)	5910.4/6572.1 = 89.9% (84.4%, 93.6%)	5492.3/6572.1 = 83.6% (77.5%, 88.3%)
White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	121	609.1/681.2 = 89.4% (77.8%, 95.3%)	609.1/681.2 = 89.4% (77.8%, 95.3%)	590.3/681.2 = 86.7% (74.6%, 93.5%)
White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	64	266.3/5953.5 = 4.5% (0.8%, 21.1%)	266.3/5953.5 = 4.5% (0.8%, 21.1%)	0/5953.5 = 0.0% (0.0%, 0.0%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	116	582/726.6 = 80.1% (68.0%, 88.4%)	582/726.6 = 80.1% (68.0%, 88.4%)	429.9/726.6 = 59.2% (46.5%, 70.7%)
White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	355	6487.7/6572.1 = 98.7% (95.8%, 99.6%)	6487.7/6572.1 = 98.7% (95.8%, 99.6%)	6467.5/6572.1 = 98.4% (95.7%, 99.4%)
White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	121	681.2/681.2 = 100.0% (100.0%, 100.0%)	681.2/681.2 = 100.0% (100.0%, 100.0%)	681.2/681.2 = 100.0% (100.0%, 100.0%)
White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	64	46.8/5953.5 = 0.8% (0.1%, 5.6%)	46.8/5953.5 = 0.8% (0.1%, 5.6%)	0/5953.5 = 0.0% (0.0%, 0.0%)
White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	116	692.7/726.6 = 95.3% (84.7%, 98.7%)	692.7/726.6 = 95.3% (84.7%, 98.7%)	663.4/726.6 = 91.3% (80.9%, 96.3%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4j. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age, Underrepresented minority status								
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	203	2887.2/3401 = 84.9% (78.1%, 89.8%)	2887.2/3401 = 84.9% (78.1%, 89.8%)	2420.5/3401 = 71.2% (63.3%, 78.0%)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	66	372.4/404 = 92.2% (79.2%, 97.3%)	374.9/404 = 92.8% (79.5%, 97.7%)	328.5/404 = 81.3% (66.9%, 90.3%)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	29	0/3308 = 0.0% (0.0%, 0.0%)	0/3308 = 0.0% (0.0%, 0.0%)	0/3308 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	66	262.6/322 = 81.5% (67.9%, 90.2%)	262.6/322 = 81.5% (67.9%, 90.2%)	218.5/322 = 67.9% (53.2%, 79.7%)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	203	3299.6/3401 = 97.0% (92.6%, 98.8%)	3299.6/3401 = 97.0% (92.6%, 98.8%)	3204.8/3401 = 94.2% (89.0%, 97.1%)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	66	401.5/404 = 99.4% (95.5%, 99.9%)	401.5/404 = 99.4% (95.5%, 99.9%)	401.5/404 = 99.4% (95.5%, 99.9%)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	29	0/3308 = 0.0% (0.0%, 0.0%)	0/3308 = 0.0% (0.0%, 0.0%)	0/3308 = 0.0% (0.0%, 0.0%)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	66	291.4/322 = 90.5% (76.9%, 96.5%)	291.4/322 = 90.5% (76.9%, 96.5%)	278/322 = 86.3% (72.8%, 93.7%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	177	4587.3/5202.9 = 88.2% (81.2%, 92.8%)	4587.3/5202.9 = 88.2% (81.2%, 92.8%)	4215.4/5202.9 = 81.0% (73.4%, 86.8%)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	57	462/529.4 = 87.3% (72.2%, 94.8%)	462/529.4 = 87.3% (72.2%, 94.8%)	443.3/529.4 = 83.7% (68.3%, 92.5%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	31	219.5/4408.3 = 5.0% (0.6%, 30.5%)	219.5/4408.3 = 5.0% (0.6%, 30.5%)	0/4408.3 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	61	453.5/587.9 = 77.1% (62.3%, 87.3%)	453.5/587.9 = 77.1% (62.3%, 87.3%)	306.4/587.9 = 52.1% (37.3%, 66.6%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	177	5118.5/5202.9 = 98.4% (94.7%, 99.5%)	5118.5/5202.9 = 98.4% (94.7%, 99.5%)	5106/5202.9 = 98.1% (94.6%, 99.4%)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	57	529.4/529.4 = 100.0% (100.0%, 100.0%)	529.4/529.4 = 100.0% (100.0%, 100.0%)	529.4/529.4 = 100.0% (100.0%, 100.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	31	0/4408.3 = 0.0% (0.0%, 0.0%)	0/4408.3 = 0.0% (0.0%, 0.0%)	0/4408.3 = 0.0% (0.0%, 0.0%)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	61	554.1/587.9 = 94.2% (81.1%, 98.4%)	554.1/587.9 = 94.2% (81.1%, 98.4%)	524.7/587.9 = 89.2% (76.5%, 95.5%)
Age ≥ 65 Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	221	905/926 = 97.7% (94.6%, 99.1%)	905/926 = 97.7% (94.6%, 99.1%)	867.3/926 = 93.7% (89.6%, 96.2%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age ≥ 65 Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	54	94.2/96 = 98.1% (87.4%, 99.8%)	94.2/96 = 98.1% (87.4%, 99.8%)	90.7/96 = 94.4% (83.7%, 98.3%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	34	0/1021 = 0.0% (0.0%, 0.0%)	0/1021 = 0.0% (0.0%, 0.0%)	0/1021 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	58	94.1/105 = 89.7% (78.5%, 95.4%)	94.1/105 = 89.7% (78.5%, 95.4%)	85.1/105 = 81.0% (68.5%, 89.3%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	221	921.8/926 = 99.5% (96.8%, 99.9%)	921.8/926 = 99.5% (96.8%, 99.9%)	909.2/926 = 98.2% (95.2%, 99.3%)
Age ≥ 65 Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	54	96/96 = 100.0% (100.0%, 100.0%)	96/96 = 100.0% (100.0%, 100.0%)	96/96 = 100.0% (100.0%, 100.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	34	0/1021 = 0.0% (0.0%, 0.0%)	0/1021 = 0.0% (0.0%, 0.0%)	0/1021 = 0.0% (0.0%, 0.0%)
Age ≥ 65 Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	58	103.2/105 = 98.3% (88.2%, 99.8%)	103.2/105 = 98.3% (88.2%, 99.8%)	103.2/105 = 98.3% (88.2%, 99.8%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	178	1323.1/1369.2 = 96.6% (92.7%, 98.5%)	1323.1/1369.2 = 96.6% (92.7%, 98.5%)	1276.9/1369.2 = 93.3% (88.5%, 96.2%)
Age ≥ 65 White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	64	147.1/151.8 = 96.9% (88.0%, 99.2%)	147.1/151.8 = 96.9% (88.0%, 99.2%)	147.1/151.8 = 96.9% (88.0%, 99.2%)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Responder	% 2-Fold Rise	% 4-Fold Rise
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	33	46.8/1545.1 = 3.0% (0.4%, 20.2%)	46.8/1545.1 = 3.0% (0.4%, 20.2%)	0/1545.1 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	55	128.5/138.6 = 92.7% (81.8%, 97.3%)	128.5/138.6 = 92.7% (81.8%, 97.3%)	123.5/138.6 = 89.1% (77.4%, 95.1%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	178	1369.2/1369.2 = 100.0% (100.0%, 100.0%)	1369.2/1369.2 = 100.0%	1361.5/1369.2 = 99.4% (96.1%, 99.9%)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	64	151.8/151.8 = 100.0% (100.0%, 100.0%)	151.8/151.8 = 100.0% (100.0%, 100.0%)	151.8/151.8 = 100.0% (100.0%, 100.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	33	46.8/1545.1 = 3.0% (0.4%, 20.2%)	46.8/1545.1 = 3.0% (0.4%, 20.2%)	0/1545.1 = 0.0% (0.0%, 0.0%)
Age ≥ 65 White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	55	138.6/138.6 = 100.0% (100.0%, 100.0%)	138.6/138.6 = 100.0% (100.0%, 100.0%)	138.6/138.6 = 100.0% (100.0%, 100.0%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 5a. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by All participants

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
All participants						
	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	904	0.02 (0.02, 0.02)
	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	904	0.27 (0.27, 0.27)
	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	904	0.09 (0.09, 0.09)
	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	904	5.07 (5.02, 5.12)
	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	904	5.15 (5.06, 5.24)
	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	277	0.02 (0.02, 0.02)
	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	277	0.27 (0.27, 0.27)
	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	277	0.09 (0.09, 0.09)
	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	277	5.03 (5.00, 5.06)
	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	277	5.07 (4.96, 5.19)
	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	155	0.02 (0.02, 0.02)
	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	155	0.27 (0.27, 0.27)
	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	155	0.09 (0.09, 0.09)
	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	155	5.07 (4.99, 5.15)
	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	155	5.02 (4.98, 5.06)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	274	0.02 (0.02, 0.02)
	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	274	0.27 (0.27, 0.28)
	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	274	0.09 (0.09, 0.09)
	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	274	5.10 (4.96, 5.25)
	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	274	5.15 (4.97, 5.34)
	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	904	63.36 (53.33, 75.29)
	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	904	777.30 (672.65, 898.24)
	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	904	448.95 (396.45, 508.40)
	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	904	117.24 (99.65, 137.93)
	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	904	193.83 (167.92, 223.73)
	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	277	78.60 (59.10, 104.52)
	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	277	984.50 (773.66, 1252.81)
	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	277	634.79 (519.07, 776.30)
	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	277	145.91 (113.68, 187.28)
	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	277	250.06 (195.89, 319.20)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	155	0.02 (0.02, 0.02)
	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	155	0.27 (0.27, 0.27)
	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	155	0.09 (0.09, 0.09)
	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	155	5.08 (4.95, 5.22)
	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	155	5.00 (5.00, 5.00)
	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	274	32.90 (24.99, 43.30)
	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	274	309.30 (239.29, 399.78)
	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	274	163.46 (132.49, 201.67)
	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	274	56.68 (42.71, 75.22)
	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	274	146.22 (113.10, 189.03)
	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	904	948.86 (771.45, 1167.08)
	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	904	34021.35 (29123.06, 39743.51)
	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	904	22817.97 (19944.94, 26104.85)
	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	904	1091.69 (937.63, 1271.06)
	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	904	806.40 (739.65, 879.17)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	277	1975.01 (1440.49, 2707.88)
	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	277	62681.63 (48801.94, 80508.81)
	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	277	42910.81 (34675.79, 53101.53)
	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	277	1909.96 (1589.03, 2295.71)
	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	277	1044.34 (942.43, 1157.26)
	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	155	0.02 (0.02, 0.02)
	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	155	0.27 (0.27, 0.28)
	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	155	0.09 (0.09, 0.09)
	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	155	5.04 (4.99, 5.09)
	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	155	5.05 (4.99, 5.10)
	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	274	385.82 (284.09, 523.97)
	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	274	13410.80 (10185.37, 17657.62)
	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	274	8203.97 (6577.21, 10233.09)
	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	274	469.42 (339.51, 649.04)
	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	274	612.04 (506.61, 739.40)

Table 5b. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age						
Age < 65	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	436	0.02 (0.02, 0.02)
Age < 65	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	436	0.27 (0.27, 0.27)
Age < 65	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	436	0.09 (0.09, 0.09)
Age < 65	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	436	5.07 (5.01, 5.13)
Age < 65	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	436	5.15 (5.04, 5.27)
Age < 65	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	145	0.02 (0.02, 0.02)
Age < 65	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	145	0.27 (0.27, 0.27)
Age < 65	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	145	0.09 (0.09, 0.09)
Age < 65	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	145	5.02 (4.99, 5.06)
Age < 65	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	145	5.07 (4.93, 5.22)
Age < 65	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	76	0.02 (0.02, 0.02)
Age < 65	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	76	0.27 (0.27, 0.27)
Age < 65	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	76	0.09 (0.09, 0.09)
Age < 65	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	76	5.06 (4.98, 5.14)
Age < 65	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	76	5.02 (4.98, 5.07)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	143	0.02 (0.02, 0.02)
Age < 65	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	143	0.27 (0.27, 0.28)
Age < 65	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	143	0.09 (0.09, 0.09)
Age < 65	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	143	5.13 (4.95, 5.32)
Age < 65	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	143	5.18 (4.95, 5.42)
Age < 65	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	436	49.48 (39.93, 61.31)
Age < 65	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	436	601.50 (502.70, 719.72)
Age < 65	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	436	343.47 (294.48, 400.61)
Age < 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	436	94.35 (77.13, 115.43)
Age < 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	436	168.42 (140.81, 201.44)
Age < 65	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	145	58.15 (41.19, 82.10)
Age < 65	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	145	747.42 (558.26, 1000.66)
Age < 65	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	145	482.24 (378.08, 615.10)
Age < 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	145	111.36 (82.40, 150.49)
Age < 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	145	213.95 (158.62, 288.57)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	76	0.02 (0.02, 0.02)
Age < 65	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	76	0.27 (0.27, 0.27)
Age < 65	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	76	0.09 (0.09, 0.09)
Age < 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	76	5.09 (4.92, 5.26)
Age < 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	76	5.00 (5.00, 5.00)
Age < 65	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	143	25.43 (18.13, 35.66)
Age < 65	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	143	220.21 (160.47, 302.20)
Age < 65	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	143	115.82 (89.55, 149.79)
Age < 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	143	44.02 (30.99, 62.52)
Age < 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	143	130.40 (94.72, 179.52)
Age < 65	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	436	733.10 (566.69, 948.39)
Age < 65	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	436	26634.96 (21956.62, 32310.13)
Age < 65	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	436	18271.32 (15460.07, 21593.77)
Age < 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	436	929.19 (768.12, 1124.03)
Age < 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	436	765.89 (687.32, 853.45)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	145	1514.86 (1031.50, 2224.72)
Age < 65	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	145	48036.51 (35397.18, 65188.99)
Age < 65	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	145	33661.72 (25910.34, 43732.02)
Age < 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	145	1673.79 (1334.76, 2098.95)
Age < 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	145	1008.82 (888.79, 1145.06)
Age < 65	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	76	0.02 (0.02, 0.02)
Age < 65	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	76	0.27 (0.27, 0.27)
Age < 65	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	76	0.09 (0.09, 0.09)
Age < 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	76	5.00 (5.00, 5.00)
Age < 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	76	5.00 (5.00, 5.00)
Age < 65	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	143	278.96 (191.64, 406.09)
Age < 65	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	143	9984.20 (7103.43, 14033.26)
Age < 65	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	143	6184.92 (4705.38, 8129.67)
Age < 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	143	332.09 (221.26, 498.44)
Age < 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	143	557.94 (440.51, 706.67)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	468	0.02 (0.02, 0.02)
Age \geq 65	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	468	0.27 (0.27, 0.27)
Age \geq 65	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	468	0.09 (0.09, 0.09)
Age \geq 65	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	468	5.06 (5.01, 5.10)
Age \geq 65	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	468	5.14 (5.05, 5.23)
Age \geq 65	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	132	0.02 (0.02, 0.02)
Age \geq 65	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	132	0.27 (0.27, 0.28)
Age \geq 65	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	132	0.09 (0.09, 0.09)
Age \geq 65	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	132	5.04 (4.96, 5.11)
Age \geq 65	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	132	5.06 (4.98, 5.14)
Age \geq 65	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	79	0.02 (0.02, 0.02)
Age \geq 65	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	79	0.27 (0.27, 0.27)
Age \geq 65	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	79	0.09 (0.09, 0.09)
Age \geq 65	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	79	5.11 (4.89, 5.34)
Age \geq 65	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	79	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	131	0.02 (0.02, 0.02)
Age \geq 65	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	131	0.27 (0.27, 0.27)
Age \geq 65	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	131	0.09 (0.09, 0.09)
Age \geq 65	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	131	5.00 (5.00, 5.00)
Age \geq 65	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	131	5.04 (4.97, 5.10)
Age \geq 65	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	468	157.96 (134.11, 186.05)
Age \geq 65	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	468	2003.94 (1740.39, 2307.40)
Age \geq 65	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	468	1207.29 (1064.30, 1369.49)
Age \geq 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	468	261.49 (222.30, 307.60)
Age \geq 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	468	325.70 (287.35, 369.18)
Age \geq 65	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	132	270.01 (200.47, 363.68)
Age \geq 65	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	132	3043.22 (2390.56, 3874.05)
Age \geq 65	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	132	1956.81 (1615.37, 2370.41)
Age \geq 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	132	441.37 (335.16, 581.26)
Age \geq 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	132	473.68 (388.74, 577.17)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age ≥ 65	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	79	0.02 (0.02, 0.02)
Age ≥ 65	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	79	0.27 (0.27, 0.27)
Age ≥ 65	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	79	0.09 (0.09, 0.09)
Age ≥ 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	79	5.06 (4.94, 5.18)
Age ≥ 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	79	5.00 (5.00, 5.00)
Age ≥ 65	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	131	83.73 (61.42, 114.13)
Age ≥ 65	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	131	1060.22 (819.23, 1372.09)
Age ≥ 65	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	131	570.26 (458.39, 709.44)
Age ≥ 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	131	141.75 (106.66, 188.39)
Age ≥ 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	131	221.47 (171.65, 285.77)
Age ≥ 65	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	468	2460.53 (2025.23, 2989.41)
Age ≥ 65	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	468	84018.56 (72438.21, 97450.20)
Age ≥ 65	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	468	51847.95 (45512.24, 59065.64)
Age ≥ 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	468	1979.85 (1753.25, 2235.73)
Age ≥ 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	468	975.49 (911.97, 1043.43)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	132	5853.72 (4347.27, 7882.18)
Age \geq 65	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	132	186431.80 (151641.75, 229203.47)
Age \geq 65	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	132	115989.53 (103450.48, 130048.43)
Age \geq 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	132	3279.60 (2909.89, 3696.28)
Age \geq 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	132	1203.35 (1127.90, 1283.84)
Age \geq 65	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	79	0.02 (0.02, 0.02)
Age \geq 65	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	79	0.28 (0.27, 0.30)
Age \geq 65	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	79	0.09 (0.09, 0.09)
Age \geq 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	79	5.19 (4.98, 5.41)
Age \geq 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	79	5.21 (4.98, 5.45)
Age \geq 65	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	131	1250.50 (875.00, 1787.13)
Age \geq 65	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	131	39096.03 (29650.90, 51549.86)
Age \geq 65	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	131	22852.60 (18500.67, 28228.25)
Age \geq 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	131	1646.62 (1311.92, 2066.72)
Age \geq 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	131	856.08 (722.74, 1014.03)

Table 5c. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Risk for Severe Covid-19						
At-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	459	0.02 (0.02, 0.02)
At-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	459	0.27 (0.27, 0.27)
At-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	459	0.09 (0.09, 0.09)
At-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	459	5.15 (5.06, 5.24)
At-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	459	5.16 (5.07, 5.25)
At-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	126	0.02 (0.02, 0.02)
At-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	126	0.27 (0.27, 0.27)
At-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	126	0.09 (0.09, 0.09)
At-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	126	5.08 (4.97, 5.18)
At-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	126	5.00 (5.00, 5.00)
At-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	76	0.02 (0.02, 0.02)
At-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	76	0.27 (0.27, 0.27)
At-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	76	0.09 (0.09, 0.09)
At-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	76	5.15 (4.94, 5.38)
At-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	76	5.06 (4.94, 5.19)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
At-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	124	0.02 (0.02, 0.02)
At-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	124	0.27 (0.27, 0.27)
At-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	124	0.09 (0.09, 0.09)
At-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	124	5.00 (5.00, 5.00)
At-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	124	5.11 (4.95, 5.28)
At-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	459	67.46 (57.00, 79.84)
At-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	459	841.10 (722.34, 979.38)
At-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	459	495.50 (428.93, 572.41)
At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	459	121.68 (102.86, 143.94)
At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	459	218.15 (188.84, 252.00)
At-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	126	132.96 (99.20, 178.21)
At-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	126	1257.23 (946.57, 1669.85)
At-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	126	803.87 (630.99, 1024.11)
At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	126	234.48 (175.57, 313.16)
At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	126	321.34 (259.19, 398.39)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
At-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	76	0.02 (0.02, 0.02)
At-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	76	0.27 (0.27, 0.27)
At-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	76	0.09 (0.09, 0.09)
At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	76	5.05 (4.96, 5.14)
At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	76	5.00 (5.00, 5.00)
At-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	124	39.92 (28.50, 55.92)
At-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	124	477.57 (352.49, 647.04)
At-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	124	251.11 (189.50, 332.74)
At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	124	65.19 (47.23, 89.97)
At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	124	143.05 (107.61, 190.16)
At-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	459	997.20 (804.46, 1236.11)
At-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	459	35753.79 (29958.65, 42669.94)
At-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	459	23580.58 (20304.48, 27385.28)
At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	459	1193.53 (1021.96, 1393.91)
At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	459	800.06 (727.31, 880.08)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
At-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	126	2635.43 (1827.75, 3800.01)
At-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	126	83821.23 (63170.57, 111222.66)
At-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	126	58491.48 (47881.59, 71452.37)
At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	126	2187.05 (1816.71, 2632.89)
At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	126	1131.34 (1025.26, 1248.40)
At-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	76	0.02 (0.02, 0.02)
At-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	76	0.28 (0.27, 0.29)
At-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	76	0.09 (0.09, 0.09)
At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	76	5.11 (4.96, 5.26)
At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	76	5.06 (4.94, 5.18)
At-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	124	408.78 (269.73, 619.51)
At-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	124	15489.70 (10811.98, 22191.21)
At-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	124	10107.03 (7648.71, 13355.45)
At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	124	601.53 (426.45, 848.48)
At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	124	589.31 (462.01, 751.67)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not at-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	445	0.02 (0.02, 0.02)
Not at-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	445	0.27 (0.27, 0.27)
Not at-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	445	0.09 (0.09, 0.09)
Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	445	5.04 (4.98, 5.10)
Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	445	5.15 (5.03, 5.27)
Not at-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	151	0.02 (0.02, 0.02)
Not at-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	151	0.27 (0.27, 0.27)
Not at-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	151	0.09 (0.09, 0.09)
Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	151	5.01 (4.99, 5.03)
Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	151	5.09 (4.94, 5.25)
Not at-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	79	0.02 (0.02, 0.02)
Not at-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	79	0.27 (0.27, 0.27)
Not at-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	79	0.09 (0.09, 0.09)
Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	79	5.04 (4.96, 5.11)
Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	79	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not at-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	150	0.02 (0.02, 0.02)
Not at-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	150	0.27 (0.27, 0.28)
Not at-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	150	0.09 (0.09, 0.09)
Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	150	5.14 (4.95, 5.33)
Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	150	5.16 (4.93, 5.40)
Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	445	61.93 (49.31, 77.77)
Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	445	755.22 (624.42, 913.41)
Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	445	433.06 (368.18, 509.36)
Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	445	115.66 (93.41, 143.21)
Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	445	185.63 (153.69, 224.22)
Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	151	66.27 (45.97, 95.54)
Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	151	909.42 (669.45, 1235.39)
Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	151	587.97 (455.33, 759.26)
Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	151	125.09 (91.08, 171.80)
Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	151	230.52 (168.09, 316.14)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	79	0.02 (0.02, 0.02)
Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	79	0.27 (0.27, 0.27)
Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	79	0.09 (0.09, 0.09)
Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	79	5.10 (4.91, 5.29)
Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	79	5.00 (5.00, 5.00)
Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	150	30.99 (21.96, 43.75)
Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	150	270.59 (195.86, 373.82)
Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	150	143.23 (110.23, 186.11)
Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	150	54.29 (37.98, 77.61)
Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	150	147.21 (106.42, 203.64)
Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	445	931.80 (709.86, 1223.11)
Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	445	33409.52 (27278.73, 40918.18)
Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	445	22545.52 (18907.87, 26883.01)
Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	445	1056.69 (865.07, 1290.75)
Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	445	808.73 (722.49, 905.26)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	151	1798.55 (1204.14, 2686.40)
Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	151	57041.52 (41456.48, 78485.57)
Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	151	38807.95 (29472.44, 51100.52)
Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	151	1827.83 (1443.12, 2315.10)
Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	151	1017.57 (891.59, 1161.35)
Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	79	0.02 (0.02, 0.02)
Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	79	0.27 (0.27, 0.27)
Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	79	0.09 (0.09, 0.09)
Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	79	5.02 (4.98, 5.05)
Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	79	5.04 (4.98, 5.10)
Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	150	379.01 (259.03, 554.56)
Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	150	12828.98 (9099.71, 18086.59)
Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	150	7693.80 (5832.20, 10149.62)
Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	150	434.92 (288.21, 656.31)
Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	150	619.21 (489.12, 783.89)

Table 5d. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age, Risk for Severe Covid-19						
Age < 65 At-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	216	0.02 (0.02, 0.02)
Age < 65 At-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	216	0.27 (0.27, 0.27)
Age < 65 At-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	216	0.09 (0.09, 0.09)
Age < 65 At-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	216	5.20 (5.06, 5.34)
Age < 65 At-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	216	5.12 (5.01, 5.23)
Age < 65 At-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	72	0.02 (0.02, 0.02)
Age < 65 At-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	72	0.27 (0.27, 0.27)
Age < 65 At-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	72	0.09 (0.09, 0.09)
Age < 65 At-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	72	5.11 (4.95, 5.28)
Age < 65 At-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	72	5.00 (5.00, 5.00)
Age < 65 At-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	36	0.02 (0.02, 0.02)
Age < 65 At-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	36	0.27 (0.27, 0.27)
Age < 65 At-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	36	0.09 (0.09, 0.09)
Age < 65 At-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	36	5.26 (4.90, 5.65)
Age < 65 At-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	36	5.11 (4.90, 5.32)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 At-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	70	0.02 (0.02, 0.02)
Age < 65 At-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	70	0.27 (0.27, 0.27)
Age < 65 At-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	70	0.09 (0.09, 0.09)
Age < 65 At-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	70	5.00 (5.00, 5.00)
Age < 65 At-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	70	5.12 (4.88, 5.38)
Age < 65 At-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	216	41.35 (32.75, 52.22)
Age < 65 At-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	216	475.30 (388.65, 581.26)
Age < 65 At-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	216	283.75 (233.55, 344.73)
Age < 65 At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	216	81.30 (64.37, 102.68)
Age < 65 At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	216	168.01 (136.18, 207.28)
Age < 65 At-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	72	92.48 (63.69, 134.30)
Age < 65 At-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	72	717.17 (505.98, 1016.50)
Age < 65 At-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	72	481.71 (356.55, 650.82)
Age < 65 At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	72	160.60 (110.70, 233.01)
Age < 65 At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	72	258.36 (195.07, 342.19)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 At-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	36	0.02 (0.02, 0.02)
Age < 65 At-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	36	0.27 (0.27, 0.27)
Age < 65 At-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	36	0.09 (0.09, 0.10)
Age < 65 At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	36	5.00 (5.00, 5.00)
Age < 65 At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	36	5.00 (5.00, 5.00)
Age < 65 At-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	70	23.90 (15.59, 36.63)
Age < 65 At-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	70	261.98 (178.78, 383.89)
Age < 65 At-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	70	139.57 (97.93, 198.92)
Age < 65 At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	70	37.06 (24.59, 55.86)
Age < 65 At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	70	107.20 (73.46, 156.42)
Age < 65 At-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	216	585.44 (433.35, 790.90)
Age < 65 At-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	216	23964.79 (18603.91, 30870.46)
Age < 65 At-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	216	16261.39 (13217.49, 20006.28)
Age < 65 At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	216	922.94 (735.66, 1157.89)
Age < 65 At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	216	701.04 (606.26, 810.65)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 At-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	72	1516.96 (931.33, 2470.83)
Age < 65 At-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	72	53858.28 (36660.92, 79122.78)
Age < 65 At-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	72	40724.37 (31129.20, 53277.12)
Age < 65 At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	72	1689.07 (1299.65, 2195.16)
Age < 65 At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	72	1083.16 (936.68, 1252.55)
Age < 65 At-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	36	0.02 (0.02, 0.02)
Age < 65 At-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	36	0.27 (0.27, 0.27)
Age < 65 At-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	36	0.09 (0.09, 0.09)
Age < 65 At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	36	5.00 (5.00, 5.00)
Age < 65 At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	36	5.00 (5.00, 5.00)
Age < 65 At-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	70	225.66 (131.53, 387.15)
Age < 65 At-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	70	8114.34 (5005.11, 13155.05)
Age < 65 At-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	70	5934.45 (4109.64, 8569.54)
Age < 65 At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	70	336.50 (209.06, 541.63)
Age < 65 At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	70	488.63 (345.36, 691.33)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Not at-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	220	0.02 (0.02, 0.02)
Age < 65 Not at-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	220	0.27 (0.27, 0.27)
Age < 65 Not at-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	220	0.09 (0.09, 0.09)
Age < 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	220	5.04 (4.97, 5.11)
Age < 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	220	5.16 (5.02, 5.30)
Age < 65 Not at-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	73	0.02 (0.02, 0.02)
Age < 65 Not at-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	73	0.27 (0.27, 0.27)
Age < 65 Not at-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	73	0.09 (0.09, 0.09)
Age < 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	73	5.00 (5.00, 5.00)
Age < 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	73	5.09 (4.91, 5.27)
Age < 65 Not at-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	40	0.02 (0.02, 0.02)
Age < 65 Not at-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	40	0.27 (0.27, 0.27)
Age < 65 Not at-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	40	0.09 (0.09, 0.09)
Age < 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	40	5.00 (5.00, 5.00)
Age < 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	40	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Not at-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	73	0.02 (0.02, 0.02)
Age < 65 Not at-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	73	0.27 (0.27, 0.28)
Age < 65 Not at-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	73	0.09 (0.09, 0.09)
Age < 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	73	5.16 (4.94, 5.40)
Age < 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	73	5.20 (4.92, 5.49)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	220	51.77 (39.84, 67.28)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	220	638.34 (512.85, 794.54)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	220	360.44 (299.15, 434.28)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	220	97.97 (76.64, 125.23)
Age < 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	220	168.52 (135.53, 209.55)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	73	51.66 (33.87, 78.78)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	73	755.34 (529.48, 1077.54)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	73	482.38 (358.92, 648.31)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	73	101.42 (70.36, 146.19)
Age < 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	73	203.89 (141.04, 294.76)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	40	0.02 (0.02, 0.02)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	40	0.27 (0.27, 0.27)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	40	0.09 (0.09, 0.09)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	40	5.11 (4.89, 5.34)
Age < 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	40	5.00 (5.00, 5.00)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	73	25.79 (17.21, 38.66)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	73	211.53 (144.72, 309.18)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	73	110.92 (81.69, 150.61)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	73	45.81 (30.06, 69.82)
Age < 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	73	136.45 (92.97, 200.28)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	220	775.93 (567.18, 1061.53)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	220	27354.86 (21662.37, 34543.24)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	220	18816.87 (15365.96, 23042.79)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	220	930.77 (738.46, 1173.17)
Age < 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	220	783.19 (687.36, 892.38)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	73	1514.32 (950.21, 2413.32)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	73	46654.53 (32211.81, 67572.90)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	73	32064.78 (23256.01, 44210.08)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	73	1669.92 (1267.00, 2200.96)
Age < 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	73	990.68 (848.77, 1156.32)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	40	0.02 (0.02, 0.02)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	40	0.27 (0.27, 0.27)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	40	0.09 (0.09, 0.09)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	40	5.00 (5.00, 5.00)
Age < 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	40	5.00 (5.00, 5.00)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	73	293.00 (187.73, 457.29)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	73	10475.19 (6993.92, 15689.26)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	73	6244.39 (4508.26, 8649.11)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	73	331.08 (203.28, 539.23)
Age < 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	73	575.34 (434.97, 761.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 At-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	243	0.02 (0.02, 0.02)
Age \geq 65 At-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	243	0.27 (0.27, 0.27)
Age \geq 65 At-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	243	0.09 (0.09, 0.09)
Age \geq 65 At-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	243	5.08 (5.00, 5.16)
Age \geq 65 At-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	243	5.21 (5.06, 5.37)
Age \geq 65 At-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	54	0.02 (0.02, 0.02)
Age \geq 65 At-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	54	0.27 (0.27, 0.27)
Age \geq 65 At-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	54	0.09 (0.09, 0.09)
Age \geq 65 At-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	54	5.00 (5.00, 5.00)
Age \geq 65 At-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	54	5.00 (5.00, 5.00)
Age \geq 65 At-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	40	0.02 (0.02, 0.02)
Age \geq 65 At-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	40	0.27 (0.27, 0.27)
Age \geq 65 At-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	40	0.09 (0.09, 0.09)
Age \geq 65 At-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	40	5.00 (5.00, 5.00)
Age \geq 65 At-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	40	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 At-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	54	0.02 (0.02, 0.02)
Age \geq 65 At-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	54	0.27 (0.27, 0.27)
Age \geq 65 At-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	54	0.09 (0.09, 0.09)
Age \geq 65 At-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	54	5.00 (5.00, 5.00)
Age \geq 65 At-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	54	5.09 (4.92, 5.26)
Age \geq 65 At-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	243	137.54 (109.88, 172.15)
Age \geq 65 At-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	243	1930.48 (1558.13, 2391.79)
Age \geq 65 At-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	243	1115.50 (918.52, 1354.74)
Age \geq 65 At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	243	218.83 (174.58, 274.29)
Age \geq 65 At-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	243	319.04 (267.97, 379.85)
Age \geq 65 At-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	54	275.15 (180.68, 419.04)
Age \geq 65 At-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	54	3871.45 (2641.46, 5674.19)
Age \geq 65 At-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	54	2242.72 (1665.25, 3020.44)
Age \geq 65 At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	54	500.50 (336.81, 743.72)
Age \geq 65 At-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	54	497.49 (371.34, 666.51)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 At-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	40	0.02 (0.02, 0.02)
Age \geq 65 At-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	40	0.27 (0.27, 0.27)
Age \geq 65 At-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	40	0.09 (0.09, 0.09)
Age \geq 65 At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	40	5.12 (4.89, 5.35)
Age \geq 65 At-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	40	5.00 (5.00, 5.00)
Age \geq 65 At-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	54	94.29 (58.02, 153.24)
Age \geq 65 At-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	54	1305.33 (870.22, 1957.98)
Age \geq 65 At-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	54	671.39 (465.80, 967.71)
Age \geq 65 At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	54	167.83 (108.18, 260.37)
Age \geq 65 At-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	54	231.89 (155.85, 345.05)
Age \geq 65 At-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	243	2165.00 (1634.23, 2868.15)
Age \geq 65 At-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	243	64007.31 (51284.51, 79886.41)
Age \geq 65 At-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	243	40502.61 (33105.81, 49552.07)
Age \geq 65 At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	243	1735.27 (1440.81, 2089.92)
Age \geq 65 At-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	243	969.70 (879.08, 1069.67)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 At-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	54	7970.17 (5316.57, 11948.24)
Age \geq 65 At-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	54	203350.87 (155935.94, 265183.11)
Age \geq 65 At-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	54	120818.40 (100844.20, 144748.88)
Age \geq 65 At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	54	3670.16 (3243.62, 4152.80)
Age \geq 65 At-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	54	1234.43 (1178.85, 1292.64)
Age \geq 65 At-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	40	0.02 (0.02, 0.02)
Age \geq 65 At-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	40	0.29 (0.27, 0.32)
Age \geq 65 At-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	40	0.09 (0.09, 0.09)
Age \geq 65 At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	40	5.27 (4.91, 5.66)
Age \geq 65 At-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	40	5.15 (4.86, 5.45)
Age \geq 65 At-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	54	1105.54 (620.86, 1968.58)
Age \geq 65 At-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	54	45733.74 (30214.56, 69224.07)
Age \geq 65 At-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	54	24651.80 (17720.18, 34294.86)
Age \geq 65 At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	54	1591.10 (1106.33, 2288.28)
Age \geq 65 At-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	54	806.46 (610.65, 1065.06)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Not at-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	225	0.02 (0.02, 0.02)
Age \geq 65 Not at-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	225	0.27 (0.27, 0.27)
Age \geq 65 Not at-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	225	0.09 (0.09, 0.09)
Age \geq 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	225	5.04 (4.98, 5.09)
Age \geq 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	225	5.06 (4.97, 5.15)
Age \geq 65 Not at-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	78	0.02 (0.02, 0.02)
Age \geq 65 Not at-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	78	0.27 (0.27, 0.28)
Age \geq 65 Not at-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	78	0.09 (0.09, 0.09)
Age \geq 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	78	5.07 (4.94, 5.19)
Age \geq 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	78	5.10 (4.96, 5.25)
Age \geq 65 Not at-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	39	0.02 (0.02, 0.02)
Age \geq 65 Not at-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	39	0.27 (0.27, 0.27)
Age \geq 65 Not at-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	39	0.09 (0.09, 0.09)
Age \geq 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	39	5.23 (4.79, 5.71)
Age \geq 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	39	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Not at-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	77	0.02 (0.02, 0.02)
Age \geq 65 Not at-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	77	0.27 (0.27, 0.27)
Age \geq 65 Not at-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	77	0.09 (0.09, 0.09)
Age \geq 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	77	5.00 (5.00, 5.00)
Age \geq 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	77	5.00 (5.00, 5.00)
Age \geq 65 Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	225	182.60 (144.14, 231.31)
Age \geq 65 Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	225	2083.86 (1738.41, 2497.95)
Age \geq 65 Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	225	1311.49 (1119.79, 1536.02)
Age \geq 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	225	315.11 (250.46, 396.45)
Age \geq 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	225	332.83 (278.04, 398.42)
Age \geq 65 Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	78	266.41 (176.32, 402.53)
Age \geq 65 Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	78	2564.37 (1893.88, 3472.22)
Age \geq 65 Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	78	1775.92 (1386.69, 2274.41)
Age \geq 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	78	403.63 (277.03, 588.07)
Age \geq 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	78	457.44 (350.62, 596.80)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	39	0.02 (0.02, 0.02)
Age \geq 65 Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	39	0.27 (0.27, 0.27)
Age \geq 65 Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	39	0.09 (0.09, 0.09)
Age \geq 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	39	5.00 (5.00, 5.00)
Age \geq 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	39	5.00 (5.00, 5.00)
Age \geq 65 Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	77	77.17 (51.81, 114.94)
Age \geq 65 Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	77	919.14 (662.16, 1275.84)
Age \geq 65 Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	77	509.80 (390.41, 665.71)
Age \geq 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	77	126.24 (87.25, 182.65)
Age \geq 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	77	214.59 (153.93, 299.17)
Age \geq 65 Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	225	2813.29 (2152.83, 3676.37)
Age \geq 65 Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	225	111705.91 (92654.21, 134675.06)
Age \geq 65 Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	225	67146.45 (57479.15, 78439.67)
Age \geq 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	225	2272.94 (1951.20, 2647.73)
Age \geq 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	225	981.58 (895.48, 1075.96)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	78	4700.04 (3111.72, 7099.08)
Age \geq 65 Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	78	175262.14 (130219.69, 235884.57)
Age \geq 65 Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	78	112673.01 (97324.95, 130441.44)
Age \geq 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	78	3027.38 (2521.27, 3635.08)
Age \geq 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	78	1181.71 (1063.55, 1313.00)
Age \geq 65 Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	39	0.02 (0.02, 0.02)
Age \geq 65 Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	39	0.27 (0.27, 0.27)
Age \geq 65 Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	39	0.09 (0.09, 0.09)
Age \geq 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	39	5.11 (4.90, 5.33)
Age \geq 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	39	5.27 (4.91, 5.66)
Age \geq 65 Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	77	1360.88 (864.11, 2143.24)
Age \geq 65 Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	77	35105.55 (24312.93, 50689.07)
Age \geq 65 Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	77	21693.98 (16545.03, 28445.32)
Age \geq 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	77	1685.86 (1256.66, 2261.65)
Age \geq 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	77	891.91 (721.03, 1103.29)

Table 5e. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Sex						
Male	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	364	0.02 (0.02, 0.02)
Male	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	364	0.27 (0.27, 0.27)
Male	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	364	0.09 (0.09, 0.09)
Male	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	364	5.06 (5.02, 5.11)
Male	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	364	5.03 (5.00, 5.07)
Male	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	115	0.02 (0.02, 0.02)
Male	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	115	0.27 (0.27, 0.27)
Male	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	115	0.09 (0.09, 0.09)
Male	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	115	5.02 (4.98, 5.05)
Male	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	115	5.00 (5.00, 5.00)
Male	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	74	0.02 (0.02, 0.02)
Male	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	74	0.27 (0.27, 0.27)
Male	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	74	0.09 (0.09, 0.09)
Male	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	74	5.11 (4.96, 5.26)
Male	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	74	5.04 (4.96, 5.12)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Male	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	125	0.02 (0.02, 0.02)
Male	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	125	0.27 (0.27, 0.27)
Male	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	125	0.09 (0.09, 0.09)
Male	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	125	5.21 (4.93, 5.50)
Male	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	125	5.21 (4.90, 5.54)
Male	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	364	57.06 (43.56, 74.74)
Male	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	364	711.23 (562.08, 899.96)
Male	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	364	393.31 (325.04, 475.92)
Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	364	105.17 (81.71, 135.38)
Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	364	179.83 (145.66, 222.02)
Male	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	115	75.01 (50.02, 112.48)
Male	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	115	962.36 (673.70, 1374.70)
Male	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	115	654.26 (514.09, 832.66)
Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	115	156.51 (106.13, 230.80)
Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	115	247.12 (169.10, 361.14)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Male	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	74	0.02 (0.02, 0.02)
Male	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	74	0.27 (0.27, 0.27)
Male	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	74	0.09 (0.09, 0.09)
Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	74	5.14 (4.87, 5.43)
Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	74	5.00 (5.00, 5.00)
Male	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	125	39.33 (25.29, 61.19)
Male	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	125	291.14 (184.69, 458.97)
Male	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	125	187.38 (134.52, 261.02)
Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	125	66.68 (42.33, 105.02)
Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	125	150.31 (102.23, 221.00)
Male	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	364	764.04 (551.00, 1059.45)
Male	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	364	32542.98 (25574.73, 41409.83)
Male	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	364	20519.27 (16817.37, 25036.06)
Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	364	964.54 (749.91, 1240.61)
Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	364	795.90 (701.37, 903.17)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Male	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	115	2417.23 (1525.27, 3830.81)
Male	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	115	59109.55 (38797.09, 90056.73)
Male	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	115	42753.89 (29462.81, 62040.76)
Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	115	2103.93 (1618.68, 2734.63)
Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	115	1185.23 (1099.74, 1277.37)
Male	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	74	0.02 (0.02, 0.02)
Male	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	74	0.27 (0.27, 0.27)
Male	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	74	0.09 (0.09, 0.09)
Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	74	5.04 (4.96, 5.12)
Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	74	5.07 (4.97, 5.16)
Male	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	125	462.79 (281.81, 759.98)
Male	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	125	14163.75 (9265.29, 21651.96)
Male	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	125	8370.65 (5941.97, 11792.01)
Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	125	579.25 (348.08, 963.95)
Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	125	642.55 (489.04, 844.26)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Female	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	540	0.02 (0.02, 0.02)
Female	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	540	0.27 (0.27, 0.27)
Female	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	540	0.09 (0.09, 0.09)
Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	540	5.07 (4.99, 5.14)
Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	540	5.22 (5.08, 5.37)
Female	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	162	0.02 (0.02, 0.02)
Female	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	162	0.27 (0.27, 0.27)
Female	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	162	0.09 (0.09, 0.09)
Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	162	5.03 (4.99, 5.07)
Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	162	5.12 (4.93, 5.32)
Female	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	81	0.02 (0.02, 0.02)
Female	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	81	0.27 (0.27, 0.27)
Female	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	81	0.09 (0.09, 0.09)
Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	81	5.04 (4.96, 5.12)
Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	81	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Female	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	149	0.02 (0.02, 0.02)
Female	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	149	0.28 (0.27, 0.28)
Female	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	149	0.09 (0.09, 0.09)
Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	149	5.00 (5.00, 5.00)
Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	149	5.09 (4.92, 5.27)
Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	540	67.69 (54.02, 84.83)
Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	540	822.09 (682.80, 989.78)
Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	540	488.02 (413.82, 575.52)
Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	540	125.55 (101.50, 155.30)
Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	540	203.21 (167.51, 246.51)
Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	162	81.10 (54.38, 120.94)
Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	162	999.64 (720.53, 1386.86)
Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	162	622.05 (460.79, 839.75)
Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	162	139.20 (99.56, 194.63)
Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	162	252.05 (182.95, 347.23)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	81	0.02 (0.02, 0.02)
Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	81	0.27 (0.27, 0.27)
Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	81	0.09 (0.09, 0.09)
Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	81	5.03 (4.98, 5.08)
Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	81	5.00 (5.00, 5.00)
Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	149	27.35 (19.64, 38.09)
Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	149	329.24 (251.93, 430.28)
Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	149	141.95 (108.33, 186.00)
Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	149	47.92 (34.31, 66.94)
Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	149	142.12 (101.26, 199.46)
Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	540	1087.77 (833.22, 1420.09)
Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	540	34987.98 (28491.76, 42965.36)
Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	540	24398.20 (20339.30, 29267.09)
Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	540	1180.35 (974.50, 1429.69)
Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	540	813.09 (723.84, 913.34)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	162	1724.72 (1124.66, 2644.94)
Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	162	65197.56 (47622.50, 89258.68)
Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	162	43016.37 (33165.90, 55792.51)
Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	162	1789.99 (1390.37, 2304.47)
Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	162	959.35 (815.73, 1128.26)
Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	81	0.02 (0.02, 0.02)
Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	81	0.28 (0.27, 0.28)
Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	81	0.09 (0.09, 0.09)
Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	81	5.05 (4.98, 5.12)
Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	81	5.03 (4.97, 5.10)
Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	149	319.71 (223.51, 457.32)
Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	149	12674.85 (8796.36, 18263.44)
Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	149	8035.24 (5989.71, 10779.34)
Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	149	377.76 (256.07, 557.27)
Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	149	582.03 (448.63, 755.09)

Table 5f. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age, sex						
Age < 65 Female	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	262	0.02 (0.02, 0.02)
Age < 65 Female	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	262	0.27 (0.27, 0.27)
Age < 65 Female	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	262	0.09 (0.09, 0.09)
Age < 65 Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	262	5.08 (4.98, 5.18)
Age < 65 Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	262	5.23 (5.05, 5.42)
Age < 65 Female	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	90	0.02 (0.02, 0.02)
Age < 65 Female	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	90	0.27 (0.27, 0.27)
Age < 65 Female	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	90	0.09 (0.09, 0.09)
Age < 65 Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	90	5.02 (4.98, 5.07)
Age < 65 Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	90	5.12 (4.89, 5.36)
Age < 65 Female	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	39	0.02 (0.02, 0.02)
Age < 65 Female	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	39	0.27 (0.27, 0.27)
Age < 65 Female	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	39	0.09 (0.09, 0.09)
Age < 65 Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	39	5.05 (4.95, 5.16)
Age < 65 Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	39	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Female	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	75	0.02 (0.02, 0.02)
Age < 65 Female	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	75	0.28 (0.27, 0.29)
Age < 65 Female	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	75	0.09 (0.09, 0.09)
Age < 65 Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	75	5.00 (5.00, 5.00)
Age < 65 Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	75	5.12 (4.89, 5.36)
Age < 65 Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	262	54.22 (41.05, 71.61)
Age < 65 Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	262	659.71 (525.13, 828.78)
Age < 65 Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	262	385.29 (314.65, 471.79)
Age < 65 Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	262	104.74 (80.61, 136.11)
Age < 65 Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	262	184.27 (145.01, 234.14)
Age < 65 Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	90	63.34 (39.49, 101.60)
Age < 65 Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	90	820.32 (555.86, 1210.61)
Age < 65 Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	90	490.12 (343.28, 699.76)
Age < 65 Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	90	111.71 (75.31, 165.68)
Age < 65 Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	90	226.94 (154.52, 333.29)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	39	0.02 (0.02, 0.02)
Age < 65 Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	39	0.27 (0.27, 0.27)
Age < 65 Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	39	0.09 (0.09, 0.09)
Age < 65 Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	39	5.00 (5.00, 5.00)
Age < 65 Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	39	5.00 (5.00, 5.00)
Age < 65 Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	75	19.88 (13.28, 29.77)
Age < 65 Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	75	226.41 (166.56, 307.78)
Age < 65 Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	75	91.84 (67.85, 124.31)
Age < 65 Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	75	34.12 (22.64, 51.41)
Age < 65 Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	75	121.91 (78.85, 188.47)
Age < 65 Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	262	899.22 (647.08, 1249.61)
Age < 65 Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	262	28155.06 (21852.09, 36276.05)
Age < 65 Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	262	20220.35 (16155.59, 25307.81)
Age < 65 Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	262	1041.80 (821.44, 1321.27)
Age < 65 Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	262	776.65 (671.94, 897.68)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	90	1398.91 (839.80, 2330.25)
Age < 65 Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	90	51957.36 (35768.80, 75472.70)
Age < 65 Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	90	35263.41 (25843.77, 48116.35)
Age < 65 Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	90	1587.57 (1171.32, 2151.75)
Age < 65 Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	90	918.44 (754.74, 1117.65)
Age < 65 Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	39	0.02 (0.02, 0.02)
Age < 65 Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	39	0.27 (0.27, 0.27)
Age < 65 Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	39	0.09 (0.09, 0.09)
Age < 65 Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	39	5.00 (5.00, 5.00)
Age < 65 Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	39	5.00 (5.00, 5.00)
Age < 65 Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	75	203.42 (133.17, 310.71)
Age < 65 Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	75	9035.74 (5737.55, 14229.89)
Age < 65 Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	75	5889.43 (4113.68, 8431.73)
Age < 65 Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	75	232.23 (144.09, 374.30)
Age < 65 Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	75	511.03 (365.19, 715.11)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Male	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	174	0.02 (0.02, 0.02)
Age < 65 Male	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	174	0.27 (0.27, 0.27)
Age < 65 Male	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	174	0.09 (0.09, 0.09)
Age < 65 Male	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	174	5.05 (5.00, 5.10)
Age < 65 Male	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	174	5.03 (4.99, 5.06)
Age < 65 Male	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	55	0.02 (0.02, 0.02)
Age < 65 Male	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	55	0.27 (0.27, 0.27)
Age < 65 Male	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	55	0.09 (0.09, 0.09)
Age < 65 Male	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	55	5.02 (4.98, 5.07)
Age < 65 Male	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	55	5.00 (5.00, 5.00)
Age < 65 Male	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	37	0.02 (0.02, 0.02)
Age < 65 Male	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	37	0.27 (0.27, 0.27)
Age < 65 Male	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	37	0.09 (0.09, 0.09)
Age < 65 Male	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	37	5.07 (4.94, 5.20)
Age < 65 Male	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	37	5.05 (4.95, 5.16)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Male	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	68	0.02 (0.02, 0.02)
Age < 65 Male	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	68	0.27 (0.27, 0.27)
Age < 65 Male	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	68	0.09 (0.09, 0.09)
Age < 65 Male	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	68	5.25 (4.91, 5.62)
Age < 65 Male	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	68	5.24 (4.86, 5.65)
Age < 65 Male	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	174	42.69 (30.49, 59.78)
Age < 65 Male	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	174	518.21 (387.13, 693.66)
Age < 65 Male	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	174	285.35 (226.54, 359.43)
Age < 65 Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	174	79.72 (58.31, 108.98)
Age < 65 Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	174	145.67 (111.94, 189.55)
Age < 65 Male	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	55	50.88 (31.32, 82.66)
Age < 65 Male	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	55	646.27 (423.23, 986.85)
Age < 65 Male	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	55	470.20 (356.47, 620.21)
Age < 65 Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	55	110.81 (69.38, 176.99)
Age < 65 Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	55	195.13 (121.31, 313.86)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Male	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	37	0.02 (0.02, 0.02)
Age < 65 Male	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	37	0.27 (0.27, 0.27)
Age < 65 Male	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	37	0.09 (0.09, 0.09)
Age < 65 Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	37	5.19 (4.83, 5.57)
Age < 65 Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	37	5.00 (5.00, 5.00)
Age < 65 Male	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	68	31.66 (18.75, 53.45)
Age < 65 Male	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	68	214.83 (124.91, 369.46)
Age < 65 Male	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	68	142.41 (96.38, 210.40)
Age < 65 Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	68	55.24 (32.08, 95.13)
Age < 65 Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	68	138.47 (87.18, 219.92)
Age < 65 Male	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	174	527.28 (351.16, 791.72)
Age < 65 Male	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	174	24353.35 (18073.98, 32814.34)
Age < 65 Male	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	174	15514.72 (12140.04, 19827.48)
Age < 65 Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	174	772.58 (562.42, 1061.25)
Age < 65 Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	174	748.84 (638.20, 878.66)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Male	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	55	1715.55 (968.05, 3040.26)
Age < 65 Male	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	55	42494.56 (25248.52, 71520.53)
Age < 65 Male	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	55	31303.69 (19711.17, 49713.99)
Age < 65 Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	55	1817.97 (1306.04, 2530.56)
Age < 65 Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	55	1168.15 (1063.97, 1282.52)
Age < 65 Male	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	37	0.02 (0.02, 0.02)
Age < 65 Male	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	37	0.27 (0.27, 0.27)
Age < 65 Male	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	37	0.09 (0.09, 0.09)
Age < 65 Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	37	5.00 (5.00, 5.00)
Age < 65 Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	37	5.00 (5.00, 5.00)
Age < 65 Male	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	68	369.62 (204.81, 667.07)
Age < 65 Male	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	68	10912.79 (6586.09, 18081.91)
Age < 65 Male	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	68	6460.65 (4298.55, 9710.23)
Age < 65 Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	68	456.72 (246.89, 844.88)
Age < 65 Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	68	603.35 (434.26, 838.28)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Male	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	190	0.02 (0.02, 0.02)
Age \geq 65 Male	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	190	0.27 (0.27, 0.27)
Age \geq 65 Male	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	190	0.09 (0.09, 0.09)
Age \geq 65 Male	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	190	5.11 (5.00, 5.23)
Age \geq 65 Male	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	190	5.06 (4.97, 5.16)
Age \geq 65 Male	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	60	0.02 (0.02, 0.02)
Age \geq 65 Male	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	60	0.28 (0.27, 0.28)
Age \geq 65 Male	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	60	0.09 (0.09, 0.09)
Age \geq 65 Male	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	60	5.00 (5.00, 5.00)
Age \geq 65 Male	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	60	5.00 (5.00, 5.00)
Age \geq 65 Male	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	37	0.02 (0.02, 0.02)
Age \geq 65 Male	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	37	0.27 (0.27, 0.27)
Age \geq 65 Male	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	37	0.09 (0.09, 0.09)
Age \geq 65 Male	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	37	5.25 (4.78, 5.76)
Age \geq 65 Male	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	37	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Male	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	57	0.02 (0.02, 0.02)
Age \geq 65 Male	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	57	0.27 (0.27, 0.27)
Age \geq 65 Male	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	57	0.09 (0.09, 0.09)
Age \geq 65 Male	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	57	5.00 (5.00, 5.00)
Age \geq 65 Male	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	57	5.08 (4.92, 5.24)
Age \geq 65 Male	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	190	158.21 (124.19, 201.55)
Age \geq 65 Male	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	190	2165.24 (1755.67, 2670.34)
Age \geq 65 Male	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	190	1215.51 (986.35, 1497.92)
Age \geq 65 Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	190	278.69 (217.94, 356.37)
Age \geq 65 Male	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	190	377.21 (314.83, 451.94)
Age \geq 65 Male	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	60	300.25 (205.73, 438.20)
Age \geq 65 Male	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	60	3994.10 (2941.29, 5423.76)
Age \geq 65 Male	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	60	2130.88 (1637.40, 2773.09)
Age \geq 65 Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	60	537.68 (372.46, 776.19)
Age \geq 65 Male	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	60	574.95 (457.11, 723.17)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age ≥ 65 Male	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	37	0.02 (0.02, 0.02)
Age ≥ 65 Male	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	37	0.27 (0.27, 0.27)
Age ≥ 65 Male	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	37	0.09 (0.09, 0.09)
Age ≥ 65 Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	37	5.00 (5.00, 5.00)
Age ≥ 65 Male	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	37	5.00 (5.00, 5.00)
Age ≥ 65 Male	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	57	102.83 (60.31, 175.34)
Age ≥ 65 Male	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	57	1118.17 (754.76, 1656.55)
Age ≥ 65 Male	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	57	631.49 (454.32, 877.75)
Age ≥ 65 Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	57	153.38 (94.61, 248.66)
Age ≥ 65 Male	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	57	216.12 (142.96, 326.73)
Age ≥ 65 Male	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	190	2815.08 (2111.24, 3753.55)
Age ≥ 65 Male	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	190	90187.00 (71558.24, 113665.38)
Age ≥ 65 Male	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	190	54839.61 (44901.48, 66977.36)
Age ≥ 65 Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	190	2104.82 (1771.51, 2500.84)
Age ≥ 65 Male	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	190	986.14 (889.51, 1093.28)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Male	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	60	8233.43 (5596.79, 12112.20)
Age \geq 65 Male	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	60	192281.53 (141321.76, 261617.09)
Age \geq 65 Male	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	60	130274.88 (112581.59, 150748.83)
Age \geq 65 Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	60	3546.44 (3110.57, 4043.40)
Age \geq 65 Male	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	60	1248.36 (1162.43, 1340.64)
Age \geq 65 Male	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	37	0.02 (0.02, 0.02)
Age \geq 65 Male	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	37	0.27 (0.27, 0.27)
Age \geq 65 Male	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	37	0.09 (0.09, 0.09)
Age \geq 65 Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	37	5.17 (4.85, 5.51)
Age \geq 65 Male	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	37	5.29 (4.90, 5.70)
Age \geq 65 Male	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	57	1251.72 (706.83, 2216.66)
Age \geq 65 Male	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	57	44920.03 (29069.90, 69412.30)
Age \geq 65 Male	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	57	26342.76 (19634.40, 35343.11)
Age \geq 65 Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	57	1658.65 (1161.47, 2368.65)
Age \geq 65 Male	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	57	849.02 (652.73, 1104.35)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Female	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	278	0.02 (0.02, 0.02)
Age \geq 65 Female	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	278	0.27 (0.27, 0.27)
Age \geq 65 Female	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	278	0.09 (0.09, 0.09)
Age \geq 65 Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	278	5.02 (4.99, 5.05)
Age \geq 65 Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	278	5.19 (5.05, 5.33)
Age \geq 65 Female	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	72	0.02 (0.02, 0.02)
Age \geq 65 Female	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	72	0.27 (0.27, 0.27)
Age \geq 65 Female	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	72	0.09 (0.09, 0.09)
Age \geq 65 Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	72	5.07 (4.94, 5.21)
Age \geq 65 Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	72	5.11 (4.96, 5.26)
Age \geq 65 Female	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	42	0.02 (0.02, 0.02)
Age \geq 65 Female	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	42	0.27 (0.27, 0.27)
Age \geq 65 Female	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	42	0.09 (0.09, 0.09)
Age \geq 65 Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	42	5.00 (5.00, 5.00)
Age \geq 65 Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	42	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Female	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	74	0.02 (0.02, 0.02)
Age \geq 65 Female	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	74	0.27 (0.27, 0.27)
Age \geq 65 Female	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	74	0.09 (0.09, 0.09)
Age \geq 65 Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	74	5.00 (5.00, 5.00)
Age \geq 65 Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	74	5.00 (5.00, 5.00)
Age \geq 65 Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	278	157.79 (126.65, 196.59)
Age \geq 65 Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	278	1902.35 (1575.09, 2297.62)
Age \geq 65 Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	278	1201.79 (1027.02, 1406.31)
Age \geq 65 Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	278	250.54 (202.01, 310.73)
Age \geq 65 Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	278	295.11 (249.06, 349.66)
Age \geq 65 Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	72	247.79 (159.19, 385.70)
Age \geq 65 Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	72	2442.24 (1716.98, 3473.84)
Age \geq 65 Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	72	1826.43 (1391.16, 2397.88)
Age \geq 65 Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	72	376.23 (253.16, 559.13)
Age \geq 65 Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	72	404.95 (299.73, 547.11)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age ≥ 65 Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	42	0.02 (0.02, 0.02)
Age ≥ 65 Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	42	0.27 (0.27, 0.27)
Age ≥ 65 Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	42	0.09 (0.09, 0.09)
Age ≥ 65 Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	42	5.11 (4.90, 5.33)
Age ≥ 65 Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	42	5.00 (5.00, 5.00)
Age ≥ 65 Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	74	71.56 (49.93, 102.56)
Age ≥ 65 Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	74	1017.95 (723.09, 1433.04)
Age ≥ 65 Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	74	527.50 (393.74, 706.70)
Age ≥ 65 Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	74	133.46 (94.95, 187.59)
Age ≥ 65 Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	74	225.65 (163.61, 311.23)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	278	2247.72 (1730.65, 2919.28)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	278	80112.09 (66048.38, 97170.39)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	278	49929.74 (42062.16, 59268.93)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	278	1900.06 (1608.06, 2245.09)
Age ≥ 65 Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	278	968.39 (886.18, 1058.23)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	72	4441.83 (2894.14, 6817.19)
Age \geq 65 Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	72	181829.21 (137645.74, 240195.32)
Age \geq 65 Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	72	105585.83 (89340.95, 124784.53)
Age \geq 65 Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	72	3078.46 (2552.12, 3713.35)
Age \geq 65 Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	72	1168.11 (1055.42, 1292.84)
Age \geq 65 Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	42	0.02 (0.02, 0.02)
Age \geq 65 Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	42	0.29 (0.27, 0.32)
Age \geq 65 Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	42	0.09 (0.09, 0.09)
Age \geq 65 Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	42	5.21 (4.93, 5.51)
Age \geq 65 Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	42	5.14 (4.87, 5.42)
Age \geq 65 Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	74	1249.56 (791.89, 1971.76)
Age \geq 65 Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	74	35158.72 (24628.10, 50192.07)
Age \geq 65 Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	74	20499.91 (15253.65, 27550.53)
Age \geq 65 Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	74	1637.49 (1217.31, 2202.70)
Age \geq 65 Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	74	861.52 (690.37, 1075.09)

Table 5g. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Hispanic or Latino ethnicity

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Hispanic or Latino ethnicity						
Hispanic or Latino	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	127	0.02 (0.02, 0.02)
Hispanic or Latino	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	127	0.27 (0.27, 0.27)
Hispanic or Latino	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	127	0.09 (0.09, 0.09)
Hispanic or Latino	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	127	5.08 (5.00, 5.17)
Hispanic or Latino	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	127	5.14 (4.94, 5.35)
Hispanic or Latino	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	29	0.02 (0.02, 0.02)
Hispanic or Latino	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	29	0.27 (0.27, 0.27)
Hispanic or Latino	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	29	0.09 (0.09, 0.09)
Hispanic or Latino	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	29	5.08 (4.93, 5.24)
Hispanic or Latino	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	29	5.00 (5.00, 5.00)
Hispanic or Latino	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	15	0.02 (0.02, 0.02)
Hispanic or Latino	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	15	0.27 (0.27, 0.27)
Hispanic or Latino	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	15	0.09 (0.09, 0.09)
Hispanic or Latino	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	15	5.00 (5.00, 5.00)
Hispanic or Latino	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	15	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Hispanic or Latino	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	46	0.02 (0.02, 0.02)
Hispanic or Latino	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	46	0.27 (0.27, 0.27)
Hispanic or Latino	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	46	0.09 (0.09, 0.09)
Hispanic or Latino	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	46	5.00 (5.00, 5.00)
Hispanic or Latino	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	46	5.00 (5.00, 5.00)
Hispanic or Latino	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	127	54.25 (32.89, 89.49)
Hispanic or Latino	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	127	738.59 (475.77, 1146.59)
Hispanic or Latino	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	127	458.30 (335.04, 626.91)
Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	127	122.12 (79.12, 188.47)
Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	127	195.26 (135.35, 281.68)
Hispanic or Latino	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	29	63.63 (24.18, 167.42)
Hispanic or Latino	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	29	671.42 (268.81, 1677.02)
Hispanic or Latino	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	29	554.48 (337.54, 910.83)
Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	29	103.70 (42.84, 251.02)
Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	29	199.58 (88.50, 450.06)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Hispanic or Latino	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	15	0.02 (0.02, 0.02)
Hispanic or Latino	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	15	0.27 (0.27, 0.27)
Hispanic or Latino	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	15	0.09 (0.09, 0.10)
Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	15	5.00 (5.00, 5.00)
Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	15	5.00 (5.00, 5.00)
Hispanic or Latino	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	46	39.34 (24.35, 63.57)
Hispanic or Latino	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	46	478.11 (305.16, 749.09)
Hispanic or Latino	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	46	212.26 (132.46, 340.16)
Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	46	56.89 (27.13, 119.26)
Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	46	122.38 (59.76, 250.61)
Hispanic or Latino	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	127	814.68 (481.21, 1379.23)
Hispanic or Latino	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	127	34964.00 (23048.31, 53039.96)
Hispanic or Latino	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	127	22813.81 (16865.24, 30860.51)
Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	127	854.62 (560.85, 1302.27)
Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	127	844.27 (704.57, 1011.67)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Hispanic or Latino	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	29	1064.02 (391.85, 2889.21)
Hispanic or Latino	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	29	50017.84 (23071.66, 108435.37)
Hispanic or Latino	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	29	27653.57 (13499.72, 56647.08)
Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	29	2163.43 (1224.36, 3822.74)
Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	29	1169.19 (1060.95, 1288.48)
Hispanic or Latino	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	15	0.02 (0.02, 0.02)
Hispanic or Latino	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	15	0.27 (0.27, 0.27)
Hispanic or Latino	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	15	0.09 (0.09, 0.09)
Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	15	5.00 (5.00, 5.00)
Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	15	5.00 (5.00, 5.00)
Hispanic or Latino	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	46	493.77 (219.83, 1109.09)
Hispanic or Latino	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	46	18749.45 (9974.36, 35244.56)
Hispanic or Latino	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	46	9513.70 (5382.70, 16815.08)
Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	46	467.24 (253.04, 862.78)
Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	46	701.90 (473.83, 1039.74)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not Hispanic or Latino	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	679	0.02 (0.02, 0.02)
Not Hispanic or Latino	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	679	0.27 (0.27, 0.27)
Not Hispanic or Latino	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	679	0.09 (0.09, 0.09)
Not Hispanic or Latino	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	679	5.04 (5.01, 5.07)
Not Hispanic or Latino	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	679	5.17 (5.06, 5.28)
Not Hispanic or Latino	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	209	0.02 (0.02, 0.02)
Not Hispanic or Latino	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	209	0.27 (0.27, 0.27)
Not Hispanic or Latino	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	209	0.09 (0.09, 0.09)
Not Hispanic or Latino	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	209	5.02 (4.99, 5.06)
Not Hispanic or Latino	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	209	5.08 (4.93, 5.24)
Not Hispanic or Latino	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	122	0.02 (0.02, 0.02)
Not Hispanic or Latino	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	122	0.27 (0.27, 0.27)
Not Hispanic or Latino	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	122	0.09 (0.09, 0.09)
Not Hispanic or Latino	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	122	5.09 (4.99, 5.20)
Not Hispanic or Latino	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	122	5.02 (4.98, 5.07)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not Hispanic or Latino	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	203	0.02 (0.02, 0.02)
Not Hispanic or Latino	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	203	0.27 (0.27, 0.28)
Not Hispanic or Latino	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	203	0.09 (0.09, 0.09)
Not Hispanic or Latino	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	203	5.13 (4.95, 5.31)
Not Hispanic or Latino	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	203	5.19 (4.96, 5.42)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	679	63.32 (51.99, 77.13)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	679	770.48 (651.56, 911.10)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	679	434.43 (375.73, 502.30)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	679	114.80 (94.93, 138.83)
Not Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	679	198.64 (168.65, 233.96)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	209	82.66 (59.08, 115.67)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	209	1077.53 (822.32, 1411.94)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	209	662.30 (517.66, 847.34)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	209	151.73 (113.85, 202.23)
Not Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	209	260.81 (197.68, 344.10)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not Hispanic or Latino	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	122	0.02 (0.02, 0.02)
Not Hispanic or Latino	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	122	0.27 (0.27, 0.27)
Not Hispanic or Latino	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	122	0.09 (0.09, 0.09)
Not Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	122	5.11 (4.93, 5.28)
Not Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	122	5.00 (5.00, 5.00)
Not Hispanic or Latino	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	203	31.38 (22.71, 43.38)
Not Hispanic or Latino	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	203	277.30 (203.68, 377.54)
Not Hispanic or Latino	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	203	149.58 (116.96, 191.31)
Not Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	203	56.35 (40.82, 77.80)
Not Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	203	148.92 (110.97, 199.85)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	679	967.79 (758.64, 1234.60)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	679	33872.91 (28244.45, 40622.99)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	679	22521.81 (19244.89, 26356.70)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	679	1097.66 (921.37, 1307.68)
Not Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	679	785.58 (708.83, 870.64)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	209	2040.56 (1414.39, 2943.97)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	209	65701.34 (49108.73, 87900.16)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	209	45749.18 (35772.79, 58507.81)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	209	1861.13 (1499.52, 2309.95)
Not Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	209	1016.42 (893.53, 1156.22)
Not Hispanic or Latino	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	122	0.02 (0.02, 0.02)
Not Hispanic or Latino	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	122	0.28 (0.27, 0.28)
Not Hispanic or Latino	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	122	0.09 (0.09, 0.09)
Not Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	122	5.03 (4.99, 5.08)
Not Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	122	5.06 (4.99, 5.13)
Not Hispanic or Latino	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	203	350.75 (246.37, 499.37)
Not Hispanic or Latino	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	203	12283.74 (8988.91, 16786.28)
Not Hispanic or Latino	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	203	7712.34 (6006.90, 9901.99)
Not Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	203	473.68 (322.64, 695.43)
Not Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	203	607.53 (493.49, 747.93)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	98	0.02 (0.02, 0.02)
Not reported and unknown	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	98	0.27 (0.27, 0.27)
Not reported and unknown	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	98	0.09 (0.09, 0.09)
Not reported and unknown	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	98	5.24 (4.85, 5.66)
Not reported and unknown	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	98	5.02 (4.98, 5.07)
Not reported and unknown	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	39	0.02 (0.02, 0.02)
Not reported and unknown	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	39	0.27 (0.27, 0.27)
Not reported and unknown	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	39	0.09 (0.09, 0.09)
Not reported and unknown	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	39	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	39	5.05 (4.95, 5.14)
Not reported and unknown	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	18	0.02 (0.02, 0.02)
Not reported and unknown	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	18	0.27 (0.27, 0.27)
Not reported and unknown	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	18	0.09 (0.09, 0.09)
Not reported and unknown	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	18	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	18	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	25	0.02 (0.02, 0.02)
Not reported and unknown	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	25	0.27 (0.27, 0.27)
Not reported and unknown	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	25	0.09 (0.09, 0.09)
Not reported and unknown	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	25	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	25	5.00 (5.00, 5.00)
Not reported and unknown	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	98	72.49 (43.23, 121.55)
Not reported and unknown	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	98	863.61 (590.53, 1262.97)
Not reported and unknown	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	98	557.02 (396.67, 782.19)
Not reported and unknown	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	98	131.50 (86.64, 199.58)
Not reported and unknown	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	98	161.93 (103.07, 254.40)
Not reported and unknown	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	39	68.63 (35.87, 131.31)
Not reported and unknown	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	39	775.10 (415.40, 1446.25)
Not reported and unknown	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	39	550.31 (364.91, 829.90)
Not reported and unknown	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	39	148.28 (77.75, 282.79)
Not reported and unknown	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	39	230.97 (117.30, 454.82)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	18	0.02 (0.02, 0.02)
Not reported and unknown	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	18	0.27 (0.27, 0.27)
Not reported and unknown	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	18	0.09 (0.09, 0.09)
Not reported and unknown	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	18	5.00 (5.00, 5.00)
Not reported and unknown	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	18	5.00 (5.00, 5.00)
Not reported and unknown	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	25	40.53 (16.70, 98.34)
Not reported and unknown	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	25	489.52 (288.78, 829.79)
Not reported and unknown	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	25	265.13 (159.26, 441.38)
Not reported and unknown	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	25	59.42 (23.13, 152.69)
Not reported and unknown	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	25	153.51 (74.65, 315.71)
Not reported and unknown	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	98	937.47 (556.39, 1579.55)
Not reported and unknown	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	98	34296.79 (22569.35, 52118.02)
Not reported and unknown	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	98	25034.26 (16740.49, 37437.03)
Not reported and unknown	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	98	1289.61 (824.01, 2018.31)
Not reported and unknown	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	98	933.95 (764.95, 1140.28)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	39	2514.57 (1174.56, 5383.36)
Not reported and unknown	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	39	56338.04 (29327.80, 108224.11)
Not reported and unknown	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	39	40615.66 (23498.38, 70201.94)
Not reported and unknown	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	39	2024.96 (1309.63, 3131.02)
Not reported and unknown	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	39	1123.51 (932.28, 1353.98)
Not reported and unknown	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	18	0.02 (0.02, 0.02)
Not reported and unknown	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	18	0.27 (0.27, 0.27)
Not reported and unknown	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	18	0.09 (0.09, 0.09)
Not reported and unknown	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	18	5.13 (4.88, 5.38)
Not reported and unknown	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	18	5.00 (5.00, 5.00)
Not reported and unknown	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	25	675.40 (387.70, 1176.59)
Not reported and unknown	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	25	19749.84 (8421.53, 46316.57)
Not reported and unknown	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	25	11964.66 (5409.29, 26464.31)
Not reported and unknown	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	25	435.27 (179.30, 1056.63)
Not reported and unknown	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	25	555.25 (237.70, 1297.01)

Table 5h. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Race

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Race						
White Non-Hispanic	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	355	0.02 (0.02, 0.02)
White Non-Hispanic	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	355	0.27 (0.27, 0.27)
White Non-Hispanic	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	355	0.09 (0.09, 0.09)
White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	355	5.04 (5.00, 5.07)
White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	355	5.18 (5.04, 5.33)
White Non-Hispanic	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	121	0.02 (0.02, 0.02)
White Non-Hispanic	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	121	0.27 (0.27, 0.27)
White Non-Hispanic	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	121	0.09 (0.09, 0.09)
White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	121	5.04 (4.98, 5.09)
White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	121	5.12 (4.89, 5.37)
White Non-Hispanic	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	64	0.02 (0.02, 0.02)
White Non-Hispanic	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	64	0.27 (0.27, 0.27)
White Non-Hispanic	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	64	0.09 (0.09, 0.09)
White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	64	5.11 (4.96, 5.26)
White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	64	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	116	0.02 (0.02, 0.02)
White Non-Hispanic	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	116	0.27 (0.27, 0.27)
White Non-Hispanic	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	116	0.09 (0.09, 0.09)
White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	116	5.19 (4.93, 5.47)
White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	116	5.24 (4.92, 5.59)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	355	69.71 (54.55, 89.08)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	355	851.96 (683.58, 1061.81)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	355	457.39 (378.96, 552.07)
White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	355	126.36 (99.23, 160.92)
White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	355	217.51 (176.19, 268.54)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	121	77.05 (48.18, 123.22)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	121	1042.78 (719.00, 1512.35)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	121	675.98 (483.56, 944.98)
White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	121	134.49 (91.52, 197.63)
White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	121	274.51 (190.56, 395.46)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	64	0.02 (0.02, 0.02)
White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	64	0.27 (0.27, 0.27)
White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	64	0.09 (0.09, 0.09)
White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	64	5.18 (4.89, 5.49)
White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	64	5.00 (5.00, 5.00)
White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	116	25.31 (16.85, 38.02)
White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	116	210.89 (142.33, 312.47)
White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	116	127.97 (94.16, 173.92)
White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	116	48.07 (32.44, 71.22)
White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	116	140.69 (97.98, 202.01)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	355	1044.69 (761.89, 1432.46)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	355	36435.10 (28737.15, 46195.14)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	355	25205.17 (20626.81, 30799.75)
White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	355	1228.38 (982.72, 1535.45)
White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	355	810.89 (707.90, 928.88)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	121	2213.21 (1336.74, 3664.34)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	121	70335.26 (47398.85, 104370.64)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	121	50675.29 (37092.29, 69232.30)
White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	121	1892.63 (1423.38, 2516.58)
White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	121	961.03 (795.48, 1161.03)
White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	64	0.02 (0.02, 0.02)
White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	64	0.28 (0.27, 0.28)
White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	64	0.09 (0.09, 0.09)
White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	64	5.03 (4.97, 5.09)
White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	64	5.08 (4.97, 5.19)
White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	116	277.45 (178.97, 430.10)
White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	116	9241.19 (6112.15, 13972.11)
White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	116	6530.55 (4820.40, 8847.43)
White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	116	457.87 (282.73, 741.51)
White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	116	581.23 (447.81, 754.40)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Black or African American	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	205	0.02 (0.02, 0.02)
Black or African American	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	205	0.27 (0.27, 0.27)
Black or African American	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	205	0.09 (0.09, 0.09)
Black or African American	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	205	5.05 (5.00, 5.11)
Black or African American	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	205	5.13 (5.00, 5.26)
Black or African American	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	61	0.02 (0.02, 0.02)
Black or African American	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	61	0.27 (0.27, 0.28)
Black or African American	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	61	0.09 (0.09, 0.09)
Black or African American	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	61	5.00 (5.00, 5.00)
Black or African American	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	61	5.06 (4.98, 5.15)
Black or African American	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	25	0.02 (0.02, 0.02)
Black or African American	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	25	0.27 (0.27, 0.27)
Black or African American	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	25	0.09 (0.09, 0.09)
Black or African American	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	25	5.17 (4.85, 5.51)
Black or African American	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	25	5.13 (4.88, 5.39)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Black or African American	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	48	0.02 (0.02, 0.02)
Black or African American	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	48	0.27 (0.27, 0.27)
Black or African American	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	48	0.09 (0.09, 0.09)
Black or African American	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	48	5.00 (5.00, 5.00)
Black or African American	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	48	5.00 (5.00, 5.00)
Black or African American	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	205	39.51 (28.40, 54.96)
Black or African American	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	205	502.63 (365.12, 691.94)
Black or African American	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	205	359.89 (273.62, 473.37)
Black or African American	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	205	73.58 (53.44, 101.31)
Black or African American	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	205	136.37 (101.63, 182.98)
Black or African American	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	61	66.93 (37.80, 118.51)
Black or African American	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	61	1178.96 (771.48, 1801.67)
Black or African American	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	61	640.62 (437.88, 937.23)
Black or African American	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	61	144.48 (80.12, 260.55)
Black or African American	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	61	216.07 (126.21, 369.92)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Black or African American	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	25	0.02 (0.02, 0.02)
Black or African American	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	25	0.27 (0.27, 0.27)
Black or African American	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	25	0.09 (0.09, 0.10)
Black or African American	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	25	5.00 (5.00, 5.00)
Black or African American	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	25	5.00 (5.00, 5.00)
Black or African American	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	48	55.30 (29.35, 104.18)
Black or African American	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	48	521.18 (316.11, 859.30)
Black or African American	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	48	239.78 (153.72, 374.02)
Black or African American	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	48	83.13 (45.45, 152.03)
Black or African American	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	48	160.07 (88.43, 289.73)
Black or African American	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	205	606.19 (384.80, 954.95)
Black or African American	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	205	21156.94 (15313.33, 29230.48)
Black or African American	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	205	15687.41 (11987.76, 20528.84)
Black or African American	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	205	668.65 (474.64, 941.96)
Black or African American	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	205	692.39 (561.27, 854.14)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Black or African American	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	61	2445.99 (1305.58, 4582.52)
Black or African American	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	61	70139.32 (41066.05, 119795.40)
Black or African American	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	61	38282.53 (23969.98, 61141.14)
Black or African American	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	61	1763.07 (1217.90, 2552.28)
Black or African American	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	61	1207.84 (1106.26, 1318.75)
Black or African American	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	25	0.02 (0.02, 0.02)
Black or African American	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	25	0.27 (0.27, 0.27)
Black or African American	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	25	0.09 (0.09, 0.09)
Black or African American	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	25	5.00 (5.00, 5.00)
Black or African American	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	25	5.00 (5.00, 5.00)
Black or African American	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	48	728.24 (329.40, 1610.00)
Black or African American	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	48	17910.96 (10256.34, 31278.45)
Black or African American	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	48	14093.55 (8027.36, 24743.90)
Black or African American	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	48	441.02 (184.45, 1054.46)
Black or African American	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	48	506.95 (299.89, 856.98)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Asian	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	57	0.02 (0.02, 0.02)
Asian	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	57	0.27 (0.27, 0.27)
Asian	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	57	0.09 (0.09, 0.09)
Asian	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	57	5.00 (5.00, 5.00)
Asian	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	57	5.00 (5.00, 5.00)
Asian	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	18	0.02 (0.02, 0.02)
Asian	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	18	0.27 (0.27, 0.27)
Asian	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	18	0.09 (0.09, 0.09)
Asian	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	18	5.00 (5.00, 5.00)
Asian	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	18	5.00 (5.00, 5.00)
Asian	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	12	0.02 (0.02, 0.02)
Asian	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	12	0.27 (0.27, 0.27)
Asian	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	12	0.09 (0.09, 0.09)
Asian	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	12	5.00 (5.00, 5.00)
Asian	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	12	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Asian	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	16	0.02 (0.02, 0.02)
Asian	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	16	0.32 (0.24, 0.42)
Asian	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	16	0.09 (0.09, 0.09)
Asian	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	16	5.00 (5.00, 5.00)
Asian	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	16	5.00 (5.00, 5.00)
Asian	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	57	48.76 (26.14, 90.95)
Asian	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	57	651.61 (410.12, 1035.31)
Asian	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	57	434.81 (292.11, 647.22)
Asian	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	57	105.45 (54.28, 204.85)
Asian	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	57	168.70 (95.98, 296.54)
Asian	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	18	107.26 (44.23, 260.11)
Asian	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	18	814.76 (361.38, 1836.93)
Asian	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	18	530.39 (243.28, 1156.31)
Asian	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	18	230.64 (57.30, 928.40)
Asian	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	18	278.37 (119.43, 648.83)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Asian	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	12	0.02 (0.02, 0.02)
Asian	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	12	0.27 (0.27, 0.27)
Asian	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	12	0.09 (0.09, 0.09)
Asian	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	12	5.00 (5.00, 5.00)
Asian	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	12	5.00 (5.00, 5.00)
Asian	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	16	56.24 (23.94, 132.13)
Asian	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	16	474.36 (214.35, 1049.76)
Asian	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	16	162.61 (51.20, 516.51)
Asian	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	16	103.62 (31.86, 337.02)
Asian	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	16	175.58 (82.12, 375.40)
Asian	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	57	884.76 (479.17, 1633.66)
Asian	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	57	31067.18 (16781.90, 57512.52)
Asian	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	57	17026.90 (10429.05, 27798.82)
Asian	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	57	901.66 (473.91, 1715.49)
Asian	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	57	973.09 (758.13, 1249.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Asian	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	18	854.63 (142.76, 5116.07)
Asian	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	18	40035.90 (13796.82, 116177.00)
Asian	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	18	34503.14 (13285.21, 89608.42)
Asian	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	18	899.41 (266.31, 3037.53)
Asian	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	18	779.08 (406.84, 1491.89)
Asian	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	12	0.02 (0.02, 0.02)
Asian	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	12	0.27 (0.27, 0.27)
Asian	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	12	0.09 (0.09, 0.09)
Asian	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	12	5.00 (5.00, 5.00)
Asian	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	12	5.00 (5.00, 5.00)
Asian	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	16	335.30 (91.06, 1234.63)
Asian	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	16	22299.26 (8400.58, 59193.15)
Asian	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	16	6891.44 (2188.67, 21698.94)
Asian	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	16	452.78 (113.03, 1813.70)
Asian	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	16	433.20 (166.20, 1129.17)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
American Indian or Alaska Native	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	22	0.02 (0.02, 0.02)
American Indian or Alaska Native	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	22	0.27 (0.27, 0.27)
American Indian or Alaska Native	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	22	0.09 (0.09, 0.09)
American Indian or Alaska Native	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	22	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	22	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	8	0.02 (0.02, 0.02)
American Indian or Alaska Native	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	8	0.27 (0.27, 0.27)
American Indian or Alaska Native	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	8	0.09 (0.09, 0.09)
American Indian or Alaska Native	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	8	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	8	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	7	0.02 (0.02, 0.02)
American Indian or Alaska Native	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	7	0.27 (0.27, 0.27)
American Indian or Alaska Native	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	7	0.09 (0.09, 0.09)
American Indian or Alaska Native	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	7	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	7	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
American Indian or Alaska Native	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	8	0.02 (0.02, 0.02)
American Indian or Alaska Native	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	8	0.27 (0.27, 0.27)
American Indian or Alaska Native	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	8	0.09 (0.09, 0.09)
American Indian or Alaska Native	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	8	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	8	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	22	159.01 (40.90, 618.23)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	22	831.76 (422.47, 1637.59)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	22	583.32 (298.62, 1139.45)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	22	152.53 (52.00, 447.43)
American Indian or Alaska Native	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	22	333.08 (182.27, 608.67)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	8	385.19 (153.99, 963.51)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	8	2901.68 (1835.24, 4587.82)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	8	1562.53 (874.42, 2792.12)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	8	666.40 (230.44, 1927.13)
American Indian or Alaska Native	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	8	433.67 (192.88, 975.09)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
American Indian or Alaska Native	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	7	0.02 (0.02, 0.02)
American Indian or Alaska Native	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	7	0.27 (0.27, 0.27)
American Indian or Alaska Native	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	7	0.09 (0.09, 0.09)
American Indian or Alaska Native	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	7	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	7	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	8	103.72 (61.10, 176.07)
American Indian or Alaska Native	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	8	836.88 (339.14, 2065.14)
American Indian or Alaska Native	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	8	311.79 (145.48, 668.19)
American Indian or Alaska Native	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	8	117.82 (67.56, 205.49)
American Indian or Alaska Native	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	8	433.54 (151.92, 1237.16)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	22	1350.63 (255.42, 7142.04)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	22	54398.18 (23537.88, 125719.10)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	22	27579.42 (12333.42, 61671.81)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	22	1495.68 (812.13, 2754.55)
American Indian or Alaska Native	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	22	745.22 (329.98, 1682.95)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
American Indian or Alaska Native	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	8	11626.70 (3273.28, 41298.09)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	8	200735.20 (102981.76, 391279.19)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	8	96737.74 (50788.36, 184258.56)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	8	3475.76 (2559.76, 4719.54)
American Indian or Alaska Native	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	8	1295.00 (1295.00, 1295.00)
American Indian or Alaska Native	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	7	0.02 (0.02, 0.02)
American Indian or Alaska Native	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	7	0.27 (0.27, 0.27)
American Indian or Alaska Native	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	7	0.09 (0.09, 0.09)
American Indian or Alaska Native	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	7	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	7	5.00 (5.00, 5.00)
American Indian or Alaska Native	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	8	677.27 (285.63, 1605.88)
American Indian or Alaska Native	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	8	29384.38 (15121.79, 57099.19)
American Indian or Alaska Native	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	8	23269.38 (11375.13, 47600.72)
American Indian or Alaska Native	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	8	608.77 (281.57, 1316.20)
American Indian or Alaska Native	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	8	1295.00 (1295.00, 1295.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	17	0.02 (0.02, 0.02)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	17	0.27 (0.27, 0.27)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	17	0.09 (0.09, 0.09)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	17	5.00 (5.00, 5.00)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	17	5.00 (5.00, 5.00)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	3	0.02 (0.02, 0.02)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	3	0.27 (0.27, 0.27)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	3	0.09 (0.09, 0.09)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	3	5.00 (5.00, 5.00)
Native Hawaiian or Other Pacific Islander	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	3	5.00 (5.00, 5.00)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	1	0.02 (0.02, 0.02)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	1	0.27 (0.27, 0.27)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	1	0.09 (0.09, 0.09)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	1	5.00 (5.00, 5.00)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	1	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	7	0.02 (0.02, 0.02)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	7	0.27 (0.27, 0.27)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	7	0.09 (0.09, 0.09)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	7	5.00 (5.00, 5.00)
Native Hawaiian or Other Pacific Islander	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	7	5.00 (5.00, 5.00)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	17	110.26 (53.37, 227.77)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	17	2806.54 (919.76, 8563.77)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	17	1028.16 (545.42, 1938.15)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	17	207.55 (131.55, 327.45)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	17	483.37 (304.41, 767.54)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	3	569.82 (278.18, 1167.20)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	3	2086.57 (367.52, 11846.26)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	3	912.56 (147.28, 5654.26)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	3	801.67 (439.13, 1463.50)
Native Hawaiian or Other Pacific Islander	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	3	610.02 (215.01, 1730.78)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	1	0.02 (0.02, 0.02)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	1	0.27 (0.27, 0.27)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	1	0.09 (0.09, 0.09)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	1	5.00 (5.00, 5.00)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	1	5.00 (5.00, 5.00)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	7	76.08 (22.05, 262.50)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	7	504.34 (315.41, 806.44)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	7	178.02 (130.83, 242.22)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	7	145.36 (45.61, 463.24)
Native Hawaiian or Other Pacific Islander	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	7	270.26 (63.92, 1142.71)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	17	4513.03 (2207.60, 9226.10)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	17	88742.44 (50304.88, 156549.82)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	17	55837.10 (30598.67, 101892.72)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	17	2139.73 (1418.45, 3227.79)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	17	1110.47 (928.83, 1327.63)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	3	4317.30 (624.92, 29826.49)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	3	141959.66 (56871.84, 354350.11)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	3	75528.02 (43231.58, 131951.72)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	3	4404.00 (4404.00, 4404.00)
Native Hawaiian or Other Pacific Islander	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	3	1295.00 (1295.00, 1295.00)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	1	0.02 (0.02, 0.02)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	1	0.27 (0.27, 0.27)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	1	0.09 (0.09, 0.09)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	1	5.00 (5.00, 5.00)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	1	5.00 (5.00, 5.00)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	7	461.79 (172.20, 1238.43)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	7	80694.40 (35476.98, 183544.00)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	7	17255.07 (6364.86, 46778.31)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	7	1053.52 (305.29, 3635.60)
Native Hawaiian or Other Pacific Islander	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	7	1292.57 (1288.26, 1296.90)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Multiracial	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	54	0.02 (0.02, 0.02)
Multiracial	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	54	0.27 (0.27, 0.27)
Multiracial	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	54	0.09 (0.09, 0.09)
Multiracial	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	54	5.03 (4.97, 5.10)
Multiracial	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	54	5.25 (4.79, 5.75)
Multiracial	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	15	0.02 (0.02, 0.02)
Multiracial	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	15	0.27 (0.27, 0.27)
Multiracial	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	15	0.09 (0.09, 0.09)
Multiracial	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	15	5.13 (4.88, 5.39)
Multiracial	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	15	5.00 (5.00, 5.00)
Multiracial	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	11	0.02 (0.02, 0.02)
Multiracial	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	11	0.27 (0.27, 0.27)
Multiracial	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	11	0.09 (0.09, 0.09)
Multiracial	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	11	5.00 (5.00, 5.00)
Multiracial	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	11	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Multiracial	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	22	0.02 (0.02, 0.02)
Multiracial	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	22	0.27 (0.27, 0.27)
Multiracial	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	22	0.09 (0.09, 0.09)
Multiracial	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	22	5.00 (5.00, 5.00)
Multiracial	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	22	5.00 (5.00, 5.00)
Multiracial	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	54	21.28 (11.12, 40.72)
Multiracial	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	54	520.84 (295.56, 917.82)
Multiracial	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	54	358.51 (216.79, 592.89)
Multiracial	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	54	46.77 (25.27, 86.56)
Multiracial	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	54	131.90 (77.15, 225.48)
Multiracial	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	15	65.14 (27.17, 156.20)
Multiracial	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	15	463.44 (162.01, 1325.67)
Multiracial	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	15	479.77 (179.76, 1280.50)
Multiracial	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	15	115.29 (56.50, 235.27)
Multiracial	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	15	249.18 (111.78, 555.48)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Multiracial	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	11	0.02 (0.02, 0.02)
Multiracial	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	11	0.27 (0.27, 0.27)
Multiracial	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	11	0.09 (0.09, 0.09)
Multiracial	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	11	5.00 (5.00, 5.00)
Multiracial	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	11	5.00 (5.00, 5.00)
Multiracial	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	22	27.97 (12.94, 60.45)
Multiracial	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	22	332.19 (198.62, 555.58)
Multiracial	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	22	202.22 (122.86, 332.85)
Multiracial	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	22	30.50 (9.70, 95.90)
Multiracial	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	22	89.67 (27.75, 289.69)
Multiracial	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	54	539.35 (260.74, 1115.66)
Multiracial	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	54	27584.18 (15110.76, 50353.99)
Multiracial	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	54	16593.57 (9214.59, 29881.56)
Multiracial	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	54	572.70 (247.09, 1327.39)
Multiracial	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	54	729.52 (536.14, 992.66)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Multiracial	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	15	483.18 (173.52, 1345.44)
Multiracial	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	15	46801.40 (17914.69, 122266.73)
Multiracial	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	15	27638.16 (12232.55, 62445.54)
Multiracial	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	15	1706.98 (755.16, 3858.51)
Multiracial	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	15	1215.80 (1072.87, 1377.77)
Multiracial	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	11	0.02 (0.02, 0.02)
Multiracial	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	11	0.27 (0.27, 0.27)
Multiracial	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	11	0.09 (0.09, 0.09)
Multiracial	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	11	5.00 (5.00, 5.00)
Multiracial	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	11	5.00 (5.00, 5.00)
Multiracial	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	22	559.74 (173.26, 1808.31)
Multiracial	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	22	15441.15 (5454.94, 43708.89)
Multiracial	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	22	8913.59 (3494.22, 22738.11)
Multiracial	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	22	432.56 (162.68, 1150.13)
Multiracial	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	22	890.99 (670.22, 1184.47)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Other	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	21	0.02 (0.02, 0.02)
Other	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	21	0.27 (0.27, 0.27)
Other	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	21	0.09 (0.09, 0.09)
Other	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	21	5.00 (5.00, 5.00)
Other	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	21	5.00 (5.00, 5.00)
Other	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	1	0.02 (0.02, 0.02)
Other	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	1	0.27 (0.27, 0.27)
Other	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	1	0.09 (0.09, 0.09)
Other	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	1	5.00 (5.00, 5.00)
Other	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	1	5.00 (5.00, 5.00)
Other	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	4	0.02 (0.02, 0.02)
Other	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0.27 (0.27, 0.27)
Other	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0.09 (0.09, 0.09)
Other	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	4	5.00 (5.00, 5.00)
Other	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	4	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Other	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	9	0.02 (0.02, 0.02)
Other	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	9	0.27 (0.27, 0.27)
Other	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	9	0.09 (0.09, 0.09)
Other	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	9	5.00 (5.00, 5.00)
Other	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	9	5.00 (5.00, 5.00)
Other	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	21	267.80 (87.02, 824.09)
Other	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	21	2017.48 (874.19, 4656.01)
Other	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	21	1046.60 (639.17, 1713.73)
Other	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	21	529.71 (274.00, 1024.07)
Other	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	21	383.37 (197.37, 744.64)
Other	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	1	75.29 (75.29, 75.29)
Other	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	1	237.61 (237.61, 237.61)
Other	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	1	145.29 (145.29, 145.29)
Other	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	1	85.04 (85.04, 85.04)
Other	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	1	30.12 (30.12, 30.12)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Other	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	4	0.02 (0.02, 0.02)
Other	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0.27 (0.27, 0.27)
Other	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0.09 (0.09, 0.09)
Other	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	4	5.00 (5.00, 5.00)
Other	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	4	5.00 (5.00, 5.00)
Other	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	9	32.42 (9.26, 113.47)
Other	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	9	587.28 (203.04, 1698.69)
Other	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	9	158.89 (57.97, 435.49)
Other	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	9	86.41 (26.90, 277.60)
Other	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	9	111.41 (41.19, 301.36)
Other	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	21	2300.07 (671.84, 7874.34)
Other	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	21	66098.27 (26023.07, 167888.80)
Other	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	21	44752.53 (22047.07, 90841.47)
Other	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	21	3023.49 (1736.08, 5265.61)
Other	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	21	1120.63 (907.27, 1384.16)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Other	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	1	1357.72 (1357.72, 1357.72)
Other	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	1	6363.10 (6363.10, 6363.10)
Other	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	1	4151.86 (4151.86, 4151.86)
Other	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	1	82.28 (82.28, 82.28)
Other	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	1	1295.00 (1295.00, 1295.00)
Other	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	4	0.02 (0.02, 0.02)
Other	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0.27 (0.27, 0.27)
Other	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0.09 (0.09, 0.09)
Other	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	4	5.00 (5.00, 5.00)
Other	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	4	5.00 (5.00, 5.00)
Other	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	9	205.61 (48.86, 865.24)
Other	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	9	10168.15 (2238.28, 46192.24)
Other	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	9	10187.96 (3280.66, 31638.33)
Other	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	9	573.37 (92.57, 3551.49)
Other	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	9	500.06 (161.56, 1547.83)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	85	0.02 (0.02, 0.02)
Not reported and unknown	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	85	0.27 (0.27, 0.27)
Not reported and unknown	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	85	0.09 (0.09, 0.09)
Not reported and unknown	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	85	5.04 (4.96, 5.13)
Not reported and unknown	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	85	5.25 (4.82, 5.71)
Not reported and unknown	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	22	0.02 (0.02, 0.02)
Not reported and unknown	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	22	0.27 (0.27, 0.27)
Not reported and unknown	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	22	0.09 (0.09, 0.09)
Not reported and unknown	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	22	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	22	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	18	0.02 (0.02, 0.02)
Not reported and unknown	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	18	0.27 (0.27, 0.27)
Not reported and unknown	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	18	0.09 (0.09, 0.09)
Not reported and unknown	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	18	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	18	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	23	0.02 (0.02, 0.02)
Not reported and unknown	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	23	0.27 (0.27, 0.27)
Not reported and unknown	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	23	0.09 (0.09, 0.09)
Not reported and unknown	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	23	5.00 (5.00, 5.00)
Not reported and unknown	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	23	5.19 (4.82, 5.59)
Not reported and unknown	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	85	77.15 (38.54, 154.43)
Not reported and unknown	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	85	773.81 (475.84, 1258.35)
Not reported and unknown	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	85	388.65 (243.31, 620.82)
Not reported and unknown	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	85	132.53 (70.21, 250.15)
Not reported and unknown	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	85	190.32 (111.02, 326.28)
Not reported and unknown	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	22	110.74 (60.17, 203.82)
Not reported and unknown	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	22	1256.62 (639.53, 2469.18)
Not reported and unknown	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	22	613.58 (354.20, 1062.89)
Not reported and unknown	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	22	148.38 (95.59, 230.34)
Not reported and unknown	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	22	190.95 (91.18, 399.93)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	18	0.02 (0.02, 0.02)
Not reported and unknown	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	18	0.27 (0.27, 0.27)
Not reported and unknown	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	18	0.09 (0.09, 0.09)
Not reported and unknown	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	18	5.00 (5.00, 5.00)
Not reported and unknown	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	18	5.00 (5.00, 5.00)
Not reported and unknown	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	23	33.36 (10.78, 103.23)
Not reported and unknown	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	23	490.91 (170.10, 1416.74)
Not reported and unknown	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	23	273.52 (114.27, 654.68)
Not reported and unknown	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	23	53.98 (14.45, 201.69)
Not reported and unknown	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	23	160.32 (53.58, 479.67)
Not reported and unknown	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	85	1092.65 (498.45, 2395.15)
Not reported and unknown	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	85	38874.41 (21745.70, 69495.12)
Not reported and unknown	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	85	20946.43 (12193.67, 35982.03)
Not reported and unknown	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	85	1180.05 (690.75, 2015.96)
Not reported and unknown	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	85	766.35 (593.58, 989.40)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Not reported and unknown	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	22	1761.08 (1204.88, 2574.04)
Not reported and unknown	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	22	49553.86 (27943.73, 87876.07)
Not reported and unknown	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	22	35543.09 (17595.77, 71796.29)
Not reported and unknown	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	22	2516.73 (1687.39, 3753.68)
Not reported and unknown	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	22	1165.95 (998.67, 1361.26)
Not reported and unknown	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	18	0.02 (0.02, 0.02)
Not reported and unknown	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	18	0.28 (0.27, 0.29)
Not reported and unknown	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	18	0.09 (0.09, 0.09)
Not reported and unknown	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	18	5.10 (4.90, 5.32)
Not reported and unknown	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	18	5.11 (4.89, 5.33)
Not reported and unknown	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	23	985.10 (348.18, 2787.08)
Not reported and unknown	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	23	17978.90 (9051.03, 35713.17)
Not reported and unknown	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	23	10481.80 (4573.44, 24023.07)
Not reported and unknown	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	23	505.69 (174.07, 1469.14)
Not reported and unknown	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	23	715.15 (310.89, 1645.10)

Table 5i. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Underrepresented minority status						
Communities of Color	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	424	0.02 (0.02, 0.02)
Communities of Color	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	424	0.27 (0.27, 0.27)
Communities of Color	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	424	0.09 (0.09, 0.09)
Communities of Color	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	424	5.05 (5.01, 5.08)
Communities of Color	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	424	5.10 (5.02, 5.19)
Communities of Color	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	120	0.02 (0.02, 0.02)
Communities of Color	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	120	0.27 (0.27, 0.27)
Communities of Color	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	120	0.09 (0.09, 0.09)
Communities of Color	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	120	5.02 (4.98, 5.06)
Communities of Color	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	120	5.03 (4.99, 5.08)
Communities of Color	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	63	0.02 (0.02, 0.02)
Communities of Color	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	63	0.27 (0.27, 0.27)
Communities of Color	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	63	0.09 (0.09, 0.09)
Communities of Color	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	63	5.07 (4.93, 5.22)
Communities of Color	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	63	5.06 (4.95, 5.17)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Communities of Color	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	124	0.02 (0.02, 0.02)
Communities of Color	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	124	0.28 (0.27, 0.29)
Communities of Color	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	124	0.09 (0.09, 0.09)
Communities of Color	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	124	5.00 (5.00, 5.00)
Communities of Color	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	124	5.00 (5.00, 5.00)
Communities of Color	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	424	48.62 (37.95, 62.30)
Communities of Color	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	424	620.12 (497.65, 772.73)
Communities of Color	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	424	411.57 (345.98, 489.61)
Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	424	94.00 (74.52, 118.56)
Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	424	166.34 (136.37, 202.89)
Communities of Color	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	120	85.46 (56.04, 130.32)
Communities of Color	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	120	1034.01 (721.44, 1482.01)
Communities of Color	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	120	623.25 (467.77, 830.42)
Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	120	171.64 (112.97, 260.78)
Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	120	237.95 (162.81, 347.76)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Communities of Color	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	63	0.02 (0.02, 0.02)
Communities of Color	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	63	0.27 (0.27, 0.27)
Communities of Color	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	63	0.09 (0.09, 0.09)
Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	63	5.00 (5.00, 5.00)
Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	63	5.00 (5.00, 5.00)
Communities of Color	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	124	49.62 (34.94, 70.46)
Communities of Color	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	124	495.72 (376.43, 652.82)
Communities of Color	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	124	205.15 (154.75, 271.97)
Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	124	73.87 (49.45, 110.35)
Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	124	153.75 (104.52, 226.17)
Communities of Color	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	424	774.71 (579.98, 1034.82)
Communities of Color	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	424	27241.35 (21864.28, 33940.79)
Communities of Color	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	424	18698.21 (15574.38, 22448.59)
Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	424	817.67 (646.79, 1033.68)
Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	424	771.84 (678.09, 878.56)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Communities of Color	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	120	1685.08 (1001.61, 2834.93)
Communities of Color	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	120	63394.56 (42857.04, 93773.88)
Communities of Color	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	120	37702.50 (27078.22, 52495.27)
Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	120	1711.69 (1260.86, 2323.72)
Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	120	1143.39 (1029.28, 1270.14)
Communities of Color	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	63	0.02 (0.02, 0.02)
Communities of Color	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	63	0.27 (0.27, 0.27)
Communities of Color	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	63	0.09 (0.09, 0.09)
Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	63	5.00 (5.00, 5.00)
Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	63	5.00 (5.00, 5.00)
Communities of Color	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	124	512.68 (321.95, 816.39)
Communities of Color	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	124	20524.99 (14310.79, 29437.60)
Communities of Color	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	124	11316.46 (7907.61, 16194.82)
Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	124	477.19 (294.63, 772.87)
Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	124	614.24 (457.65, 824.40)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	355	0.02 (0.02, 0.02)
White Non-Hispanic	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	355	0.27 (0.27, 0.27)
White Non-Hispanic	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	355	0.09 (0.09, 0.09)
White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	355	5.04 (5.00, 5.07)
White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	355	5.18 (5.04, 5.33)
White Non-Hispanic	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	121	0.02 (0.02, 0.02)
White Non-Hispanic	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	121	0.27 (0.27, 0.27)
White Non-Hispanic	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	121	0.09 (0.09, 0.09)
White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	121	5.04 (4.98, 5.09)
White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	121	5.12 (4.89, 5.37)
White Non-Hispanic	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	64	0.02 (0.02, 0.02)
White Non-Hispanic	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	64	0.27 (0.27, 0.27)
White Non-Hispanic	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	64	0.09 (0.09, 0.09)
White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	64	5.11 (4.96, 5.26)
White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	64	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	116	0.02 (0.02, 0.02)
White Non-Hispanic	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	116	0.27 (0.27, 0.27)
White Non-Hispanic	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	116	0.09 (0.09, 0.09)
White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	116	5.19 (4.93, 5.47)
White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	116	5.24 (4.92, 5.59)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	355	69.71 (54.55, 89.08)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	355	851.96 (683.58, 1061.81)
White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	355	457.39 (378.96, 552.07)
White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	355	126.36 (99.23, 160.92)
White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	355	217.51 (176.19, 268.54)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	121	77.05 (48.18, 123.22)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	121	1042.78 (719.00, 1512.35)
White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	121	675.98 (483.56, 944.98)
White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	121	134.49 (91.52, 197.63)
White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	121	274.51 (190.56, 395.46)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	64	0.02 (0.02, 0.02)
White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	64	0.27 (0.27, 0.27)
White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	64	0.09 (0.09, 0.09)
White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	64	5.18 (4.89, 5.49)
White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	64	5.00 (5.00, 5.00)
White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	116	25.31 (16.85, 38.02)
White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	116	210.89 (142.33, 312.47)
White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	116	127.97 (94.16, 173.92)
White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	116	48.07 (32.44, 71.22)
White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	116	140.69 (97.98, 202.01)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	355	1044.69 (761.89, 1432.46)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	355	36435.10 (28737.15, 46195.14)
White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	355	25205.17 (20626.81, 30799.75)
White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	355	1228.38 (982.72, 1535.45)
White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	355	810.89 (707.90, 928.88)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	121	2213.21 (1336.74, 3664.34)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	121	70335.26 (47398.85, 104370.64)
White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	121	50675.29 (37092.29, 69232.30)
White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	121	1892.63 (1423.38, 2516.58)
White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	121	961.03 (795.48, 1161.03)
White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	64	0.02 (0.02, 0.02)
White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	64	0.28 (0.27, 0.28)
White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	64	0.09 (0.09, 0.09)
White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	64	5.03 (4.97, 5.09)
White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	64	5.08 (4.97, 5.19)
White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	116	277.45 (178.97, 430.10)
White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	116	9241.19 (6112.15, 13972.11)
White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	116	6530.55 (4820.40, 8847.43)
White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	116	457.87 (282.73, 741.51)
White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	116	581.23 (447.81, 754.40)

Table 5j. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age, Underrepresented minority status						
Age < 65 Communities of Color	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	203	0.02 (0.02, 0.02)
Age < 65 Communities of Color	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	203	0.27 (0.27, 0.27)
Age < 65 Communities of Color	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	203	0.09 (0.09, 0.09)
Age < 65 Communities of Color	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	203	5.02 (4.99, 5.05)
Age < 65 Communities of Color	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	203	5.09 (4.99, 5.20)
Age < 65 Communities of Color	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	66	0.02 (0.02, 0.02)
Age < 65 Communities of Color	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	66	0.27 (0.27, 0.27)
Age < 65 Communities of Color	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	66	0.09 (0.09, 0.09)
Age < 65 Communities of Color	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	66	5.03 (4.98, 5.08)
Age < 65 Communities of Color	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	66	5.00 (5.00, 5.00)
Age < 65 Communities of Color	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	29	0.02 (0.02, 0.02)
Age < 65 Communities of Color	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	29	0.27 (0.27, 0.27)
Age < 65 Communities of Color	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	29	0.09 (0.09, 0.09)
Age < 65 Communities of Color	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	29	5.10 (4.91, 5.29)
Age < 65 Communities of Color	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	29	5.07 (4.93, 5.23)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Communities of Color	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	66	0.02 (0.02, 0.02)
Age < 65 Communities of Color	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	66	0.28 (0.26, 0.30)
Age < 65 Communities of Color	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	66	0.09 (0.09, 0.09)
Age < 65 Communities of Color	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	66	5.00 (5.00, 5.00)
Age < 65 Communities of Color	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	66	5.00 (5.00, 5.00)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	203	35.10 (25.78, 47.78)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	203	457.32 (347.73, 601.46)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	203	301.12 (242.80, 373.46)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	203	71.12 (53.27, 94.95)
Age < 65 Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	203	137.79 (107.57, 176.50)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	66	67.04 (40.26, 111.64)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	66	785.84 (509.91, 1211.08)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	66	477.06 (338.24, 672.86)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	66	141.65 (85.33, 235.13)
Age < 65 Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	66	203.23 (128.13, 322.36)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Communities of Color	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	29	0.02 (0.02, 0.02)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	29	0.27 (0.27, 0.27)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	29	0.09 (0.09, 0.09)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	29	5.00 (5.00, 5.00)
Age < 65 Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	29	5.00 (5.00, 5.00)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	66	44.74 (29.05, 68.91)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	66	421.42 (299.53, 592.92)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	66	162.56 (114.18, 231.43)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	66	66.65 (39.96, 111.15)
Age < 65 Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	66	149.80 (91.54, 245.16)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	203	573.44 (400.05, 821.98)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	203	19732.41 (15024.14, 25916.16)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	203	13918.06 (11091.08, 17465.61)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	203	654.79 (488.18, 878.25)
Age < 65 Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	203	721.51 (613.35, 848.75)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	66	1267.45 (673.93, 2383.66)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	66	48327.69 (30091.49, 77615.49)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	66	29299.82 (19581.06, 43842.32)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	66	1495.40 (1028.98, 2173.23)
Age < 65 Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	66	1128.59 (991.94, 1284.07)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	29	0.02 (0.02, 0.02)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	29	0.27 (0.27, 0.27)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	29	0.09 (0.09, 0.09)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	29	5.00 (5.00, 5.00)
Age < 65 Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	29	5.00 (5.00, 5.00)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	66	436.86 (242.39, 787.35)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	66	18408.36 (11677.02, 29020.05)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	66	9505.76 (5985.27, 15096.96)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	66	361.05 (193.83, 672.53)
Age < 65 Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	66	581.07 (398.22, 847.86)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 White Non-Hispanic	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	177	0.02 (0.02, 0.02)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	177	0.27 (0.27, 0.27)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	177	0.09 (0.09, 0.09)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	177	5.04 (5.00, 5.09)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	177	5.18 (5.01, 5.36)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	57	0.02 (0.02, 0.02)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	57	0.27 (0.27, 0.27)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	57	0.09 (0.09, 0.09)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	57	5.03 (4.97, 5.09)
Age < 65 White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	57	5.16 (4.85, 5.48)
Age < 65 White Non-Hispanic	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	31	0.02 (0.02, 0.02)
Age < 65 White Non-Hispanic	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	31	0.27 (0.27, 0.27)
Age < 65 White Non-Hispanic	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	31	0.09 (0.09, 0.09)
Age < 65 White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	31	5.07 (4.94, 5.20)
Age < 65 White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	31	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 White Non-Hispanic	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	61	0.02 (0.02, 0.02)
Age < 65 White Non-Hispanic	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	61	0.27 (0.27, 0.27)
Age < 65 White Non-Hispanic	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	61	0.09 (0.09, 0.09)
Age < 65 White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	61	5.24 (4.91, 5.59)
Age < 65 White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	61	5.29 (4.89, 5.72)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	177	55.39 (40.98, 74.87)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	177	668.94 (510.31, 876.89)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	177	357.78 (284.42, 450.06)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	177	102.20 (75.95, 137.52)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	177	194.70 (150.00, 252.73)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	57	53.74 (30.04, 96.12)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	57	790.08 (497.54, 1254.63)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	57	496.01 (327.46, 751.32)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	57	94.80 (59.19, 151.84)
Age < 65 White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	57	232.72 (146.88, 368.73)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	31	0.02 (0.02, 0.02)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	31	0.27 (0.27, 0.27)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	31	0.09 (0.09, 0.09)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	31	5.20 (4.82, 5.62)
Age < 65 White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	31	5.00 (5.00, 5.00)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	61	18.86 (11.62, 30.62)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	61	144.34 (90.52, 230.17)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	61	87.15 (60.97, 124.58)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	61	36.07 (22.56, 57.67)
Age < 65 White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	61	121.94 (78.69, 188.96)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	177	837.41 (567.11, 1236.53)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	177	29343.43 (21901.35, 39314.34)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	177	21011.62 (16421.53, 26884.72)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	177	1083.80 (821.28, 1430.23)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	177	775.43 (654.62, 918.52)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	57	1651.20 (876.59, 3110.31)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	57	52698.61 (32118.50, 86465.56)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	57	39615.10 (26730.87, 58709.51)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	57	1612.80 (1124.20, 2313.76)
Age < 65 White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	57	905.79 (712.35, 1151.76)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	31	0.02 (0.02, 0.02)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	31	0.27 (0.27, 0.27)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	31	0.09 (0.09, 0.09)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	31	5.00 (5.00, 5.00)
Age < 65 White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	31	5.00 (5.00, 5.00)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	61	184.40 (109.92, 309.37)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	61	6337.83 (3870.94, 10376.84)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	61	4830.98 (3371.45, 6922.33)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	61	323.36 (180.12, 580.50)
Age < 65 White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	61	528.03 (385.10, 724.01)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Communities of Color	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	221	0.02 (0.02, 0.02)
Age \geq 65 Communities of Color	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	221	0.27 (0.27, 0.27)
Age \geq 65 Communities of Color	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	221	0.09 (0.09, 0.09)
Age \geq 65 Communities of Color	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	221	5.14 (5.01, 5.27)
Age \geq 65 Communities of Color	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	221	5.14 (4.99, 5.29)
Age \geq 65 Communities of Color	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	54	0.02 (0.02, 0.02)
Age \geq 65 Communities of Color	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	54	0.28 (0.27, 0.28)
Age \geq 65 Communities of Color	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	54	0.09 (0.09, 0.09)
Age \geq 65 Communities of Color	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	54	5.00 (5.00, 5.00)
Age \geq 65 Communities of Color	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	54	5.18 (4.94, 5.43)
Age \geq 65 Communities of Color	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	34	0.02 (0.02, 0.02)
Age \geq 65 Communities of Color	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	34	0.27 (0.27, 0.27)
Age \geq 65 Communities of Color	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	34	0.09 (0.09, 0.09)
Age \geq 65 Communities of Color	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	34	5.00 (5.00, 5.00)
Age \geq 65 Communities of Color	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	34	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Communities of Color	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	58	0.02 (0.02, 0.02)
Age \geq 65 Communities of Color	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	58	0.27 (0.27, 0.27)
Age \geq 65 Communities of Color	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	58	0.09 (0.09, 0.09)
Age \geq 65 Communities of Color	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	58	5.00 (5.00, 5.00)
Age \geq 65 Communities of Color	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	58	5.00 (5.00, 5.00)
Age \geq 65 Communities of Color	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	221	161.04 (128.67, 201.54)
Age \geq 65 Communities of Color	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	221	1897.60 (1562.13, 2305.12)
Age \geq 65 Communities of Color	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	221	1296.72 (1103.57, 1523.67)
Age \geq 65 Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	221	261.75 (211.61, 323.78)
Age \geq 65 Communities of Color	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	221	332.15 (277.76, 397.19)
Age \geq 65 Communities of Color	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	54	237.29 (156.57, 359.63)
Age \geq 65 Communities of Color	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	54	3281.99 (2271.10, 4742.84)
Age \geq 65 Communities of Color	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	54	1919.60 (1454.20, 2533.94)
Age \geq 65 Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	54	385.20 (256.78, 577.84)
Age \geq 65 Communities of Color	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	54	462.04 (328.86, 649.14)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Communities of Color	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	34	0.02 (0.02, 0.02)
Age \geq 65 Communities of Color	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	34	0.27 (0.27, 0.27)
Age \geq 65 Communities of Color	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	34	0.09 (0.09, 0.10)
Age \geq 65 Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	34	5.00 (5.00, 5.00)
Age \geq 65 Communities of Color	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	34	5.00 (5.00, 5.00)
Age \geq 65 Communities of Color	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	58	68.17 (40.39, 115.05)
Age \geq 65 Communities of Color	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	58	815.63 (557.34, 1193.63)
Age \geq 65 Communities of Color	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	58	418.82 (297.74, 589.15)
Age \geq 65 Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	58	101.29 (64.91, 158.04)
Age \geq 65 Communities of Color	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	58	166.51 (108.77, 254.91)
Age \geq 65 Communities of Color	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	221	2338.70 (1779.47, 3073.68)
Age \geq 65 Communities of Color	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	221	89042.34 (71881.88, 110299.55)
Age \geq 65 Communities of Color	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	221	55300.46 (46772.64, 65383.11)
Age \geq 65 Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	221	1848.87 (1539.61, 2220.25)
Age \geq 65 Communities of Color	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	221	988.75 (894.42, 1093.04)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 Communities of Color	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	54	5586.62 (3555.82, 8777.25)
Age \geq 65 Communities of Color	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	54	198622.80 (140812.45, 280167.10)
Age \geq 65 Communities of Color	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	54	108944.36 (89269.24, 132955.92)
Age \geq 65 Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	54	3022.19 (2449.99, 3728.02)
Age \geq 65 Communities of Color	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	54	1207.81 (1127.83, 1293.47)
Age \geq 65 Communities of Color	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	34	0.02 (0.02, 0.02)
Age \geq 65 Communities of Color	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	34	0.27 (0.27, 0.27)
Age \geq 65 Communities of Color	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	34	0.09 (0.09, 0.09)
Age \geq 65 Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	34	5.00 (5.00, 5.00)
Age \geq 65 Communities of Color	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	34	5.00 (5.00, 5.00)
Age \geq 65 Communities of Color	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	58	837.50 (482.22, 1454.52)
Age \geq 65 Communities of Color	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	58	28657.50 (18388.19, 44661.94)
Age \geq 65 Communities of Color	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	58	19316.61 (14117.67, 26430.09)
Age \geq 65 Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	58	1122.30 (742.14, 1697.21)
Age \geq 65 Communities of Color	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	58	728.24 (541.27, 979.80)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 White Non-Hispanic	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	178	0.02 (0.02, 0.02)
Age \geq 65 White Non-Hispanic	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	178	0.27 (0.27, 0.27)
Age \geq 65 White Non-Hispanic	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	178	0.09 (0.09, 0.09)
Age \geq 65 White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	178	5.02 (4.98, 5.07)
Age \geq 65 White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	178	5.17 (5.02, 5.32)
Age \geq 65 White Non-Hispanic	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	64	0.02 (0.02, 0.02)
Age \geq 65 White Non-Hispanic	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	64	0.27 (0.27, 0.27)
Age \geq 65 White Non-Hispanic	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	64	0.09 (0.09, 0.09)
Age \geq 65 White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	64	5.07 (4.93, 5.21)
Age \geq 65 White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	64	5.00 (5.00, 5.00)
Age \geq 65 White Non-Hispanic	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	33	0.02 (0.02, 0.02)
Age \geq 65 White Non-Hispanic	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	33	0.27 (0.27, 0.27)
Age \geq 65 White Non-Hispanic	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	33	0.09 (0.09, 0.09)
Age \geq 65 White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	33	5.23 (4.79, 5.71)
Age \geq 65 White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	33	5.00 (5.00, 5.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 White Non-Hispanic	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	55	0.02 (0.02, 0.02)
Age \geq 65 White Non-Hispanic	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	55	0.27 (0.27, 0.27)
Age \geq 65 White Non-Hispanic	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	55	0.09 (0.09, 0.09)
Age \geq 65 White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	55	5.00 (5.00, 5.00)
Age \geq 65 White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	55	5.07 (4.93, 5.22)
Age \geq 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	178	167.00 (129.64, 215.14)
Age \geq 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	178	2135.58 (1712.90, 2662.56)
Age \geq 65 White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	178	1163.20 (943.92, 1433.41)
Age \geq 65 White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	178	283.03 (219.38, 365.16)
Age \geq 65 White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	178	331.39 (272.22, 403.43)
Age \geq 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	64	270.81 (175.40, 418.11)
Age \geq 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	64	2745.01 (1949.23, 3865.67)
Age \geq 65 White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	64	1990.03 (1494.71, 2649.48)
Age \geq 65 White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	64	455.38 (303.46, 683.36)
Age \geq 65 White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	64	488.38 (368.60, 647.09)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	33	0.02 (0.02, 0.02)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	33	0.27 (0.27, 0.27)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	33	0.09 (0.09, 0.09)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	33	5.12 (4.89, 5.37)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	33	5.00 (5.00, 5.00)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	55	88.12 (54.62, 142.16)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	55	1053.05 (704.65, 1573.72)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	55	652.65 (460.03, 925.93)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	55	162.42 (104.14, 253.31)
Age ≥ 65 White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	55	258.06 (181.76, 366.39)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	178	2420.76 (1777.81, 3296.22)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	178	82935.48 (65873.73, 104416.34)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	178	50325.96 (40914.21, 61902.76)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	178	1976.84 (1645.30, 2375.19)
Age ≥ 65 White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	178	961.10 (866.03, 1066.60)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	GMT/GMC
Age \geq 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	64	6148.26 (4069.75, 9288.30)
Age \geq 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	64	192512.51 (145245.72, 255161.18)
Age \geq 65 White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	64	119611.06 (102347.32, 139786.82)
Age \geq 65 White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	64	3306.86 (2785.89, 3925.26)
Age \geq 65 White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	64	1181.40 (1056.92, 1320.55)
Age \geq 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	33	0.02 (0.02, 0.02)
Age \geq 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	33	0.29 (0.27, 0.31)
Age \geq 65 White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	33	0.09 (0.09, 0.09)
Age \geq 65 White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	33	5.12 (4.89, 5.35)
Age \geq 65 White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	33	5.31 (4.89, 5.76)
Age \geq 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	55	1568.89 (919.65, 2676.47)
Age \geq 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	55	45747.99 (30341.55, 68977.32)
Age \geq 65 White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	55	23451.99 (16867.71, 32606.42)
Age \geq 65 White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	55	2001.70 (1467.62, 2730.14)
Age \geq 65 White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	55	873.31 (672.31, 1134.40)

Table 6a. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by All participants

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
All participants								
	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	904	0.02 (0.02, 0.02)	63.36 (53.33, 75.29)	2640.13 (2221.93, 3137.04)
	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	904	0.27 (0.27, 0.27)	777.30 (672.65, 898.24)	2857.72 (2472.96, 3302.35)
	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	904	0.09 (0.09, 0.09)	448.95 (396.45, 508.40)	4985.18 (4402.25, 5645.30)
	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	904	5.07 (5.02, 5.12)	117.24 (99.65, 137.93)	23.15 (19.70, 27.20)
	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	904	5.15 (5.06, 5.24)	193.83 (167.92, 223.73)	37.64 (32.67, 43.37)
	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	277	0.02 (0.02, 0.02)	78.60 (59.10, 104.52)	3274.81 (2462.47, 4355.12)
	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	277	0.27 (0.27, 0.27)	984.50 (773.66, 1252.81)	3615.75 (2841.41, 4601.11)
	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	277	0.09 (0.09, 0.09)	634.79 (519.07, 776.30)	7053.22 (5767.47, 8625.59)
	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	277	5.03 (5.00, 5.06)	145.91 (113.68, 187.28)	29.03 (22.61, 37.27)
	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	277	5.07 (4.96, 5.19)	250.06 (195.89, 319.20)	49.32 (38.74, 62.80)
	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	155	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	155	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	155	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.01 (1.00, 1.01)
	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	155	5.07 (4.99, 5.15)	5.08 (4.95, 5.22)	1.00 (0.97, 1.03)
	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	155	5.02 (4.98, 5.06)	5.00 (5.00, 5.00)	1.00 (0.99, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	274	0.02 (0.02, 0.02)	32.90 (24.99, 43.30)	1370.73 (1041.38, 1804.23)
	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	274	0.27 (0.27, 0.28)	309.30 (239.29, 399.78)	1129.45 (872.28, 1462.44)
	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	274	0.09 (0.09, 0.09)	163.46 (132.49, 201.67)	1816.23 (1472.14, 2240.74)
	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	274	5.10 (4.96, 5.25)	56.68 (42.71, 75.22)	11.11 (8.36, 14.76)
	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	274	5.15 (4.97, 5.34)	146.22 (113.10, 189.03)	28.39 (21.89, 36.83)
	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	904	0.02 (0.02, 0.02)	948.86 (771.45, 1167.08)	39536.03 (32143.75, 48628.35)
	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	904	0.27 (0.27, 0.27)	34021.35 (29123.06, 39743.51)	125078.51 (107070.06, 146115.86)
	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	904	0.09 (0.09, 0.09)	22817.97 (19944.94, 26104.85)	253371.43 (221470.14, 289867.90)
	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	904	5.07 (5.02, 5.12)	1091.69 (937.63, 1271.06)	215.52 (185.18, 250.84)
	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	904	5.15 (5.06, 5.24)	806.40 (739.65, 879.17)	156.61 (143.60, 170.80)
	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	277	0.02 (0.02, 0.02)	1975.01 (1440.49, 2707.88)	82292.25 (60020.40, 112828.53)
	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	277	0.27 (0.27, 0.27)	62681.63 (48801.94, 80508.81)	230208.61 (179230.59, 295686.16)
	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	277	0.09 (0.09, 0.09)	42910.81 (34675.79, 53101.53)	476786.77 (385286.59, 590016.96)
	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	277	5.03 (5.00, 5.06)	1909.96 (1589.03, 2295.71)	380.02 (316.13, 456.83)
	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	277	5.07 (4.96, 5.19)	1044.34 (942.43, 1157.26)	205.98 (185.71, 228.46)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	155	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	155	0.27 (0.27, 0.27)	0.27 (0.27, 0.28)	1.01 (1.00, 1.02)
	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	155	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	155	5.07 (4.99, 5.15)	5.04 (4.99, 5.09)	0.99 (0.98, 1.01)
	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	155	5.02 (4.98, 5.06)	5.05 (4.99, 5.10)	1.01 (0.99, 1.02)
	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	274	0.02 (0.02, 0.02)	385.82 (284.09, 523.97)	16075.73 (11837.09, 21832.15)
	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	274	0.27 (0.27, 0.28)	13410.80 (10185.37, 17657.62)	48972.16 (37141.16, 64571.84)
	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	274	0.09 (0.09, 0.09)	8203.97 (6577.21, 10233.09)	91155.26 (73080.07, 113701.05)
	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	274	5.10 (4.96, 5.25)	469.42 (339.51, 649.04)	91.97 (66.64, 126.93)
	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	274	5.15 (4.97, 5.34)	612.04 (506.61, 739.40)	118.84 (97.84, 144.35)

Table 6b. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age								
Age < 65	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	436	0.02 (0.02, 0.02)	49.48 (39.93, 61.31)	2061.68 (1663.88, 2554.58)
Age < 65	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	436	0.27 (0.27, 0.27)	601.50 (502.70, 719.72)	2211.39 (1848.15, 2646.02)
Age < 65	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	436	0.09 (0.09, 0.09)	343.47 (294.48, 400.61)	3816.32 (3271.96, 4451.24)
Age < 65	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	436	5.07 (5.01, 5.13)	94.35 (77.13, 115.43)	18.62 (15.24, 22.74)
Age < 65	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	436	5.15 (5.04, 5.27)	168.42 (140.81, 201.44)	32.69 (27.40, 39.01)
Age < 65	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	145	0.02 (0.02, 0.02)	58.15 (41.19, 82.10)	2422.88 (1716.05, 3420.86)
Age < 65	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	145	0.27 (0.27, 0.27)	747.42 (558.26, 1000.66)	2747.85 (2052.43, 3678.91)
Age < 65	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	145	0.09 (0.09, 0.09)	482.24 (378.08, 615.10)	5358.27 (4200.91, 6834.50)
Age < 65	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	145	5.02 (4.99, 5.06)	111.36 (82.40, 150.49)	22.17 (16.40, 29.97)
Age < 65	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	145	5.07 (4.93, 5.22)	213.95 (158.62, 288.57)	42.18 (31.37, 56.70)
Age < 65	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	76	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age < 65	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	76	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	76	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.01)
Age < 65	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	76	5.06 (4.98, 5.14)	5.09 (4.92, 5.26)	1.01 (0.97, 1.04)
Age < 65	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	76	5.02 (4.98, 5.07)	5.00 (5.00, 5.00)	1.00 (0.99, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	143	0.02 (0.02, 0.02)	25.43 (18.13, 35.66)	1059.42 (755.32, 1485.97)
Age < 65	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	143	0.27 (0.27, 0.28)	220.21 (160.47, 302.20)	802.64 (583.55, 1103.98)
Age < 65	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	143	0.09 (0.09, 0.09)	115.82 (89.55, 149.79)	1286.84 (994.97, 1664.32)
Age < 65	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	143	5.13 (4.95, 5.32)	44.02 (30.99, 62.52)	8.58 (6.03, 12.20)
Age < 65	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	143	5.18 (4.95, 5.42)	130.40 (94.72, 179.52)	25.16 (18.19, 34.80)
Age < 65	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	436	0.02 (0.02, 0.02)	733.10 (566.69, 948.39)	30545.93 (23611.98, 39516.12)
Age < 65	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	436	0.27 (0.27, 0.27)	26634.96 (21956.62, 32310.13)	97922.65 (80722.87, 118787.23)
Age < 65	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	436	0.09 (0.09, 0.09)	18271.32 (15460.07, 21593.77)	203014.65 (171778.53, 239930.74)
Age < 65	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	436	5.07 (5.01, 5.13)	929.19 (768.12, 1124.03)	183.35 (151.64, 221.69)
Age < 65	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	436	5.15 (5.04, 5.27)	765.89 (687.32, 853.45)	148.67 (133.37, 165.73)
Age < 65	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	145	0.02 (0.02, 0.02)	1514.86 (1031.50, 2224.72)	63119.10 (42979.14, 92696.60)
Age < 65	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	145	0.27 (0.27, 0.27)	48036.51 (35397.18, 65188.99)	176604.81 (130136.69, 239665.39)
Age < 65	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	145	0.09 (0.09, 0.09)	33661.72 (25910.34, 43732.02)	374019.08 (287892.62, 485911.28)
Age < 65	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	145	5.02 (4.99, 5.06)	1673.79 (1334.76, 2098.95)	333.23 (265.69, 417.93)
Age < 65	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	145	5.07 (4.93, 5.22)	1008.82 (888.79, 1145.06)	198.88 (175.03, 225.98)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	76	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age < 65	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	76	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	76	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	76	5.06 (4.98, 5.14)	5.00 (5.00, 5.00)	0.99 (0.97, 1.00)
Age < 65	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	76	5.02 (4.98, 5.07)	5.00 (5.00, 5.00)	1.00 (0.99, 1.00)
Age < 65	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	143	0.02 (0.02, 0.02)	278.96 (191.64, 406.09)	11623.53 (7984.81, 16920.44)
Age < 65	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	143	0.27 (0.27, 0.28)	9984.20 (7103.43, 14033.26)	36391.37 (25843.70, 51243.88)
Age < 65	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	143	0.09 (0.09, 0.09)	6184.92 (4705.38, 8129.67)	68721.31 (52282.05, 90329.65)
Age < 65	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	143	5.13 (4.95, 5.32)	332.09 (221.26, 498.44)	64.70 (43.21, 96.87)
Age < 65	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	143	5.18 (4.95, 5.42)	557.94 (440.51, 706.67)	107.66 (84.41, 137.32)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	468	0.02 (0.02, 0.02)	157.96 (134.11, 186.05)	6581.59 (5587.94, 7751.92)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	468	0.27 (0.27, 0.27)	2003.94 (1740.39, 2307.40)	7367.43 (6398.50, 8483.09)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	468	0.09 (0.09, 0.09)	1207.29 (1064.30, 1369.49)	13374.24 (11791.15, 15169.88)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	468	5.06 (5.01, 5.10)	261.49 (222.30, 307.60)	51.72 (43.98, 60.82)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	468	5.14 (5.05, 5.23)	325.70 (287.35, 369.18)	63.37 (55.95, 71.79)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	132	0.02 (0.02, 0.02)	270.01 (200.47, 363.68)	11250.47 (8352.83, 15153.32)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	132	0.27 (0.27, 0.28)	3043.22 (2390.56, 3874.05)	11129.40 (8742.36, 14168.21)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	132	0.09 (0.09, 0.09)	1956.81 (1615.37, 2370.41)	21742.31 (17948.57, 26337.92)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	132	5.04 (4.96, 5.11)	441.37 (335.16, 581.26)	87.61 (66.62, 115.21)
Age ≥ 65	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	132	5.06 (4.98, 5.14)	473.68 (388.74, 577.17)	93.61 (76.88, 113.98)
Age ≥ 65	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	79	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	79	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	79	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.01 (0.99, 1.02)
Age ≥ 65	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	79	5.11 (4.89, 5.34)	5.06 (4.94, 5.18)	0.99 (0.94, 1.04)
Age ≥ 65	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	79	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	131	0.02 (0.02, 0.02)	83.73 (61.42, 114.13)	3488.70 (2559.31, 4755.59)
Age ≥ 65	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	131	0.27 (0.27, 0.27)	1060.22 (819.23, 1372.09)	3897.85 (3011.87, 5044.45)
Age ≥ 65	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	131	0.09 (0.09, 0.09)	570.26 (458.39, 709.44)	6336.28 (5093.26, 7882.66)
Age ≥ 65	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	131	5.00 (5.00, 5.00)	141.75 (106.66, 188.39)	28.35 (21.33, 37.68)
Age ≥ 65	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	131	5.04 (4.97, 5.10)	221.47 (171.65, 285.77)	43.99 (34.13, 56.69)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	468	0.02 (0.02, 0.02)	2460.53 (2025.23, 2989.41)	102522.29 (84384.49, 124558.66)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	468	0.27 (0.27, 0.27)	84018.56 (72438.21, 97450.20)	308891.76 (266316.94, 358272.81)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	468	0.09 (0.09, 0.09)	51847.95 (45512.24, 59065.64)	574367.52 (504216.72, 654278.27)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	468	5.06 (5.01, 5.10)	1979.85 (1753.25, 2235.73)	391.59 (346.74, 442.25)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	468	5.14 (5.05, 5.23)	975.49 (911.97, 1043.43)	189.80 (177.22, 203.28)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	132	0.02 (0.02, 0.02)	5853.72 (4347.27, 7882.18)	243904.81 (181136.26, 328424.33)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	132	0.27 (0.27, 0.28)	186431.80 (151641.75, 229203.47)	681803.07 (554109.10, 838924.00)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	132	0.09 (0.09, 0.09)	115989.53 (103450.48, 130048.43)	1288772.60 (1149449.72, 1444982.58)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	132	5.04 (4.96, 5.11)	3279.60 (2909.89, 3696.28)	650.97 (577.38, 733.94)
Age ≥ 65	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	132	5.06 (4.98, 5.14)	1203.35 (1127.90, 1283.84)	237.81 (222.51, 254.16)
Age ≥ 65	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	79	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	79	0.27 (0.27, 0.27)	0.28 (0.27, 0.30)	1.04 (1.00, 1.09)
Age ≥ 65	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	79	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	79	5.11 (4.89, 5.34)	5.19 (4.98, 5.41)	1.02 (0.95, 1.08)
Age ≥ 65	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	79	5.00 (5.00, 5.00)	5.21 (4.98, 5.45)	1.04 (1.00, 1.09)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	131	0.02 (0.02, 0.02)	1250.50 (875.00, 1787.13)	52104.11 (36458.54, 74463.71)
Age ≥ 65	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	131	0.27 (0.27, 0.27)	39096.03 (29650.90, 51549.86)	143735.40 (109010.64, 189521.54)
Age ≥ 65	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	131	0.09 (0.09, 0.09)	22852.60 (18500.67, 28228.25)	253917.77 (205562.95, 313647.17)
Age ≥ 65	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	131	5.00 (5.00, 5.00)	1646.62 (1311.92, 2066.72)	329.32 (262.38, 413.34)
Age ≥ 65	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	131	5.04 (4.97, 5.10)	856.08 (722.74, 1014.03)	170.02 (143.53, 201.40)

Table 6c. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Risk for Severe Covid-19								
At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	459	0.02 (0.02, 0.02)	67.46 (57.00, 79.84)	2810.79 (2374.80, 3326.82)
At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	459	0.27 (0.27, 0.27)	841.10 (722.34, 979.38)	3092.28 (2655.66, 3600.68)
At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	459	0.09 (0.09, 0.09)	495.50 (428.93, 572.41)	5492.49 (4754.99, 6344.37)
At-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	459	5.15 (5.06, 5.24)	121.68 (102.86, 143.94)	23.64 (20.03, 27.90)
At-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	459	5.16 (5.07, 5.25)	218.15 (188.84, 252.00)	42.28 (36.62, 48.82)
At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	126	0.02 (0.02, 0.02)	132.96 (99.20, 178.21)	5539.89 (4133.16, 7425.41)
At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	126	0.27 (0.27, 0.27)	1257.23 (946.57, 1669.85)	4622.17 (3480.02, 6139.16)
At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	126	0.09 (0.09, 0.09)	803.87 (630.99, 1024.11)	8931.89 (7011.05, 11378.99)
At-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	126	5.08 (4.97, 5.18)	234.48 (175.57, 313.16)	46.20 (34.42, 62.00)
At-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	126	5.00 (5.00, 5.00)	321.34 (259.19, 398.39)	64.27 (51.84, 79.68)
At-risk	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	76	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
At-risk	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	76	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
At-risk	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	76	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.01 (0.99, 1.04)
At-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	76	5.15 (4.94, 5.38)	5.05 (4.96, 5.14)	0.98 (0.93, 1.03)
At-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	76	5.06 (4.94, 5.19)	5.00 (5.00, 5.00)	0.99 (0.96, 1.01)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
At-risk	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	124	0.02 (0.02, 0.02)	39.92 (28.50, 55.92)	1663.48 (1187.69, 2329.85)
At-risk	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	124	0.27 (0.27, 0.27)	477.57 (352.49, 647.04)	1755.78 (1295.91, 2378.84)
At-risk	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	124	0.09 (0.09, 0.09)	251.11 (189.50, 332.74)	2790.07 (2105.57, 3697.11)
At-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	124	5.00 (5.00, 5.00)	65.19 (47.23, 89.97)	13.04 (9.45, 17.99)
At-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	124	5.11 (4.95, 5.28)	143.05 (107.61, 190.16)	27.99 (21.13, 37.08)
At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	459	0.02 (0.02, 0.02)	997.20 (804.46, 1236.11)	41549.90 (33519.37, 51504.38)
At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	459	0.27 (0.27, 0.27)	35753.79 (29958.65, 42669.94)	131447.77 (110142.08, 156874.79)
At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	459	0.09 (0.09, 0.09)	23580.58 (20304.48, 27385.28)	261383.17 (225091.65, 303525.96)
At-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	459	5.15 (5.06, 5.24)	1193.53 (1021.96, 1393.91)	231.87 (198.74, 270.53)
At-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	459	5.16 (5.07, 5.25)	800.06 (727.31, 880.08)	155.08 (140.96, 170.61)
At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	126	0.02 (0.02, 0.02)	2635.43 (1827.75, 3800.01)	109809.53 (76156.38, 158333.85)
At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	126	0.27 (0.27, 0.27)	83821.23 (63170.57, 111222.66)	308166.29 (232244.75, 408906.82)
At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	126	0.09 (0.09, 0.09)	58491.48 (47881.59, 71452.37)	649905.36 (532017.71, 793915.27)
At-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	126	5.08 (4.97, 5.18)	2187.05 (1816.71, 2632.89)	430.89 (357.14, 519.87)
At-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	126	5.00 (5.00, 5.00)	1131.34 (1025.26, 1248.40)	226.27 (205.05, 249.68)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
At-risk	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	76	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
At-risk	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	76	0.27 (0.27, 0.27)	0.28 (0.27, 0.29)	1.03 (1.00, 1.07)
At-risk	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	76	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
At-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	76	5.15 (4.94, 5.38)	5.11 (4.96, 5.26)	0.99 (0.94, 1.04)
At-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	76	5.06 (4.94, 5.19)	5.06 (4.94, 5.18)	1.00 (0.97, 1.03)
At-risk	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	124	0.02 (0.02, 0.02)	408.78 (269.73, 619.51)	17032.48 (11238.79, 25812.86)
At-risk	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	124	0.27 (0.27, 0.27)	15489.70 (10811.98, 22191.21)	56947.42 (39749.91, 81585.32)
At-risk	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	124	0.09 (0.09, 0.09)	10107.03 (7648.71, 13355.45)	112300.28 (84985.64, 148393.92)
At-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	124	5.00 (5.00, 5.00)	601.53 (426.45, 848.48)	120.31 (85.29, 169.70)
At-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	124	5.11 (4.95, 5.28)	589.31 (462.01, 751.67)	115.32 (90.32, 147.23)
Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	445	0.02 (0.02, 0.02)	61.93 (49.31, 77.77)	2580.40 (2054.72, 3240.56)
Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	445	0.27 (0.27, 0.27)	755.22 (624.42, 913.41)	2776.53 (2295.66, 3358.13)
Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	445	0.09 (0.09, 0.09)	433.06 (368.18, 509.36)	4811.75 (4090.93, 5659.58)
Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	445	5.04 (4.98, 5.10)	115.66 (93.41, 143.21)	22.97 (18.58, 28.39)
Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	445	5.15 (5.03, 5.27)	185.63 (153.69, 224.22)	36.08 (29.94, 43.47)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	151	0.02 (0.02, 0.02)	66.27 (45.97, 95.54)	2761.28 (1915.34, 3980.85)
Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	151	0.27 (0.27, 0.27)	909.42 (669.45, 1235.39)	3338.86 (2457.91, 4535.54)
Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	151	0.09 (0.09, 0.09)	587.97 (455.33, 759.26)	6533.01 (5059.18, 8436.21)
Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	151	5.01 (4.99, 5.03)	125.09 (91.08, 171.80)	24.97 (18.18, 34.29)
Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	151	5.09 (4.94, 5.25)	230.52 (168.09, 316.14)	45.26 (33.12, 61.85)
Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	79	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	79	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	79	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.01)
Not at-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	79	5.04 (4.96, 5.11)	5.10 (4.91, 5.29)	1.01 (0.97, 1.05)
Not at-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	79	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	150	0.02 (0.02, 0.02)	30.99 (21.96, 43.75)	1291.45 (914.86, 1823.07)
Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	150	0.27 (0.27, 0.28)	270.59 (195.86, 373.82)	986.05 (712.05, 1365.49)
Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	150	0.09 (0.09, 0.09)	143.23 (110.23, 186.11)	1591.43 (1224.73, 2067.93)
Not at-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	150	5.14 (4.95, 5.33)	54.29 (37.98, 77.61)	10.57 (7.38, 15.14)
Not at-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	150	5.16 (4.93, 5.40)	147.21 (106.42, 203.64)	28.52 (20.51, 39.64)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	445	0.02 (0.02, 0.02)	931.80 (709.86, 1223.11)	38824.81 (29577.68, 50962.95)
Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	445	0.27 (0.27, 0.27)	33409.52 (27278.73, 40918.18)	122829.12 (100289.45, 150434.50)
Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	445	0.09 (0.09, 0.09)	22545.52 (18907.87, 26883.01)	250505.80 (210087.46, 298700.14)
Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	445	5.04 (4.98, 5.10)	1056.69 (865.07, 1290.75)	209.84 (171.86, 256.22)
Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	445	5.15 (5.03, 5.27)	808.73 (722.49, 905.26)	157.18 (140.35, 176.02)
Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	151	0.02 (0.02, 0.02)	1798.55 (1204.14, 2686.40)	74939.77 (50172.37, 111933.50)
Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	151	0.27 (0.27, 0.27)	57041.52 (41456.48, 78485.57)	209424.02 (152202.31, 288158.68)
Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	151	0.09 (0.09, 0.09)	38807.95 (29472.44, 51100.52)	431199.48 (327471.57, 567783.61)
Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	151	5.01 (4.99, 5.03)	1827.83 (1443.12, 2315.10)	364.85 (288.06, 462.10)
Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	151	5.09 (4.94, 5.25)	1017.57 (891.59, 1161.35)	199.80 (174.85, 228.31)
Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	79	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	79	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	79	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Not at-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	79	5.04 (4.96, 5.11)	5.02 (4.98, 5.05)	1.00 (0.98, 1.01)
Not at-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	79	5.00 (5.00, 5.00)	5.04 (4.98, 5.10)	1.01 (1.00, 1.02)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	150	0.02 (0.02, 0.02)	379.01 (259.03, 554.56)	15792.24 (10793.11, 23106.86)
Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	150	0.27 (0.27, 0.28)	12828.98 (9099.71, 18086.59)	46750.16 (33095.80, 66037.91)
Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	150	0.09 (0.09, 0.09)	7693.80 (5832.20, 10149.62)	85486.70 (64802.20, 112773.59)
Not at-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	150	5.14 (4.95, 5.33)	434.92 (288.21, 656.31)	84.68 (56.25, 127.47)
Not at-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	150	5.16 (4.93, 5.40)	619.21 (489.12, 783.89)	119.94 (94.05, 152.96)

Table 6d. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, Risk for Severe Covid-19

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age, Risk for Severe Covid-19								
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	216	0.02 (0.02, 0.02)	41.35 (32.75, 52.22)	1723.00 (1364.46, 2175.75)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	216	0.27 (0.27, 0.27)	475.30 (388.65, 581.26)	1747.42 (1428.86, 2136.98)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	216	0.09 (0.09, 0.09)	283.75 (233.55, 344.73)	3152.73 (2594.96, 3830.38)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	216	5.20 (5.06, 5.34)	81.30 (64.37, 102.68)	15.64 (12.44, 19.67)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	216	5.12 (5.01, 5.23)	168.01 (136.18, 207.28)	32.80 (26.59, 40.48)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	72	0.02 (0.02, 0.02)	92.48 (63.69, 134.30)	3853.47 (2653.60, 5595.88)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	72	0.27 (0.27, 0.27)	717.17 (505.98, 1016.50)	2636.65 (1860.22, 3737.15)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	72	0.09 (0.09, 0.09)	481.71 (356.55, 650.82)	5352.38 (3961.68, 7231.28)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	72	5.11 (4.95, 5.28)	160.60 (110.70, 233.01)	31.41 (21.47, 45.93)
Age < 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	72	5.00 (5.00, 5.00)	258.36 (195.07, 342.19)	51.67 (39.01, 68.44)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	36	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	36	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	36	0.09 (0.09, 0.09)	0.09 (0.09, 0.10)	1.02 (0.98, 1.06)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	36	5.26 (4.90, 5.65)	5.00 (5.00, 5.00)	0.95 (0.89, 1.02)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	36	5.11 (4.90, 5.32)	5.00 (5.00, 5.00)	0.98 (0.94, 1.02)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	70	0.02 (0.02, 0.02)	23.90 (15.59, 36.63)	995.67 (649.50, 1526.34)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	70	0.27 (0.27, 0.27)	261.98 (178.78, 383.89)	963.15 (657.28, 1411.38)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	70	0.09 (0.09, 0.09)	139.57 (97.93, 198.92)	1550.78 (1088.09, 2210.24)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	70	5.00 (5.00, 5.00)	37.06 (24.59, 55.86)	7.41 (4.92, 11.17)
Age < 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	70	5.12 (4.88, 5.38)	107.20 (73.46, 156.42)	20.92 (14.41, 30.36)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	216	0.02 (0.02, 0.02)	585.44 (433.35, 790.90)	24393.37 (18056.43, 32954.27)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	216	0.27 (0.27, 0.27)	23964.79 (18603.91, 30870.46)	88105.85 (68396.72, 113494.34)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	216	0.09 (0.09, 0.09)	16261.39 (13217.49, 20006.28)	180682.10 (146860.98, 222292.01)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	216	5.20 (5.06, 5.34)	922.94 (735.66, 1157.89)	177.58 (141.86, 222.29)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	216	5.12 (5.01, 5.23)	701.04 (606.26, 810.65)	136.88 (118.42, 158.22)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	72	0.02 (0.02, 0.02)	1516.96 (931.33, 2470.83)	63206.53 (38805.36, 102951.37)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	72	0.27 (0.27, 0.27)	53858.28 (36660.92, 79122.78)	198008.38 (134782.81, 290892.57)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	72	0.09 (0.09, 0.09)	40724.37 (31129.20, 53277.12)	452492.96 (345879.97, 591968.01)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	72	5.11 (4.95, 5.28)	1689.07 (1299.65, 2195.16)	330.29 (253.39, 430.53)
Age < 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	72	5.00 (5.00, 5.00)	1083.16 (936.68, 1252.55)	216.63 (187.34, 250.51)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	36	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	36	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	36	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	36	5.26 (4.90, 5.65)	5.00 (5.00, 5.00)	0.95 (0.89, 1.02)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	36	5.11 (4.90, 5.32)	5.00 (5.00, 5.00)	0.98 (0.94, 1.02)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	70	0.02 (0.02, 0.02)	225.66 (131.53, 387.15)	9402.54 (5480.50, 16131.32)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	70	0.27 (0.27, 0.27)	8114.34 (5005.11, 13155.05)	29832.12 (18401.14, 48364.16)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	70	0.09 (0.09, 0.09)	5934.45 (4109.64, 8569.54)	65938.33 (45662.65, 95217.07)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	70	5.00 (5.00, 5.00)	336.50 (209.06, 541.63)	67.30 (41.81, 108.33)
Age < 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	70	5.12 (4.88, 5.38)	488.63 (345.36, 691.33)	95.35 (67.28, 135.13)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	220	0.02 (0.02, 0.02)	51.77 (39.84, 67.28)	2157.23 (1660.12, 2803.21)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	220	0.27 (0.27, 0.27)	638.34 (512.85, 794.54)	2346.84 (1885.46, 2921.12)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	220	0.09 (0.09, 0.09)	360.44 (299.15, 434.28)	4004.87 (3323.93, 4825.30)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	220	5.04 (4.97, 5.11)	97.97 (76.64, 125.23)	19.45 (15.25, 24.82)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	220	5.16 (5.02, 5.30)	168.52 (135.53, 209.55)	32.66 (26.35, 40.49)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	73	0.02 (0.02, 0.02)	51.66 (33.87, 78.78)	2152.33 (1411.33, 3282.37)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	73	0.27 (0.27, 0.27)	755.34 (529.48, 1077.54)	2776.97 (1946.61, 3961.55)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	73	0.09 (0.09, 0.09)	482.38 (358.92, 648.31)	5359.78 (3988.01, 7203.40)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	73	5.00 (5.00, 5.00)	101.42 (70.36, 146.19)	20.28 (14.07, 29.24)
Age < 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	73	5.09 (4.91, 5.27)	203.89 (141.04, 294.76)	40.05 (27.82, 57.66)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	40	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	40	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	40	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	40	5.00 (5.00, 5.00)	5.11 (4.89, 5.34)	1.02 (0.98, 1.07)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	40	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	73	0.02 (0.02, 0.02)	25.79 (17.21, 38.66)	1074.76 (717.01, 1610.99)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	73	0.27 (0.27, 0.28)	211.53 (144.72, 309.18)	769.47 (524.94, 1127.91)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	73	0.09 (0.09, 0.09)	110.92 (81.69, 150.61)	1232.44 (907.64, 1673.47)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	73	5.16 (4.94, 5.40)	45.81 (30.06, 69.82)	8.87 (5.81, 13.55)
Age < 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	73	5.20 (4.92, 5.49)	136.45 (92.97, 200.28)	26.26 (17.78, 38.78)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	220	0.02 (0.02, 0.02)	775.93 (567.18, 1061.53)	32330.62 (23632.34, 44230.44)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	220	0.27 (0.27, 0.27)	27354.86 (21662.37, 34543.24)	100569.35 (79641.07, 126997.22)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	220	0.09 (0.09, 0.09)	18816.87 (15365.96, 23042.79)	209076.37 (170732.93, 256031.02)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	220	5.04 (4.97, 5.11)	930.77 (738.46, 1173.17)	184.84 (146.72, 232.86)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	220	5.16 (5.02, 5.30)	783.19 (687.36, 892.38)	151.80 (133.16, 173.06)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	73	0.02 (0.02, 0.02)	1514.32 (950.21, 2413.32)	63096.80 (39592.29, 100555.10)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	73	0.27 (0.27, 0.27)	46654.53 (32211.81, 67572.90)	171524.01 (118425.76, 248429.79)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	73	0.09 (0.09, 0.09)	32064.78 (23256.01, 44210.08)	356275.34 (258400.13, 491223.12)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	73	5.00 (5.00, 5.00)	1669.92 (1267.00, 2200.96)	333.98 (253.40, 440.19)
Age < 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	73	5.09 (4.91, 5.27)	990.68 (848.77, 1156.32)	194.59 (166.49, 227.43)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	40	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	40	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	40	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	40	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	40	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	73	0.02 (0.02, 0.02)	293.00 (187.73, 457.29)	12208.35 (7822.27, 19053.78)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	73	0.27 (0.27, 0.28)	10475.19 (6993.92, 15689.26)	38104.78 (25381.42, 57206.17)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	73	0.09 (0.09, 0.09)	6244.39 (4508.26, 8649.11)	69382.12 (50091.74, 96101.24)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	73	5.16 (4.94, 5.40)	331.08 (203.28, 539.23)	64.11 (39.49, 104.09)
Age < 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	73	5.20 (4.92, 5.49)	575.34 (434.97, 761.00)	110.73 (82.98, 147.77)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	243	0.02 (0.02, 0.02)	137.54 (109.88, 172.15)	5730.68 (4578.33, 7173.06)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	243	0.27 (0.27, 0.27)	1930.48 (1558.13, 2391.79)	7097.34 (5728.44, 8793.36)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	243	0.09 (0.09, 0.09)	1115.50 (918.52, 1354.74)	12322.22 (10148.71, 14961.21)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	243	5.08 (5.00, 5.16)	218.83 (174.58, 274.29)	43.12 (34.42, 54.01)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	243	5.21 (5.06, 5.37)	319.04 (267.97, 379.85)	61.18 (51.50, 72.69)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	54	0.02 (0.02, 0.02)	275.15 (180.68, 419.04)	11464.76 (7528.14, 17459.92)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	54	0.27 (0.27, 0.27)	3871.45 (2641.46, 5674.19)	14233.28 (9711.25, 20861.00)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	54	0.09 (0.09, 0.09)	2242.72 (1665.25, 3020.44)	24919.12 (18502.83, 33560.41)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	54	5.00 (5.00, 5.00)	500.50 (336.81, 743.72)	100.10 (67.36, 148.74)
Age ≥ 65 At-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	54	5.00 (5.00, 5.00)	497.49 (371.34, 666.51)	99.50 (74.27, 133.30)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	40	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	40	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	40	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	40	5.00 (5.00, 5.00)	5.12 (4.89, 5.35)	1.02 (0.98, 1.07)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	40	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	54	0.02 (0.02, 0.02)	94.29 (58.02, 153.24)	3928.93 (2417.57, 6385.11)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	54	0.27 (0.27, 0.27)	1305.33 (870.22, 1957.98)	4798.99 (3199.35, 7198.45)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	54	0.09 (0.09, 0.09)	671.39 (465.80, 967.71)	7459.87 (5175.58, 10752.35)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	54	5.00 (5.00, 5.00)	167.83 (108.18, 260.37)	33.57 (21.64, 52.07)
Age ≥ 65 At-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	54	5.09 (4.92, 5.26)	231.89 (155.85, 345.05)	45.59 (30.77, 67.54)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	243	0.02 (0.02, 0.02)	2165.00 (1634.23, 2868.15)	90208.31 (68092.91, 119506.43)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	243	0.27 (0.27, 0.27)	64007.31 (51284.51, 79886.41)	235320.99 (188546.01, 293700.02)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	243	0.09 (0.09, 0.09)	40502.61 (33105.81, 49552.07)	447404.59 (365815.69, 547190.49)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	243	5.08 (5.00, 5.16)	1735.27 (1440.81, 2089.92)	341.90 (283.82, 411.87)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	243	5.21 (5.06, 5.37)	969.70 (879.08, 1069.67)	185.96 (168.19, 205.60)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	54	0.02 (0.02, 0.02)	7970.17 (5316.57, 11948.24)	332090.47 (221523.63, 497843.40)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	54	0.27 (0.27, 0.27)	203350.87 (155935.94, 265183.11)	747613.50 (573293.90, 974937.89)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	54	0.09 (0.09, 0.09)	120818.40 (100844.20, 144748.88)	1342426.63 (1120491.10, 1608320.90)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	54	5.00 (5.00, 5.00)	3670.16 (3243.62, 4152.80)	734.03 (648.72, 830.56)
Age ≥ 65 At-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	54	5.00 (5.00, 5.00)	1234.43 (1178.85, 1292.64)	246.89 (235.77, 258.53)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	40	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	40	0.27 (0.27, 0.27)	0.29 (0.27, 0.32)	1.08 (0.99, 1.18)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	40	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	40	5.00 (5.00, 5.00)	5.27 (4.91, 5.66)	1.05 (0.98, 1.13)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	40	5.00 (5.00, 5.00)	5.15 (4.86, 5.45)	1.03 (0.97, 1.09)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	54	0.02 (0.02, 0.02)	1105.54 (620.86, 1968.58)	46064.21 (25869.29, 82024.34)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	54	0.27 (0.27, 0.27)	45733.74 (30214.56, 69224.07)	168138.73 (111082.93, 254500.26)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	54	0.09 (0.09, 0.09)	24651.80 (17720.18, 34294.86)	273908.86 (196890.91, 381053.98)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	54	5.00 (5.00, 5.00)	1591.10 (1106.33, 2288.28)	318.22 (221.27, 457.66)
Age ≥ 65 At-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	54	5.09 (4.92, 5.26)	806.46 (610.65, 1065.06)	158.54 (120.06, 209.35)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	225	0.02 (0.02, 0.02)	182.60 (144.14, 231.31)	7608.21 (6005.92, 9637.96)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	225	0.27 (0.27, 0.27)	2083.86 (1738.41, 2497.95)	7661.24 (6391.22, 9183.64)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	225	0.09 (0.09, 0.09)	1311.49 (1119.79, 1536.02)	14572.12 (12442.06, 17066.84)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	225	5.04 (4.98, 5.09)	315.11 (250.46, 396.45)	62.58 (49.76, 78.70)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	225	5.06 (4.97, 5.15)	332.83 (278.04, 398.42)	65.75 (54.92, 78.72)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	78	0.02 (0.02, 0.02)	266.41 (176.32, 402.53)	11100.51 (7346.73, 16772.26)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	78	0.27 (0.27, 0.28)	2564.37 (1893.88, 3472.22)	9343.05 (6901.12, 12649.06)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	78	0.09 (0.09, 0.09)	1775.92 (1386.69, 2274.41)	19732.48 (15407.68, 25271.21)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	78	5.07 (4.94, 5.19)	403.63 (277.03, 588.07)	79.69 (54.87, 115.72)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	78	5.10 (4.96, 5.25)	457.44 (350.62, 596.80)	89.64 (68.82, 116.75)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	39	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	39	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	39	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.02 (0.98, 1.05)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	39	5.23 (4.79, 5.71)	5.00 (5.00, 5.00)	0.96 (0.88, 1.04)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	39	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	77	0.02 (0.02, 0.02)	77.17 (51.81, 114.94)	3215.37 (2158.84, 4788.97)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	77	0.27 (0.27, 0.27)	919.14 (662.16, 1275.84)	3379.19 (2434.42, 4690.60)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	77	0.09 (0.09, 0.09)	509.80 (390.41, 665.71)	5664.48 (4337.87, 7396.78)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	77	5.00 (5.00, 5.00)	126.24 (87.25, 182.65)	25.25 (17.45, 36.53)
Age ≥ 65 Not at-risk	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	77	5.00 (5.00, 5.00)	214.59 (153.93, 299.17)	42.92 (30.79, 59.83)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	225	0.02 (0.02, 0.02)	2813.29 (2152.83, 3676.37)	117220.35 (89701.05, 153182.29)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	225	0.27 (0.27, 0.27)	111705.91 (92654.21, 134675.06)	410683.51 (340640.49, 495128.89)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	225	0.09 (0.09, 0.09)	67146.45 (57479.15, 78439.67)	746071.68 (638657.28, 871551.89)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	225	5.04 (4.98, 5.09)	2272.94 (1951.20, 2647.73)	451.37 (387.49, 525.79)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	225	5.06 (4.97, 5.15)	981.58 (895.48, 1075.96)	193.91 (176.68, 212.82)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	78	0.02 (0.02, 0.02)	4700.04 (3111.72, 7099.08)	195834.84 (129654.98, 295794.92)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	78	0.27 (0.27, 0.28)	175262.14 (130219.69, 235884.57)	638552.83 (473668.39, 860833.70)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	78	0.09 (0.09, 0.09)	112673.01 (97324.95, 130441.44)	1251922.33 (1081388.37, 1449349.34)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	78	5.07 (4.94, 5.19)	3027.38 (2521.27, 3635.08)	597.68 (497.61, 717.89)
Age ≥ 65 Not at-risk	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	78	5.10 (4.96, 5.25)	1181.71 (1063.55, 1313.00)	231.56 (207.76, 258.08)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age \geq 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	39	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age \geq 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	39	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age \geq 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	39	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age \geq 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	39	5.23 (4.79, 5.71)	5.11 (4.90, 5.33)	0.98 (0.89, 1.08)
Age \geq 65 Not at-risk	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	39	5.00 (5.00, 5.00)	5.27 (4.91, 5.66)	1.05 (0.98, 1.13)
Age \geq 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	77	0.02 (0.02, 0.02)	1360.88 (864.11, 2143.24)	56703.27 (36004.55, 89301.51)
Age \geq 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	77	0.27 (0.27, 0.27)	35105.55 (24312.93, 50689.07)	129064.53 (89385.76, 186356.88)
Age \geq 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	77	0.09 (0.09, 0.09)	21693.98 (16545.03, 28445.32)	241044.20 (183833.65, 316059.14)
Age \geq 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	77	5.00 (5.00, 5.00)	1685.86 (1256.66, 2261.65)	337.17 (251.33, 452.33)
Age \geq 65 Not at-risk	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	77	5.00 (5.00, 5.00)	891.91 (721.03, 1103.29)	178.38 (144.21, 220.66)



Table 6e. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Sex								
Male	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	364	0.02 (0.02, 0.02)	57.06 (43.56, 74.74)	2377.40 (1814.86, 3114.31)
Male	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	364	0.27 (0.27, 0.27)	711.23 (562.08, 899.96)	2614.80 (2066.45, 3308.66)
Male	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	364	0.09 (0.09, 0.09)	393.31 (325.04, 475.92)	4370.12 (3611.58, 5287.97)
Male	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	364	5.06 (5.02, 5.11)	105.17 (81.71, 135.38)	20.77 (16.15, 26.71)
Male	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	364	5.03 (5.00, 5.07)	179.83 (145.66, 222.02)	35.72 (28.94, 44.09)
Male	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	115	0.02 (0.02, 0.02)	75.01 (50.02, 112.48)	3125.23 (2084.08, 4686.49)
Male	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	115	0.27 (0.27, 0.27)	962.36 (673.70, 1374.70)	3528.97 (2470.89, 5040.14)
Male	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	115	0.09 (0.09, 0.09)	654.26 (514.09, 832.66)	7269.61 (5712.08, 9251.83)
Male	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	115	5.02 (4.98, 5.05)	156.51 (106.13, 230.80)	31.19 (21.14, 46.00)
Male	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	115	5.00 (5.00, 5.00)	247.12 (169.10, 361.14)	49.42 (33.82, 72.23)
Male	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	74	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Male	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	74	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Male	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	74	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.01 (0.99, 1.02)
Male	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	74	5.11 (4.96, 5.26)	5.14 (4.87, 5.43)	1.01 (0.95, 1.07)
Male	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	74	5.04 (4.96, 5.12)	5.00 (5.00, 5.00)	0.99 (0.98, 1.01)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Male	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	125	0.02 (0.02, 0.02)	39.33 (25.29, 61.19)	1638.95 (1053.57, 2549.60)
Male	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	125	0.27 (0.27, 0.27)	291.14 (184.69, 458.97)	1070.39 (678.99, 1687.39)
Male	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	125	0.09 (0.09, 0.09)	187.38 (134.52, 261.02)	2082.01 (1494.62, 2900.25)
Male	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	125	5.21 (4.93, 5.50)	66.68 (42.33, 105.02)	12.81 (8.09, 20.29)
Male	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	125	5.21 (4.90, 5.54)	150.31 (102.23, 221.00)	28.86 (19.42, 42.88)
Male	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	364	0.02 (0.02, 0.02)	764.04 (551.00, 1059.45)	31834.97 (22958.33, 44143.68)
Male	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	364	0.27 (0.27, 0.27)	32542.98 (25574.73, 41409.83)	119643.30 (94024.76, 152242.03)
Male	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	364	0.09 (0.09, 0.09)	20519.27 (16817.37, 25036.06)	227991.93 (186859.62, 278178.45)
Male	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	364	5.06 (5.02, 5.11)	964.54 (749.91, 1240.61)	190.46 (148.13, 244.89)
Male	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	364	5.03 (5.00, 5.07)	795.90 (701.37, 903.17)	158.10 (139.31, 179.41)
Male	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	115	0.02 (0.02, 0.02)	2417.23 (1525.27, 3830.81)	100718.12 (63552.90, 159617.28)
Male	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	115	0.27 (0.27, 0.27)	59109.55 (38797.09, 90056.73)	216754.62 (142272.25, 330230.01)
Male	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	115	0.09 (0.09, 0.09)	42753.89 (29462.81, 62040.76)	475043.26 (327364.58, 689341.83)
Male	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	115	5.02 (4.98, 5.05)	2103.93 (1618.68, 2734.63)	419.24 (322.41, 545.15)
Male	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	115	5.00 (5.00, 5.00)	1185.23 (1099.74, 1277.37)	237.05 (219.95, 255.47)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Male	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	74	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Male	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	74	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Male	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	74	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Male	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	74	5.11 (4.96, 5.26)	5.04 (4.96, 5.12)	0.99 (0.95, 1.02)
Male	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	74	5.04 (4.96, 5.12)	5.07 (4.97, 5.16)	1.01 (0.98, 1.03)
Male	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	125	0.02 (0.02, 0.02)	462.79 (281.81, 759.98)	19282.79 (11742.22, 31665.71)
Male	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	125	0.27 (0.27, 0.27)	14163.75 (9265.29, 21651.96)	52072.60 (34063.58, 79602.79)
Male	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	125	0.09 (0.09, 0.09)	8370.65 (5941.97, 11792.01)	93007.24 (66021.94, 131022.31)
Male	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	125	5.21 (4.93, 5.50)	579.25 (348.08, 963.95)	111.26 (66.97, 184.82)
Male	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	125	5.21 (4.90, 5.54)	642.55 (489.04, 844.26)	123.36 (92.38, 164.73)
Female	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	540	0.02 (0.02, 0.02)	67.69 (54.02, 84.83)	2820.54 (2250.74, 3534.60)
Female	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	540	0.27 (0.27, 0.27)	822.09 (682.80, 989.78)	3022.38 (2510.31, 3638.91)
Female	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	540	0.09 (0.09, 0.09)	488.02 (413.82, 575.52)	5416.83 (4593.35, 6387.94)
Female	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	540	5.07 (4.99, 5.14)	125.55 (101.50, 155.30)	24.78 (20.08, 30.59)
Female	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	540	5.22 (5.08, 5.37)	203.21 (167.51, 246.51)	38.91 (32.18, 47.04)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Female	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	162	0.02 (0.02, 0.02)	81.10 (54.38, 120.94)	3379.12 (2265.88, 5039.30)
Female	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	162	0.27 (0.27, 0.27)	999.64 (720.53, 1386.86)	3675.15 (2649.02, 5098.76)
Female	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	162	0.09 (0.09, 0.09)	622.05 (460.79, 839.75)	6911.70 (5119.91, 9330.56)
Female	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	162	5.03 (4.99, 5.07)	139.20 (99.56, 194.63)	27.67 (19.79, 38.69)
Female	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	162	5.12 (4.93, 5.32)	252.05 (182.95, 347.23)	49.25 (35.95, 67.48)
Female	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	81	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Female	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	81	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Female	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	81	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.01)
Female	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	81	5.04 (4.96, 5.12)	5.03 (4.98, 5.08)	1.00 (0.98, 1.02)
Female	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	81	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Female	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	149	0.02 (0.02, 0.02)	27.35 (19.64, 38.09)	1139.61 (818.39, 1586.90)
Female	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	149	0.28 (0.27, 0.28)	329.24 (251.93, 430.28)	1193.91 (908.19, 1569.53)
Female	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	149	0.09 (0.09, 0.09)	141.95 (108.33, 186.00)	1577.19 (1203.65, 2066.67)
Female	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	149	5.00 (5.00, 5.00)	47.92 (34.31, 66.94)	9.58 (6.86, 13.39)
Female	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	149	5.09 (4.92, 5.27)	142.12 (101.26, 199.46)	27.92 (19.92, 39.13)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Female	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	540	0.02 (0.02, 0.02)	1087.77 (833.22, 1420.09)	45323.84 (34717.44, 59170.57)
Female	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	540	0.27 (0.27, 0.27)	34987.98 (28491.76, 42965.36)	128632.28 (104749.12, 157960.89)
Female	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	540	0.09 (0.09, 0.09)	24398.20 (20339.30, 29267.09)	270809.50 (225761.01, 324846.99)
Female	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	540	5.07 (4.99, 5.14)	1180.35 (974.50, 1429.69)	233.00 (192.47, 282.05)
Female	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	540	5.22 (5.08, 5.37)	813.09 (723.84, 913.34)	155.68 (138.53, 174.96)
Female	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	162	0.02 (0.02, 0.02)	1724.72 (1124.66, 2644.94)	71863.14 (46860.64, 110205.73)
Female	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	162	0.27 (0.27, 0.27)	65197.56 (47622.50, 89258.68)	239696.90 (175082.72, 328156.90)
Female	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	162	0.09 (0.09, 0.09)	43016.37 (33165.90, 55792.51)	477959.72 (368509.96, 619916.74)
Female	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	162	5.03 (4.99, 5.07)	1789.99 (1390.37, 2304.47)	355.80 (276.37, 458.06)
Female	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	162	5.12 (4.93, 5.32)	959.35 (815.73, 1128.26)	187.46 (159.24, 220.68)
Female	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	81	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Female	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	81	0.27 (0.27, 0.27)	0.28 (0.27, 0.28)	1.02 (1.00, 1.04)
Female	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	81	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Female	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	81	5.04 (4.96, 5.12)	5.05 (4.98, 5.12)	1.00 (0.98, 1.02)
Female	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	81	5.00 (5.00, 5.00)	5.03 (4.97, 5.10)	1.01 (0.99, 1.02)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Female	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	149	0.02 (0.02, 0.02)	319.71 (223.51, 457.32)	13321.31 (9312.88, 19055.04)
Female	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	149	0.28 (0.27, 0.28)	12674.85 (8796.36, 18263.44)	45962.49 (31783.96, 66465.93)
Female	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	149	0.09 (0.09, 0.09)	8035.24 (5989.71, 10779.34)	89280.46 (66552.35, 119770.39)
Female	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	149	5.00 (5.00, 5.00)	377.76 (256.07, 557.27)	75.55 (51.21, 111.45)
Female	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	149	5.09 (4.92, 5.27)	582.03 (448.63, 755.09)	114.34 (88.28, 148.09)

Table 6f. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, sex

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age, sex								
Age < 65 Female	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	262	0.02 (0.02, 0.02)	54.22 (41.05, 71.61)	2259.11 (1710.46, 2983.73)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	262	0.27 (0.27, 0.27)	659.71 (525.13, 828.78)	2425.39 (1930.62, 3046.97)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	262	0.09 (0.09, 0.09)	385.29 (314.65, 471.79)	4280.97 (3496.06, 5242.11)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	262	5.08 (4.98, 5.18)	104.74 (80.61, 136.11)	20.63 (15.92, 26.72)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	262	5.23 (5.05, 5.42)	184.27 (145.01, 234.14)	35.23 (27.84, 44.57)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	90	0.02 (0.02, 0.02)	63.34 (39.49, 101.60)	2639.05 (1645.25, 4233.16)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	90	0.27 (0.27, 0.27)	820.32 (555.86, 1210.61)	3015.88 (2043.59, 4450.76)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	90	0.09 (0.09, 0.09)	490.12 (343.28, 699.76)	5445.73 (3814.22, 7775.10)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	90	5.02 (4.98, 5.07)	111.71 (75.31, 165.68)	22.24 (14.99, 33.01)
Age < 65 Female	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	90	5.12 (4.89, 5.36)	226.94 (154.52, 333.29)	44.33 (30.39, 64.66)
Age < 65 Female	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	39	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age < 65 Female	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	39	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 Female	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	39	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 Female	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	39	5.05 (4.95, 5.16)	5.00 (5.00, 5.00)	0.99 (0.97, 1.01)
Age < 65 Female	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	39	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Female	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	75	0.02 (0.02, 0.02)	19.88 (13.28, 29.77)	828.33 (553.13, 1240.46)
Age < 65 Female	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	75	0.28 (0.27, 0.29)	226.41 (166.56, 307.78)	817.30 (595.86, 1121.03)
Age < 65 Female	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	75	0.09 (0.09, 0.09)	91.84 (67.85, 124.31)	1020.42 (753.89, 1381.17)
Age < 65 Female	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	75	5.00 (5.00, 5.00)	34.12 (22.64, 51.41)	6.82 (4.53, 10.28)
Age < 65 Female	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	75	5.12 (4.89, 5.36)	121.91 (78.85, 188.47)	23.81 (15.44, 36.72)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	262	0.02 (0.02, 0.02)	899.22 (647.08, 1249.61)	37467.54 (26961.61, 52067.24)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	262	0.27 (0.27, 0.27)	28155.06 (21852.09, 36276.05)	103511.25 (80338.56, 133367.83)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	262	0.09 (0.09, 0.09)	20220.35 (16155.59, 25307.81)	224670.55 (179506.52, 281197.90)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	262	5.08 (4.98, 5.18)	1041.80 (821.44, 1321.27)	205.15 (161.88, 259.99)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	262	5.23 (5.05, 5.42)	776.65 (671.94, 897.68)	148.47 (128.39, 171.69)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	90	0.02 (0.02, 0.02)	1398.91 (839.80, 2330.25)	58287.71 (34991.58, 97093.55)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	90	0.27 (0.27, 0.27)	51957.36 (35768.80, 75472.70)	191019.72 (131502.93, 277473.17)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	90	0.09 (0.09, 0.09)	35263.41 (25843.77, 48116.35)	391815.62 (287153.01, 534626.06)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	90	5.02 (4.98, 5.07)	1587.57 (1171.32, 2151.75)	316.09 (233.20, 428.44)
Age < 65 Female	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	90	5.12 (4.89, 5.36)	918.44 (754.74, 1117.65)	179.40 (147.26, 218.55)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Female	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	39	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age < 65 Female	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	39	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 Female	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	39	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 Female	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	39	5.05 (4.95, 5.16)	5.00 (5.00, 5.00)	0.99 (0.97, 1.01)
Age < 65 Female	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	39	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 Female	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	75	0.02 (0.02, 0.02)	203.42 (133.17, 310.71)	8475.64 (5548.87, 12946.15)
Age < 65 Female	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	75	0.28 (0.27, 0.29)	9035.74 (5737.55, 14229.89)	32617.00 (20607.11, 51626.31)
Age < 65 Female	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	75	0.09 (0.09, 0.09)	5889.43 (4113.68, 8431.73)	65438.15 (45707.53, 93685.92)
Age < 65 Female	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	75	5.00 (5.00, 5.00)	232.23 (144.09, 374.30)	46.45 (28.82, 74.86)
Age < 65 Female	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	75	5.12 (4.89, 5.36)	511.03 (365.19, 715.11)	99.80 (71.52, 139.25)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	174	0.02 (0.02, 0.02)	42.69 (30.49, 59.78)	1778.85 (1270.44, 2490.71)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	174	0.27 (0.27, 0.27)	518.21 (387.13, 693.66)	1905.17 (1423.29, 2550.21)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	174	0.09 (0.09, 0.09)	285.35 (226.54, 359.43)	3170.53 (2517.08, 3993.62)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	174	5.05 (5.00, 5.10)	79.72 (58.31, 108.98)	15.78 (11.55, 21.56)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	174	5.03 (4.99, 5.06)	145.67 (111.94, 189.55)	28.98 (22.27, 37.71)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Male	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	55	0.02 (0.02, 0.02)	50.88 (31.32, 82.66)	2120.04 (1304.94, 3444.28)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	55	0.27 (0.27, 0.27)	646.27 (423.23, 986.85)	2375.98 (1555.97, 3628.14)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	55	0.09 (0.09, 0.09)	470.20 (356.47, 620.21)	5224.44 (3960.81, 6891.19)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	55	5.02 (4.98, 5.07)	110.81 (69.38, 176.99)	22.06 (13.81, 35.25)
Age < 65 Male	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	55	5.00 (5.00, 5.00)	195.13 (121.31, 313.86)	39.03 (24.26, 62.77)
Age < 65 Male	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	37	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age < 65 Male	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	37	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 Male	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	37	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.01 (0.99, 1.03)
Age < 65 Male	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	37	5.07 (4.94, 5.20)	5.19 (4.83, 5.57)	1.02 (0.95, 1.11)
Age < 65 Male	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	37	5.05 (4.95, 5.16)	5.00 (5.00, 5.00)	0.99 (0.97, 1.01)
Age < 65 Male	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	68	0.02 (0.02, 0.02)	31.66 (18.75, 53.45)	1319.11 (781.31, 2227.12)
Age < 65 Male	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	68	0.27 (0.27, 0.27)	214.83 (124.91, 369.46)	789.80 (459.23, 1358.33)
Age < 65 Male	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	68	0.09 (0.09, 0.09)	142.41 (96.38, 210.40)	1582.28 (1070.94, 2337.77)
Age < 65 Male	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	68	5.25 (4.91, 5.62)	55.24 (32.08, 95.13)	10.51 (6.06, 18.23)
Age < 65 Male	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	68	5.24 (4.86, 5.65)	138.47 (87.18, 219.92)	26.43 (16.43, 42.54)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Male	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	174	0.02 (0.02, 0.02)	527.28 (351.16, 791.72)	21969.97 (14631.82, 32988.33)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	174	0.27 (0.27, 0.27)	24353.35 (18073.98, 32814.34)	89534.38 (66448.46, 120640.96)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	174	0.09 (0.09, 0.09)	15514.72 (12140.04, 19827.48)	172385.76 (134889.36, 220305.36)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	174	5.05 (5.00, 5.10)	772.58 (562.42, 1061.25)	152.95 (111.38, 210.03)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	174	5.03 (4.99, 5.06)	748.84 (638.20, 878.66)	148.99 (126.98, 174.83)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	55	0.02 (0.02, 0.02)	1715.55 (968.05, 3040.26)	71481.35 (40335.30, 126677.71)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	55	0.27 (0.27, 0.27)	42494.56 (25248.52, 71520.53)	156229.99 (92825.44, 262943.11)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	55	0.09 (0.09, 0.09)	31303.69 (19711.17, 49713.99)	347818.80 (219013.05, 552377.66)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	55	5.02 (4.98, 5.07)	1817.97 (1306.04, 2530.56)	361.89 (259.83, 504.04)
Age < 65 Male	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	55	5.00 (5.00, 5.00)	1168.15 (1063.97, 1282.52)	233.63 (212.79, 256.50)
Age < 65 Male	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	37	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age < 65 Male	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	37	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 Male	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	37	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 Male	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	37	5.07 (4.94, 5.20)	5.00 (5.00, 5.00)	0.99 (0.96, 1.01)
Age < 65 Male	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	37	5.05 (4.95, 5.16)	5.00 (5.00, 5.00)	0.99 (0.97, 1.01)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Male	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	68	0.02 (0.02, 0.02)	369.62 (204.81, 667.07)	15400.90 (8533.56, 27794.69)
Age < 65 Male	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	68	0.27 (0.27, 0.27)	10912.79 (6586.09, 18081.91)	40120.56 (24213.55, 66477.60)
Age < 65 Male	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	68	0.09 (0.09, 0.09)	6460.65 (4298.55, 9710.23)	71784.96 (47761.72, 107891.45)
Age < 65 Male	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	68	5.25 (4.91, 5.62)	456.72 (246.89, 844.88)	86.92 (47.11, 160.38)
Age < 65 Male	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	68	5.24 (4.86, 5.65)	603.35 (434.26, 838.28)	115.19 (81.26, 163.29)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	190	0.02 (0.02, 0.02)	158.21 (124.19, 201.55)	6592.05 (5174.49, 8397.96)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	190	0.27 (0.27, 0.27)	2165.24 (1755.67, 2670.34)	7960.43 (6454.69, 9817.43)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	190	0.09 (0.09, 0.09)	1215.51 (986.35, 1497.92)	13505.68 (10959.39, 16643.56)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	190	5.11 (5.00, 5.23)	278.69 (217.94, 356.37)	54.53 (42.66, 69.72)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	190	5.06 (4.97, 5.16)	377.21 (314.83, 451.94)	74.49 (62.23, 89.17)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	60	0.02 (0.02, 0.02)	300.25 (205.73, 438.20)	12510.55 (8572.12, 18258.48)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	60	0.28 (0.27, 0.28)	3994.10 (2941.29, 5423.76)	14511.93 (10679.65, 19719.37)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	60	0.09 (0.09, 0.09)	2130.88 (1637.40, 2773.09)	23676.44 (18193.29, 30812.11)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	60	5.00 (5.00, 5.00)	537.68 (372.46, 776.19)	107.54 (74.49, 155.24)
Age ≥ 65 Male	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	60	5.00 (5.00, 5.00)	574.95 (457.11, 723.17)	114.99 (91.42, 144.63)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	37	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	37	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	37	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	37	5.25 (4.78, 5.76)	5.00 (5.00, 5.00)	0.95 (0.87, 1.05)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	37	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	57	0.02 (0.02, 0.02)	102.83 (60.31, 175.34)	4284.62 (2512.82, 7305.73)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	57	0.27 (0.27, 0.27)	1118.17 (754.76, 1656.55)	4110.93 (2774.87, 6090.27)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	57	0.09 (0.09, 0.09)	631.49 (454.32, 877.75)	7016.51 (5047.95, 9752.74)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	57	5.00 (5.00, 5.00)	153.38 (94.61, 248.66)	30.68 (18.92, 49.73)
Age ≥ 65 Male	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	57	5.08 (4.92, 5.24)	216.12 (142.96, 326.73)	42.53 (28.25, 64.03)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	190	0.02 (0.02, 0.02)	2815.08 (2111.24, 3753.55)	117294.86 (87968.49, 156397.87)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	190	0.27 (0.27, 0.27)	90187.00 (71558.24, 113665.38)	331569.85 (263081.76, 417887.44)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	190	0.09 (0.09, 0.09)	54839.61 (44901.48, 66977.36)	609328.98 (498905.32, 744192.92)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	190	5.11 (5.00, 5.23)	2104.82 (1771.51, 2500.84)	411.87 (346.34, 489.78)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	190	5.06 (4.97, 5.16)	986.14 (889.51, 1093.28)	194.74 (175.50, 216.09)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	60	0.02 (0.02, 0.02)	8233.43 (5596.79, 12112.20)	343059.67 (233199.41, 504675.09)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	60	0.28 (0.27, 0.28)	192281.53 (141321.76, 261617.09)	698624.22 (512018.80, 953238.03)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	60	0.09 (0.09, 0.09)	130274.88 (112581.59, 150748.83)	1447498.66 (1250906.60, 1674987.05)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	60	5.00 (5.00, 5.00)	3546.44 (3110.57, 4043.40)	709.29 (622.11, 808.68)
Age ≥ 65 Male	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	60	5.00 (5.00, 5.00)	1248.36 (1162.43, 1340.64)	249.67 (232.49, 268.13)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	37	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	37	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	37	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	37	5.25 (4.78, 5.76)	5.17 (4.85, 5.51)	0.99 (0.88, 1.11)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	37	5.00 (5.00, 5.00)	5.29 (4.90, 5.70)	1.06 (0.98, 1.14)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	57	0.02 (0.02, 0.02)	1251.72 (706.83, 2216.66)	52155.05 (29451.30, 92360.92)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	57	0.27 (0.27, 0.27)	44920.03 (29069.90, 69412.30)	165147.16 (106874.65, 255192.28)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	57	0.09 (0.09, 0.09)	26342.76 (19634.40, 35343.11)	292697.31 (218160.04, 392701.23)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	57	5.00 (5.00, 5.00)	1658.65 (1161.47, 2368.65)	331.73 (232.29, 473.73)
Age ≥ 65 Male	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	57	5.08 (4.92, 5.24)	849.02 (652.73, 1104.35)	167.08 (128.43, 217.37)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	278	0.02 (0.02, 0.02)	157.79 (126.65, 196.59)	6574.56 (5277.03, 8191.14)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	278	0.27 (0.27, 0.27)	1902.35 (1575.09, 2297.62)	6993.94 (5790.77, 8447.12)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	278	0.09 (0.09, 0.09)	1201.79 (1027.02, 1406.31)	13286.64 (11356.19, 15545.25)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	278	5.02 (4.99, 5.05)	250.54 (202.01, 310.73)	49.91 (40.26, 61.88)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	278	5.19 (5.05, 5.33)	295.11 (249.06, 349.66)	56.85 (48.03, 67.28)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	72	0.02 (0.02, 0.02)	247.79 (159.19, 385.70)	10324.43 (6632.74, 16070.86)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	72	0.27 (0.27, 0.27)	2442.24 (1716.98, 3473.84)	8978.81 (6312.44, 12771.46)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	72	0.09 (0.09, 0.09)	1826.43 (1391.16, 2397.88)	20293.64 (15457.32, 26643.16)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	72	5.07 (4.94, 5.21)	376.23 (253.16, 559.13)	74.22 (50.12, 109.92)
Age ≥ 65 Female	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	72	5.11 (4.96, 5.26)	404.95 (299.73, 547.11)	79.26 (58.79, 106.85)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	42	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	42	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	42	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.01 (0.99, 1.04)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	42	5.00 (5.00, 5.00)	5.11 (4.90, 5.33)	1.02 (0.98, 1.07)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	42	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	74	0.02 (0.02, 0.02)	71.56 (49.93, 102.56)	2981.54 (2080.26, 4273.32)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	74	0.27 (0.27, 0.27)	1017.95 (723.09, 1433.04)	3742.45 (2658.41, 5268.54)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	74	0.09 (0.09, 0.09)	527.50 (393.74, 706.70)	5861.12 (4374.90, 7852.23)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	74	5.00 (5.00, 5.00)	133.46 (94.95, 187.59)	26.69 (18.99, 37.52)
Age ≥ 65 Female	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	74	5.00 (5.00, 5.00)	225.65 (163.61, 311.23)	45.13 (32.72, 62.25)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	278	0.02 (0.02, 0.02)	2247.72 (1730.65, 2919.28)	93655.13 (72110.54, 121636.64)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	278	0.27 (0.27, 0.27)	80112.09 (66048.38, 97170.39)	294529.74 (242824.93, 357244.09)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	278	0.09 (0.09, 0.09)	49929.74 (42062.16, 59268.93)	552006.94 (465095.15, 655159.84)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	278	5.02 (4.99, 5.05)	1900.06 (1608.06, 2245.09)	378.53 (320.39, 447.22)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	278	5.19 (5.05, 5.33)	968.39 (886.18, 1058.23)	186.55 (170.34, 204.31)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	72	0.02 (0.02, 0.02)	4441.83 (2894.14, 6817.19)	185076.35 (120589.02, 284049.54)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	72	0.27 (0.27, 0.27)	181829.21 (137645.74, 240195.32)	668489.75 (506050.51, 883071.02)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	72	0.09 (0.09, 0.09)	105585.83 (89340.95, 124784.53)	1173175.94 (992677.25, 1386494.75)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	72	5.07 (4.94, 5.21)	3078.46 (2552.12, 3713.35)	607.32 (503.24, 732.92)
Age ≥ 65 Female	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	72	5.11 (4.96, 5.26)	1168.11 (1055.42, 1292.84)	228.63 (205.90, 253.86)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	42	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	42	0.27 (0.27, 0.27)	0.29 (0.27, 0.32)	1.08 (0.99, 1.17)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	42	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	42	5.00 (5.00, 5.00)	5.21 (4.93, 5.51)	1.04 (0.99, 1.10)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	42	5.00 (5.00, 5.00)	5.14 (4.87, 5.42)	1.03 (0.97, 1.08)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	74	0.02 (0.02, 0.02)	1249.56 (791.89, 1971.76)	52065.20 (32995.36, 82156.56)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	74	0.27 (0.27, 0.27)	35158.72 (24628.10, 50192.07)	129259.99 (90544.50, 184529.65)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	74	0.09 (0.09, 0.09)	20499.91 (15253.65, 27550.53)	227776.73 (169485.01, 306116.97)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	74	5.00 (5.00, 5.00)	1637.49 (1217.31, 2202.70)	327.50 (243.46, 440.54)
Age ≥ 65 Female	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	74	5.00 (5.00, 5.00)	861.52 (690.37, 1075.09)	172.30 (138.07, 215.02)

Table 6g. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Hispanic or Latino ethnicity

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Hispanic or Latino ethnicity								
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	127	0.02 (0.02, 0.02)	54.25 (32.89, 89.49)	2260.48 (1370.32, 3728.89)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	127	0.27 (0.27, 0.27)	738.59 (475.77, 1146.59)	2715.39 (1749.14, 4215.41)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	127	0.09 (0.09, 0.09)	458.30 (335.04, 626.91)	5092.24 (3722.67, 6965.67)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	127	5.08 (5.00, 5.17)	122.12 (79.12, 188.47)	24.02 (15.58, 37.03)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	127	5.14 (4.94, 5.35)	195.26 (135.35, 281.68)	38.00 (26.36, 54.77)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	29	0.02 (0.02, 0.02)	63.63 (24.18, 167.42)	2651.31 (1007.68, 6975.85)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	29	0.27 (0.27, 0.27)	671.42 (268.81, 1677.02)	2468.46 (988.29, 6165.51)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	29	0.09 (0.09, 0.09)	554.48 (337.54, 910.83)	6160.85 (3750.47, 10120.37)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	29	5.08 (4.93, 5.24)	103.70 (42.84, 251.02)	20.42 (8.42, 49.52)
Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	29	5.00 (5.00, 5.00)	199.58 (88.50, 450.06)	39.92 (17.70, 90.01)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	15	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	15	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	15	0.09 (0.09, 0.09)	0.09 (0.09, 0.10)	1.02 (0.98, 1.07)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	15	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	15	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	46	0.02 (0.02, 0.02)	39.34 (24.35, 63.57)	1639.27 (1014.56, 2648.66)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	46	0.27 (0.27, 0.27)	478.11 (305.16, 749.09)	1757.77 (1121.90, 2754.02)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	46	0.09 (0.09, 0.09)	212.26 (132.46, 340.16)	2358.49 (1471.73, 3779.54)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	46	5.00 (5.00, 5.00)	56.89 (27.13, 119.26)	11.38 (5.43, 23.85)
Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	46	5.00 (5.00, 5.00)	122.38 (59.76, 250.61)	24.48 (11.95, 50.12)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	127	0.02 (0.02, 0.02)	814.68 (481.21, 1379.23)	33945.09 (20050.59, 57468.08)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	127	0.27 (0.27, 0.27)	34964.00 (23048.31, 53039.96)	128544.12 (84736.42, 194999.87)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	127	0.09 (0.09, 0.09)	22813.81 (16865.24, 30860.51)	253486.75 (187391.54, 342894.53)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	127	5.08 (5.00, 5.17)	854.62 (560.85, 1302.27)	168.11 (110.45, 255.88)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	127	5.14 (4.94, 5.35)	844.27 (704.57, 1011.67)	164.31 (137.13, 196.87)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	29	0.02 (0.02, 0.02)	1064.02 (391.85, 2889.21)	44333.98 (16326.94, 120383.92)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	29	0.27 (0.27, 0.27)	50017.84 (23071.66, 108435.37)	183889.10 (84822.28, 398659.44)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	29	0.09 (0.09, 0.09)	27653.57 (13499.72, 56647.08)	307261.88 (149996.92, 629412.00)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	29	5.08 (4.93, 5.24)	2163.43 (1224.36, 3822.74)	425.99 (240.19, 755.51)
Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	29	5.00 (5.00, 5.00)	1169.19 (1060.95, 1288.48)	233.84 (212.19, 257.70)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	15	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	15	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	15	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	15	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	15	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	46	0.02 (0.02, 0.02)	493.77 (219.83, 1109.09)	20573.93 (9159.65, 46212.10)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	46	0.27 (0.27, 0.27)	18749.45 (9974.36, 35244.56)	68931.79 (36670.42, 129575.61)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	46	0.09 (0.09, 0.09)	9513.70 (5382.70, 16815.08)	105707.76 (59807.74, 186834.18)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	46	5.00 (5.00, 5.00)	467.24 (253.04, 862.78)	93.45 (50.61, 172.56)
Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	46	5.00 (5.00, 5.00)	701.90 (473.83, 1039.74)	140.38 (94.77, 207.95)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	679	0.02 (0.02, 0.02)	63.32 (51.99, 77.13)	2638.50 (2166.16, 3213.83)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	679	0.27 (0.27, 0.27)	770.48 (651.56, 911.10)	2832.63 (2395.43, 3349.62)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	679	0.09 (0.09, 0.09)	434.43 (375.73, 502.30)	4826.98 (4174.76, 5581.09)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	679	5.04 (5.01, 5.07)	114.80 (94.93, 138.83)	22.78 (18.84, 27.54)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	679	5.17 (5.06, 5.28)	198.64 (168.65, 233.96)	38.43 (32.71, 45.16)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	209	0.02 (0.02, 0.02)	82.66 (59.08, 115.67)	3444.35 (2461.60, 4819.45)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	209	0.27 (0.27, 0.27)	1077.53 (822.32, 1411.94)	3956.16 (3019.25, 5183.82)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	209	0.09 (0.09, 0.09)	662.30 (517.66, 847.34)	7358.87 (5751.81, 9414.93)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	209	5.02 (4.99, 5.06)	151.73 (113.85, 202.23)	30.20 (22.66, 40.26)
Not Hispanic or Latino	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	209	5.08 (4.93, 5.24)	260.81 (197.68, 344.10)	51.31 (39.03, 67.45)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	122	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	122	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	122	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.01)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	122	5.09 (4.99, 5.20)	5.11 (4.93, 5.28)	1.00 (0.96, 1.04)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	122	5.02 (4.98, 5.07)	5.00 (5.00, 5.00)	1.00 (0.99, 1.00)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	203	0.02 (0.02, 0.02)	31.38 (22.71, 43.38)	1307.69 (946.18, 1807.33)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	203	0.27 (0.27, 0.28)	277.30 (203.68, 377.54)	1010.95 (740.98, 1379.28)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	203	0.09 (0.09, 0.09)	149.58 (116.96, 191.31)	1662.04 (1299.55, 2125.63)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	203	5.13 (4.95, 5.31)	56.35 (40.82, 77.80)	10.99 (7.94, 15.19)
Not Hispanic or Latino	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	203	5.19 (4.96, 5.42)	148.92 (110.97, 199.85)	28.71 (21.29, 38.70)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	679	0.02 (0.02, 0.02)	967.79 (758.64, 1234.60)	40324.62 (31610.08, 51441.66)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	679	0.27 (0.27, 0.27)	33872.91 (28244.45, 40622.99)	124532.76 (103839.90, 149349.23)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	679	0.09 (0.09, 0.09)	22521.81 (19244.89, 26356.70)	250242.31 (213832.10, 292852.25)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	679	5.04 (5.01, 5.07)	1097.66 (921.37, 1307.68)	217.82 (182.85, 259.47)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	679	5.17 (5.06, 5.28)	785.58 (708.83, 870.64)	152.00 (137.10, 168.51)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	209	0.02 (0.02, 0.02)	2040.56 (1414.39, 2943.97)	85023.54 (58932.71, 122665.35)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	209	0.27 (0.27, 0.27)	65701.34 (49108.73, 87900.16)	241223.15 (180301.69, 322729.14)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	209	0.09 (0.09, 0.09)	45749.18 (35772.79, 58507.81)	508324.21 (397475.41, 650086.75)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	209	5.02 (4.99, 5.06)	1861.13 (1499.52, 2309.95)	370.44 (298.46, 459.77)
Not Hispanic or Latino	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	209	5.08 (4.93, 5.24)	1016.42 (893.53, 1156.22)	199.97 (175.60, 227.72)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	122	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	122	0.27 (0.27, 0.27)	0.28 (0.27, 0.28)	1.01 (1.00, 1.03)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	122	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	122	5.09 (4.99, 5.20)	5.03 (4.99, 5.08)	0.99 (0.97, 1.01)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	122	5.02 (4.98, 5.07)	5.06 (4.99, 5.13)	1.01 (0.99, 1.02)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	203	0.02 (0.02, 0.02)	350.75 (246.37, 499.37)	14614.66 (10265.22, 20806.98)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	203	0.27 (0.27, 0.28)	12283.74 (8988.91, 16786.28)	44782.36 (32712.25, 61306.07)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	203	0.09 (0.09, 0.09)	7712.34 (6006.90, 9901.99)	85692.69 (66743.31, 110022.07)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	203	5.13 (4.95, 5.31)	473.68 (322.64, 695.43)	92.34 (63.05, 135.25)
Not Hispanic or Latino	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	203	5.19 (4.96, 5.42)	607.53 (493.49, 747.93)	117.11 (94.38, 145.32)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	98	0.02 (0.02, 0.02)	72.49 (43.23, 121.55)	3020.36 (1801.26, 5064.55)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	98	0.27 (0.27, 0.27)	863.61 (590.53, 1262.97)	3175.05 (2171.08, 4643.28)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	98	0.09 (0.09, 0.09)	557.02 (396.67, 782.19)	6154.03 (4383.87, 8638.95)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	98	5.24 (4.85, 5.66)	131.50 (86.64, 199.58)	25.11 (17.14, 36.79)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	98	5.02 (4.98, 5.07)	161.93 (103.07, 254.40)	32.24 (20.52, 50.65)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	39	0.02 (0.02, 0.02)	68.63 (35.87, 131.31)	2859.55 (1494.50, 5471.41)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	39	0.27 (0.27, 0.27)	775.10 (415.40, 1446.25)	2849.62 (1527.21, 5317.09)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	39	0.09 (0.09, 0.09)	550.31 (364.91, 829.90)	6114.58 (4054.61, 9221.13)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	39	5.00 (5.00, 5.00)	148.28 (77.75, 282.79)	29.66 (15.55, 56.56)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	39	5.05 (4.95, 5.14)	230.97 (117.30, 454.82)	45.76 (23.27, 90.02)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	18	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	18	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	18	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	18	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	18	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	25	0.02 (0.02, 0.02)	40.53 (16.70, 98.34)	1688.59 (695.90, 4097.39)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	25	0.27 (0.27, 0.27)	489.52 (288.78, 829.79)	1799.70 (1061.69, 3050.71)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	25	0.09 (0.09, 0.09)	265.13 (159.26, 441.38)	2945.87 (1769.51, 4904.26)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	25	5.00 (5.00, 5.00)	59.42 (23.13, 152.69)	11.88 (4.63, 30.54)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	25	5.00 (5.00, 5.00)	153.51 (74.65, 315.71)	30.70 (14.93, 63.14)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	98	0.02 (0.02, 0.02)	937.47 (556.39, 1579.55)	39061.19 (23182.94, 65814.63)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	98	0.27 (0.27, 0.27)	34296.79 (22569.35, 52118.02)	126091.14 (82975.55, 191610.38)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	98	0.09 (0.09, 0.09)	25034.26 (16740.49, 37437.03)	276581.16 (185012.52, 413470.06)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	98	5.24 (4.85, 5.66)	1289.61 (824.01, 2018.31)	246.26 (158.62, 382.30)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	98	5.02 (4.98, 5.07)	933.95 (764.95, 1140.28)	185.92 (152.26, 227.03)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	39	0.02 (0.02, 0.02)	2514.57 (1174.56, 5383.36)	104773.92 (48939.99, 224306.85)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	39	0.27 (0.27, 0.27)	56338.04 (29327.80, 108224.11)	207125.15 (107822.79, 397882.76)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	39	0.09 (0.09, 0.09)	40615.66 (23498.38, 70201.94)	451285.11 (261093.11, 780021.54)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	39	5.00 (5.00, 5.00)	2024.96 (1309.63, 3131.02)	404.99 (261.93, 626.20)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	39	5.05 (4.95, 5.14)	1123.51 (932.28, 1353.98)	222.61 (184.62, 268.42)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	18	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	18	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	18	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	18	5.00 (5.00, 5.00)	5.13 (4.88, 5.38)	1.03 (0.98, 1.08)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	18	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	25	0.02 (0.02, 0.02)	675.40 (387.70, 1176.59)	28141.50 (16154.01, 49024.60)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	25	0.27 (0.27, 0.27)	19749.84 (8421.53, 46316.57)	72609.71 (30961.50, 170281.49)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	25	0.09 (0.09, 0.09)	11964.66 (5409.29, 26464.31)	132940.69 (60103.24, 294047.85)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	25	5.00 (5.00, 5.00)	435.27 (179.30, 1056.63)	87.05 (35.86, 211.33)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	25	5.00 (5.00, 5.00)	555.25 (237.70, 1297.01)	111.05 (47.54, 259.40)

Table 6h. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Race

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Race								
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	355	0.02 (0.02, 0.02)	69.71 (54.55, 89.08)	2904.49 (2272.85, 3711.65)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	355	0.27 (0.27, 0.27)	851.96 (683.58, 1061.81)	3132.19 (2513.16, 3903.70)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	355	0.09 (0.09, 0.09)	457.39 (378.96, 552.07)	5082.15 (4210.63, 6134.07)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	355	5.04 (5.00, 5.07)	126.36 (99.23, 160.92)	25.07 (19.69, 31.92)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	355	5.18 (5.04, 5.33)	217.51 (176.19, 268.54)	42.00 (34.11, 51.71)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	121	0.02 (0.02, 0.02)	77.05 (48.18, 123.22)	3210.56 (2007.62, 5134.30)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	121	0.27 (0.27, 0.27)	1042.78 (719.00, 1512.35)	3833.74 (2643.39, 5560.12)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	121	0.09 (0.09, 0.09)	675.98 (483.56, 944.98)	7510.94 (5372.88, 10499.82)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	121	5.04 (4.98, 5.09)	134.49 (91.52, 197.63)	26.69 (18.16, 39.23)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	121	5.12 (4.89, 5.37)	274.51 (190.56, 395.46)	53.58 (37.46, 76.65)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	64	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	64	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	64	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	64	5.11 (4.96, 5.26)	5.18 (4.89, 5.49)	1.01 (0.95, 1.08)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	64	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	116	0.02 (0.02, 0.02)	25.31 (16.85, 38.02)	1054.73 (702.26, 1584.10)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	116	0.27 (0.27, 0.27)	210.89 (142.33, 312.47)	775.34 (523.29, 1148.80)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	116	0.09 (0.09, 0.09)	127.97 (94.16, 173.92)	1421.87 (1046.21, 1932.41)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	116	5.19 (4.93, 5.47)	48.07 (32.44, 71.22)	9.26 (6.23, 13.75)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	116	5.24 (4.92, 5.59)	140.69 (97.98, 202.01)	26.82 (18.53, 38.83)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	355	0.02 (0.02, 0.02)	1044.69 (761.89, 1432.46)	43528.57 (31745.26, 59685.65)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	355	0.27 (0.27, 0.27)	36435.10 (28737.15, 46195.14)	133952.59 (105651.29, 169835.08)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	355	0.09 (0.09, 0.09)	25205.17 (20626.81, 30799.75)	280057.47 (229186.83, 342219.43)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	355	5.04 (5.00, 5.07)	1228.38 (982.72, 1535.45)	243.75 (195.01, 304.66)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	355	5.18 (5.04, 5.33)	810.89 (707.90, 928.88)	156.57 (136.62, 179.43)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	121	0.02 (0.02, 0.02)	2213.21 (1336.74, 3664.34)	92216.92 (55697.64, 152680.79)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	121	0.27 (0.27, 0.27)	70335.26 (47398.85, 104370.64)	258585.50 (174260.47, 383715.60)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	121	0.09 (0.09, 0.09)	50675.29 (37092.29, 69232.30)	563058.72 (412136.55, 769247.78)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	121	5.04 (4.98, 5.09)	1892.63 (1423.38, 2516.58)	375.60 (282.48, 499.42)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	121	5.12 (4.89, 5.37)	961.03 (795.48, 1161.03)	187.59 (155.07, 226.92)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	64	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	64	0.27 (0.27, 0.27)	0.28 (0.27, 0.28)	1.02 (0.99, 1.04)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	64	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	64	5.11 (4.96, 5.26)	5.03 (4.97, 5.09)	0.98 (0.95, 1.02)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	64	5.00 (5.00, 5.00)	5.08 (4.97, 5.19)	1.02 (0.99, 1.04)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	116	0.02 (0.02, 0.02)	277.45 (178.97, 430.10)	11560.27 (7457.29, 17920.70)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	116	0.27 (0.27, 0.27)	9241.19 (6112.15, 13972.11)	33974.96 (22471.12, 51368.05)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	116	0.09 (0.09, 0.09)	6530.55 (4820.40, 8847.43)	72561.72 (53559.97, 98304.82)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	116	5.19 (4.93, 5.47)	457.87 (282.73, 741.51)	88.17 (54.67, 142.20)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	116	5.24 (4.92, 5.59)	581.23 (447.81, 754.40)	110.82 (84.33, 145.64)
Black or African American	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	205	0.02 (0.02, 0.02)	39.51 (28.40, 54.96)	1646.08 (1183.16, 2290.13)
Black or African American	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	205	0.27 (0.27, 0.27)	502.63 (365.12, 691.94)	1847.92 (1342.35, 2543.91)
Black or African American	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	205	0.09 (0.09, 0.09)	359.89 (273.62, 473.37)	3998.82 (3040.24, 5259.65)
Black or African American	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	205	5.05 (5.00, 5.11)	73.58 (53.44, 101.31)	14.57 (10.59, 20.04)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Black or African American	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	205	5.13 (5.00, 5.26)	136.37 (101.63, 182.98)	26.60 (19.90, 35.55)
Black or African American	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	61	0.02 (0.02, 0.02)	66.93 (37.80, 118.51)	2788.78 (1574.98, 4938.01)
Black or African American	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	61	0.27 (0.27, 0.28)	1178.96 (771.48, 1801.67)	4311.50 (2822.06, 6587.06)
Black or African American	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	61	0.09 (0.09, 0.09)	640.62 (437.88, 937.23)	7117.97 (4865.31, 10413.62)
Black or African American	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	61	5.00 (5.00, 5.00)	144.48 (80.12, 260.55)	28.90 (16.02, 52.11)
Black or African American	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	61	5.06 (4.98, 5.15)	216.07 (126.21, 369.92)	42.70 (24.96, 73.05)
Black or African American	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	25	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Black or African American	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	25	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Black or African American	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	25	0.09 (0.09, 0.09)	0.09 (0.09, 0.10)	1.04 (0.98, 1.09)
Black or African American	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	25	5.17 (4.85, 5.51)	5.00 (5.00, 5.00)	0.97 (0.91, 1.03)
Black or African American	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	25	5.13 (4.88, 5.39)	5.00 (5.00, 5.00)	0.97 (0.93, 1.02)
Black or African American	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	48	0.02 (0.02, 0.02)	55.30 (29.35, 104.18)	2304.04 (1222.96, 4340.76)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Black or African American	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	48	0.27 (0.27, 0.27)	521.18 (316.11, 859.30)	1916.11 (1162.16, 3159.20)
Black or African American	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	48	0.09 (0.09, 0.09)	239.78 (153.72, 374.02)	2664.19 (1707.95, 4155.79)
Black or African American	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	48	5.00 (5.00, 5.00)	83.13 (45.45, 152.03)	16.63 (9.09, 30.41)
Black or African American	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	48	5.00 (5.00, 5.00)	160.07 (88.43, 289.73)	32.01 (17.69, 57.95)
Black or African American	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	205	0.02 (0.02, 0.02)	606.19 (384.80, 954.95)	25257.85 (16033.37, 39789.45)
Black or African American	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	205	0.27 (0.27, 0.27)	21156.94 (15313.33, 29230.48)	77782.86 (56299.01, 107465.00)
Black or African American	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	205	0.09 (0.09, 0.09)	15687.41 (11987.76, 20528.84)	174304.54 (133197.31, 228098.24)
Black or African American	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	205	5.05 (5.00, 5.11)	668.65 (474.64, 941.96)	132.38 (94.00, 186.44)
Black or African American	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	205	5.13 (5.00, 5.26)	692.39 (561.27, 854.14)	135.05 (109.57, 166.46)
Black or African American	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	61	0.02 (0.02, 0.02)	2445.99 (1305.58, 4582.52)	101916.17 (54399.27, 190938.32)
Black or African American	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	61	0.27 (0.27, 0.28)	70139.32 (41066.05, 119795.40)	256502.34 (150161.46, 438151.39)
Black or African American	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	61	0.09 (0.09, 0.09)	38282.53 (23969.98, 61141.14)	425361.45 (266333.16, 679346.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Black or African American	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	61	5.00 (5.00, 5.00)	1763.07 (1217.90, 2552.28)	352.61 (243.58, 510.46)
Black or African American	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	61	5.06 (4.98, 5.15)	1207.84 (1106.26, 1318.75)	238.69 (218.28, 261.00)
Black or African American	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	25	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Black or African American	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	25	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Black or African American	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	25	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Black or African American	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	25	5.17 (4.85, 5.51)	5.00 (5.00, 5.00)	0.97 (0.91, 1.03)
Black or African American	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	25	5.13 (4.88, 5.39)	5.00 (5.00, 5.00)	0.97 (0.93, 1.02)
Black or African American	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	48	0.02 (0.02, 0.02)	728.24 (329.40, 1610.00)	30343.24 (13724.88, 67083.44)
Black or African American	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	48	0.27 (0.27, 0.27)	17910.96 (10256.34, 31278.45)	65849.10 (37707.12, 114994.30)
Black or African American	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	48	0.09 (0.09, 0.09)	14093.55 (8027.36, 24743.90)	156595.00 (89192.87, 274932.23)
Black or African American	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	48	5.00 (5.00, 5.00)	441.02 (184.45, 1054.46)	88.20 (36.89, 210.89)
Black or African American	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	48	5.00 (5.00, 5.00)	506.95 (299.89, 856.98)	101.39 (59.98, 171.40)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Asian	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	57	0.02 (0.02, 0.02)	48.76 (26.14, 90.95)	2031.68 (1089.27, 3789.45)
Asian	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	57	0.27 (0.27, 0.27)	651.61 (410.12, 1035.31)	2395.64 (1507.79, 3806.29)
Asian	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	57	0.09 (0.09, 0.09)	434.81 (292.11, 647.22)	4831.25 (3245.70, 7191.38)
Asian	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	57	5.00 (5.00, 5.00)	105.45 (54.28, 204.85)	21.09 (10.86, 40.97)
Asian	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	57	5.00 (5.00, 5.00)	168.70 (95.98, 296.54)	33.74 (19.20, 59.31)
Asian	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	18	0.02 (0.02, 0.02)	107.26 (44.23, 260.11)	4469.12 (1842.87, 10838.00)
Asian	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	18	0.27 (0.27, 0.27)	814.76 (361.38, 1836.93)	2995.44 (1328.61, 6753.40)
Asian	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	18	0.09 (0.09, 0.09)	530.39 (243.28, 1156.31)	5893.23 (2703.17, 12847.94)
Asian	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	18	5.00 (5.00, 5.00)	230.64 (57.30, 928.40)	46.13 (11.46, 185.68)
Asian	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	18	5.00 (5.00, 5.00)	278.37 (119.43, 648.83)	55.67 (23.89, 129.77)
Asian	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	12	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Asian	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	12	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Asian	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	12	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Asian	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	12	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Asian	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	12	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Asian	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	16	0.02 (0.02, 0.02)	56.24 (23.94, 132.13)	2343.53 (997.56, 5505.53)
Asian	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	16	0.32 (0.24, 0.42)	474.36 (214.35, 1049.76)	1494.89 (531.28, 4206.24)
Asian	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	16	0.09 (0.09, 0.09)	162.61 (51.20, 516.51)	1806.81 (568.84, 5738.95)
Asian	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	16	5.00 (5.00, 5.00)	103.62 (31.86, 337.02)	20.72 (6.37, 67.40)
Asian	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	16	5.00 (5.00, 5.00)	175.58 (82.12, 375.40)	35.12 (16.42, 75.08)
Asian	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	57	0.02 (0.02, 0.02)	884.76 (479.17, 1633.66)	36865.03 (19965.40, 68069.30)
Asian	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	57	0.27 (0.27, 0.27)	31067.18 (16781.90, 57512.52)	114217.56 (61698.17, 211443.08)
Asian	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	57	0.09 (0.09, 0.09)	17026.90 (10429.05, 27798.82)	189187.79 (115878.39, 308875.73)
Asian	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	57	5.00 (5.00, 5.00)	901.66 (473.91, 1715.49)	180.33 (94.78, 343.10)
Asian	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	57	5.00 (5.00, 5.00)	973.09 (758.13, 1249.00)	194.62 (151.63, 249.80)
Asian	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	18	0.02 (0.02, 0.02)	854.63 (142.76, 5116.07)	35609.48 (5948.48, 213169.63)
Asian	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	18	0.27 (0.27, 0.27)	40035.90 (13796.82, 116177.00)	147190.79 (50723.59, 427121.33)
Asian	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	18	0.09 (0.09, 0.09)	34503.14 (13285.21, 89608.42)	383368.27 (147613.49, 995649.06)
Asian	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	18	5.00 (5.00, 5.00)	899.41 (266.31, 3037.53)	179.88 (53.26, 607.51)
Asian	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	18	5.00 (5.00, 5.00)	779.08 (406.84, 1491.89)	155.82 (81.37, 298.38)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Asian	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	12	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Asian	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	12	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Asian	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	12	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Asian	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	12	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Asian	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	12	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Asian	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	16	0.02 (0.02, 0.02)	335.30 (91.06, 1234.63)	13970.63 (3794.07, 51443.12)
Asian	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	16	0.32 (0.24, 0.42)	22299.26 (8400.58, 59193.15)	70273.38 (21960.41, 224875.00)
Asian	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	16	0.09 (0.09, 0.09)	6891.44 (2188.67, 21698.94)	76571.50 (24318.59, 241099.36)
Asian	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	16	5.00 (5.00, 5.00)	452.78 (113.03, 1813.70)	90.56 (22.61, 362.74)
Asian	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	16	5.00 (5.00, 5.00)	433.20 (166.20, 1129.17)	86.64 (33.24, 225.83)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	22	0.02 (0.02, 0.02)	159.01 (40.90, 618.23)	6625.44 (1704.08, 25759.54)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	22	0.27 (0.27, 0.27)	831.76 (422.47, 1637.59)	3057.95 (1553.19, 6020.55)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	22	0.09 (0.09, 0.09)	583.32 (298.62, 1139.45)	6481.32 (3317.99, 12660.53)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	22	5.00 (5.00, 5.00)	152.53 (52.00, 447.43)	30.51 (10.40, 89.49)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	22	5.00 (5.00, 5.00)	333.08 (182.27, 608.67)	66.62 (36.45, 121.73)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	8	0.02 (0.02, 0.02)	385.19 (153.99, 963.51)	16049.39 (6416.09, 40146.40)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	8	0.27 (0.27, 0.27)	2901.68 (1835.24, 4587.82)	10667.94 (6747.20, 16866.99)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	8	0.09 (0.09, 0.09)	1562.53 (874.42, 2792.12)	17361.41 (9715.79, 31023.59)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	8	5.00 (5.00, 5.00)	666.40 (230.44, 1927.13)	133.28 (46.09, 385.43)
American Indian or Alaska Native	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	8	5.00 (5.00, 5.00)	433.67 (192.88, 975.09)	86.73 (38.58, 195.02)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	7	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	7	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	7	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	7	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	7	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	8	0.02 (0.02, 0.02)	103.72 (61.10, 176.07)	4321.78 (2545.91, 7336.38)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	8	0.27 (0.27, 0.27)	836.88 (339.14, 2065.14)	3076.75 (1246.82, 7592.42)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	8	0.09 (0.09, 0.09)	311.79 (145.48, 668.19)	3464.28 (1616.48, 7424.33)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	8	5.00 (5.00, 5.00)	117.82 (67.56, 205.49)	23.56 (13.51, 41.10)
American Indian or Alaska Native	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	8	5.00 (5.00, 5.00)	433.54 (151.92, 1237.16)	86.71 (30.38, 247.43)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	22	0.02 (0.02, 0.02)	1350.63 (255.42, 7142.04)	56276.33 (10642.42, 297584.98)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	22	0.27 (0.27, 0.27)	54398.18 (23537.88, 125719.10)	199993.30 (86536.34, 462202.57)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	22	0.09 (0.09, 0.09)	27579.42 (12333.42, 61671.81)	306438.03 (137038.04, 685242.35)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	22	5.00 (5.00, 5.00)	1495.68 (812.13, 2754.55)	299.14 (162.43, 550.91)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	22	5.00 (5.00, 5.00)	745.22 (329.98, 1682.95)	149.04 (66.00, 336.59)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	8	0.02 (0.02, 0.02)	11626.70 (3273.28, 41298.09)	484445.90 (136386.66, 1720753.62)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	8	0.27 (0.27, 0.27)	200735.20 (102981.76, 391279.19)	737997.06 (378609.42, 1438526.43)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	8	0.09 (0.09, 0.09)	96737.74 (50788.36, 184258.56)	1074863.75 (564315.10, 2047317.34)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	8	5.00 (5.00, 5.00)	3475.76 (2559.76, 4719.54)	695.15 (511.95, 943.91)
American Indian or Alaska Native	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	8	5.00 (5.00, 5.00)	1295.00 (1295.00, 1295.00)	259.00 (259.00, 259.00)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	7	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	7	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	7	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	7	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	7	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	8	0.02 (0.02, 0.02)	677.27 (285.63, 1605.88)	28219.39 (11901.26, 66911.73)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	8	0.27 (0.27, 0.27)	29384.38 (15121.79, 57099.19)	108030.82 (55594.81, 209923.51)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	8	0.09 (0.09, 0.09)	23269.38 (11375.13, 47600.72)	258548.70 (126390.29, 528896.89)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	8	5.00 (5.00, 5.00)	608.77 (281.57, 1316.20)	121.75 (56.31, 263.24)
American Indian or Alaska Native	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	8	5.00 (5.00, 5.00)	1295.00 (1295.00, 1295.00)	259.00 (259.00, 259.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	17	0.02 (0.02, 0.02)	110.26 (53.37, 227.77)	4594.12 (2223.95, 9490.29)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	17	0.27 (0.27, 0.27)	2806.54 (919.76, 8563.77)	10318.14 (3381.48, 31484.43)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	17	0.09 (0.09, 0.09)	1028.16 (545.42, 1938.15)	11423.99 (6060.26, 21534.96)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	17	5.00 (5.00, 5.00)	207.55 (131.55, 327.45)	41.51 (26.31, 65.49)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	17	5.00 (5.00, 5.00)	483.37 (304.41, 767.54)	96.67 (60.88, 153.51)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	3	0.02 (0.02, 0.02)	569.82 (278.18, 1167.20)	23742.57 (11591.01, 48633.35)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	3	0.27 (0.27, 0.27)	2086.57 (367.52, 11846.26)	7671.22 (1351.19, 43552.42)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	3	0.09 (0.09, 0.09)	912.56 (147.28, 5654.26)	10139.61 (1636.47, 62825.15)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	3	5.00 (5.00, 5.00)	801.67 (439.13, 1463.50)	160.33 (87.83, 292.70)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	3	5.00 (5.00, 5.00)	610.02 (215.01, 1730.78)	122.00 (43.00, 346.16)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	1	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	1	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	1	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	1	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	1	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	7	0.02 (0.02, 0.02)	76.08 (22.05, 262.50)	3170.09 (918.82, 10937.30)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	7	0.27 (0.27, 0.27)	504.34 (315.41, 806.44)	1854.18 (1159.58, 2964.84)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	7	0.09 (0.09, 0.09)	178.02 (130.83, 242.22)	1977.95 (1453.67, 2691.30)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	7	5.00 (5.00, 5.00)	145.36 (45.61, 463.24)	29.07 (9.12, 92.65)
Native Hawaiian or Other Pacific Islander	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	7	5.00 (5.00, 5.00)	270.26 (63.92, 1142.71)	54.05 (12.78, 228.54)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	17	0.02 (0.02, 0.02)	4513.03 (2207.60, 9226.10)	188043.12 (91983.13, 384420.67)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	17	0.27 (0.27, 0.27)	88742.44 (50304.88, 156549.82)	326258.96 (184944.41, 575550.81)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	17	0.09 (0.09, 0.09)	55837.10 (30598.67, 101892.72)	620412.21 (339985.21, 1132141.31)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	17	5.00 (5.00, 5.00)	2139.73 (1418.45, 3227.79)	427.95 (283.69, 645.56)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	17	5.00 (5.00, 5.00)	1110.47 (928.83, 1327.63)	222.09 (185.77, 265.53)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	3	0.02 (0.02, 0.02)	4317.30 (624.92, 29826.49)	179887.37 (26038.16, 1242770.57)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	3	0.27 (0.27, 0.27)	141959.66 (56871.84, 354350.11)	521910.50 (209087.66, 1302757.74)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	3	0.09 (0.09, 0.09)	75528.02 (43231.58, 131951.72)	839200.17 (480350.89, 1466130.17)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	3	5.00 (5.00, 5.00)	4404.00 (4404.00, 4404.00)	880.80 (880.80, 880.80)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	3	5.00 (5.00, 5.00)	1295.00 (1295.00, 1295.00)	259.00 (259.00, 259.00)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	1	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	1	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	1	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	1	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	1	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	7	0.02 (0.02, 0.02)	461.79 (172.20, 1238.43)	19241.38 (7174.83, 51601.32)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	7	0.27 (0.27, 0.27)	80694.40 (35476.98, 183544.00)	296670.60 (130430.08, 674794.10)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	7	0.09 (0.09, 0.09)	17255.07 (6364.86, 46778.31)	191722.98 (70720.66, 519759.01)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	7	5.00 (5.00, 5.00)	1053.52 (305.29, 3635.60)	210.70 (61.06, 727.12)
Native Hawaiian or Other Pacific Islander	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	7	5.00 (5.00, 5.00)	1292.57 (1288.26, 1296.90)	258.51 (257.65, 259.38)
Multiracial	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	54	0.02 (0.02, 0.02)	21.28 (11.12, 40.72)	886.78 (463.49, 1696.64)
Multiracial	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	54	0.27 (0.27, 0.27)	520.84 (295.56, 917.82)	1914.85 (1086.63, 3374.33)
Multiracial	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	54	0.09 (0.09, 0.09)	358.51 (216.79, 592.89)	3983.48 (2408.77, 6587.64)
Multiracial	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	54	5.03 (4.97, 5.10)	46.77 (25.27, 86.56)	9.29 (5.03, 17.16)
Multiracial	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	54	5.25 (4.79, 5.75)	131.90 (77.15, 225.48)	25.13 (14.89, 42.42)
Multiracial	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	15	0.02 (0.02, 0.02)	65.14 (27.17, 156.20)	2714.13 (1131.89, 6508.13)
Multiracial	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	15	0.27 (0.27, 0.27)	463.44 (162.01, 1325.67)	1703.81 (595.63, 4873.79)
Multiracial	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	15	0.09 (0.09, 0.09)	479.77 (179.76, 1280.50)	5330.81 (1997.33, 14227.79)
Multiracial	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	15	5.13 (4.88, 5.39)	115.29 (56.50, 235.27)	22.48 (10.95, 46.14)
Multiracial	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	15	5.00 (5.00, 5.00)	249.18 (111.78, 555.48)	49.84 (22.36, 111.10)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Multiracial	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	11	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Multiracial	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	11	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Multiracial	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	11	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Multiracial	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	11	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Multiracial	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	11	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Multiracial	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	22	0.02 (0.02, 0.02)	27.97 (12.94, 60.45)	1165.36 (539.19, 2518.73)
Multiracial	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	22	0.27 (0.27, 0.27)	332.19 (198.62, 555.58)	1221.28 (730.22, 2042.56)
Multiracial	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	22	0.09 (0.09, 0.09)	202.22 (122.86, 332.85)	2246.90 (1365.09, 3698.35)
Multiracial	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	22	5.00 (5.00, 5.00)	30.50 (9.70, 95.90)	6.10 (1.94, 19.18)
Multiracial	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	22	5.00 (5.00, 5.00)	89.67 (27.75, 289.69)	17.93 (5.55, 57.94)
Multiracial	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	54	0.02 (0.02, 0.02)	539.35 (260.74, 1115.66)	22473.03 (10864.37, 46485.66)
Multiracial	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	54	0.27 (0.27, 0.27)	27584.18 (15110.76, 50353.99)	101412.42 (55554.26, 185124.95)
Multiracial	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	54	0.09 (0.09, 0.09)	16593.57 (9214.59, 29881.56)	184372.95 (102384.38, 332017.31)
Multiracial	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	54	5.03 (4.97, 5.10)	572.70 (247.09, 1327.39)	113.77 (49.14, 263.42)
Multiracial	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	54	5.25 (4.79, 5.75)	729.52 (536.14, 992.66)	139.02 (102.97, 187.69)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Multiracial	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	15	0.02 (0.02, 0.02)	483.18 (173.52, 1345.44)	20132.53 (7230.10, 56059.92)
Multiracial	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	15	0.27 (0.27, 0.27)	46801.40 (17914.69, 122266.73)	172063.98 (65862.85, 449510.05)
Multiracial	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	15	0.09 (0.09, 0.09)	27638.16 (12232.55, 62445.54)	307090.71 (135917.21, 693839.30)
Multiracial	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	15	5.13 (4.88, 5.39)	1706.98 (755.16, 3858.51)	332.81 (146.43, 756.42)
Multiracial	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	15	5.00 (5.00, 5.00)	1215.80 (1072.87, 1377.77)	243.16 (214.57, 275.55)
Multiracial	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	11	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Multiracial	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	11	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Multiracial	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	11	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Multiracial	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	11	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Multiracial	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	11	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Multiracial	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	22	0.02 (0.02, 0.02)	559.74 (173.26, 1808.31)	23322.51 (7219.20, 75346.22)
Multiracial	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	22	0.27 (0.27, 0.27)	15441.15 (5454.94, 43708.89)	56768.94 (20054.91, 160694.43)
Multiracial	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	22	0.09 (0.09, 0.09)	8913.59 (3494.22, 22738.11)	99039.86 (38824.70, 252645.69)
Multiracial	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	22	5.00 (5.00, 5.00)	432.56 (162.68, 1150.13)	86.51 (32.54, 230.03)
Multiracial	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	22	5.00 (5.00, 5.00)	890.99 (670.22, 1184.47)	178.20 (134.04, 236.89)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Other	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	21	0.02 (0.02, 0.02)	267.80 (87.02, 824.09)	11158.22 (3625.97, 34337.26)
Other	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	21	0.27 (0.27, 0.27)	2017.48 (874.19, 4656.01)	7417.21 (3213.92, 17117.69)
Other	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	21	0.09 (0.09, 0.09)	1046.60 (639.17, 1713.73)	11628.85 (7101.89, 19041.44)
Other	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	21	5.00 (5.00, 5.00)	529.71 (274.00, 1024.07)	105.94 (54.80, 204.81)
Other	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	21	5.00 (5.00, 5.00)	383.37 (197.37, 744.64)	76.67 (39.47, 148.93)
Other	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	1	0.02 (0.02, 0.02)	75.29 (75.29, 75.29)	3136.90 (3136.90, 3136.90)
Other	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	1	0.27 (0.27, 0.27)	237.61 (237.61, 237.61)	873.57 (873.57, 873.57)
Other	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	1	0.09 (0.09, 0.09)	145.29 (145.29, 145.29)	1614.36 (1614.36, 1614.36)
Other	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	1	5.00 (5.00, 5.00)	85.04 (85.04, 85.04)	17.01 (17.01, 17.01)
Other	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	1	5.00 (5.00, 5.00)	30.12 (30.12, 30.12)	6.02 (6.02, 6.02)
Other	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	4	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Other	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Other	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Other	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	4	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Other	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	4	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Other	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	9	0.02 (0.02, 0.02)	32.42 (9.26, 113.47)	1350.79 (385.94, 4727.81)
Other	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	9	0.27 (0.27, 0.27)	587.28 (203.04, 1698.69)	2159.13 (746.47, 6245.20)
Other	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	9	0.09 (0.09, 0.09)	158.89 (57.97, 435.49)	1765.47 (644.15, 4838.76)
Other	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	9	5.00 (5.00, 5.00)	86.41 (26.90, 277.60)	17.28 (5.38, 55.52)
Other	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	9	5.00 (5.00, 5.00)	111.41 (41.19, 301.36)	22.28 (8.24, 60.27)
Other	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	21	0.02 (0.02, 0.02)	2300.07 (671.84, 7874.34)	95836.28 (27993.50, 328097.36)
Other	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	21	0.27 (0.27, 0.27)	66098.27 (26023.07, 167888.80)	243008.36 (95673.05, 617238.22)
Other	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	21	0.09 (0.09, 0.09)	44752.53 (22047.07, 90841.47)	497250.29 (244967.49, 1009349.63)
Other	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	21	5.00 (5.00, 5.00)	3023.49 (1736.08, 5265.61)	604.70 (347.22, 1053.12)
Other	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	21	5.00 (5.00, 5.00)	1120.63 (907.27, 1384.16)	224.13 (181.45, 276.83)
Other	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	1	0.02 (0.02, 0.02)	1357.72 (1357.72, 1357.72)	56571.80 (56571.80, 56571.80)
Other	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	1	0.27 (0.27, 0.27)	6363.10 (6363.10, 6363.10)	23393.76 (23393.76, 23393.76)
Other	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	1	0.09 (0.09, 0.09)	4151.86 (4151.86, 4151.86)	46131.76 (46131.76, 46131.76)
Other	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	1	5.00 (5.00, 5.00)	82.28 (82.28, 82.28)	16.46 (16.46, 16.46)
Other	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	1	5.00 (5.00, 5.00)	1295.00 (1295.00, 1295.00)	259.00 (259.00, 259.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Other	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	4	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Other	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	4	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Other	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	4	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Other	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	4	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Other	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	4	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Other	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	9	0.02 (0.02, 0.02)	205.61 (48.86, 865.24)	8566.90 (2035.74, 36051.76)
Other	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	9	0.27 (0.27, 0.27)	10168.15 (2238.28, 46192.24)	37382.91 (8228.98, 169824.42)
Other	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	9	0.09 (0.09, 0.09)	10187.96 (3280.66, 31638.33)	113199.52 (36451.72, 351537.02)
Other	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	9	5.00 (5.00, 5.00)	573.37 (92.57, 3551.49)	114.67 (18.51, 710.30)
Other	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	9	5.00 (5.00, 5.00)	500.06 (161.56, 1547.83)	100.01 (32.31, 309.57)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	85	0.02 (0.02, 0.02)	77.15 (38.54, 154.43)	3214.58 (1605.91, 6434.71)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	85	0.27 (0.27, 0.27)	773.81 (475.84, 1258.35)	2844.87 (1749.41, 4626.30)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	85	0.09 (0.09, 0.09)	388.65 (243.31, 620.82)	4293.52 (2689.25, 6854.82)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	85	5.04 (4.96, 5.13)	132.53 (70.21, 250.15)	26.28 (13.93, 49.57)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not reported and unknown	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	85	5.25 (4.82, 5.71)	190.32 (111.02, 326.28)	36.27 (21.44, 61.36)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	22	0.02 (0.02, 0.02)	110.74 (60.17, 203.82)	4614.20 (2507.02, 8492.47)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	22	0.27 (0.27, 0.27)	1256.62 (639.53, 2469.18)	4619.94 (2351.20, 9077.86)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	22	0.09 (0.09, 0.09)	613.58 (354.20, 1062.89)	6817.51 (3935.54, 11809.93)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	22	5.00 (5.00, 5.00)	148.38 (95.59, 230.34)	29.68 (19.12, 46.07)
Not reported and unknown	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	22	5.00 (5.00, 5.00)	190.95 (91.18, 399.93)	38.19 (18.24, 79.99)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	18	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	18	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	18	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	18	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	18	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	23	0.02 (0.02, 0.02)	33.36 (10.78, 103.23)	1390.17 (449.28, 4301.46)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	23	0.27 (0.27, 0.27)	490.91 (170.10, 1416.74)	1804.81 (625.38, 5208.61)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	23	0.09 (0.09, 0.09)	273.52 (114.27, 654.68)	3039.11 (1269.71, 7274.26)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	23	5.00 (5.00, 5.00)	53.98 (14.45, 201.69)	10.80 (2.89, 40.34)
Not reported and unknown	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	23	5.19 (4.82, 5.59)	160.32 (53.58, 479.67)	30.88 (10.37, 91.98)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	85	0.02 (0.02, 0.02)	1092.65 (498.45, 2395.15)	45526.90 (20768.94, 99797.96)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	85	0.27 (0.27, 0.27)	38874.41 (21745.70, 69495.12)	142920.63 (79947.42, 255496.75)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	85	0.09 (0.09, 0.09)	20946.43 (12193.67, 35982.03)	231401.42 (134753.32, 397367.72)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	85	5.04 (4.96, 5.13)	1180.05 (690.75, 2015.96)	234.01 (137.06, 399.54)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	85	5.25 (4.82, 5.71)	766.35 (593.58, 989.40)	146.05 (112.80, 189.08)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	22	0.02 (0.02, 0.02)	1761.08 (1204.88, 2574.04)	73378.43 (50203.26, 107251.86)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	22	0.27 (0.27, 0.27)	49553.86 (27943.73, 87876.07)	182183.32 (102734.30, 323073.78)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	22	0.09 (0.09, 0.09)	35543.09 (17595.77, 71796.29)	394923.19 (195508.55, 797736.58)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	22	5.00 (5.00, 5.00)	2516.73 (1687.39, 3753.68)	503.35 (337.48, 750.74)
Not reported and unknown	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	22	5.00 (5.00, 5.00)	1165.95 (998.67, 1361.26)	233.19 (199.73, 272.25)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	18	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	18	0.27 (0.27, 0.27)	0.28 (0.27, 0.29)	1.02 (0.98, 1.07)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	18	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	18	5.00 (5.00, 5.00)	5.10 (4.90, 5.32)	1.02 (0.98, 1.06)
Not reported and unknown	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	18	5.00 (5.00, 5.00)	5.11 (4.89, 5.33)	1.02 (0.98, 1.07)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	23	0.02 (0.02, 0.02)	985.10 (348.18, 2787.08)	41045.75 (14507.69, 116128.36)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	23	0.27 (0.27, 0.27)	17978.90 (9051.03, 35713.17)	66098.90 (33275.83, 131298.44)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	23	0.09 (0.09, 0.09)	10481.80 (4573.44, 24023.07)	116464.40 (50815.98, 266923.03)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	23	5.00 (5.00, 5.00)	505.69 (174.07, 1469.14)	101.14 (34.81, 293.83)
Not reported and unknown	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	23	5.19 (4.82, 5.59)	715.15 (310.89, 1645.10)	137.76 (59.75, 317.59)

Table 6i. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Underrepresented minority status								
Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	424	0.02 (0.02, 0.02)	48.62 (37.95, 62.30)	2026.00 (1581.16, 2596.01)
Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	424	0.27 (0.27, 0.27)	620.12 (497.65, 772.73)	2279.84 (1829.58, 2840.91)
Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	424	0.09 (0.09, 0.09)	411.57 (345.98, 489.61)	4573.03 (3844.17, 5440.08)
Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	424	5.05 (5.01, 5.08)	94.00 (74.52, 118.56)	18.63 (14.77, 23.49)
Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	424	5.10 (5.02, 5.19)	166.34 (136.37, 202.89)	32.60 (26.77, 39.71)
Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	120	0.02 (0.02, 0.02)	85.46 (56.04, 130.32)	3560.63 (2334.83, 5429.99)
Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	120	0.27 (0.27, 0.27)	1034.01 (721.44, 1482.01)	3790.26 (2644.67, 5432.09)
Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	120	0.09 (0.09, 0.09)	623.25 (467.77, 830.42)	6925.04 (5197.42, 9226.91)
Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	120	5.02 (4.98, 5.06)	171.64 (112.97, 260.78)	34.18 (22.49, 51.96)
Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	120	5.03 (4.99, 5.08)	237.95 (162.81, 347.76)	47.27 (32.35, 69.07)
Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	63	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	63	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	63	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.02 (0.99, 1.04)
Communities of Color	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	63	5.07 (4.93, 5.22)	5.00 (5.00, 5.00)	0.99 (0.96, 1.01)
Communities of Color	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	63	5.06 (4.95, 5.17)	5.00 (5.00, 5.00)	0.99 (0.97, 1.01)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	124	0.02 (0.02, 0.02)	49.62 (34.94, 70.46)	2067.47 (1455.99, 2935.76)
Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	124	0.28 (0.27, 0.29)	495.72 (376.43, 652.82)	1784.33 (1333.56, 2387.46)
Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	124	0.09 (0.09, 0.09)	205.15 (154.75, 271.97)	2279.48 (1719.47, 3021.88)
Communities of Color	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	124	5.00 (5.00, 5.00)	73.87 (49.45, 110.35)	14.77 (9.89, 22.07)
Communities of Color	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	124	5.00 (5.00, 5.00)	153.75 (104.52, 226.17)	30.75 (20.90, 45.23)
Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	424	0.02 (0.02, 0.02)	774.71 (579.98, 1034.82)	32279.44 (24165.66, 43117.46)
Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	424	0.27 (0.27, 0.27)	27241.35 (21864.28, 33940.79)	100152.01 (80383.40, 124782.30)
Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	424	0.09 (0.09, 0.09)	18698.21 (15574.38, 22448.59)	207757.85 (173048.71, 249428.76)
Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	424	5.05 (5.01, 5.08)	817.67 (646.79, 1033.68)	162.06 (128.21, 204.86)
Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	424	5.10 (5.02, 5.19)	771.84 (678.09, 878.56)	151.28 (132.94, 172.14)
Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	120	0.02 (0.02, 0.02)	1685.08 (1001.61, 2834.93)	70211.71 (41733.81, 118122.09)
Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	120	0.27 (0.27, 0.27)	63394.56 (42857.04, 93773.88)	232377.96 (157083.94, 343762.16)
Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	120	0.09 (0.09, 0.09)	37702.50 (27078.22, 52495.27)	418916.66 (300869.08, 583280.83)
Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	120	5.02 (4.98, 5.06)	1711.69 (1260.86, 2323.72)	340.90 (250.99, 463.00)
Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	120	5.03 (4.99, 5.08)	1143.39 (1029.28, 1270.14)	227.15 (204.41, 252.41)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	63	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	63	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	63	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Communities of Color	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	63	5.07 (4.93, 5.22)	5.00 (5.00, 5.00)	0.99 (0.96, 1.01)
Communities of Color	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	63	5.06 (4.95, 5.17)	5.00 (5.00, 5.00)	0.99 (0.97, 1.01)
Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	124	0.02 (0.02, 0.02)	512.68 (321.95, 816.39)	21361.65 (13414.78, 34016.23)
Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	124	0.28 (0.27, 0.29)	20524.99 (14310.79, 29437.60)	73878.78 (50962.76, 107099.29)
Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	124	0.09 (0.09, 0.09)	11316.46 (7907.61, 16194.82)	125738.46 (87862.29, 179942.50)
Communities of Color	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	124	5.00 (5.00, 5.00)	477.19 (294.63, 772.87)	95.44 (58.93, 154.57)
Communities of Color	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	124	5.00 (5.00, 5.00)	614.24 (457.65, 824.40)	122.85 (91.53, 164.88)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	355	0.02 (0.02, 0.02)	69.71 (54.55, 89.08)	2904.49 (2272.85, 3711.65)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	355	0.27 (0.27, 0.27)	851.96 (683.58, 1061.81)	3132.19 (2513.16, 3903.70)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	355	0.09 (0.09, 0.09)	457.39 (378.96, 552.07)	5082.15 (4210.63, 6134.07)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	355	5.04 (5.00, 5.07)	126.36 (99.23, 160.92)	25.07 (19.69, 31.92)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	355	5.18 (5.04, 5.33)	217.51 (176.19, 268.54)	42.00 (34.11, 51.71)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	121	0.02 (0.02, 0.02)	77.05 (48.18, 123.22)	3210.56 (2007.62, 5134.30)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	121	0.27 (0.27, 0.27)	1042.78 (719.00, 1512.35)	3833.74 (2643.39, 5560.12)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	121	0.09 (0.09, 0.09)	675.98 (483.56, 944.98)	7510.94 (5372.88, 10499.82)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	121	5.04 (4.98, 5.09)	134.49 (91.52, 197.63)	26.69 (18.16, 39.23)
White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	121	5.12 (4.89, 5.37)	274.51 (190.56, 395.46)	53.58 (37.46, 76.65)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	64	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	64	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	64	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	64	5.11 (4.96, 5.26)	5.18 (4.89, 5.49)	1.01 (0.95, 1.08)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	64	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	116	0.02 (0.02, 0.02)	25.31 (16.85, 38.02)	1054.73 (702.26, 1584.10)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	116	0.27 (0.27, 0.27)	210.89 (142.33, 312.47)	775.34 (523.29, 1148.80)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	116	0.09 (0.09, 0.09)	127.97 (94.16, 173.92)	1421.87 (1046.21, 1932.41)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	116	5.19 (4.93, 5.47)	48.07 (32.44, 71.22)	9.26 (6.23, 13.75)
White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	116	5.24 (4.92, 5.59)	140.69 (97.98, 202.01)	26.82 (18.53, 38.83)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	355	0.02 (0.02, 0.02)	1044.69 (761.89, 1432.46)	43528.57 (31745.26, 59685.65)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	355	0.27 (0.27, 0.27)	36435.10 (28737.15, 46195.14)	133952.59 (105651.29, 169835.08)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	355	0.09 (0.09, 0.09)	25205.17 (20626.81, 30799.75)	280057.47 (229186.83, 342219.43)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	355	5.04 (5.00, 5.07)	1228.38 (982.72, 1535.45)	243.75 (195.01, 304.66)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	355	5.18 (5.04, 5.33)	810.89 (707.90, 928.88)	156.57 (136.62, 179.43)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	121	0.02 (0.02, 0.02)	2213.21 (1336.74, 3664.34)	92216.92 (55697.64, 152680.79)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	121	0.27 (0.27, 0.27)	70335.26 (47398.85, 104370.64)	258585.50 (174260.47, 383715.60)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	121	0.09 (0.09, 0.09)	50675.29 (37092.29, 69232.30)	563058.72 (412136.55, 769247.78)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	121	5.04 (4.98, 5.09)	1892.63 (1423.38, 2516.58)	375.60 (282.48, 499.42)
White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	121	5.12 (4.89, 5.37)	961.03 (795.48, 1161.03)	187.59 (155.07, 226.92)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	64	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	64	0.27 (0.27, 0.27)	0.28 (0.27, 0.28)	1.02 (0.99, 1.04)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	64	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	64	5.11 (4.96, 5.26)	5.03 (4.97, 5.09)	0.98 (0.95, 1.02)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	64	5.00 (5.00, 5.00)	5.08 (4.97, 5.19)	1.02 (0.99, 1.04)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	116	0.02 (0.02, 0.02)	277.45 (178.97, 430.10)	11560.27 (7457.29, 17920.70)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	116	0.27 (0.27, 0.27)	9241.19 (6112.15, 13972.11)	33974.96 (22471.12, 51368.05)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	116	0.09 (0.09, 0.09)	6530.55 (4820.40, 8847.43)	72561.72 (53559.97, 98304.82)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	116	5.19 (4.93, 5.47)	457.87 (282.73, 741.51)	88.17 (54.67, 142.20)
White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	116	5.24 (4.92, 5.59)	581.23 (447.81, 754.40)	110.82 (84.33, 145.64)




Table 6j. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, Underrepresented minority status

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age, Underrepresented minority status								
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	203	0.02 (0.02, 0.02)	35.10 (25.78, 47.78)	1462.31 (1074.11, 1990.82)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	203	0.27 (0.27, 0.27)	457.32 (347.73, 601.46)	1681.33 (1278.40, 2211.26)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	203	0.09 (0.09, 0.09)	301.12 (242.80, 373.46)	3345.83 (2697.78, 4149.55)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	203	5.02 (4.99, 5.05)	71.12 (53.27, 94.95)	14.17 (10.61, 18.91)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	203	5.09 (4.99, 5.20)	137.79 (107.57, 176.50)	27.06 (21.16, 34.59)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	66	0.02 (0.02, 0.02)	67.04 (40.26, 111.64)	2793.37 (1677.42, 4651.76)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	66	0.27 (0.27, 0.27)	785.84 (509.91, 1211.08)	2889.10 (1874.66, 4452.49)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	66	0.09 (0.09, 0.09)	477.06 (338.24, 672.86)	5300.68 (3758.24, 7476.17)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	66	5.03 (4.98, 5.08)	141.65 (85.33, 235.13)	28.18 (16.97, 46.81)
Age < 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	66	5.00 (5.00, 5.00)	203.23 (128.13, 322.36)	40.65 (25.63, 64.47)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	29	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	29	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	29	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.01 (0.99, 1.04)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	29	5.10 (4.91, 5.29)	5.00 (5.00, 5.00)	0.98 (0.95, 1.02)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	29	5.07 (4.93, 5.23)	5.00 (5.00, 5.00)	0.99 (0.96, 1.01)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	66	0.02 (0.02, 0.02)	44.74 (29.05, 68.91)	1864.07 (1210.28, 2871.06)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	66	0.28 (0.26, 0.30)	421.42 (299.53, 592.92)	1506.46 (1047.11, 2167.31)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	66	0.09 (0.09, 0.09)	162.56 (114.18, 231.43)	1806.20 (1268.71, 2571.39)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	66	5.00 (5.00, 5.00)	66.65 (39.96, 111.15)	13.33 (7.99, 22.23)
Age < 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	66	5.00 (5.00, 5.00)	149.80 (91.54, 245.16)	29.96 (18.31, 49.03)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	203	0.02 (0.02, 0.02)	573.44 (400.05, 821.98)	23893.46 (16668.85, 34249.37)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	203	0.27 (0.27, 0.27)	19732.41 (15024.14, 25916.16)	72545.62 (55235.81, 95279.99)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	203	0.09 (0.09, 0.09)	13918.06 (11091.08, 17465.61)	154645.16 (123234.23, 194062.35)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	203	5.02 (4.99, 5.05)	654.79 (488.18, 878.25)	130.42 (97.24, 174.90)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	203	5.09 (4.99, 5.20)	721.51 (613.35, 848.75)	141.67 (120.49, 166.57)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	66	0.02 (0.02, 0.02)	1267.45 (673.93, 2383.66)	52810.43 (28080.58, 99319.22)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	66	0.27 (0.27, 0.27)	48327.69 (30091.49, 77615.49)	177675.35 (110630.49, 285351.06)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	66	0.09 (0.09, 0.09)	29299.82 (19581.06, 43842.32)	325553.51 (217567.33, 487136.94)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	66	5.03 (4.98, 5.08)	1495.40 (1028.98, 2173.23)	297.52 (204.61, 432.63)
Age < 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	66	5.00 (5.00, 5.00)	1128.59 (991.94, 1284.07)	225.72 (198.39, 256.81)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	29	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	29	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	29	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	29	5.10 (4.91, 5.29)	5.00 (5.00, 5.00)	0.98 (0.95, 1.02)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	29	5.07 (4.93, 5.23)	5.00 (5.00, 5.00)	0.99 (0.96, 1.01)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	66	0.02 (0.02, 0.02)	436.86 (242.39, 787.35)	18202.60 (10099.77, 32806.16)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	66	0.28 (0.26, 0.30)	18408.36 (11677.02, 29020.05)	65804.19 (41128.21, 105285.19)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	66	0.09 (0.09, 0.09)	9505.76 (5985.27, 15096.96)	105619.51 (66503.01, 167744.00)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	66	5.00 (5.00, 5.00)	361.05 (193.83, 672.53)	72.21 (38.77, 134.51)
Age < 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	66	5.00 (5.00, 5.00)	581.07 (398.22, 847.86)	116.21 (79.64, 169.57)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	177	0.02 (0.02, 0.02)	55.39 (40.98, 74.87)	2307.87 (1707.36, 3119.59)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	177	0.27 (0.27, 0.27)	668.94 (510.31, 876.89)	2459.34 (1876.13, 3223.86)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	177	0.09 (0.09, 0.09)	357.78 (284.42, 450.06)	3975.29 (3160.18, 5000.65)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	177	5.04 (5.00, 5.09)	102.20 (75.95, 137.52)	20.26 (15.06, 27.26)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	177	5.18 (5.01, 5.36)	194.70 (150.00, 252.73)	37.58 (29.05, 48.61)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	57	0.02 (0.02, 0.02)	53.74 (30.04, 96.12)	2239.11 (1251.77, 4005.20)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	57	0.27 (0.27, 0.27)	790.08 (497.54, 1254.63)	2904.72 (1829.20, 4612.61)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	57	0.09 (0.09, 0.09)	496.01 (327.46, 751.32)	5511.25 (3638.48, 8347.96)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	57	5.03 (4.97, 5.09)	94.80 (59.19, 151.84)	18.85 (11.76, 30.21)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	57	5.16 (4.85, 5.48)	232.72 (146.88, 368.73)	45.11 (28.74, 70.80)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	31	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	31	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	31	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	31	5.07 (4.94, 5.20)	5.20 (4.82, 5.62)	1.03 (0.95, 1.11)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	31	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	61	0.02 (0.02, 0.02)	18.86 (11.62, 30.62)	785.98 (484.19, 1275.88)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	61	0.27 (0.27, 0.27)	144.34 (90.52, 230.17)	530.67 (332.78, 846.22)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	61	0.09 (0.09, 0.09)	87.15 (60.97, 124.58)	968.33 (677.41, 1384.18)
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	61	5.24 (4.91, 5.59)	36.07 (22.56, 57.67)	6.88 (4.29, 11.04)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	61	5.29 (4.89, 5.72)	121.94 (78.69, 188.96)	23.07 (14.73, 36.12)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	177	0.02 (0.02, 0.02)	837.41 (567.11, 1236.53)	34892.10 (23629.79, 51522.19)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	177	0.27 (0.27, 0.27)	29343.43 (21901.35, 39314.34)	107880.27 (80519.67, 144538.00)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	177	0.09 (0.09, 0.09)	21011.62 (16421.53, 26884.72)	233462.46 (182461.46, 298719.08)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	177	5.04 (5.00, 5.09)	1083.80 (821.28, 1430.23)	214.88 (162.85, 283.55)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	177	5.18 (5.01, 5.36)	775.43 (654.62, 918.52)	149.66 (126.28, 177.36)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	57	0.02 (0.02, 0.02)	1651.20 (876.59, 3110.31)	68800.10 (36524.66, 129596.10)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	57	0.27 (0.27, 0.27)	52698.61 (32118.50, 86465.56)	193744.90 (118082.70, 317888.09)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	57	0.09 (0.09, 0.09)	39615.10 (26730.87, 58709.51)	440167.82 (297009.72, 652327.85)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	57	5.03 (4.97, 5.09)	1612.80 (1124.20, 2313.76)	320.64 (223.49, 460.02)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	57	5.16 (4.85, 5.48)	905.79 (712.35, 1151.76)	175.58 (137.88, 223.59)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	31	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	31	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	31	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	31	5.07 (4.94, 5.20)	5.00 (5.00, 5.00)	0.99 (0.96, 1.01)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	31	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	61	0.02 (0.02, 0.02)	184.40 (109.92, 309.37)	7683.51 (4579.85, 12890.44)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	61	0.27 (0.27, 0.27)	6337.83 (3870.94, 10376.84)	23300.85 (14231.38, 38150.16)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	61	0.09 (0.09, 0.09)	4830.98 (3371.45, 6922.33)	53677.50 (37460.59, 76914.80)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	61	5.24 (4.91, 5.59)	323.36 (180.12, 580.50)	61.72 (34.57, 110.17)
Age < 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	61	5.29 (4.89, 5.72)	528.03 (385.10, 724.01)	99.89 (71.73, 139.11)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	221	0.02 (0.02, 0.02)	161.04 (128.67, 201.54)	6709.83 (5361.37, 8397.46)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	221	0.27 (0.27, 0.27)	1897.60 (1562.13, 2305.12)	6976.48 (5743.11, 8474.72)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	221	0.09 (0.09, 0.09)	1296.72 (1103.57, 1523.67)	14407.97 (12261.86, 16929.69)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age \geq 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	221	5.14 (5.01, 5.27)	261.75 (211.61, 323.78)	50.96 (41.34, 62.81)
Age \geq 65 Communities of Color	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	221	5.14 (4.99, 5.29)	332.15 (277.76, 397.19)	64.66 (54.08, 77.31)
Age \geq 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	54	0.02 (0.02, 0.02)	237.29 (156.57, 359.63)	9887.26 (6523.91, 14984.55)
Age \geq 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	54	0.28 (0.27, 0.28)	3281.99 (2271.10, 4742.84)	11881.17 (8219.55, 17173.97)
Age \geq 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	54	0.09 (0.09, 0.09)	1919.60 (1454.20, 2533.94)	21328.90 (16157.82, 28154.92)
Age \geq 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	54	5.00 (5.00, 5.00)	385.20 (256.78, 577.84)	77.04 (51.36, 115.57)
Age \geq 65 Communities of Color	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	54	5.18 (4.94, 5.43)	462.04 (328.86, 649.14)	89.23 (63.76, 124.88)
Age \geq 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	34	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age \geq 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	34	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age \geq 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	34	0.09 (0.09, 0.09)	0.09 (0.09, 0.10)	1.02 (0.98, 1.08)
Age \geq 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	34	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age \geq 65 Communities of Color	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	34	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	58	0.02 (0.02, 0.02)	68.17 (40.39, 115.05)	2840.33 (1682.85, 4793.94)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	58	0.27 (0.27, 0.27)	815.63 (557.34, 1193.63)	2998.65 (2049.05, 4388.33)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	58	0.09 (0.09, 0.09)	418.82 (297.74, 589.15)	4653.57 (3308.20, 6546.07)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	58	5.00 (5.00, 5.00)	101.29 (64.91, 158.04)	20.26 (12.98, 31.61)
Age ≥ 65 Communities of Color	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	58	5.00 (5.00, 5.00)	166.51 (108.77, 254.91)	33.30 (21.75, 50.98)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	221	0.02 (0.02, 0.02)	2338.70 (1779.47, 3073.68)	97445.93 (74144.57, 128070.20)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	221	0.27 (0.27, 0.27)	89042.34 (71881.88, 110299.55)	327361.56 (264271.62, 405513.04)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	221	0.09 (0.09, 0.09)	55300.46 (46772.64, 65383.11)	614449.51 (519695.95, 726479.01)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	221	5.14 (5.01, 5.27)	1848.87 (1539.61, 2220.25)	359.95 (299.88, 432.06)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	221	5.14 (4.99, 5.29)	988.75 (894.42, 1093.04)	192.49 (173.64, 213.38)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	54	0.02 (0.02, 0.02)	5586.62 (3555.82, 8777.25)	232775.78 (148159.14, 365718.68)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	54	0.28 (0.27, 0.28)	198622.80 (140812.45, 280167.10)	719036.49 (507529.17, 1018687.21)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	54	0.09 (0.09, 0.09)	108944.36 (89269.24, 132955.92)	1210492.93 (991880.47, 1477288.03)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	54	5.00 (5.00, 5.00)	3022.19 (2449.99, 3728.02)	604.44 (490.00, 745.60)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	54	5.18 (4.94, 5.43)	1207.81 (1127.83, 1293.47)	233.26 (214.99, 253.08)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	34	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	34	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	34	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	34	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	34	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	58	0.02 (0.02, 0.02)	837.50 (482.22, 1454.52)	34895.76 (20092.57, 60605.18)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	58	0.27 (0.27, 0.27)	28657.50 (18388.19, 44661.94)	105358.47 (67603.66, 164198.31)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	58	0.09 (0.09, 0.09)	19316.61 (14117.67, 26430.09)	214629.00 (156863.04, 293667.69)
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	58	5.00 (5.00, 5.00)	1122.30 (742.14, 1697.21)	224.46 (148.43, 339.44)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 Communities of Color	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	58	5.00 (5.00, 5.00)	728.24 (541.27, 979.80)	145.65 (108.25, 195.96)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	178	0.02 (0.02, 0.02)	167.00 (129.64, 215.14)	6958.48 (5401.46, 8964.34)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	178	0.27 (0.27, 0.27)	2135.58 (1712.90, 2662.56)	7851.39 (6297.43, 9788.81)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	178	0.09 (0.09, 0.09)	1163.20 (943.92, 1433.41)	12924.43 (10488.05, 15926.77)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	178	5.02 (4.98, 5.07)	283.03 (219.38, 365.16)	56.34 (43.64, 72.73)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	178	5.17 (5.02, 5.32)	331.39 (272.22, 403.43)	64.09 (52.79, 77.82)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	64	0.02 (0.02, 0.02)	270.81 (175.40, 418.11)	11283.70 (7308.34, 17421.46)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	64	0.27 (0.27, 0.27)	2745.01 (1949.23, 3865.67)	10091.95 (7166.28, 14212.03)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	64	0.09 (0.09, 0.09)	1990.03 (1494.71, 2649.48)	22111.45 (16607.94, 29438.70)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	64	5.07 (4.93, 5.21)	455.38 (303.46, 683.36)	89.81 (60.04, 134.33)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	64	5.00 (5.00, 5.00)	488.38 (368.60, 647.09)	97.68 (73.72, 129.42)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	33	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	33	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	33	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	33	5.23 (4.79, 5.71)	5.12 (4.89, 5.37)	0.98 (0.89, 1.08)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	33	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	55	0.02 (0.02, 0.02)	88.12 (54.62, 142.16)	3671.69 (2276.04, 5923.13)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	55	0.27 (0.27, 0.27)	1053.05 (704.65, 1573.72)	3871.52 (2590.63, 5785.73)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	55	0.09 (0.09, 0.09)	652.65 (460.03, 925.93)	7251.70 (5111.47, 10288.07)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	55	5.00 (5.00, 5.00)	162.42 (104.14, 253.31)	32.48 (20.83, 50.66)
Age ≥ 65 White Non-Hispanic	D29 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	55	5.07 (4.93, 5.22)	258.06 (181.76, 366.39)	50.86 (35.95, 71.96)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti N IgG (IU/ml)	178	0.02 (0.02, 0.02)	2420.76 (1777.81, 3296.22)	100864.87 (74075.51, 137342.57)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti RBD IgG (IU/ml)	178	0.27 (0.27, 0.27)	82935.48 (65873.73, 104416.34)	304909.85 (242182.83, 383883.61)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Anti Spike IgG (IU/ml)	178	0.09 (0.09, 0.09)	50325.96 (40914.21, 61902.76)	559177.37 (454602.35, 687808.42)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID50	178	5.02 (4.98, 5.07)	1976.84 (1645.30, 2375.19)	393.50 (327.35, 473.01)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Negative	Pseudovirus-nAb ID80	178	5.17 (5.02, 5.32)	961.10 (866.03, 1066.60)	185.89 (167.15, 206.71)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti N IgG (IU/ml)	64	0.02 (0.02, 0.02)	6148.26 (4069.75, 9288.30)	256177.39 (169572.91, 387012.64)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti RBD IgG (IU/ml)	64	0.27 (0.27, 0.27)	192512.51 (145245.72, 255161.18)	707766.60 (533991.61, 938092.57)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Anti Spike IgG (IU/ml)	64	0.09 (0.09, 0.09)	119611.06 (102347.32, 139786.82)	1329011.83 (1137192.48, 1553186.87)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID50	64	5.07 (4.93, 5.21)	3306.86 (2785.89, 3925.26)	652.17 (549.01, 774.72)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Vaccine	Positive	Pseudovirus-nAb ID80	64	5.00 (5.00, 5.00)	1181.40 (1056.92, 1320.55)	236.28 (211.38, 264.11)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti N IgG (IU/ml)	33	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti RBD IgG (IU/ml)	33	0.27 (0.27, 0.27)	0.29 (0.27, 0.31)	1.06 (0.98, 1.15)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Anti Spike IgG (IU/ml)	33	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID50	33	5.23 (4.79, 5.71)	5.12 (4.89, 5.35)	0.98 (0.89, 1.08)
Age ≥ 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Negative	Pseudovirus-nAb ID80	33	5.00 (5.00, 5.00)	5.31 (4.89, 5.76)	1.06 (0.98, 1.15)

(continued)

Group	Visit	Arm	Baseline SARS-CoV-2	Marker	N	Baseline GMT/GMC	Post Baseline GMT/GMC	GMTR/GMCR
Age \geq 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti N IgG (IU/ml)	55	0.02 (0.02, 0.02)	1568.89 (919.65, 2676.47)	65370.38 (38318.78, 111519.41)
Age \geq 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti RBD IgG (IU/ml)	55	0.27 (0.27, 0.27)	45747.99 (30341.55, 68977.32)	168191.13 (111549.80, 253593.07)
Age \geq 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Anti Spike IgG (IU/ml)	55	0.09 (0.09, 0.09)	23451.99 (16867.71, 32606.42)	260577.62 (187419.01, 362293.52)
Age \geq 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID50	55	5.00 (5.00, 5.00)	2001.70 (1467.62, 2730.14)	400.34 (293.52, 546.03)
Age \geq 65 White Non-Hispanic	D57 fold-rise over D1	Placebo	Positive	Pseudovirus-nAb ID80	55	5.07 (4.93, 5.22)	873.31 (672.31, 1134.40)	172.13 (132.51, 223.59)

Table 7a. The ratios of GMTs/GMCs between groups by Age

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age							
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.01)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5.06 (5.01, 5.10)	5.07 (5.01, 5.13)	1.00 (0.98, 1.01)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5.14 (5.05, 5.23)	5.15 (5.04, 5.27)	1.00 (0.97, 1.03)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.28)	0.27 (0.27, 0.27)	1.01 (0.99, 1.02)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5.04 (4.96, 5.11)	5.02 (4.99, 5.06)	1.00 (0.99, 1.02)
Age ≥ 65 vs Age < 65	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5.06 (4.98, 5.14)	5.07 (4.93, 5.22)	1.00 (0.97, 1.03)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5.11 (4.89, 5.34)	5.06 (4.98, 5.14)	1.01 (0.96, 1.06)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.02 (4.98, 5.07)	1.00 (0.99, 1.00)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age ≥ 65 vs Age < 65	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.28)	0.99 (0.97, 1.01)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.13 (4.95, 5.32)	0.97 (0.94, 1.01)
Age ≥ 65 vs Age < 65	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5.04 (4.97, 5.10)	5.18 (4.95, 5.42)	0.97 (0.93, 1.02)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	157.96 (134.11, 186.05)	49.48 (39.93, 61.31)	3.19 (2.44, 4.18)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	2003.94 (1740.39, 2307.40)	601.50 (502.70, 719.72)	3.33 (2.65, 4.19)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	1207.29 (1064.30, 1369.49)	343.47 (294.48, 400.61)	3.51 (2.88, 4.29)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	261.49 (222.30, 307.60)	94.35 (77.13, 115.43)	2.77 (2.14, 3.59)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	325.70 (287.35, 369.18)	168.42 (140.81, 201.44)	1.93 (1.55, 2.41)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	270.01 (200.47, 363.68)	58.15 (41.19, 82.10)	4.64 (2.94, 7.32)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	3043.22 (2390.56, 3874.05)	747.42 (558.26, 1000.66)	4.07 (2.79, 5.95)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	1956.81 (1615.37, 2370.41)	482.24 (378.08, 615.10)	4.06 (2.98, 5.53)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	441.37 (335.16, 581.26)	111.36 (82.40, 150.49)	3.96 (2.64, 5.96)
Age ≥ 65 vs Age < 65	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	473.68 (388.74, 577.17)	213.95 (158.62, 288.57)	2.21 (1.55, 3.17)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age ≥ 65 vs Age < 65	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (0.99, 1.02)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5.06 (4.94, 5.18)	5.09 (4.92, 5.26)	0.99 (0.95, 1.04)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	83.73 (61.42, 114.13)	25.43 (18.13, 35.66)	3.29 (2.08, 5.21)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	1060.22 (819.23, 1372.09)	220.21 (160.47, 302.20)	4.81 (3.20, 7.24)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	570.26 (458.39, 709.44)	115.82 (89.55, 149.79)	4.92 (3.51, 6.90)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	141.75 (106.66, 188.39)	44.02 (30.99, 62.52)	3.22 (2.05, 5.06)
Age ≥ 65 vs Age < 65	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	221.47 (171.65, 285.77)	130.40 (94.72, 179.52)	1.70 (1.13, 2.56)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	2460.53 (2025.23, 2989.41)	733.10 (566.69, 948.39)	3.36 (2.43, 4.64)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	84018.56 (72438.21, 97450.20)	26634.96 (21956.62, 32310.13)	3.15 (2.47, 4.02)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	51847.95 (45512.24, 59065.64)	18271.32 (15460.07, 21593.77)	2.84 (2.30, 3.51)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	1979.85 (1753.25, 2235.73)	929.19 (768.12, 1124.03)	2.13 (1.70, 2.67)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	975.49 (911.97, 1043.43)	765.89 (687.32, 853.45)	1.27 (1.12, 1.45)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	5853.72 (4347.27, 7882.18)	1514.86 (1031.50, 2224.72)	3.86 (2.38, 6.28)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	186431.80 (151641.75, 229203.47)	48036.51 (35397.18, 65188.99)	3.88 (2.68, 5.61)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	115989.53 (103450.48, 130048.43)	33661.72 (25910.34, 43732.02)	3.45 (2.59, 4.58)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	3279.60 (2909.89, 3696.28)	1673.79 (1334.76, 2098.95)	1.96 (1.52, 2.53)
Age ≥ 65 vs Age < 65	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	1203.35 (1127.90, 1283.84)	1008.82 (888.79, 1145.06)	1.19 (1.03, 1.38)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	0.28 (0.27, 0.30)	0.27 (0.27, 0.27)	1.04 (1.00, 1.09)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5.19 (4.98, 5.41)	5.00 (5.00, 5.00)	1.04 (1.00, 1.08)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5.21 (4.98, 5.45)	5.00 (5.00, 5.00)	1.04 (1.00, 1.09)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	1250.50 (875.00, 1787.13)	278.96 (191.64, 406.09)	4.48 (2.67, 7.53)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	39096.03 (29650.90, 51549.86)	9984.20 (7103.43, 14033.26)	3.92 (2.53, 6.07)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	22852.60 (18500.67, 28228.25)	6184.92 (4705.38, 8129.67)	3.69 (2.62, 5.22)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	1646.62 (1311.92, 2066.72)	332.09 (221.26, 498.44)	4.96 (3.11, 7.90)
Age ≥ 65 vs Age < 65	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	856.08 (722.74, 1014.03)	557.94 (440.51, 706.67)	1.53 (1.15, 2.05)

Table 7b. The ratios of GMTs/GMCs between groups by Risk for Severe Covid-19

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Risk for Severe Covid-19							
At-risk vs Not at-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.01)
At-risk vs Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5.15 (5.06, 5.24)	5.04 (4.98, 5.10)	1.02 (1.00, 1.04)
At-risk vs Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5.16 (5.07, 5.25)	5.15 (5.03, 5.27)	1.00 (0.97, 1.03)
At-risk vs Not at-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5.08 (4.97, 5.18)	5.01 (4.99, 5.03)	1.01 (0.99, 1.04)
At-risk vs Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.09 (4.94, 5.25)	0.98 (0.95, 1.01)
At-risk vs Not at-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5.15 (4.94, 5.38)	5.04 (4.96, 5.11)	1.02 (0.98, 1.07)
At-risk vs Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5.06 (4.94, 5.19)	5.00 (5.00, 5.00)	1.01 (0.99, 1.04)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
At-risk vs Not at-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.28)	0.99 (0.97, 1.01)
At-risk vs Not at-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.14 (4.95, 5.33)	0.97 (0.94, 1.01)
At-risk vs Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5.11 (4.95, 5.28)	5.16 (4.93, 5.40)	0.99 (0.94, 1.05)
At-risk vs Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	67.46 (57.00, 79.84)	61.93 (49.31, 77.77)	1.09 (0.82, 1.45)
At-risk vs Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	841.10 (722.34, 979.38)	755.22 (624.42, 913.41)	1.11 (0.87, 1.42)
At-risk vs Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	495.50 (428.93, 572.41)	433.06 (368.18, 509.36)	1.14 (0.92, 1.42)
At-risk vs Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	121.68 (102.86, 143.94)	115.66 (93.41, 143.21)	1.05 (0.80, 1.38)
At-risk vs Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	218.15 (188.84, 252.00)	185.63 (153.69, 224.22)	1.18 (0.93, 1.49)
At-risk vs Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	132.96 (99.20, 178.21)	66.27 (45.97, 95.54)	2.01 (1.25, 3.21)
At-risk vs Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	1257.23 (946.57, 1669.85)	909.42 (669.45, 1235.39)	1.38 (0.91, 2.10)
At-risk vs Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	803.87 (630.99, 1024.11)	587.97 (455.33, 759.26)	1.37 (0.96, 1.95)
At-risk vs Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	234.48 (175.57, 313.16)	125.09 (91.08, 171.80)	1.87 (1.22, 2.88)
At-risk vs Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	321.34 (259.19, 398.39)	230.52 (168.09, 316.14)	1.39 (0.95, 2.04)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
At-risk vs Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.01 (0.99, 1.03)
At-risk vs Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5.05 (4.96, 5.14)	5.10 (4.91, 5.29)	0.99 (0.95, 1.03)
At-risk vs Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	39.92 (28.50, 55.92)	30.99 (21.96, 43.75)	1.29 (0.79, 2.09)
At-risk vs Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	477.57 (352.49, 647.04)	270.59 (195.86, 373.82)	1.76 (1.13, 2.76)
At-risk vs Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	251.11 (189.50, 332.74)	143.23 (110.23, 186.11)	1.75 (1.19, 2.59)
At-risk vs Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	65.19 (47.23, 89.97)	54.29 (37.98, 77.61)	1.20 (0.74, 1.95)
At-risk vs Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	143.05 (107.61, 190.16)	147.21 (106.42, 203.64)	0.97 (0.63, 1.50)
At-risk vs Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	997.20 (804.46, 1236.11)	931.80 (709.86, 1223.11)	1.07 (0.76, 1.52)
At-risk vs Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	35753.79 (29958.65, 42669.94)	33409.52 (27278.73, 40918.18)	1.07 (0.82, 1.40)
At-risk vs Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	23580.58 (20304.48, 27385.28)	22545.52 (18907.87, 26883.01)	1.05 (0.83, 1.32)
At-risk vs Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	1193.53 (1021.96, 1393.91)	1056.69 (865.07, 1290.75)	1.13 (0.88, 1.46)
At-risk vs Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	800.06 (727.31, 880.08)	808.73 (722.49, 905.26)	0.99 (0.85, 1.15)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
At-risk vs Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	2635.43 (1827.75, 3800.01)	1798.55 (1204.14, 2686.40)	1.47 (0.85, 2.53)
At-risk vs Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	83821.23 (63170.57, 111222.66)	57041.52 (41456.48, 78485.57)	1.47 (0.96, 2.26)
At-risk vs Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	58491.48 (47881.59, 71452.37)	38807.95 (29472.44, 51100.52)	1.51 (1.07, 2.12)
At-risk vs Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	2187.05 (1816.71, 2632.89)	1827.83 (1443.12, 2315.10)	1.20 (0.89, 1.62)
At-risk vs Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	1131.34 (1025.26, 1248.40)	1017.57 (891.59, 1161.35)	1.11 (0.94, 1.31)
At-risk vs Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	0.28 (0.27, 0.29)	0.27 (0.27, 0.27)	1.03 (1.00, 1.07)
At-risk vs Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
At-risk vs Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5.11 (4.96, 5.26)	5.02 (4.98, 5.05)	1.02 (0.99, 1.05)
At-risk vs Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5.06 (4.94, 5.18)	5.04 (4.98, 5.10)	1.00 (0.98, 1.03)
At-risk vs Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	408.78 (269.73, 619.51)	379.01 (259.03, 554.56)	1.08 (0.61, 1.90)
At-risk vs Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	15489.70 (10811.98, 22191.21)	12828.98 (9099.71, 18086.59)	1.21 (0.73, 1.99)
At-risk vs Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	10107.03 (7648.71, 13355.45)	7693.80 (5832.20, 10149.62)	1.31 (0.88, 1.95)
At-risk vs Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	601.53 (426.45, 848.48)	434.92 (288.21, 656.31)	1.38 (0.81, 2.37)
At-risk vs Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	589.31 (462.01, 751.67)	619.21 (489.12, 783.89)	0.95 (0.68, 1.34)

Table 7c. The ratios of GMTs/GMCs between groups by Age < 65, Risk for Severe Covid-19

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age < 65, Risk for Severe Covid-19							
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5.20 (5.06, 5.34)	5.04 (4.97, 5.11)	1.03 (1.00, 1.06)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5.12 (5.01, 5.23)	5.16 (5.02, 5.30)	0.99 (0.96, 1.03)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5.11 (4.95, 5.28)	5.00 (5.00, 5.00)	1.02 (0.99, 1.06)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.09 (4.91, 5.27)	0.98 (0.95, 1.02)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5.26 (4.90, 5.65)	5.00 (5.00, 5.00)	1.05 (0.98, 1.13)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5.11 (4.90, 5.32)	5.00 (5.00, 5.00)	1.02 (0.98, 1.06)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.28)	0.99 (0.97, 1.01)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.16 (4.94, 5.40)	0.97 (0.93, 1.01)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5.12 (4.88, 5.38)	5.20 (4.92, 5.49)	0.99 (0.92, 1.06)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	41.35 (32.75, 52.22)	51.77 (39.84, 67.28)	0.80 (0.56, 1.13)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	475.30 (388.65, 581.26)	638.34 (512.85, 794.54)	0.74 (0.55, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	283.75 (233.55, 344.73)	360.44 (299.15, 434.28)	0.79 (0.60, 1.03)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	81.30 (64.37, 102.68)	97.97 (76.64, 125.23)	0.83 (0.59, 1.16)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	168.01 (136.18, 207.28)	168.52 (135.53, 209.55)	1.00 (0.74, 1.35)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	92.48 (63.69, 134.30)	51.66 (33.87, 78.78)	1.79 (1.02, 3.14)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	717.17 (505.98, 1016.50)	755.34 (529.48, 1077.54)	0.95 (0.58, 1.56)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	481.71 (356.55, 650.82)	482.38 (358.92, 648.31)	1.00 (0.65, 1.52)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	160.60 (110.70, 233.01)	101.42 (70.36, 146.19)	1.58 (0.94, 2.67)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	258.36 (195.07, 342.19)	203.89 (141.04, 294.76)	1.27 (0.80, 2.01)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.10)	0.09 (0.09, 0.09)	1.02 (0.98, 1.06)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.11 (4.89, 5.34)	0.98 (0.94, 1.02)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	23.90 (15.59, 36.63)	25.79 (17.21, 38.66)	0.93 (0.51, 1.67)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	261.98 (178.78, 383.89)	211.53 (144.72, 309.18)	1.24 (0.72, 2.12)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	139.57 (97.93, 198.92)	110.92 (81.69, 150.61)	1.26 (0.79, 2.01)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	37.06 (24.59, 55.86)	45.81 (30.06, 69.82)	0.81 (0.45, 1.46)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	107.20 (73.46, 156.42)	136.45 (92.97, 200.28)	0.79 (0.46, 1.35)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	585.44 (433.35, 790.90)	775.93 (567.18, 1061.53)	0.75 (0.49, 1.16)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	23964.79 (18603.91, 30870.46)	27354.86 (21662.37, 34543.24)	0.88 (0.62, 1.24)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	16261.39 (13217.49, 20006.28)	18816.87 (15365.96, 23042.79)	0.86 (0.65, 1.15)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	922.94 (735.66, 1157.89)	930.77 (738.46, 1173.17)	0.99 (0.72, 1.37)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	701.04 (606.26, 810.65)	783.19 (687.36, 892.38)	0.90 (0.74, 1.09)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	1516.96 (931.33, 2470.83)	1514.32 (950.21, 2413.32)	1.00 (0.51, 1.97)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	53858.28 (36660.92, 79122.78)	46654.53 (32211.81, 67572.90)	1.15 (0.68, 1.97)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	40724.37 (31129.20, 53277.12)	32064.78 (23256.01, 44210.08)	1.27 (0.84, 1.93)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	1689.07 (1299.65, 2195.16)	1669.92 (1267.00, 2200.96)	1.01 (0.69, 1.48)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	1083.16 (936.68, 1252.55)	990.68 (848.77, 1156.32)	1.09 (0.88, 1.35)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	225.66 (131.53, 387.15)	293.00 (187.73, 457.29)	0.77 (0.38, 1.55)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	8114.34 (5005.11, 13155.05)	10475.19 (6993.92, 15689.26)	0.77 (0.41, 1.45)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	5934.45 (4109.64, 8569.54)	6244.39 (4508.26, 8649.11)	0.95 (0.58, 1.55)
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	336.50 (209.06, 541.63)	331.08 (203.28, 539.23)	1.02 (0.51, 2.01)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age < 65 At-risk vs Age < 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	488.63 (345.36, 691.33)	575.34 (434.97, 761.00)	0.85 (0.54, 1.33)

MOCK

Table 7d. The ratios of GMTs/GMCs between groups by Age ≥ 65 , Risk for Severe Covid-19

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age ≥ 65, Risk for Severe Covid-19							
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.01 (0.99, 1.02)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5.08 (5.00, 5.16)	5.04 (4.98, 5.09)	1.01 (0.99, 1.03)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5.21 (5.06, 5.37)	5.06 (4.97, 5.15)	1.03 (0.99, 1.07)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.28)	0.99 (0.97, 1.01)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.07 (4.94, 5.19)	0.99 (0.96, 1.01)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.10 (4.96, 5.25)	0.98 (0.95, 1.01)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.23 (4.79, 5.71)	0.96 (0.88, 1.04)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5.09 (4.92, 5.26)	5.00 (5.00, 5.00)	1.02 (0.98, 1.05)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	137.54 (109.88, 172.15)	182.60 (144.14, 231.31)	0.75 (0.54, 1.04)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	1930.48 (1558.13, 2391.79)	2083.86 (1738.41, 2497.95)	0.93 (0.70, 1.23)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	1115.50 (918.52, 1354.74)	1311.49 (1119.79, 1536.02)	0.85 (0.66, 1.09)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	218.83 (174.58, 274.29)	315.11 (250.46, 396.45)	0.69 (0.50, 0.96)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	319.04 (267.97, 379.85)	332.83 (278.04, 398.42)	0.96 (0.75, 1.23)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	275.15 (180.68, 419.04)	266.41 (176.32, 402.53)	1.03 (0.57, 1.86)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	3871.45 (2641.46, 5674.19)	2564.37 (1893.88, 3472.22)	1.51 (0.93, 2.46)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	2242.72 (1665.25, 3020.44)	1775.92 (1386.69, 2274.41)	1.26 (0.86, 1.86)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	500.50 (336.81, 743.72)	403.63 (277.03, 588.07)	1.24 (0.72, 2.14)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	497.49 (371.34, 666.51)	457.44 (350.62, 596.80)	1.09 (0.73, 1.61)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	0.98 (0.95, 1.02)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5.12 (4.89, 5.35)	5.00 (5.00, 5.00)	1.02 (0.98, 1.07)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	94.29 (58.02, 153.24)	77.17 (51.81, 114.94)	1.22 (0.65, 2.29)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	1305.33 (870.22, 1957.98)	919.14 (662.16, 1275.84)	1.42 (0.84, 2.39)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	671.39 (465.80, 967.71)	509.80 (390.41, 665.71)	1.32 (0.84, 2.07)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	167.83 (108.18, 260.37)	126.24 (87.25, 182.65)	1.33 (0.75, 2.36)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	231.89 (155.85, 345.05)	214.59 (153.93, 299.17)	1.08 (0.64, 1.82)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	2165.00 (1634.23, 2868.15)	2813.29 (2152.83, 3676.37)	0.77 (0.52, 1.13)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	64007.31 (51284.51, 79886.41)	111705.91 (92654.21, 134675.06)	0.57 (0.43, 0.77)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	40502.61 (33105.81, 49552.07)	67146.45 (57479.15, 78439.67)	0.60 (0.47, 0.78)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	1735.27 (1440.81, 2089.92)	2272.94 (1951.20, 2647.73)	0.76 (0.60, 0.97)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	969.70 (879.08, 1069.67)	981.58 (895.48, 1075.96)	0.99 (0.86, 1.13)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	7970.17 (5316.57, 11948.24)	4700.04 (3111.72, 7099.08)	1.70 (0.95, 3.02)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	203350.87 (155935.94, 265183.11)	175262.14 (130219.69, 235884.57)	1.16 (0.78, 1.73)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	120818.40 (100844.20, 144748.88)	112673.01 (97324.95, 130441.44)	1.07 (0.85, 1.35)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	3670.16 (3243.62, 4152.80)	3027.38 (2521.27, 3635.08)	1.21 (0.97, 1.51)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	1234.43 (1178.85, 1292.64)	1181.71 (1063.55, 1313.00)	1.04 (0.93, 1.17)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	0.29 (0.27, 0.32)	0.27 (0.27, 0.27)	1.08 (0.99, 1.18)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5.27 (4.91, 5.66)	5.11 (4.90, 5.33)	1.03 (0.95, 1.12)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5.15 (4.86, 5.45)	5.27 (4.91, 5.66)	0.98 (0.89, 1.07)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	1105.54 (620.86, 1968.58)	1360.88 (864.11, 2143.24)	0.81 (0.39, 1.69)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	45733.74 (30214.56, 69224.07)	35105.55 (24312.93, 50689.07)	1.30 (0.75, 2.27)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	24651.80 (17720.18, 34294.86)	21693.98 (16545.03, 28445.32)	1.14 (0.74, 1.74)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	1591.10 (1106.33, 2288.28)	1685.86 (1256.66, 2261.65)	0.94 (0.59, 1.51)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	806.46 (610.65, 1065.06)	891.91 (721.03, 1103.29)	0.90 (0.64, 1.28)

MOCK

Table 7e. The ratios of GMTs/GMCs between groups by Sex

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Sex							
Male vs Female	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5.06 (5.02, 5.11)	5.07 (4.99, 5.14)	1.00 (0.98, 1.02)
Male vs Female	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5.03 (5.00, 5.07)	5.22 (5.08, 5.37)	0.96 (0.94, 0.99)
Male vs Female	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.01)
Male vs Female	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5.02 (4.98, 5.05)	5.03 (4.99, 5.07)	1.00 (0.99, 1.01)
Male vs Female	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.12 (4.93, 5.32)	0.98 (0.94, 1.01)
Male vs Female	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5.11 (4.96, 5.26)	5.04 (4.96, 5.12)	1.01 (0.98, 1.05)
Male vs Female	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5.04 (4.96, 5.12)	5.00 (5.00, 5.00)	1.01 (0.99, 1.02)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Male vs Female	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.28 (0.27, 0.28)	0.99 (0.96, 1.01)
Male vs Female	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Male vs Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5.21 (4.93, 5.50)	5.00 (5.00, 5.00)	1.04 (0.99, 1.10)
Male vs Female	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5.21 (4.90, 5.54)	5.09 (4.92, 5.27)	1.02 (0.95, 1.10)
Male vs Female	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	57.06 (43.56, 74.74)	67.69 (54.02, 84.83)	0.84 (0.59, 1.20)
Male vs Female	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	711.23 (562.08, 899.96)	822.09 (682.80, 989.78)	0.87 (0.64, 1.17)
Male vs Female	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	393.31 (325.04, 475.92)	488.02 (413.82, 575.52)	0.81 (0.62, 1.04)
Male vs Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	105.17 (81.71, 135.38)	125.55 (101.50, 155.30)	0.84 (0.60, 1.17)
Male vs Female	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	179.83 (145.66, 222.02)	203.21 (167.51, 246.51)	0.88 (0.66, 1.18)
Male vs Female	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	75.01 (50.02, 112.48)	81.10 (54.38, 120.94)	0.92 (0.52, 1.65)
Male vs Female	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	962.36 (673.70, 1374.70)	999.64 (720.53, 1386.86)	0.96 (0.59, 1.57)
Male vs Female	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	654.26 (514.09, 832.66)	622.05 (460.79, 839.75)	1.05 (0.71, 1.55)
Male vs Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	156.51 (106.13, 230.80)	139.20 (99.56, 194.63)	1.12 (0.67, 1.89)
Male vs Female	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	247.12 (169.10, 361.14)	252.05 (182.95, 347.23)	0.98 (0.60, 1.61)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Male vs Female	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Male vs Female	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Male vs Female	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (0.99, 1.02)
Male vs Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5.14 (4.87, 5.43)	5.03 (4.98, 5.08)	1.02 (0.97, 1.08)
Male vs Female	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)
Male vs Female	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	39.33 (25.29, 61.19)	27.35 (19.64, 38.09)	1.44 (0.82, 2.53)
Male vs Female	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	291.14 (184.69, 458.97)	329.24 (251.93, 430.28)	0.88 (0.51, 1.53)
Male vs Female	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	187.38 (134.52, 261.02)	141.95 (108.33, 186.00)	1.32 (0.85, 2.06)
Male vs Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	66.68 (42.33, 105.02)	47.92 (34.31, 66.94)	1.39 (0.78, 2.47)
Male vs Female	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	150.31 (102.23, 221.00)	142.12 (101.26, 199.46)	1.06 (0.63, 1.77)
Male vs Female	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	764.04 (551.00, 1059.45)	1087.77 (833.22, 1420.09)	0.70 (0.46, 1.07)
Male vs Female	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	32542.98 (25574.73, 41409.83)	34987.98 (28491.76, 42965.36)	0.93 (0.68, 1.28)
Male vs Female	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	20519.27 (16817.37, 25036.06)	24398.20 (20339.30, 29267.09)	0.84 (0.64, 1.10)
Male vs Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	964.54 (749.91, 1240.61)	1180.35 (974.50, 1429.69)	0.82 (0.59, 1.12)
Male vs Female	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	795.90 (701.37, 903.17)	813.09 (723.84, 913.34)	0.98 (0.82, 1.16)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Male vs Female	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	2417.23 (1525.27, 3830.81)	1724.72 (1124.66, 2644.94)	1.40 (0.75, 2.64)
Male vs Female	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	59109.55 (38797.09, 90056.73)	65197.56 (47622.50, 89258.68)	0.91 (0.53, 1.54)
Male vs Female	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	42753.89 (29462.81, 62040.76)	43016.37 (33165.90, 55792.51)	0.99 (0.63, 1.57)
Male vs Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	2103.93 (1618.68, 2734.63)	1789.99 (1390.37, 2304.47)	1.18 (0.82, 1.69)
Male vs Female	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	1185.23 (1099.74, 1277.37)	959.35 (815.73, 1128.26)	1.24 (1.03, 1.48)
Male vs Female	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Male vs Female	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.28 (0.27, 0.28)	0.98 (0.96, 1.00)
Male vs Female	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Male vs Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5.04 (4.96, 5.12)	5.05 (4.98, 5.12)	1.00 (0.98, 1.02)
Male vs Female	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5.07 (4.97, 5.16)	5.03 (4.97, 5.10)	1.01 (0.98, 1.03)
Male vs Female	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	462.79 (281.81, 759.98)	319.71 (223.51, 457.32)	1.45 (0.78, 2.70)
Male vs Female	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	14163.75 (9265.29, 21651.96)	12674.85 (8796.36, 18263.44)	1.12 (0.63, 1.98)
Male vs Female	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	8370.65 (5941.97, 11792.01)	8035.24 (5989.71, 10779.34)	1.04 (0.66, 1.65)
Male vs Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	579.25 (348.08, 963.95)	377.76 (256.07, 557.27)	1.53 (0.80, 2.93)
Male vs Female	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	642.55 (489.04, 844.26)	582.03 (448.63, 755.09)	1.10 (0.76, 1.61)

Table 7f. The ratios of GMTs/GMCs between groups by Hispanic or Latino ethnicity

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Hispanic or Latino ethnicity							
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5.08 (5.00, 5.17)	5.04 (5.01, 5.07)	1.01 (0.99, 1.03)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5.14 (4.94, 5.35)	5.17 (5.06, 5.28)	0.99 (0.95, 1.04)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5.08 (4.93, 5.24)	5.02 (4.99, 5.06)	1.01 (0.98, 1.04)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.08 (4.93, 5.24)	0.98 (0.95, 1.01)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.09 (4.99, 5.20)	0.98 (0.96, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.02 (4.98, 5.07)	1.00 (0.99, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.28)	0.99 (0.98, 1.01)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.13 (4.95, 5.31)	0.97 (0.94, 1.01)
Hispanic or Latino vs Not Hispanic or Latino	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.19 (4.96, 5.42)	0.96 (0.92, 1.01)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	54.25 (32.89, 89.49)	63.32 (51.99, 77.13)	0.86 (0.50, 1.47)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	738.59 (475.77, 1146.59)	770.48 (651.56, 911.10)	0.96 (0.60, 1.54)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	458.30 (335.04, 626.91)	434.43 (375.73, 502.30)	1.05 (0.75, 1.49)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	122.12 (79.12, 188.47)	114.80 (94.93, 138.83)	1.06 (0.66, 1.71)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	195.26 (135.35, 281.68)	198.64 (168.65, 233.96)	0.98 (0.66, 1.47)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	63.63 (24.18, 167.42)	82.66 (59.08, 115.67)	0.77 (0.28, 2.15)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	671.42 (268.81, 1677.02)	1077.53 (822.32, 1411.94)	0.62 (0.24, 1.62)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	554.48 (337.54, 910.83)	662.30 (517.66, 847.34)	0.84 (0.48, 1.46)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	103.70 (42.84, 251.02)	151.73 (113.85, 202.23)	0.68 (0.27, 1.73)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	199.58 (88.50, 450.06)	260.81 (197.68, 344.10)	0.77 (0.32, 1.81)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.10)	0.09 (0.09, 0.09)	1.02 (0.97, 1.06)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.11 (4.93, 5.28)	0.98 (0.95, 1.01)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	39.34 (24.35, 63.57)	31.38 (22.71, 43.38)	1.25 (0.70, 2.24)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	478.11 (305.16, 749.09)	277.30 (203.68, 377.54)	1.72 (1.00, 2.97)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	212.26 (132.46, 340.16)	149.58 (116.96, 191.31)	1.42 (0.83, 2.42)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	56.89 (27.13, 119.26)	56.35 (40.82, 77.80)	1.01 (0.45, 2.26)
Hispanic or Latino vs Not Hispanic or Latino	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	122.38 (59.76, 250.61)	148.92 (110.97, 199.85)	0.82 (0.38, 1.78)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	814.68 (481.21, 1379.23)	967.79 (758.64, 1234.60)	0.84 (0.47, 1.51)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	34964.00 (23048.31, 53039.96)	33872.91 (28244.45, 40622.99)	1.03 (0.65, 1.63)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	22813.81 (16865.24, 30860.51)	22521.81 (19244.89, 26356.70)	1.01 (0.72, 1.43)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	854.62 (560.85, 1302.27)	1097.66 (921.37, 1307.68)	0.78 (0.49, 1.23)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	844.27 (704.57, 1011.67)	785.58 (708.83, 870.64)	1.07 (0.87, 1.32)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	1064.02 (391.85, 2889.21)	2040.56 (1414.39, 2943.97)	0.52 (0.18, 1.51)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	50017.84 (23071.66, 108435.37)	65701.34 (49108.73, 87900.16)	0.76 (0.33, 1.74)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	27653.57 (13499.72, 56647.08)	45749.18 (35772.79, 58507.81)	0.60 (0.28, 1.29)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	2163.43 (1224.36, 3822.74)	1861.13 (1499.52, 2309.95)	1.16 (0.63, 2.14)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	1169.19 (1060.95, 1288.48)	1016.42 (893.53, 1156.22)	1.15 (0.98, 1.35)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.28 (0.27, 0.28)	0.99 (0.97, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.03 (4.99, 5.08)	0.99 (0.98, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.06 (4.99, 5.13)	0.99 (0.97, 1.00)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	493.77 (219.83, 1109.09)	350.75 (246.37, 499.37)	1.41 (0.58, 3.40)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	18749.45 (9974.36, 35244.56)	12283.74 (8988.91, 16786.28)	1.53 (0.75, 3.09)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	9513.70 (5382.70, 16815.08)	7712.34 (6006.90, 9901.99)	1.23 (0.66, 2.30)
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	467.24 (253.04, 862.78)	473.68 (322.64, 695.43)	0.99 (0.48, 2.04)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Hispanic or Latino vs Not Hispanic or Latino	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	701.90 (473.83, 1039.74)	607.53 (493.49, 747.93)	1.16 (0.74, 1.80)

MOCK

Table 7g. The ratios of GMTs/GMCs between groups by Underrepresented minority status

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Underrepresented minority status							
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID50	5.05 (5.01, 5.08)	5.04 (5.00, 5.07)	1.00 (0.99, 1.01)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Negative	Pseudovirus-nAb ID80	5.10 (5.02, 5.19)	5.18 (5.04, 5.33)	0.99 (0.95, 1.02)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Positive	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.01)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID50	5.02 (4.98, 5.06)	5.04 (4.98, 5.09)	1.00 (0.98, 1.01)
Communities of Color vs White Non-Hispanic	Day 1	Vaccine	Positive	Pseudovirus-nAb ID80	5.03 (4.99, 5.08)	5.12 (4.89, 5.37)	0.98 (0.94, 1.03)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID50	5.07 (4.93, 5.22)	5.11 (4.96, 5.26)	0.99 (0.95, 1.03)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Negative	Pseudovirus-nAb ID80	5.06 (4.95, 5.17)	5.00 (5.00, 5.00)	1.01 (0.99, 1.03)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Positive	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Positive	Anti RBD IgG (IU/ml)	0.28 (0.27, 0.29)	0.27 (0.27, 0.27)	1.02 (0.98, 1.06)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Positive	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.19 (4.93, 5.47)	0.96 (0.91, 1.01)
Communities of Color vs White Non-Hispanic	Day 1	Placebo	Positive	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.24 (4.92, 5.59)	0.95 (0.89, 1.02)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Negative	Anti N IgG (IU/ml)	48.62 (37.95, 62.30)	69.71 (54.55, 89.08)	0.70 (0.49, 0.99)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Negative	Anti RBD IgG (IU/ml)	620.12 (497.65, 772.73)	851.96 (683.58, 1061.81)	0.73 (0.53, 0.99)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Negative	Anti Spike IgG (IU/ml)	411.57 (345.98, 489.61)	457.39 (378.96, 552.07)	0.90 (0.70, 1.16)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID50	94.00 (74.52, 118.56)	126.36 (99.23, 160.92)	0.74 (0.53, 1.04)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Negative	Pseudovirus-nAb ID80	166.34 (136.37, 202.89)	217.51 (176.19, 268.54)	0.76 (0.57, 1.02)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Positive	Anti N IgG (IU/ml)	85.46 (56.04, 130.32)	77.05 (48.18, 123.22)	1.11 (0.59, 2.09)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Positive	Anti RBD IgG (IU/ml)	1034.01 (721.44, 1482.01)	1042.78 (719.00, 1512.35)	0.99 (0.59, 1.66)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Positive	Anti Spike IgG (IU/ml)	623.25 (467.77, 830.42)	675.98 (483.56, 944.98)	0.92 (0.59, 1.43)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID50	171.64 (112.97, 260.78)	134.49 (91.52, 197.63)	1.28 (0.72, 2.25)
Communities of Color vs White Non-Hispanic	Day 29	Vaccine	Positive	Pseudovirus-nAb ID80	237.95 (162.81, 347.76)	274.51 (190.56, 395.46)	0.87 (0.51, 1.47)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.27 (0.27, 0.27)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.02 (0.99, 1.04)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.18 (4.89, 5.49)	0.96 (0.91, 1.02)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.00 (5.00, 5.00)	1.00 (1.00, 1.00)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Positive	Anti N IgG (IU/ml)	49.62 (34.94, 70.46)	25.31 (16.85, 38.02)	1.96 (1.15, 3.35)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Positive	Anti RBD IgG (IU/ml)	495.72 (376.43, 652.82)	210.89 (142.33, 312.47)	2.35 (1.45, 3.80)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Positive	Anti Spike IgG (IU/ml)	205.15 (154.75, 271.97)	127.97 (94.16, 173.92)	1.60 (1.06, 2.43)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID50	73.87 (49.45, 110.35)	48.07 (32.44, 71.22)	1.54 (0.88, 2.70)
Communities of Color vs White Non-Hispanic	Day 29	Placebo	Positive	Pseudovirus-nAb ID80	153.75 (104.52, 226.17)	140.69 (97.98, 202.01)	1.09 (0.64, 1.85)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Negative	Anti N IgG (IU/ml)	774.71 (579.98, 1034.82)	1044.69 (761.89, 1432.46)	0.74 (0.48, 1.14)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Negative	Anti RBD IgG (IU/ml)	27241.35 (21864.28, 33940.79)	36435.10 (28737.15, 46195.14)	0.75 (0.54, 1.03)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Negative	Anti Spike IgG (IU/ml)	18698.21 (15574.38, 22448.59)	25205.17 (20626.81, 30799.75)	0.74 (0.57, 0.97)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID50	817.67 (646.79, 1033.68)	1228.38 (982.72, 1535.45)	0.67 (0.48, 0.92)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Negative	Pseudovirus-nAb ID80	771.84 (678.09, 878.56)	810.89 (707.90, 928.88)	0.95 (0.79, 1.15)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Positive	Anti N IgG (IU/ml)	1685.08 (1001.61, 2834.93)	2213.21 (1336.74, 3664.34)	0.76 (0.37, 1.57)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Positive	Anti RBD IgG (IU/ml)	63394.56 (42857.04, 93773.88)	70335.26 (47398.85, 104370.64)	0.90 (0.52, 1.57)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Positive	Anti Spike IgG (IU/ml)	37702.50 (27078.22, 52495.27)	50675.29 (37092.29, 69232.30)	0.74 (0.47, 1.17)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID50	1711.69 (1260.86, 2323.72)	1892.63 (1423.38, 2516.58)	0.90 (0.60, 1.37)
Communities of Color vs White Non-Hispanic	Day 57	Vaccine	Positive	Pseudovirus-nAb ID80	1143.39 (1029.28, 1270.14)	961.03 (795.48, 1161.03)	1.19 (0.96, 1.48)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Negative	Anti N IgG (IU/ml)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Negative	Anti RBD IgG (IU/ml)	0.27 (0.27, 0.27)	0.28 (0.27, 0.28)	0.99 (0.96, 1.01)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Negative	Anti Spike IgG (IU/ml)	0.09 (0.09, 0.09)	0.09 (0.09, 0.09)	1.00 (1.00, 1.00)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID50	5.00 (5.00, 5.00)	5.03 (4.97, 5.09)	0.99 (0.98, 1.01)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Negative	Pseudovirus-nAb ID80	5.00 (5.00, 5.00)	5.08 (4.97, 5.19)	0.98 (0.96, 1.01)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Positive	Anti N IgG (IU/ml)	512.68 (321.95, 816.39)	277.45 (178.97, 430.10)	1.85 (0.98, 3.50)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Positive	Anti RBD IgG (IU/ml)	20524.99 (14310.79, 29437.60)	9241.19 (6112.15, 13972.11)	2.22 (1.28, 3.84)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Positive	Anti Spike IgG (IU/ml)	11316.46 (7907.61, 16194.82)	6530.55 (4820.40, 8847.43)	1.73 (1.08, 2.77)
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID50	477.19 (294.63, 772.87)	457.87 (282.73, 741.51)	1.04 (0.53, 2.06)

(continued)

Group 1 vs 2	Visit	Arm	Baseline SARS-CoV-2	Marker	Group 1 GMT/GMC	Group 2 GMT/GMC	Ratios of GMT/GMC
Communities of Color vs White Non-Hispanic	Day 57	Placebo	Positive	Pseudovirus-nAb ID80	614.24 (457.65, 824.40)	581.23 (447.81, 754.40)	1.06 (0.71, 1.57)

MOCK

Table 8a. Differences in the responder rates, 2FRs, 4FRs between the groups by Arm

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Arm							
Vaccine vs Placebo	Negative	-	Day 29	Anti N IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Vaccine vs Placebo	Negative	-	Day 29	Anti RBD IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Vaccine vs Placebo	Negative	-	Day 29	Anti Spike IgG (IU/ml)	100% (100%, 100%)	99.3% (97.1%, 99.8%)	99.3% (97.1%, 99.8%)
Vaccine vs Placebo	Negative	-	Day 29	Pseudovirus-nAb ID50	81.3% (77.5%, 84.7%)	87.3% (78.6%, 90.4%)	87.3% (78.6%, 90.4%)
Vaccine vs Placebo	Negative	-	Day 29	Pseudovirus-nAb ID80	91.8% (88.8%, 94%)	96.6% (94.4%, 98%)	96.6% (94.4%, 98%)
Vaccine vs Placebo	Positive	-	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Vaccine vs Placebo	Positive	-	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Vaccine vs Placebo	Positive	-	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Vaccine vs Placebo	Positive	-	Day 29	Pseudovirus-nAb ID50	23% (12.7%, 32.7%)	12.2% (3.3%, 20.9%)	12% (3.1%, 20.7%)
Vaccine vs Placebo	Positive	-	Day 29	Pseudovirus-nAb ID80	7.1% (-0.9%, 14.9%)	4.1% (-0.6%, 10.2%)	5.3% (0.3%, 11.8%)
Vaccine vs Placebo	Negative	-	Day 57	Anti N IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Vaccine vs Placebo	Negative	-	Day 57	Anti RBD IgG (IU/ml)	100% (100%, 100%)	98.9% (96.8%, 99.7%)	98.9% (96.8%, 99.7%)
Vaccine vs Placebo	Negative	-	Day 57	Anti Spike IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Vaccine vs Placebo	Negative	-	Day 57	Pseudovirus-nAb ID50	97.1% (95.3%, 98.3%)	97.2% (94.4%, 98.3%)	97.2% (94.4%, 98.3%)
Vaccine vs Placebo	Negative	-	Day 57	Pseudovirus-nAb ID80	99.2% (97.7%, 99.7%)	98.9% (96.8%, 99.6%)	98.9% (96.8%, 99.6%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Vaccine vs Placebo	Positive	-	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Vaccine vs Placebo	Positive	-	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Vaccine vs Placebo	Positive	-	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Vaccine vs Placebo	Positive	-	Day 57	Pseudovirus-nAb ID50	8.2% (4.5%, 14.2%)	5% (2.1%, 10.6%)	5% (2.1%, 10.6%)
Vaccine vs Placebo	Positive	-	Day 57	Pseudovirus-nAb ID80	1% (-0.4%, 3.4%)	0.3% (0.1%, 1.3%)	0.3% (0.1%, 1.3%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 8b. Differences in the responder rates, 2FRs, 4FRs between the groups by Baseline SARS-CoV-2

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Baseline SARS-CoV-2							
Positive vs Negative	-	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Positive vs Negative	-	Placebo	Day 29	Anti N IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Positive vs Negative	-	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Positive vs Negative	-	Placebo	Day 29	Anti RBD IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Positive vs Negative	-	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Positive vs Negative	-	Placebo	Day 29	Anti Spike IgG (IU/ml)	100% (100%, 100%)	99.3% (97.1%, 99.8%)	99.3% (97.1%, 99.8%)
Positive vs Negative	-	Vaccine	Day 29	Pseudovirus-nAb ID50	5.4% (-2.4%, 11.5%)	2.4% (-4.6%, 7.5%)	2.2% (-4.8%, 7.3%)
Positive vs Negative	-	Placebo	Day 29	Pseudovirus-nAb ID50	63.7% (55.3%, 71.3%)	77.5% (66.3%, 83.8%)	77.5% (66.3%, 83.8%)
Positive vs Negative	-	Vaccine	Day 29	Pseudovirus-nAb ID80	0.9% (-5.7%, 5.5%)	1.9% (-2%, 4.3%)	1.9% (-2%, 4.3%)
Positive vs Negative	-	Placebo	Day 29	Pseudovirus-nAb ID80	85.6% (78.6%, 90.6%)	94.4% (88.4%, 97.4%)	93.2% (86.8%, 96.6%)
Positive vs Negative	-	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Positive vs Negative	-	Placebo	Day 57	Anti N IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Positive vs Negative	-	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Positive vs Negative	-	Placebo	Day 57	Anti RBD IgG (IU/ml)	100% (100%, 100%)	98.9% (96.8%, 99.7%)	98.9% (96.8%, 99.7%)
Positive vs Negative	-	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Positive vs Negative	-	Placebo	Day 57	Anti Spike IgG (IU/ml)	100% (100%, 100%)	100% (100%, 100%)	100% (100%, 100%)
Positive vs Negative	-	Vaccine	Day 57	Pseudovirus-nAb ID50	2.7% (1.1%, 4.6%)	1.6% (0.2%, 3.4%)	1.6% (0.2%, 3.4%)
Positive vs Negative	-	Placebo	Day 57	Pseudovirus-nAb ID50	91.6% (85.6%, 95.2%)	93.7% (87.8%, 96.6%)	93.7% (87.8%, 96.6%)
Positive vs Negative	-	Vaccine	Day 57	Pseudovirus-nAb ID80	0.6% (-0.6%, 2.1%)	0% (0%, 0.2%)	0% (0%, 0.2%)
Positive vs Negative	-	Placebo	Day 57	Pseudovirus-nAb ID80	98.8% (96.4%, 99.6%)	98.6% (96.3%, 99.4%)	98.6% (96.3%, 99.4%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 8c. Differences in the responder rates, 2FRs, 4FRs between the groups by Age

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age							
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0.4% (-3.3%, 6.2%)	0.4% (-3.3%, 6.2%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 29	Pseudovirus-nAb ID50	14.8% (9.8%, 20.1%)	8.8% (4.8%, 13.3%)	8.8% (4.8%, 13.3%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	-0.7% (-13%, 8.3%)	-0.7% (-13%, 8.3%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 29	Pseudovirus-nAb ID80	7% (3.6%, 11%)	3.2% (1.1%, 6.1%)	3.2% (1.1%, 6.1%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 29	Pseudovirus-nAb ID50	12.1% (4.4%, 21%)	7.4% (0.7%, 15.7%)	7.6% (0.9%, 15.9%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 29	Pseudovirus-nAb ID50	29.8% (17.9%, 41.1%)	15.7% (5.9%, 26.2%)	15.7% (5.9%, 26.2%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 29	Pseudovirus-nAb ID80	6.2% (-0.2%, 14.1%)	1.1% (-3%, 5.9%)	1.1% (-3%, 5.9%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 29	Pseudovirus-nAb ID80	9.1% (0.5%, 18.6%)	4.8% (-0.5%, 12.6%)	6.2% (0.5%, 14.6%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	4.5% (1.4%, 13.2%)	4.5% (1.4%, 13.2%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 57	Pseudovirus-nAb ID50	1.8% (-0.3%, 4.4%)	2.1% (0.6%, 4.4%)	2.1% (0.6%, 4.4%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	4.5% (1.4%, 13.2%)	4.5% (1.4%, 13.2%)
Age ≥ 65 vs Age < 65	Negative	Vaccine	Day 57	Pseudovirus-nAb ID80	0.6% (-0.5%, 2.6%)	-0.1% (-1.1%, 0%)	-0.1% (-1.1%, 0%)
Age ≥ 65 vs Age < 65	Negative	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	4.5% (1.4%, 13.2%)	4.5% (1.4%, 13.2%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 57	Pseudovirus-nAb ID50	0.2% (0%, 1.6%)	0.2% (0%, 1.6%)	0.2% (0%, 1.6%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 57	Pseudovirus-nAb ID50	9.9% (4%, 17.5%)	5.9% (0.7%, 12.9%)	5.9% (0.7%, 12.9%)
Age ≥ 65 vs Age < 65	Positive	Vaccine	Day 57	Pseudovirus-nAb ID80	0.2% (0%, 1.6%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 vs Age < 65	Positive	Placebo	Day 57	Pseudovirus-nAb ID80	-0.4% (-5%, 3.3%)	-1.5% (-6%, -0.4%)	-1.5% (-6%, -0.4%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 8d. Differences in the responder rates, 2FRs, 4FRs between the groups by Risk for Severe Covid-19

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Risk for Severe Covid-19							
At-risk vs Not at-risk	Negative	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	1.2% (-1.2%, 9.9%)	1.2% (-1.2%, 9.9%)
At-risk vs Not at-risk	Negative	Vaccine	Day 29	Pseudovirus-nAb ID50	1.7% (-4.2%, 7.9%)	2.6% (-2.1%, 7.7%)	2.6% (-2.1%, 7.7%)
At-risk vs Not at-risk	Negative	Placebo	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	-1.2% (-14.5%, 6.1%)	-1.2% (-14.5%, 6.1%)
At-risk vs Not at-risk	Negative	Vaccine	Day 29	Pseudovirus-nAb ID80	1.1% (-3.1%, 5.8%)	0.4% (-2.5%, 3.7%)	0.4% (-2.5%, 3.7%)
At-risk vs Not at-risk	Negative	Placebo	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
At-risk vs Not at-risk	Positive	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Vaccine	Day 29	Pseudovirus-nAb ID50	8.3% (-0.9%, 18.1%)	8% (0%, 16.8%)	7.3% (-0.5%, 16.1%)
At-risk vs Not at-risk	Positive	Placebo	Day 29	Pseudovirus-nAb ID50	9.5% (-3.7%, 22.6%)	1.6% (-9.8%, 13.6%)	1.6% (-9.8%, 13.6%)
At-risk vs Not at-risk	Positive	Vaccine	Day 29	Pseudovirus-nAb ID80	5.6% (-1.2%, 14.1%)	1.3% (-2.1%, 6.4%)	1.3% (-2.1%, 6.4%)
At-risk vs Not at-risk	Positive	Placebo	Day 29	Pseudovirus-nAb ID80	1.5% (-8.4%, 12.1%)	2.8% (-4.1%, 11.2%)	4.3% (-2.9%, 13.1%)
At-risk vs Not at-risk	Negative	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	3.6% (1.2%, 10.4%)	3.6% (1.2%, 10.4%)
At-risk vs Not at-risk	Negative	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Negative	Vaccine	Day 57	Pseudovirus-nAb ID50	-0.2% (-2.9%, 2.7%)	0.1% (-2.3%, 2.8%)	0.1% (-2.3%, 2.8%)
At-risk vs Not at-risk	Negative	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	1.9% (-1.7%, 8.6%)	1.9% (-1.7%, 8.6%)
At-risk vs Not at-risk	Negative	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (-1.7%, 2.4%)	-0.1% (-0.8%, 0%)	-0.1% (-0.8%, 0%)
At-risk vs Not at-risk	Negative	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0.2% (-2.9%, 7.2%)	0.2% (-2.9%, 7.2%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
At-risk vs Not at-risk	Positive	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Vaccine	Day 57	Pseudovirus-nAb ID50	-0.7% (-5.1%, -0.1%)	-0.7% (-5.1%, -0.1%)	-0.7% (-5.1%, -0.1%)
At-risk vs Not at-risk	Positive	Placebo	Day 57	Pseudovirus-nAb ID50	-1% (-9.5%, 8.1%)	3.1% (-3.8%, 10.7%)	3.1% (-3.8%, 10.7%)
At-risk vs Not at-risk	Positive	Vaccine	Day 57	Pseudovirus-nAb ID80	-0.7% (-5.1%, -0.1%)	0% (0%, 0%)	0% (0%, 0%)
At-risk vs Not at-risk	Positive	Placebo	Day 57	Pseudovirus-nAb ID80	-0.7% (-6.2%, 3.2%)	-0.3% (-3.8%, 1.3%)	-0.3% (-3.8%, 1.3%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 8e. Differences in the responder rates, 2FRs, 4FRs between the groups by Age < 65, Risk for Severe Covid-19

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age < 65, Risk for Severe Covid-19							
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	2.5% (0.3%, 17%)	2.5% (0.3%, 17%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 29	Pseudovirus-nAb ID50	-2.9% (-11%, 5.2%)	1.1% (-5.3%, 7.6%)	1.1% (-5.3%, 7.6%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	-2.8% (-18.8%, -0.4%)	-2.8% (-18.8%, -0.4%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 29	Pseudovirus-nAb ID80	-0.8% (-6.9%, 5.1%)	-1% (-5.4%, 3.3%)	-1% (-5.4%, 3.3%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 29	Pseudovirus-nAb ID50	7.3% (-5%, 19.4%)	8% (-2.8%, 18.6%)	6.9% (-3.6%, 17.7%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 29	Pseudovirus-nAb ID50	5% (-12.2%, 21.8%)	-3.5% (-18.9%, 12%)	-3.5% (-18.9%, 12%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 29	Pseudovirus-nAb ID80	5.9% (-3.6%, 16.1%)	2.1% (0.5%, 8.2%)	2.1% (0.5%, 8.2%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 29	Pseudovirus-nAb ID80	-1.3% (-15.2%, 12.3%)	2.5% (-7.9%, 12.9%)	4.3% (-6.4%, 15.2%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 57	Pseudovirus-nAb ID50	-0.9% (-5%, 2.8%)	-0.6% (-4.3%, 2.8%)	-0.6% (-4.3%, 2.8%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (-3%, 2.9%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Negative	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 57	Pseudovirus-nAb ID50	-1.1% (-7.6%, -0.1%)	-1.1% (-7.6%, -0.1%)	-1.1% (-7.6%, -0.1%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 57	Pseudovirus-nAb ID50	-3.9% (-16.4%, 7.8%)	3.5% (-7.3%, 12.8%)	3.5% (-7.3%, 12.8%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Vaccine	Day 57	Pseudovirus-nAb ID80	-1.1% (-7.6%, -0.1%)	0% (0%, 0%)	0% (0%, 0%)
Age < 65 At-risk vs Age < 65 Not at-risk	Positive	Placebo	Day 57	Pseudovirus-nAb ID80	-0.9% (-11.4%, 4.8%)	0% (0%, 0%)	0% (0%, 0%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 8f. Differences in the responder rates, 2FRs, 4FRs between the groups by Age ≥ 65 , Risk for Severe Covid-19

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age ≥ 65, Risk for Severe Covid-19							
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	-1.9% (-13.5%, -0.3%)	-1.9% (-13.5%, -0.3%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Vaccine	Day 29	Pseudovirus-nAb ID50	-1.4% (-6.5%, 3.8%)	-1.8% (-6%, 2.4%)	-1.8% (-6%, 2.4%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Placebo	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	2.9% (0.4%, 19.4%)	2.9% (0.4%, 19.4%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Vaccine	Day 29	Pseudovirus-nAb ID80	-0.7% (-4.3%, 2.7%)	0.6% (-1.3%, 3.2%)	0.6% (-1.3%, 3.2%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Placebo	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Positive	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Vaccine	Day 29	Pseudovirus-nAb ID50	3.5% (-6%, 11.6%)	4% (1.2%, 11.9%)	4% (1.2%, 11.9%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Placebo	Day 29	Pseudovirus-nAb ID50	0.1% (-12.7%, 12%)	2.3% (-9.2%, 12.4%)	2.3% (-9.2%, 12.4%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Vaccine	Day 29	Pseudovirus-nAb ID80	1.4% (-7.9%, 9.6%)	-1.5% (-10.5%, -0.2%)	-1.5% (-10.5%, -0.2%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Placebo	Day 29	Pseudovirus-nAb ID80	1.8% (-8.6%, 11.7%)	0.6% (-8.6%, 6.8%)	0.6% (-8.6%, 6.8%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Negative	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Negative	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Negative	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	8.8% (2.8%, 24.7%)	8.8% (2.8%, 24.7%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Vaccine	Day 57	Pseudovirus-nAb ID50	-0.5% (-3.5%, 2.3%)	-0.3% (-2.1%, 0%)	-0.3% (-2.1%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	2.9% (-14.6%, 18.7%)	2.9% (-14.6%, 18.7%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Vaccine	Day 57	Pseudovirus-nAb ID80	-0.6% (-2.3%, -0.1%)	-0.3% (-2.1%, 0%)	-0.3% (-2.1%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Negative	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	-3.1% (-19.4%, 13.9%)	-3.1% (-19.4%, 13.9%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Positive	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Positive	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Positive	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Positive	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk	Positive	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Vaccine	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Placebo	Day 57	Pseudovirus-nAb ID50	-1.5% (-10.6%, -0.2%)	-1.5% (-10.6%, -0.2%)	-1.5% (-10.6%, -0.2%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Age \geq 65 At-risk vs Age \geq 65 Not at-risk	Positive	Placebo	Day 57	Pseudovirus-nAb ID80	-0.1% (-9.2%, 8.6%)	-0.1% (-9.2%, 8.6%)	-0.1% (-9.2%, 8.6%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 8g. Differences in the responder rates, 2FRs, 4FRs between the groups by Sex

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Sex							
Male vs Female	Negative	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0.5% (-2.2%, 6.3%)	0.5% (-2.2%, 6.3%)
Male vs Female	Negative	Vaccine	Day 29	Pseudovirus-nAb ID50	-5.6% (-13.5%, 1.8%)	-0.5% (-7%, 5.4%)	-0.5% (-7%, 5.4%)
Male vs Female	Negative	Placebo	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	2.9% (-2.2%, 21.2%)	2.9% (-2.2%, 21.2%)
Male vs Female	Negative	Vaccine	Day 29	Pseudovirus-nAb ID80	0.1% (-5.8%, 5.2%)	1% (-3.2%, 4.5%)	1% (-3.2%, 4.5%)
Male vs Female	Negative	Placebo	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Male vs Female	Positive	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Vaccine	Day 29	Pseudovirus-nAb ID50	9.9% (-2.8%, 21%)	2.2% (-9.8%, 12.8%)	1.7% (-10.1%, 12.4%)
Male vs Female	Positive	Placebo	Day 29	Pseudovirus-nAb ID50	-1.3% (-17.6%, 14.7%)	1.3% (-13.2%, 15.2%)	1.3% (-13.2%, 15.2%)
Male vs Female	Positive	Vaccine	Day 29	Pseudovirus-nAb ID80	0.3% (-11.3%, 10.5%)	-0.3% (-10.1%, 5.5%)	-0.3% (-10.1%, 5.5%)
Male vs Female	Positive	Placebo	Day 29	Pseudovirus-nAb ID80	4.6% (-8.2%, 16.8%)	-1.6% (-12.5%, 8.2%)	-3.8% (-15.6%, 6.5%)
Male vs Female	Negative	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	-2% (-6%, -0.6%)	-2% (-6%, -0.6%)
Male vs Female	Negative	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Negative	Vaccine	Day 57	Pseudovirus-nAb ID50	-0.3% (-4.2%, 2.7%)	-0.3% (-4.2%, 2.5%)	-0.3% (-4.2%, 2.5%)
Male vs Female	Negative	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	-0.6% (-4.5%, 4.2%)	-0.6% (-4.5%, 4.2%)
Male vs Female	Negative	Vaccine	Day 57	Pseudovirus-nAb ID80	0% (-2.4%, 2.8%)	0.1% (0%, 0.4%)	0.1% (0%, 0.4%)
Male vs Female	Negative	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	0.9% (-3.4%, 5.3%)	0.9% (-3.4%, 5.3%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Male vs Female	Positive	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Vaccine	Day 57	Pseudovirus-nAb ID50	0.3% (0%, 2.1%)	0.3% (0%, 2.1%)	0.3% (0%, 2.1%)
Male vs Female	Positive	Placebo	Day 57	Pseudovirus-nAb ID50	3.1% (-8.3%, 12.8%)	-2.3% (-13.2%, 5.4%)	-2.3% (-13.2%, 5.4%)
Male vs Female	Positive	Vaccine	Day 57	Pseudovirus-nAb ID80	0.3% (0%, 2.1%)	0% (0%, 0%)	0% (0%, 0%)
Male vs Female	Positive	Placebo	Day 57	Pseudovirus-nAb ID80	1.8% (-0.4%, 7%)	0.1% (-1.6%, 2.5%)	0.1% (-1.6%, 2.5%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 8h. Differences in the responder rates, 2FRs, 4FRs between the groups by Hispanic or Latino ethnicity

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Hispanic or Latino ethnicity							
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	2% (-2.2%, 20.1%)	2% (-2.2%, 20.1%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 29	Pseudovirus-nAb ID50	1.6% (-10.3%, 10.5%)	-0.7% (-12.3%, 6.6%)	-0.7% (-12.3%, 6.6%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	-2.6% (-12.9%, -0.5%)	-2.6% (-12.9%, -0.5%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 29	Pseudovirus-nAb ID80	-2.9% (-14.7%, 3.8%)	-0.1% (-8.8%, 3.7%)	-0.1% (-8.8%, 3.7%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 29	Pseudovirus-nAb ID50	-10.3% (-38.7%, 7%)	1.3% (-31.4%, 11.3%)	-0.6% (-28.9%, 10.2%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 29	Pseudovirus-nAb ID50	2.5% (-19.2%, 20.8%)	-3.9% (-25.6%, 11.9%)	-3.9% (-25.6%, 11.9%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 29	Pseudovirus-nAb ID80	-3.5% (-29.8%, 7.4%)	0.5% (-8.2%, 5.5%)	0.5% (-8.2%, 5.5%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 29	Pseudovirus-nAb ID80	-8.8% (-30.4%, 6.4%)	-2% (-22.3%, 7.6%)	-0.6% (-21%, 9.4%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	-1.4% (-4.2%, -0.4%)	-1.4% (-4.2%, -0.4%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 57	Pseudovirus-nAb ID50	-3.5% (-13.4%, 1%)	-1.4% (-10.7%, 1.8%)	-1.4% (-10.7%, 1.8%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	-0.9% (-3.6%, -0.2%)	-0.9% (-3.6%, -0.2%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Vaccine	Day 57	Pseudovirus-nAb ID80	0.6% (-1.6%, 2.5%)	-0.3% (-2.4%, 0%)	-0.3% (-2.4%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Negative	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	-1.4% (-4.2%, -0.4%)	-1.4% (-4.2%, -0.4%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 57	Pseudovirus-nAb ID50	0.2% (0%, 1.6%)	0.2% (0%, 1.6%)	0.2% (0%, 1.6%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 57	Pseudovirus-nAb ID50	4.9% (-4.3%, 12.7%)	4.7% (-3.7%, 11.7%)	4.7% (-3.7%, 11.7%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Vaccine	Day 57	Pseudovirus-nAb ID80	0.2% (0%, 1.6%)	0% (0%, 0%)	0% (0%, 0%)
Hispanic or Latino vs Not Hispanic or Latino	Positive	Placebo	Day 57	Pseudovirus-nAb ID80	0% (-7.8%, 3.4%)	-1% (-8.8%, 0.8%)	-1% (-8.8%, 0.8%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 8i. Differences in the responder rates, 2FRs, 4FRs between the groups by Underrepresented minority status

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Underrepresented minority status							
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	2.1% (0.5%, 8.7%)	2.1% (0.5%, 8.7%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 29	Pseudovirus-nAb ID50	-7.6% (-15.4%, 0.5%)	-2.3% (-8.8%, 4.5%)	-2.3% (-8.8%, 4.5%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 29	Pseudovirus-nAb ID50	0% (0%, 0%)	-4.5% (-21.1%, -0.8%)	-4.5% (-21.1%, -0.8%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 29	Pseudovirus-nAb ID80	-4% (-9.6%, 1.5%)	-2.1% (-6.2%, 1.8%)	-2.1% (-6.2%, 1.8%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 29	Pseudovirus-nAb ID80	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 29	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 29	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 29	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 29	Pseudovirus-nAb ID50	-2.8% (-16.3%, 11.3%)	4.4% (-7.7%, 16.8%)	3.9% (-8%, 16.3%)
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 29	Pseudovirus-nAb ID50	11.9% (-4.3%, 27.6%)	3.4% (-9.8%, 17.3%)	3.4% (-9.8%, 17.3%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 29	Pseudovirus-nAb ID80	0.6% (-10.6%, 12.7%)	-4.2% (-14.3%, -1.2%)	-4.2% (-14.3%, -1.2%)
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 29	Pseudovirus-nAb ID80	-0.6% (-13.1%, 12.6%)	-0.2% (-9.2%, 10.6%)	1.9% (-7.6%, 13.4%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	-1.6% (-6.2%, -0.4%)	-1.6% (-6.2%, -0.4%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 57	Pseudovirus-nAb ID50	-3.3% (-7.5%, 0.2%)	-1.2% (-4.7%, 2.1%)	-1.2% (-4.7%, 2.1%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 57	Pseudovirus-nAb ID50	0% (0%, 0%)	-0.8% (-5.6%, -0.1%)	-0.8% (-5.6%, -0.1%)
Communities of Color vs White Non-Hispanic	Negative	Vaccine	Day 57	Pseudovirus-nAb ID80	-0.1% (-2.8%, 3.5%)	-0.1% (-0.7%, 0%)	-0.1% (-0.7%, 0%)
Communities of Color vs White Non-Hispanic	Negative	Placebo	Day 57	Pseudovirus-nAb ID80	0% (0%, 0%)	-1.6% (-6.2%, -0.4%)	-1.6% (-6.2%, -0.4%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 57	Anti N IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 57	Anti RBD IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)

(continued)

Comparison	Baseline SARS-CoV-2	Arm	Visit	Marker	% 4-Fold Rise	% 2-Fold Rise	Responder
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 57	Anti Spike IgG (IU/ml)	0% (0%, 0%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 57	Pseudovirus-nAb ID50	-0.5% (-3.6%, -0.1%)	-0.5% (-3.6%, -0.1%)	-0.5% (-3.6%, -0.1%)
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 57	Pseudovirus-nAb ID50	-2% (-13.5%, 9.7%)	-2.9% (-13.7%, 8.7%)	-2.9% (-13.7%, 8.7%)
Communities of Color vs White Non-Hispanic	Positive	Vaccine	Day 57	Pseudovirus-nAb ID80	-0.5% (-3.6%, -0.1%)	0% (0%, 0%)	0% (0%, 0%)
Communities of Color vs White Non-Hispanic	Positive	Placebo	Day 57	Pseudovirus-nAb ID80	-1.4% (-10%, 1.8%)	-0.1% (-2.7%, 2.1%)	-0.1% (-2.7%, 2.1%)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 9. Antibody levels in the baseline SARS-CoV-2 negative per-protocol cohort (vaccine vs. placebo)

Visit	Marker	Baseline SARS-CoV-2 Negative						Comparison	
		N	Resp rate	Vaccine	N	Resp rate	Placebo		
Day 29	Anti N IgG (IU/ml)	904	13264/13264 = 100.0% (100.0%, 100.0%)	63.36 (53.33, 75.29)	155	0/13308 = 0.0% (0.0%, 0.0%)	0.02 (0.02, 0.02)	100% (100%, 100%)	2640.13 (2221.93, 3137.04)
Day 29	Anti RBD IgG (IU/ml)	904	13264/13264 = 100.0% (100.0%, 100.0%)	777.30 (672.65, 898.24)	155	0/13308 = 0.0% (0.0%, 0.0%)	0.27 (0.27, 0.27)	100% (100%, 100%)	2857.72 (2472.96, 3302.35)
Day 29	Anti Spike IgG (IU/ml)	904	13264/13264 = 100.0% (100.0%, 100.0%)	448.95 (396.45, 508.40)	155	88.8/13308 = 0.7% (0.2%, 2.9%)	0.09 (0.09, 0.09)	99.3% (97.1%, 99.8%)	4961.71 (4380.44, 5620.10)
Day 29	Pseudovirus-nAb ID50	904	11850.9/13264 = 89.3% (86.0%, 92.0%)	117.24 (99.65, 137.93)	155	266.3/13308 = 2.0% (0.4%, 10.0%)	5.08 (4.95, 5.22)	87.3% (78.6%, 90.4%)	23.08 (19.57, 27.21)
Day 29	Pseudovirus-nAb ID80	904	12813.8/13264 = 96.6% (94.4%, 98.0%)	193.83 (167.92, 223.73)	155	0/13308 = 0.0% (0.0%, 0.0%)	5.00 (5.00, 5.00)	96.6% (94.4%, 98%)	38.77 (33.58, 44.75)
Day 57	Anti N IgG (IU/ml)	904	13264/13264 = 100.0% (100.0%, 100.0%)	948.86 (771.45, 1167.08)	155	0/13308 = 0.0% (0.0%, 0.0%)	0.02 (0.02, 0.02)	100% (100%, 100%)	39536.03 (32143.75, 48628.35)
Day 57	Anti RBD IgG (IU/ml)	904	13264/13264 = 100.0% (100.0%, 100.0%)	34021.35 (29123.06, 39743.51)	155	140.5/13308 = 1.1% (0.3%, 3.2%)	0.27 (0.27, 0.28)	98.9% (96.8%, 99.7%)	123902.26 (106024.84, 144794.10)
Day 57	Anti Spike IgG (IU/ml)	904	13264/13264 = 100.0% (100.0%, 100.0%)	22817.97 (19944.94, 26104.85)	155	0/13308 = 0.0% (0.0%, 0.0%)	0.09 (0.09, 0.09)	100% (100%, 100%)	253532.98 (221610.40, 290053.94)
Day 57	Pseudovirus-nAb ID50	904	13027.1/13264 = 98.2% (96.4%, 99.1%)	1091.69 (937.63, 1271.06)	155	140.5/13308 = 1.1% (0.3%, 3.2%)	5.04 (4.99, 5.09)	97.2% (94.4%, 98.3%)	216.42 (185.82, 252.06)
Day 57	Pseudovirus-nAb ID80	904	13259.8/13264 = 100.0% (99.8%, 100.0%)	806.40 (739.65, 879.17)	155	140.5/13308 = 1.1% (0.3%, 3.2%)	5.05 (4.99, 5.10)	98.9% (96.8%, 99.6%)	159.74 (146.42, 174.27)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 10. Antibody levels in the baseline SARS-CoV-2 positive per-protocol cohort (vaccine vs. placebo)

Visit	Marker	Baseline SARS-CoV-2 Positive							
		Vaccine				Placebo			
		N	Resp rate	GMT/GMC	N	Resp rate	GMT/GMC	Resp Rate Difference	GMTR/GMCR
Day 29	Anti N IgG (IU/ml)	277	1432/1432 = 100.0% (100.0%, 100.0%)	78.60 (59.10, 104.52)	274	1337/1337 = 100.0% (100.0%, 100.0%)	32.90 (24.99, 43.30)	0% (0%, 0%)	2.39 (1.61, 3.55)
Day 29	Anti RBD IgG (IU/ml)	277	1432/1432 = 100.0% (100.0%, 100.0%)	984.50 (773.66, 1252.81)	274	1337/1337 = 100.0% (100.0%, 100.0%)	309.30 (239.29, 399.78)	0% (0%, 0%)	3.18 (2.24, 4.53)
Day 29	Anti Spike IgG (IU/ml)	277	1432/1432 = 100.0% (100.0%, 100.0%)	634.79 (519.07, 776.30)	274	1337/1337 = 100.0% (100.0%, 100.0%)	163.46 (132.49, 201.67)	0% (0%, 0%)	3.88 (2.90, 5.19)
Day 29	Pseudovirus-nAb ID50	277	1311.5/1432 = 91.6% (85.1%, 95.4%)	145.91 (113.68, 187.28)	274	1063.5/1337 = 79.5% (71.7%, 85.6%)	56.68 (42.71, 75.22)	12% (3.1%, 20.7%)	2.57 (1.77, 3.75)
Day 29	Pseudovirus-nAb ID80	277	1410.8/1432 = 98.5% (94.8%, 99.6%)	250.06 (195.89, 319.20)	274	1246.6/1337 = 93.2% (86.8%, 96.6%)	146.22 (113.10, 189.03)	5.3% (0.3%, 11.8%)	1.71 (1.20, 2.44)
Day 57	Anti N IgG (IU/ml)	277	1432/1432 = 100.0% (100.0%, 100.0%)	1975.01 (1440.49, 2707.88)	274	1337/1337 = 100.0% (100.0%, 100.0%)	385.82 (284.09, 523.97)	0% (0%, 0%)	5.12 (3.30, 7.95)
Day 57	Anti RBD IgG (IU/ml)	277	1432/1432 = 100.0% (100.0%, 100.0%)	62681.63 (48801.94, 80508.81)	274	1337/1337 = 100.0% (100.0%, 100.0%)	13410.80 (10185.37, 17657.62)	0% (0%, 0%)	4.67 (3.22, 6.78)
Day 57	Anti Spike IgG (IU/ml)	277	1432/1432 = 100.0% (100.0%, 100.0%)	42910.81 (34675.79, 53101.53)	274	1337/1337 = 100.0% (100.0%, 100.0%)	8203.97 (6577.21, 10233.09)	0% (0%, 0%)	5.23 (3.85, 7.11)
Day 57	Pseudovirus-nAb ID50	277	1429.5/1432 = 99.8% (98.7%, 100.0%)	1909.96 (1589.03, 2295.71)	274	1267.2/1337 = 94.8% (89.3%, 97.5%)	469.42 (339.51, 649.04)	5% (2.1%, 10.6%)	4.07 (2.80, 5.91)
Day 57	Pseudovirus-nAb ID80	277	1432/1432 = 100.0% (100.0%, 100.0%)	1044.34 (942.43, 1157.26)	274	1332.7/1337 = 99.7% (98.7%, 99.9%)	612.04 (506.61, 739.40)	0.3% (0.1%, 1.3%)	1.71 (1.38, 2.12)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 11. Antibody levels in the per-protocol cohort (vaccine recipients)

Visit	Marker	Vaccine Recipients						Comparison	
		Baseline SARS-CoV-2 Positive			Baseline SARS-CoV-2 Negative				
N	Resp rate	GMT/GMC	N	Resp rate	GMT/GMC	Resp Rate Difference	GMTR/GMCR		
Day 29	Anti N IgG (IU/ml)	277	1432/1432 = 100.0% (100.0%, 100.0%)	78.60 (59.10, 104.52)	904	13264/13264 = 100.0% (100.0%, 100.0%)	63.36 (53.33, 75.29)	0% (0%, 0%)	1.24 (0.89, 1.73)
Day 29	Anti RBD IgG (IU/ml)	277	1432/1432 = 100.0% (100.0%, 100.0%)	984.50 (773.66, 1252.81)	904	13264/13264 = 100.0% (100.0%, 100.0%)	777.30 (672.65, 898.24)	0% (0%, 0%)	1.27 (0.96, 1.68)
Day 29	Anti Spike IgG (IU/ml)	277	1432/1432 = 100.0% (100.0%, 100.0%)	634.79 (519.07, 776.30)	904	13264/13264 = 100.0% (100.0%, 100.0%)	448.95 (396.45, 508.40)	0% (0%, 0%)	1.41 (1.12, 1.79)
Day 29	Pseudovirus-nAb ID50	277	1311.5/1432 = 91.6% (85.1%, 95.4%)	145.91 (113.68, 187.28)	904	11850.9/13264 = 89.3% (86.0%, 92.0%)	117.24 (99.65, 137.93)	2.2% (-4.8%, 7.3%)	1.24 (0.92, 1.68)
Day 29	Pseudovirus-nAb ID80	277	1410.8/1432 = 98.5% (94.8%, 99.6%)	250.06 (195.89, 319.20)	904	12813.8/13264 = 96.6% (94.4%, 98.0%)	193.83 (167.92, 223.73)	1.9% (-2%, 4.3%)	1.29 (0.97, 1.71)
Day 57	Anti N IgG (IU/ml)	277	1432/1432 = 100.0% (100.0%, 100.0%)	1975.01 (1440.49, 2707.88)	904	13264/13264 = 100.0% (100.0%, 100.0%)	948.86 (771.45, 1167.08)	0% (0%, 0%)	2.08 (1.43, 3.04)
Day 57	Anti RBD IgG (IU/ml)	277	1432/1432 = 100.0% (100.0%, 100.0%)	62681.63 (48801.94, 80508.81)	904	13264/13264 = 100.0% (100.0%, 100.0%)	34021.35 (29123.06, 39743.51)	0% (0%, 0%)	1.84 (1.37, 2.47)
Day 57	Anti Spike IgG (IU/ml)	277	1432/1432 = 100.0% (100.0%, 100.0%)	42910.81 (34675.79, 53101.53)	904	13264/13264 = 100.0% (100.0%, 100.0%)	22817.97 (19944.94, 26104.85)	0% (0%, 0%)	1.88 (1.46, 2.42)
Day 57	Pseudovirus-nAb ID50	277	1429.5/1432 = 99.8% (98.7%, 100.0%)	1909.96 (1589.03, 2295.71)	904	13027.1/13264 = 98.2% (96.4%, 99.1%)	1091.69 (937.63, 1271.06)	1.6% (0.2%, 3.4%)	1.75 (1.38, 2.22)
Day 57	Pseudovirus-nAb ID80	277	1432/1432 = 100.0% (100.0%, 100.0%)	1044.34 (942.43, 1157.26)	904	13259.8/13264 = 100.0% (99.8%, 100.0%)	806.40 (739.65, 879.17)	0% (0%, 0.2%)	1.30 (1.13, 1.48)

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 12. Antibody levels in the per-protocol cohort (placebo recipients)

Visit	Marker	Placebo Recipients						
		Baseline SARS-CoV-2 Positive			Baseline SARS-CoV-2 Negative			Comparison
N	Resp rate	GMT/GMC	N	Resp rate	GMT/GMC	Resp Rate Difference	GMTR/GMCR	
Day 29	Anti N IgG (IU/ml)	274 1337/1337 = 100.0% (100.0%, 100.0%)	32.90 (24.99, 43.30)	155 0/13308 = 0.0% (0.0%, 0.0%)	0.02 (0.02, 0.02)	100% (100%, 100%)	1370.73 (1041.38, 1804.23)	
Day 29	Anti RBD IgG (IU/ml)	274 1337/1337 = 100.0% (100.0%, 100.0%)	309.30 (239.29, 399.78)	155 0/13308 = 0.0% (0.0%, 0.0%)	0.27 (0.27, 0.27)	100% (100%, 100%)	1137.12 (879.74, 1469.79)	
Day 29	Anti Spike IgG (IU/ml)	274 1337/1337 = 100.0% (100.0%, 100.0%)	163.46 (132.49, 201.67)	155 88.8/13308 = 0.7% (0.2%, 2.9%)	0.09 (0.09, 0.09)	99.3% (97.1%, 99.8%)	1806.52 (1464.06, 2229.09)	
Day 29	Pseudovirus-nAb ID50	274 1063.5/1337 = 79.5% (71.7%, 85.6%)	56.68 (42.71, 75.22)	155 266.3/13308 = 2.0% (0.4%, 10.0%)	5.08 (4.95, 5.22)	77.5% (66.3%, 83.8%)	11.16 (8.40, 14.82)	
Day 29	Pseudovirus-nAb ID80	274 1246.6/1337 = 93.2% (86.8%, 96.6%)	146.22 (113.10, 189.03)	155 0/13308 = 0.0% (0.0%, 0.0%)	5.00 (5.00, 5.00)	93.2% (86.8%, 96.6%)	29.24 (22.62, 37.81)	
Day 57	Anti N IgG (IU/ml)	274 1337/1337 = 100.0% (100.0%, 100.0%)	385.82 (284.09, 523.97)	155 0/13308 = 0.0% (0.0%, 0.0%)	0.02 (0.02, 0.02)	100% (100%, 100%)	16075.73 (11837.09, 21832.15)	
Day 57	Anti RBD IgG (IU/ml)	274 1337/1337 = 100.0% (100.0%, 100.0%)	13410.80 (10185.37, 17657.62)	155 140.5/13308 = 1.1% (0.3%, 3.2%)	0.27 (0.27, 0.28)	98.9% (96.8%, 99.7%)	48840.74 (37086.50, 64320.39)	
Day 57	Anti Spike IgG (IU/ml)	274 1337/1337 = 100.0% (100.0%, 100.0%)	8203.97 (6577.21, 10233.09)	155 0/13308 = 0.0% (0.0%, 0.0%)	0.09 (0.09, 0.09)	100% (100%, 100%)	91155.26 (73080.07, 113701.05)	
Day 57	Pseudovirus-nAb ID50	274 1267.2/1337 = 94.8% (89.3%, 97.5%)	469.42 (339.51, 649.04)	155 140.5/13308 = 1.1% (0.3%, 3.2%)	5.04 (4.99, 5.09)	93.7% (87.8%, 96.6%)	93.06 (67.30, 128.69)	
Day 57	Pseudovirus-nAb ID80	274 1332.7/1337 = 99.7% (98.7%, 99.9%)	612.04 (506.61, 739.40)	155 140.5/13308 = 1.1% (0.3%, 3.2%)	5.05 (4.99, 5.10)	98.6% (96.3%, 99.4%)	121.24 (100.32, 146.51)	

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Chapter 2

Graphical Description of Immunogenicity Data

2.1 Pairs plots of antibody markers for overall per-protocol cohort

2.1.1 Baseline SARS-CoV-2 Negative




Figure 2.1: Pair plots of D29 Ab markers: baseline negative vaccine arm




Figure 2.2: Pair plots of D57 Ab markers: baseline negative vaccine arm




Figure 2.3: Pair plots of D29 fold-rise over D1 Ab markers: baseline negative vaccine arm




Figure 2.4: Pair plots of D57 fold-rise over D1 Ab markers: baseline negative vaccine arm




Figure 2.5: Pair plots of D1, D29 and D57 Binding Antibody to Spike: baseline negative vaccine arm




Figure 2.6: Pair plots of D1, D29 and D57 Binding Antibody to RBD: baseline negative vaccine arm




Figure 2.7: Pair plots of D1, D29 and D57 PsV Neutralization 50% Titer: baseline negative vaccine arm




Figure 2.8: Pair plots of D1, D29 and D57 PsV Neutralization 80% Titer: Baseline negative vaccine arm

2.1.2 Baseline SARS-CoV-2 Positive




Figure 2.9: Pair plots of D29 Ab markers: baseline positive vaccine arm




Figure 2.10: Pair plots of D57 Ab markers: baseline positive vaccine arm




Figure 2.11: Pair plots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm




Figure 2.12: Pair plots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm




Figure 2.13: Pair plots of D1, D29 and D57 Binding Antibody to Spike: baseline positive vaccine arm




Figure 2.14: Pair plots of D1, D29 and D57 Binding Antibody to RBD: baseline positive vaccine arm

PsV Neutralization 50% Titer: baseline positive vaccine arm




Figure 2.15: Pair plots of D1, D29 and D57 PsV Neutralization 50% Titer: baseline positive vaccine arm




Figure 2.16: Pair plots of D1, D29 and D57 PsV Neutralization 80% Titer: Baseline positive vaccine arm

2.2 RCDF plots of antibody markers for overall per-protocol cohort




Figure 2.17: RCDF plots for D29 Ab markers: by baseline status x randomization arm




Figure 2.18: RCDF plots for D57 Ab markers: by baseline status x randomization arm




Figure 2.19: RCDF plots for D29 fold-rise over D1 Ab markers: by baseline status x randomization arm




Figure 2.20: RCDF plots for D57 fold-rise over D1 Ab markers: by baseline status x randomization arm




Figure 2.21: RCDF plots for D29 Ab markers: by baseline status for the vaccine arm




Figure 2.22: RCDF plots for D57 Ab markers: by baseline status for the vaccine arm




Figure 2.23: RCDF plots for D29 over D1 fold-rise Ab markers: by baseline status for the vaccine arm




Figure 2.24: RCDF plots for D57 fold-rise over D1 Ab markers: by baseline status for the vaccine arm




Figure 2.25: RCDF plots for D29 Ab markers: baseline negative vaccine arm




Figure 2.26: RCDF plots for D57 Ab markers: baseline negative vaccine arm




Figure 2.27: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm




Figure 2.28: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm




Figure 2.29: RCDF plots for D29 Ab markers: baseline positive vaccine arm




Figure 2.30: RCDF plots for D57 Ab markers: baseline positive vaccine arm




Figure 2.31: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm




Figure 2.32: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm

2.3 Scatter plots of antibody markers versus age for overall per-protocol cohort

2.3.1 Baseline SARS-CoV-2 negative




Figure 2.33: Scatter plots for D29 Ab markers vs. age: baseline negative vaccine arm

2.3. SCATTER PLOTS OF ANTIBODY MARKERS VERSUS AGE FOR OVERALL PER-PROTOCOL COHORT445




Figure 2.34: Scatter plots for D57 Ab markers vs. age: baseline negative vaccine arm

2.3.2 Baseline SARS-CoV-2 positive




Figure 2.35: Scatter plots for D29 Ab markers vs. age: baseline positive vaccine arm

2.3. SCATTER PLOTS OF ANTIBODY MARKERS VERSUS AGE FOR OVERALL PER-PROTOCOL COHORT447




Figure 2.36: Scatter plots for D57 Ab markers vs. age: baseline positive vaccine arm

2.4 Box plots of antibody markers for overall per-protocol cohort

2.4.1 Baseline SARS-CoV-2 negative




Figure 2.37: Boxplots of D29 Ab markers: baseline negative vaccine + placebo arms




Figure 2.38: Boxplots of D57 Ab markers: baseline negative vaccine + placebo arms




Figure 2.39: Boxplots of D29 fold-rise over D1 Ab markers: baseline negative vaccine + placebo arms




Figure 2.40: Boxplots of D57 fold-rise over D1 Ab markers: baseline negative vaccine + placebo arms

2.4.2 Baseline SARS-CoV-2 positive




Figure 2.41: Boxplots of D29 Ab markers: baseline positive vaccine + placebo arms




Figure 2.42: Boxplots of D57 Ab markers: baseline positive vaccine + placebo arms




Figure 2.43: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine + placebo arms




Figure 2.44: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine + placebo arms

2.4.3 Baseline negative vs. positive vaccine recipients




Figure 2.45: Boxplots of D29 Ab markers: baseline positive + negative vaccine arm




Figure 2.46: Boxplots of D57 Ab markers: baseline positive + negative vaccine arm




Figure 2.47: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive + negative vaccine arm




Figure 2.48: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive + negative vaccine arm

2.4.4 Baseline negative vs. positive placebo recipients




Figure 2.49: Boxplots of D29 Ab markers: baseline positive + negative placebo arm




Figure 2.50: Boxplots of D57 Ab markers: baseline positive + negative placebo arm




Figure 2.51: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive + negative placebo arm




Figure 2.52: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive + negative placebo arm

2.5 Spaghetti plots of antibody markers over time for the overall per-protocol cohort

2.5.1 Baseline SARS-CoV-2 negative




Figure 2.53: Spaghetti plots of Ab markers over time: baseline negative vaccine + placebo arm

2.5.2 Baseline SARS-CoV-2 positive




Figure 2.54: Spaghetti plots of Ab markers over time: baseline positive vaccine + placebo arm

2.6 RCDF plots of antibody markers by demographics for per-protocol cohort

2.6.1 Baseline SARS-CoV-2 negative




Figure 2.55: RCDF plots for D29 Ab markers: baseline negative vaccine arm by age groups.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT467




Figure 2.56: RCDF plots for D57 Ab markers: baseline negative vaccine arm by age groups.




Figure 2.57: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age groups.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT469




Figure 2.58: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age groups.




Figure 2.59: RCDF plots for D29 Ab markers: baseline negative vaccine arm by high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT471




Figure 2.60: RCDF plots for D57 Ab markers: baseline negative vaccine arm by high-risk condition.




Figure 2.61: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT473




Figure 2.62: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by high-risk condition.




Figure 2.63: RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and high-risk condition.




Figure 2.64: RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and high-risk condition.




Figure 2.65: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT477




Figure 2.66: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and high-risk condition.




Figure 2.67: RCDF plots for D29 Ab markers: baseline negative vaccine arm by sex assigned at birth.




Figure 2.68: RCDF plots for D57 Ab markers: baseline negative vaccine arm by sex assigned at birth.




Figure 2.69: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT481




Figure 2.70: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by sex assigned at birth.




Figure 2.71: RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT483




Figure 2.72: RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and sex assigned at birth.




Figure 2.73: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT485




Figure 2.74: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and sex at birth.




Figure 2.75: RCDF plots for D29 Ab markers: baseline negative vaccine arm by ethnicity.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT487




Figure 2.76: RCDF plots for D57 Ab markers: baseline negative vaccine arm by ethnicity.




Figure 2.77: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by ethnicity.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT489




Figure 2.78: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by ethnicity.




Figure 2.79: RCDF plots for D29 Ab markers: baseline negative vaccine arm by race.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT491




Figure 2.80: RCDF plots for D57 Ab markers: baseline negative vaccine arm by race.




Figure 2.81: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by race.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT493




Figure 2.82: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by race.




Figure 2.83: RCDF plots for D29 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT495




Figure 2.84: RCDF plots for D57 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.85: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT497




Figure 2.86: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.87: RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT499




Figure 2.88: RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.




Figure 2.89: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT501




Figure 2.90: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.

2.6.2 Baseline SARS-CoV-2 positive




Figure 2.91: RCDF plots for D29 Ab markers: baseline positive vaccine arm by age groups.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT503




Figure 2.92: RCDF plots for D57 Ab markers: baseline positive vaccine arm by age groups.




Figure 2.93: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age groups.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT505




Figure 2.94: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age groups.




Figure 2.95: RCDF plots for D29 Ab markers: baseline positive vaccine arm by high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT507




Figure 2.96: RCDF plots for D57 Ab markers: baseline positive vaccine arm by high-risk condition.




Figure 2.97: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT509




Figure 2.98: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.




Figure 2.99: RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT511




Figure 2.100: RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and high-risk condition.




Figure 2.101: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT513




Figure 2.102: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.




Figure 2.103: RCDF plots for D29 Ab markers: baseline positive vaccine arm by sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT515




Figure 2.104: RCDF plots for D57 Ab markers: baseline positive vaccine arm by sex assigned at birth.




Figure 2.105: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT517




Figure 2.106: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.




Figure 2.107: RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT519




Figure 2.108: RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.




Figure 2.109: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT521




Figure 2.110: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.




Figure 2.111: RCDF plots for D29 Ab markers: baseline positive vaccine arm by ethnicity.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT523




Figure 2.112: RCDF plots for D57 Ab markers: baseline positive vaccine arm by ethnicity.




Figure 2.113: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT525




Figure 2.114: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity.




Figure 2.115: RCDF plots for D29 Ab markers: baseline positive vaccine arm by race.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT527




Figure 2.116: RCDF plots for D57 Ab markers: baseline positive vaccine arm by race.




Figure 2.117: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by race.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT529




Figure 2.118: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by race.




Figure 2.119: RCDF plots for D29 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT531




Figure 2.120: RCDF plots for D57 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.121: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT533




Figure 2.122: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.123: RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT535




Figure 2.124: RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.




Figure 2.125: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT537




Figure 2.126: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.

2.7 Boxplots of antibody markers by demographics for per-protocol cohort

2.7.1 Baseline SARS-CoV-2 negative




Figure 2.127: Boxplots of D29 Ab markers: Baseline negative vaccine arm by age group.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT539




Figure 2.128: Boxplots of D57 Ab markers: Baseline negative vaccine arm by age group.




Figure 2.129: Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and sex assigned at birth.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT541




Figure 2.130: Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and sex assigned at birth.




Figure 2.131: Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by ethnicity.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT543




Figure 2.132: Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by ethnicity.




Figure 2.133: Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by race.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT545




Figure 2.134: Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by race.




Figure 2.135: Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by dichotomous classification of race and ethnic group.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT547




Figure 2.136: Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.137: Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT549




Figure 2.138: Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.

2.7.2 Baseline SARS-CoV-2 positive

MOCK

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT551




Figure 2.139: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age group.




Figure 2.140: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age group.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT553




Figure 2.141: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.




Figure 2.142: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT555




Figure 2.143: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.




Figure 2.144: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT557




Figure 2.145: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.




Figure 2.146: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT559




Figure 2.147: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.




Figure 2.148: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT561




Figure 2.149: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity.




Figure 2.150: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT563




Figure 2.151: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by race.




Figure 2.152: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by race.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT565




Figure 2.153: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.154: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT567




Figure 2.155: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.




Figure 2.156: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.